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ABSTRACT 
AP-2 transcription factors are highly conserved basic helix-span-helix proteins whose 
members ((x, ß, y, S and c) are crucial regulators of bryonic development. They also 
play an important role in human neoplasia. uohis ochemical studies have detected 
high levels of AP-2y expression in primary tumo of breast cancer patients. This high 
expression has been correlated with reduced survival in all patients and reduced survival 
in an ERa positive subset treated with hormone therapy. In breast cancer cell lines, AP- 
2 factors have been implicated in the regulation of the ERBB2 proto-oncogene and ERa. 
In an effort to further understand the role of AP-2y in breast carcinoma, this study has 
sought to identify additional AP-2 activated cellular pathways and ultimately novel 
transcriptional targets for AP-2 through the use of gene expression profiling. 
RNAi using three independent AP-2y targeting sequences, has been used to deplete AP- 
2y levels in the ERa positive MCF-7 breast carcinoma cell line, chosen as it exclusively 
expresses the AP-2y family member. Microarrays were then utilised to create an AP-2y 
dependent transcription profile. Statistical comparisons between non-silencing control 
siRNA and AP-2y targeting siRNA groups identified a total of 162 gene expression 
changes (p<0.01). These changes implicate AP-2y in the control of cell cycle 
progression and developmental signalling. Indeed a role for AP-2y in the control of cell 
cycle, in particular at the GUS transition, has been verified using flow cytometry. 
Several of these gene expression changes, including IGFBP3, Transgelin and 
KIAA1324, have been confirmed using qPCR and immunoblotting. 
Finally, elevated levels of p21 mRNA and protein have been observed following AP-2y 
silencing in MCF-7 cells. Additionally, the activity of a p21 promoter reporter is 
repressed following transfection with an AP-2y expression construct in HepG2 cells. 
These results coupled with ChIP experiments showing AP-2y occupancy at the proximal 
promoter region of p21 in cycling MCF-7 cells, implicate AP-2y in the repression of 
p21 transcription and suggest a role for AP2y in- the, control of cell cycle in breast 
carcinoma in part through the transcriptional repression of p21. 
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qPCR qPCR 
RA Retinoic Acid 
Rb Retinoblastoma 
RMA Robust Multi-array Average 
RNAi RNA Interference 
RNase Ribonuclease 
RSV Respiratory syncytial virus 
RT Room Temperature 
SDS Sodium Dodecyl (lauryl) Sulphate 
SERM Selective oestrogen receptor modulator 
shRNA short hairpin RNA 
siRNA short interfering RNA 
Sp Specificity Protein 
SUMO Small Ubiquitin-Related Modifier 
SV40 Simian Virus 40 
TBP TATA-box Binding Protein 
TEB Terminal End Bud 
TFBS Transcription Factor Binding Site 
TNF Tumour Necrosis Factor 
url Uniform resource locater 
VEGF Vascular endothelial growth factor 
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CHAPTER 1: INTRODUCTION 
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Changes in the abundance and activity of specific transcription factors are fundamental 
to faithful execution of the processes control growth and differentiation in the life of an 
organism. Of further interest and greater clinical importance is their involvement in 
growth related diseases such as cancer. Research presented herein will focus upon the 
AP-2 family of transcription factors and their involvement in a disease that causes the 
premature death of more than 14,000 women a year in the UK, breast cancer. 
1.1. The AP-2 family of transcription factors 
Activator protein-2 (AP-2) is the term given to a family of five related DNA-binding 
transcription factors: AP-2a, AP-2ß, AP-2y, AP-28 and AP-2c (Williams et al., 1988; 
Moser et al., 1995; Bosher et al., 1995; Zhao et al., 2001; Feng et al., 2003). These 
closely related mammalian family members are transcribed from different genes and 
each has a molecular weight of approximately 50kDa. A generalised protein structure is 
outlined in Figure 1.1. 
NH2 
NH2 
COOH 
COOH 
Figure 1.1. A representation of AP-2 protein structure. AP-2 proteins share highly conserved C- 
terminal basic DNA binding and helix-span-helix dimerisation domains. The less conserved proline rich 
transactivation domain is located toward the N-terminus. Detailed amino acid sequence alignments are 
shown in Figurel. 2. 
All AP-2 proteins can homo- and hetero- dimerise through a unique C-terminal helix- 
span-helix motif and bind DNA through a basic domain that lies immediately N- 
terminal of the dimerisation motif (Mohibullah et al., 1999). A third less conserved 
region toward the N-terminus contains residues critical for modulation of AP-2 activity. 
The remarkable degree of amino acid conservation across these regions is shown for the 
human AP-2 family members in Figure 1.2. Very high amino acid sequence 
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conservation is observed across the DNA binding and dimerisation regions; it is 
therefore unsurprising that, with the exception of AP-28, family members show 
identical DNA binding specificity in vitro (McPherson & Weigel, 1999). AP-28 
contains three amino acid changes in its basic domain that are thought to cause an 
altered binding specificity (Zhao et al., 2001). The other AP-2 proteins have been 
shown in vitro to bind the consensus sequence palindrome 5'-GCCN3.4GGC-3' 
(Mohibullah et al., 1999). PCR-assisted binding site selection and competitive gel shift 
assays for AP-2a and AP-2y have refined this consensus and these family members 
showed optimal binding to the 5'-SCCNNVRGB-3' sequence (McPherson & Weigel, 
1999). 
AP-2 consensus sequences exist in promoters and enhancers of AP-2 target genes and in 
vitro studies have shown that these sequences are important for AP-2 transactivation 
and some examples include SV40 5'-CCCCAGGC-3' (Mitchell et al., 1987), ERBB2 
5'- CTGCAGG-3', ERBB3 5'-GCCTCTGGC-3' (Skinner & Hurst, 1993), and Bcl-2 5'- 
CTCTCCCCGC-3' (Wajapeyee et al., 2006). However, due to its GC-rich nature the 
AP-2 consensus sequence occurs very frequently in the human genome especially 
within promoter sequences (Bajic et al., 2004), it is likely therefore, that constraints 
other than DNA sequence alone must regulate AP-2 DNA binding specificity. 
AP-2 family members are remarkably conserved throughout evolution, homologues 
exist in Chicken (Gallus gallus), Frog (Xenopus laevis), Fruit Fly (Drosophila 
melanogaster), Zebrafish (Danio rerio) and even in the invertebrate Caenorhabditis 
elegans (Shen et al., 1997; Winning et al., 1991; Bauer et al., 1998; Monge & Mitchell, 
1998; Knight et al., 2003). A phyloge e is analysis, conducted by Eckert and 
colleagues, summarising the amino acid conservation of family members across these 
species is shown in Figure 1.3 (Eckert et al., 2005). In particular, the DNA-binding and 
dimerisation requirements of AP-2 proteins have been evolutionarily conserved. Within 
this region Drosophila melanogaster AP-2 contains a stretch of 107 amino showing 
92% identity with the vertebrate AP-2 proteins (Bauer et al., 1998). Given that no AP-2 
family members have been found in yeast, and that the AP-2 proteins of C. elegans and 
D. melanogaster show the weakest relationship with the vertebrate and protochordate 
AP-2 family members (Figure 1.3), it has been suggested that AP-2 proteins originated 
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at this stage in evolution and subsequently expanded to give the five members known in 
higher species (Eckert et al., 2005). In both human and mouse the genes are spatially 
located in a similar pattern on their respective chromosomes, shown in Table 1.1. 
AP-2a AP-2ß AP-27 AP-28 AP-2c 
TFAP2A TFAP2B TFAP2C TFAP2D TFAP2E 
Human 
6p24 6p12 20g13.2 6p12 1p34.3 
tfap2a tfap2b tfap2c tfap2d tfap2e 
Mouse 
13A5-B 1 1 A2-4 2H3-4 1 A2-4 4D2-2 
Table 1.1 Gene Names and chromosomal locations of each of the AP-2 family members in human 
and mouse. Table adapted from Feng & Williams, 2003. 
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H. sapiens AP-28 
8 
M. musculusAP-2S 100 
D9 R. norvegicus AP-28' 
D. melanogasterAP-2 
C. elegans AP-2 F28C6.2 
C. elegans AP-2 F28C6.1 
Figure 1.3. A phylogenetic tree of the AP-2 family (Adapted from Eckert et al., 2(05). This 
phylogenetic analysis was based on amino acid sequence alignments. A scale bar indicates the number of 
amino acid residue changes and asterisks indicate where predicted proteins have been included. 
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1.2. AP-2 and Gene Transcription 
As described in the section above, AP-2 transcription factors can bind specific DNA 
sequences within promoter or enhancer regions of their target genes through their highly 
conserved basic domains. However, until relatively recently it was unclear how AP-2 
factors were able to regulate gene transcription. 
1.2.1. Mechanisms of Gene Transcription 
In eukaryotes, genomic DNA exists as highly compacted repeating nucleosome arrays 
called chromatin. Each nucleosome is comprised of 147bp stretches of DNA wrapped 
around an octamer of the four basic histone proteins (H2A, H2B, H3 and H4). The 
linker histone (H1) and other non-histone proteins bind between nucleosomes and 
facilitate the higher organisation and further compaction of the chromatin fibre within 
the nucleus. The packaging of the DNA in this manner results in a stable chromatin 
state, where DNA is inaccessible to the transcriptional machinery. Thus, it has become 
apparent that chromatin structure forms the physiological substrate for all DNA 
dependent pathways and not just the DNA sequence itself. Chromatin has been shown 
to affect transcription through multiple mechanisms including: histone modification, 
chromatin remodelling, histone variant incorporation . and 
histone eviction (reviewed by 
the following: Li et al., 2007; Kouzarides, 2007; Bernstein et at., 2007). 
1.2.1.1. Histone modifications 
The majority of histone modifications occur in the N-terminal tail domains which 
protrude from the nucleosome surface where modifications at approximately 60 
different residues have been described to date. Some of the better understood include 
the acetylation (ac) and methylation (me) of lysine (K) residues. Acetylation of lysines 
on H3 and H4, facilitated by histone acetyltransferase (HAT) enzymes, is commonly 
associated with chromatin in the process of active transcription. Acetylation occurs on 
multiple lysines and is thought to act cumulatively to alter the net electrostatic charge of 
histones, through the neutralisation of the positive lysine charges. A consequence of 
this is a destabilisation of histone-DNA interactions and an increased propensity of 
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histones to be displaced by chromatin remodelling enzymes (described below), thus 
making the DNA more accessible for transcription. Histone deacetylatases (HDACs) 
can reverse this process and their activity is therefore often associated with 
transcriptional repression. 
Histone modifications can also recruit specific non-histone proteins to chromatin. For 
example, Heterochromatin Protein 1 (HP1) is specifically recruited to methylated 
H3K9, via its chromodomain. HP1 binding is associated with de cee activity 
leading to transcriptional repression. HP1 binding also facilitates further H3K9 
met ly ting activity and is thought to transmit H3K9me to adjacent nucleosomes and in 
ý t4COL4( this way is s ýIphect in the establishment and maintenance of a global heterochromatin 
environment (reviewed by Grewal & Jia, 2007). 
1.2.1.2. Chromatin remodelling 
In vitro studies have shown that nucleosomes exist in equilibrium between a fully 
wrapped state and a set of partially unwrapped states. The propensity of nucleosomes to 
rewrap is negatively regulated by ATP-dependant chromatin remodelling complexes, 
which actively alter the histone-DNA contacts. This activity is also necessary for 
displacement (or sliding) of nucleosomes away from conformationally stable positions 
on the DNA. 
1.2.1.3. Transcription factor recruitment and Pre Initiation Complex 
(PIC) Assembly. 
It is generally thought that spontaneous unwrapping of nucleosomal associated DNA is 
sufficient to reveal buried DNA consensus-binding sequences required for the 
recruitment of specific transcription factors like AP-2. Histone modifications like those 
discussed above affect the inclination of a nucleosome to remodel and thus specific 
transcription factors may only be able to access their DNA consensus binding sites 
given an appropriate chromatin context. Indeed, recently a genome-wide study showed 
that high levels of acH3 and H3K4/79me were prerequisite for recognition of any target 
site by the Myc transcription factor (Guccione et al., 2006). Additional genome-wide 
studies in yeast have shown that nucleosome density at promoter regions is typically 
lower than that at adjacent coding regions (reviewed by Li et al., 2007). This would 
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suggest that DNA consensus binding sequences within promoter regions are more 
amenable to specific transcription factors. Conversely, increased nucleosome density 
outside of promoter regions might serve to mask spurious recognition sequences that 
occur coincidently in large genomes. 
Once bound to a promoter or enhancer, sequence specific transcription factors have 
been suggested to stimulate transcription via multiple mechanisms. Firstly, this might 
involve recruitment of coactivator complexes that include the HAT and chromatin 
remodelling activities described above. These facilitate the further binding of specific 
transcription factors but also act to adjust chromatin structure sufficiently to 
accommodate the recruitment and positioning of the PIC. Given a favourable chromatin 
environment, a second mechanism might' involve transcription factors directly 
interacting with components 
ptsactivity 
PIC stimulating its positioning within the core 
promoter or indeed stimulatinonce positioned. 
1.2.2. Mechanisms for transcriptional regulation by AP -2 family 
members 
1.2.2.1 AP-2, CITED and CBP/p300 
AP-2 proteins were generally considered to be weak activators of transcription when 
analysed in reporter gene assays. However, it is now known that AP-2 proteins can be 
co-activated by the recruitment of the p300 and CREB-binding protein (CBP) to their 
target gene promoter and that this recruitment is mediated by the CITED (CBP/p300 
interacting transactivators with ED-rich termini), family of proteins (Bamforth et al., 
2001; Braganca et al., 2002; Braganca et al., 2003). 
CBP and p300 are two homologous proteins that were first identified through their 
ability to activate gene transcription (reviewed in Chan & La Thangue, 2001; 
Kalkhoven, 2004). Subsequent studies have shown that this activity is dep dant n the 
coactivation of a wide variety of gene specific transcription factors, inclu ing AP-2 
family members. CBP and p300 have been shown to interact with gene specific 
transcription factors, which then guide them to their target genes. Transcriptional 
activation by CBP. and p300, involves multiple domains of these proteins (shown for 
23 
p300 in Figure 1.4). Once the target gene has been accessed the intrinsic HAT activity 
is required for the acetylation of target lysine residues on the histone tails. Within the 
region required for p300 HAT activity, two functionally important domains have been 
characterised. A PHD type zinc finger (CH2) is important for HAT activity whilst the 
preceding bromodomain (B) has been shown to tether p300 to chromatin through 
binding to acetylated lysines, which is thought to stabilise its interaction with 
chromatin. In addition to histones, CBP/p300 can also acetylate other non-histone 
chromatin associated proteins, including transcription factors. Interestingly, auto- 
acetylation has been shown to be important in controlling p300 activity. The basal 
catalytic activity of p300 was shown to be stimulated by autoacetylation of several key 
lysine sites within an activation loop motif (Thompson et al., 2004). In addition to this 
activity, recent work has shown that the autoacetylation activity of p300 is required for 
ordered PIC assembly. It was shown that TFIID and p300 compete for binding to 
Mediator (a general coactivator complex) at promoters, with p300 autoacetylation 
tipping the balance in favour of TFIID (reviewed by Pugh, 2006). TFIID is a general 
transcription factor which, in cooperation with Mediator directs rapid and efficient PIC 
assembly. Both CBP and p300 have the ability to bind TBP and TFIIB and/or form a 
complex with RNA pol II, through N- and C-Terminal activation domains (reviewed in 
Kalkhoven 2004). In summary, it has been suggested that CBP and p300 form a bridge 
between gene specific transcription factors and the general transcription machinery. 
Their intrinsic HAT activity is important for establishing a favourable chromatin 
environment for both specific and general transcription machinery, indeed p300 can 
interact with components of this machinery and this interaction is important for the 
subsequent ordered assembly of the PIC. 
The majority of DNA binding transcription factors that bind CBP/p300 do so by direct 
interaction. AP-2 factors however need an adapter protein, CITED. AP-2 transcription 
factors were first linked to CITED proteins after the observation that the embryonic 
lethal phenotype of CITED2 knockout mice displayed cardiac malformation and neural 
crest defects remarkably similar to those seen in AP-2a null mice (described below) and 
indeed those seen in the human condition Rubinstein-Taybi syndrome caused by CBP 
mutations (Bamforth et al., 2001). In parallel, a Far-Western screen identified CITED2 
as an interacting partner for AP-2a, AP-20 and AP-2y (Bamforth, et al. 2001). In order 
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to determine the functional significance of the CITED2/AP-2 interaction, the reporter 
activity of an AP-2 depe an reporter construct (p3XAP2-Bluc) was compared in 
Cited2+1+ or Cited24- mouse embryonic fibroblast cells following transfection of AP- 
2a, AP-20 or AP-2y. A considerable decrease in reporter activity was observed in the 
CITED2 null cells and this decrease could not be rescued by increasing level 
1P-2 
family member expression. However, expression of exogenous CITED2 was ale to 
restore the activating potential of AP-2 (Bamforth, et al. 2001). Subsequent work has 
shown that CITED4 can also potei e the activation of AP-2 reporter constructs 
(Braganca et al., 2002; Braganca et al., 2003). These studies suggested that CITED 
proteins might act as adapter proteins bringing CBP/p300 to AP-2 factors and thus 
allowing co-activation of AP-2 target genes. Indeed all three proteins were 
immunoprecipitated together from U2-OS cells, indicating that they interact with each 
other in vivo. The nature of the AP-2, CITED and CBP/p300 interaction has been 
further characterised to understand how these proteins interact to mediate transcription 
activation and is summarised in Figure 1.4 (Braganca et al., 2003). 
Recent Chromatin Immuno Precipitation (ChIP) experiments in our lab, conducted by 
Karsten Friedrich, have shown that ERBB2 transcriptional activation by endogenous 
AP-2y is accompanied by an increase in AP-2y occupancy of the ERBB2 enhancer 
region and concurrently, an increase in o1h6o ancy of the AP-2 associated transcriptional 
machinery: CITED2 and CBP/p300. 'gis data suggest] that AP-2? can also recruit 
these factors in vivo (Helen Hurst, personal communication). 
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Figure 1.4. Interactions between AP-2, CITED and CBP/p300 (from Braganca et al., 2003). The 
interactions between AP-2, CITED and CBP/p300 are have been determined using co- 
immunoprecipitation and yeast two-hybrid techniques (Bamforth et al., 2001; Braganca et al., 2002; 
Braganca et al., 2003). CoIP experiments have demonstrated that AP-2 family members, CITED2 and 
p300 can interact physically in vivo. This interaction required the presence of the CR2 domain of 
CITED2 and an intact binding site on p300 for CITED proteins (the CHI domain). CITED2 interacts with 
the residues contained within the first dimerisation helix of AP-2a and AP-2y (DIM). AP-2a was also 
shown to interact with p300 independently of CITED2, via the N-terminal residues that make up its 
activation domain. Therefore, it was suggested that that CITED proteins act as a bridge between AP-2 
family members and p300 permitting their proximity and thus allowing them to interact via the N- 
terminal domain of AP-2. Evidence suggests that some of the AP-2/p300 interaction may be direct, 
although the N terminus of AP-2 has also been shown to recruit other co-activators and these could also 
be important for this interaction. Finally a HAT deficient p300 mutant (D1399Y) was unable to activate 
full length AP-2 mediated transcription despite being able to interact with CITED2 suggesting that this 
activity is necessary for AP-2 transcriptional activation. 
Protein domains are labelled as follows: 
p300: CHI-3, Cysteine- Histidine-rich 1-3; B, Bromodomain; Q-Rich, Glutamine-rich. 
AP-2: AD, Activation Domain; DBD, DNA Binding Domain; DIM, Dimerisation Domain. 
CITED: CRI-3, Conserved Region 1-3. 
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Several other proteins have been reported to interact with AP-2 factors and the more 
intriguing are summarised below. However, many of these are highly abundant proteins 
and the functional significance of their interaction with AP-2 remains to be established. 
The AP-2, CITED, p300 interaction is therefore the only example with a genetically 
verified functional role. 
1.2.2.2 AP-2, PC4 and PARP1 
Work by Kannan and Tainsky has identified two further potential transcriptional 
cofactors of AP-2 using a GST-AP-2 fusion protein to identify AP-2a interacting 
proteins in human teratocarcinoma cells (Kannan & Tainsky, 1999). One of these PC4 
was shown to interact with the N-terminal domain of AP-2 in yeast two hybrid assays 
and increase transcriptional activation in luciferase reporter assays. The second AP-2 
interacting protein identified in this study was poly-ADP-ribose polymerase 1 or PARP- 
1 (Kannan et al., 1999). PARP-1 was shown to interact with the C-terminal domains of 
AP-2a and was also implicated in coactivation of AP-2a in luciferase reporter assays. 
Although this study requires further validation, the interaction of these cofactors with 
AP-2 provides evidence for additional mechanisms that AP-2 family members may 
employ to activate transcription. PC4 is thought to promote transcription through direct 
interactions with components of the general transcription machinery (Fukuda et al., 
2004), whereas PARP-1 plays multiple and diverse roles in transcription, including the 
ADP-ribosylation of core histones and chromatin associated proteins, which acts to 
promote chromatin decondensation and nucleosome dissociation (Reviewed in 
Schreiber et al., 2006). 
1.2.2.3 AP-2 and GAS41 
A recent study has identified a physical and functional interaction of AP-20 with an 
additional known transcriptional coactivator, GAS41 (also known as YEATS4) (Ding et 
al., 2006). An in vivo interaction was demonstrated by their coimmunoprecipition in 
HeLa cells and GST pull downs showed that the C terminal portion, encompassing the 
DNA binding and dimerisation domains of AP-20, was required for this interaction in 
vitro. Although the functional significance of this interaction requires further 
elaboration, in cotransfection experiments GAS41 acted to enhance transcriptional 
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activation by AP-2(3 in reporter gene assays (Ding et al., 2006). Interestingly, 
GAS41 
has been shown to interact with INI1 a component of the human SWI/SNF chromatin 
remodelling complex (Debernardi et al., 2002), suggesting that via GAS41, AP-2ß 
could function by recruiting these complexes to enhance gene transcription. 
1.2.2.4 AP-2 and SUMO modification 
As well as activating gene transcription, AP-2 family members have also been reported 
to act as/repressors of transcriptions notably AP-2a represses EGFR expression during 
epidermal differentiation in mice (Wang et al., 2006) and AP-2a represses 
transcriptional of Bcl-2 in colon carcinoma cells (Wajapeyee et al., 2006). 
It is thought that the conjugation of the small ubiquitin-like modifier, SUMO to AP-2 
proteins might lead to such modification of transcriptional activity. Indeed the AP-2a, 
AP-2ß and AP-2y family members have been shown to be modified by SUMO 
polypeptides. Work in our lab has shown that AP-2a, AP-P and AP-2y can interact 
with the E2 SUMO conjugating enzyme UBC9. This interaction results in SUMO 
conjugation at the conserved lysine residue (lys 10) in the N-terminal region of AP-2, 
and was shown to reduce the ability of AP-2 to activate transcription when analysed in 
reporter gene assays (Eloranta et al., 2002). This lysine is part of a SUMO modification 
motif cpKXE (where (p is any hydrophobic amino acid), conserved between AP-2a, AP- 
20 and AP-2y (shown in Figure 1.2. ). The transcriptional mechanism of this effect is at 
present uncertain but SUMO modification of other transcription factors is known to 
modulate their function. In particular, SUMO modification of CBP and p300 allows 
them to recruit histone deacetylases which lead to transcriptional repression (Girdwood, 
et al. 2003). Whilst sumolation reduces the activating potential of AP-2, there are no 
reports that this modification alters the function of AP-2 to a transcriptional repressor, 
such that it recruits known co-repressors or repression complexes. 
1.2.2.5 AP-2 and WW domain containing proteins 
Another mechanism of regulating the transcriptional potential of AP-2 family members 
is thought to be through the interaction with WW domain containing proteins. With the 
exception of AP-25, AP-2 family members possess the highly conserved PY (XPPXY) 
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motif required for such interactions, these residues are marked by a dotted underline in 
Figure 1.2. Mutation of the PY motif from FPPPY to FAPPY reduced the 
transactivating potential of AP-2a by approximately 35% (Wankhade et at. 2000). 
Early work showed that the WW domain containing YES associated protein (YAP) was 
able to interact with peptides corresponding to the PY motif of AP-2a (Yagi et al., 
1999). More recently, the WW domain containing protein Wwox was shown to directly 
interact with AP2y via the highly conserved PY motif. Interestingly, cotransfection of 
AP-2y and Wwox reduced the ability of AP-2y to activate transcription in reporter 
assays, and confocal microscopy suggested that the AP-2y-Wwox interaction facilitated 
the redistribution of AP-2y to the cytoplasm limiting its transcriptional potential 
(Aqeilan et al., 2004). However, these experiments involved the over expression of 
tagged AP-2y and WWox in a cell line where both proteins are already expressed 
endogenously at high levels. Therefore the physiological relevance of this interaction 
and the functional consequence of redistribution of AP-2y are difficult to interpret. 
Subsequent work in our laboratory by Amelie Morin, has shown that endogenous AP-2y 
and WWox can interact in breast cancer cell lines, although the functional consequences 
of this interaction still remain unclear. Additionally an interaction was also observed 
for endogenous AP-2y and other WW domain proteins including YAP and ITCH (Helen 
Hurst, personal communication). Although further work is required, YAP and ITCH 
appear to affect the protein stability of AP-2y. YAP promotes AP-2y stability whereas 
ITCH promotes AP-2y degradation. In reporter assays YAP clearly enhances AP-2y 
transactivation and ITCH appears to antagonise the effect of YAP. A role for WWox in 
this fashion was not determined. Interestingly, YAP and ITCH have also been shown to 
effect the stability of the p73 transcription factor. YAP binds p73 on the same epitope as 
ITCH and prevents ITCH mediated ubiquitination (Levy et al, 2007). A similar 
mechanism could be controlling stability of AP-2y. 
1.2.2.6 AP-2 and phosphorylation 
AP-2a has been reported to be phosphorylated both in vitro and in vivo by cAMP- 
dependent protein kinase A (PKA) (Park & Kim 1993; Garcia, et al. 1999) at Ser239. 
Mutation of the Ser239 to Ala abolished phosphorylation of AP-2 by PKA in vitro, 
however, the protein was still able to bind to DNA. Luciferase reporter assays using the 
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APOE promoter, a potential AP-2a target gene in neuroectodermal cells, were utilised 
to look at the effects of phosphorylation of AP-2a on gene activation. HepG2 cells, 
which do not express AP-2a, were co-transfected with the catalytic subunit of PKA and 
either wild type AP-2a or AP-2a S239A. The results showed that phosphorylation of 
AP-2a appreciably enhanced the reporter activity, suggesting that cAMP is able to 
modulate the activity of AP-2a through phosphorylation by PKA, and not through 
increased transcription of the endogenous AP-2a gene (Garcia et al. 1999). The 
significance of these observations to AP-2 function however remains uncertain as these 
data have never been repeated. 
1.2.2.7 AP-2 and other gene specific transcription factors 
As well as the interactions described above, AP-2 has been shown to cooperate or 
antagonise the activity of other sequence specific transcription factors through direct 
protein-protein interactions. These include p53, Myc, and SP1 and are discussed with 
reference to their cellular contexts later in the study. 
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1.3. AP-2 and embryogenesis 
AP-2 family members are widely expressed during vertebrate embryogenesis, showing 
overlapping and distinct patterns of expression. In particular AP-2 proteins are 
expressed in neural crest, neural tube and epidermal structures which all develop from 
the primitive ectoderm during embryogenesis. Table 1.2 summarises the expression of 
AP-2a, AP-2ß and AP-2y family members during early mouse embryogenesis (Mitchell 
et al., 1991; Chazaud et al., 1996; Moser et al., 1997a). In particular, AP-2a, AP-2ß and 
AP-2y are recognised markers of the migratory neural crest and developing neural tube 
in mice. These family members are also co-expressed in the central and peripheral 
nervous systems (derivatives of the neural crest), as well in limb buds, epidermal, facial, 
kidney and placental tissues (Mitchell et al., 1991; Chazaud et al., 1996; Moser et al., 
1997a). Considering the significant homology between these proteins, particularly 
within their DNA binding and dimerisation domains (Figure 1.3) and the remarkable 
degree of overlap in expression patterns, early studies of AP-2 mutants in mice, 
zebrafish, frog and chicken revealed surprisingly little redundancy between family 
members in their overall function. 
1.3.1 AP 2a 
Mice containing homologous gene disruptions of tfap2a die just before birth from 
multiple defects in neural tube and body wall closure, in limb morphogenesis and in the 
development of neural crest-derived tissues of the cranio-facial skeleton, cranial ganglia 
(Schorle et al., 1996, Zhang et al., 1996, Nottoli et al., 1998; Brewer & Williams, 2004; 
Brewer et al., 2004) and the outflow tract of the heart (Brewer et al., 2002). 
Interestingly, early neural crest cell migration appeared largely unaffected (Schorle et 
al., 1996): 
This role is supported by analyses of the lockjaw mutation in Zebrafish. Caused by a 
truncation of the DNA binding domain of AP-2a, lockjaw zebrafish display defects in 
cranio-facial skeleton, pigment cells and peripheral nervous system development, a 
phenotype that could be recapitulated using anti-sense directed to AP-2a (Holzschuh, et 
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Days post coitum Tissue AP-2a AP-2ß AP-2y 
Neural fold +++ +++ +++ 
8 
Trophoectoderm ++ ++ ++ 
Lateral Head Mesenchyme +++ +++* +++* 
Neural Tube + + +++ 
Forebrain - - +++ 
Midbrain +++ +++ - 
Hindbrain ++ ++ - 
9-10 
Dorsal Root Ganglia +++ + - 
Limb Buds - - +++ 
Facial Mesenchyme ++* +++* +* 
Cranial ganglia +++ +++ - 
Epidermis ++ ++ n. d 
Limb Buds ++ - +++ 
Cranial ganglia +++ + - 
Metencephelon ++ ++ - 
Myelencephelon ++ ++ + 
Spinal Cord ++ ++ + 
11-12 
Facial Mesenchyme ++* +++* ++* 
Dorsal Root Ganglia +++ +/- - 
Dental Lamina ++ - - 
Kidney ++ ++ n. d 
Adrenal Medulla - ++ n. d 
Cornea - ++ n. d 
Epidermis +++ +++ ++. 
Table 1.2. Expression patterns of three different AP-2 transcription factors during murine 
embryogenesis. In situ hybridisation was scored on the strength of signal as follows; no signal -, weak 
+/-, +, moderate ++, strong +++, n. d not determined. An asterisk indicates distinct spatial distribution 
within this tissue type. Figure adapted from Chazaud et al. 1996 and Moser et al. 1997a. 
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al. 2003; Knight et al., 2003; Knight et al., 2004; Knight et al., 2005). Similarly to 
mice lacking AP-2a, neural crest cell migration in zebrafish also appeared largely 
unaffected (Knight et al., 2005). 
Ablation of AP-2a during chicken embryogenesis also produced embryos showing 
critical defects in cranio-facial structures and limb bud formation (Shen et al., 1997). 
Supporting this data, AP-2a has been shown to negatively regulate chondrocyte 
differentiation (Hating et al., 2004), a process that occurs in the limb buds of developing 
embryos and is the first step in bone formation. Levels of AP-2a were shown to decline 
during normal chondrocyte differentiation. The forced expression of AP-2a inhibited 
differentiation, via the suppression of key chondrocyte matrix genes including type II 
collagen, aggrecan, and type X collagen and the suppression of transcription factors 
Sox5 and Sox6. The multiple skeletal/cartilage defects found in the AP-2a knockout 
mice are postulated to be a result of premature chondrogenic differentiation in the 
absence of AP-2a regulation. 
Another interesting feature of AP-2a expression with respect to embryonic 
development is the activation of its expression following Retinoic Acid (RA) treatment 
(Löscher et al., 1989; Mitchell et al., 1991; Holzschuh et al., 2003). Congenital 
malformations resulting from aberrant levels of RA show similar phenotypes to those 
described above and it has been suggested that AP-2a may be an integral component of 
the response of an organism to RA signalling (Nottoli et al., 1998; Holzschuh et al., 
2003). 
In an effort to identify potential genes that are controlled by AP-2a during this 
developmental programme a subtractive cloning and differential screening approach 
was conducted to compare expression changes in an tfap2a knockout mouse embryo 
heads compared to embryo heads from a control animal at 8.75 d. p. c. (Pfisterer, et al. 
2002). Although these results require validation and follow up, a set of genes repressed 
by AP-2a were identified with known roles in the inhibition of cellular proliferation, 
activation of differentiation and apoptosis. These included KLF4 (Kruppel-like factor 
4), mEFEMP1 (epidermal growth factor-containing fibulin-like extracellular matrix 
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protein 1), Mtd (matador) and Stra13 (stimulated by retinoic acid 13) (Pfisterer et al. 
2002). 
1.3.2 AP 2ß 
Mice containing homologous gene disruptions of tfap2b displayed fewer gross 
phenotypic defects than those observed in mice lacking tfap2a. Nevertheless, mice 
lacking tfap2b died shortly after birth due to kidney failure (Moser et al., 1997b). In the 
normal developing mouse AP-2a is expressed in proximal tubular kidney epithelial 
cells compared to the distal tubular kidney epithelial cell expression observed for AP- 
20. AP-2a is down regulated after birth while AP-20 expression persists (Moser et al., 
1997a). The study of tfap2b null mice showed that this factor is required only for 
normal adult kidney function. At the end of a largely normal embryonic renal 
development, distal tubular kidney epithelial cells of tfap2b null mice undergo enhanced 
apoptosis preceded by down-regulation of anti-apoptotic genes of the BCL gene family. 
This leads to failure to form vital structures for water retention and homeostasis and 
death of tfap2b null mice after birth. Of direct relevance to this phenotype is recent 
work in human cell lines implicating AP-2a in the direct transcriptional repression of 
BCL2 (Wajapeyee et al., 2006). It is tempting to speculate that BCL2 expression may 
also be influenced by AP-20, perhaps the imbalance of AP-2a with respect to AP-20 
expression may contribute to BCL2 down regulation and to the enhanced apoptotic 
phenotype seen in these mice. 
Mutations of TFAP2B have been implicated in the human condition Char Syndrome 
(Satoda et al., 2000; Zhao et al., 2001). The main characteristics of this condition 
include abnormal heart development and facial dysmorphism. Interestingly they share 
similarities with phenotypes observed following tfap2a ablation in mice (described 
above). This suggests that, rather than producing a non-functional AP-20 protein, these 
mutations are able to modulate the activity of other AP-2 family members, perhaps 
through their capacity to form non-productive heterodimers (so-called dominant 
negative factors). 
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1.3.3 AP 2y 
Generation of mice lacking tfap2c showed it is vital for embryonic survival during early 
post-implantation development (Auman et al., 2002 and Werling & Schorle, 2002). 
AP-2y deficient mice died at 7 to 9 d. p. c. due to failure of the cells derived from 
trophoectoderm (the first specialised cells which arise from the fertilised egg) and the 
ectoplacental cone to proliferate. Failure of the placenta to develop and subsequent 
nutrient deprivation caused the early embryonic lethality (Werling and Schorle, 2002). 
In contrast to AP-2a and AP-2ß, it was suggested that AP-2y does not appear to play an 
autonomous role within the embryo proper (Auman et al., 2002). Chimeras mad form 
tfap2c null ES cells injected in to wild type blastocytes survived beyond birth with no 
obvious defects, although the authors admit a detailed histological analysis was not 
conducted (Auman et al., 2002; Koster et al., 2006). Consistent with these findings AP- 
2y has been reported to positively regulate genes involved in early placental 
development in vitro. These include amongst others: adenosine deaminase, chorionic 
gonadotrophin beta, placental lactogen gene and placental leucine aminopeptidase (Shi 
& Kellens 1998, Jin et al., 2004, Richardson et al., 2000 and Ito et al., 2002). 
1.3.4AP28 andAP2s 
The more recently described, AP-28 and AP-26 genes seem be more temporally and 
spatially restricted in their expression patterns. AP-28 is expressed in the central 
nervous system, retina, and the developing heart (Zhao et al., 2003) wherea<AP-2E is 
expressed in the developing olfactory bulb (Feng & Williams, 2003). Compared to the 
other family members these expression patterns are distinct and non-overlapping. This 
is perhaps reflective of the reduced sequence homology of AP-28 and AP-2E compared 
to the other members. 
1.3.5 Drosophila AP -2 protein 
Expression pattern analysis of the single Drosophila AP-2 protein shows expression in 
discrete regions of neuroectoderm, brain, ventral nerve cord, and maxillary segment 
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during Drosophila embryogenesis. In the third instar larvae, expression is seen in the 
brain, optic lobes, ventral nerve cord, antennal-maxillary complex, and antennal and leg 
imaginal disks (Monge & Mitchell, 1998). This is consistent with the work described 
above and implies that AP-2 has been structurally and functionally conserved during 
metazoan evolution. 
1.3.6 Redundant activities of AP -2 Family Members 
The studies of mutant AP-2 family members described above suggest that there is little 
redundancy in their overall function. However, studies examining mouse and zebrafish 
with mutations in two AP-2 family members provide evidence that at least some 
redundant activity of these proteins is occurring. For example, AP-2a and AP-2y are 
co-expressed in early extra-embryonic placental tissues, but only tfap2c knockout mice 
display placental defects dying at 8.5 d. p. c., whereas tfap2a knockout mice show no 
placental defects and die shortly before birth. Recent work by Winger and colleagues, 
however, highlights their redundant activity by generating mutants knocked out for both 
tfap2c and tfap2a. These mice die at 3.5 d. p. c., even earlier than tfap2c knockout mice, 
demonstrating that a level of genetic redundancy of these factors exists within these 
extra embryonic tissues (Winger et al., 2006). 
An additional example of redundancy has been shown in zebrafish embryos. Despite 
the co-expression of AP-2a and AP-20 in the hindbrain of zebrafish embryos, anti- 
sense directed to AP-2a caused severe craniofacial defects, whereas anti-sense directed 
to AP-20 had no visible effect. However, simultaneous anti-sense directed to AP-2a 
and AP-20 resulted in far more severe defects in craniofacial cartilage than for AP-2a 
alone. Again this suggests a redundant activity of these factors in cranial epidermal 
development (Knight et al., 2005; Li & Cornell, 2007). 
Most recently a redundant activity of AP-2 family members has been shown to be 
important for their role in neural crest induction. Neural crest induction refers to the 
specification of ectoderm cells to the neural crest lineage. Despite AP-2 expression in 
early stages of neural crest induction, the single mutant studies above describe defects 
only in cells derived from the neural crest, with early stages of neural crest cell 
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migration largely unaffected (Schorle et al., 1996; Knight et al., 2005). It is interesting 
therefore that recent work by Li and Cornell showed the failure of neural crest induction 
altogether in zebrafish embryos deficient in both AP-2a and AP-2y, but no induction 
defect in embryos singly deficient in either gene (Li & Cornell, 2007). Additional 
phenotypes observed in the double AP-2a and AP-2y mutants but not single mutants 
included abnormal epidermal, lens, ear, and olfactory placode development and 
highlight further redundant activities for these two proteins. 
Together these three examples suggest AP-2 family members can compensate for each 
other's absence in many contexts during mouse and zebrafish development and when 
considered with single AP-2 mutant phenotypes, suggest that AP-2 family members 
function both separately and in tandem to coordinate the development of ectoderm 
derivatives during embryogenesis. 
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1.4 AP-2 and tissue specific development 
The embryological defects described in tfap2 null mice clearly implicate a role for AP-2 
in the regulation of differentiation and proliferation during embryogenesis. However, 
the severe perinatal defects observed in tfap2 null mice have precluded much of the 
analysis of their involvement in postnatal tissues. Recent studies have revealed an 
important role for AP-2 family members in other ectoderm lineages particularly in the 
self-renewing tissue of mammalian skin epidermis, and differentiating mammary gland 
tissue but also during gonocyte development. 
1.4.1 AP -2 and gonocyte development 
Initial work by Jager and colleagues showed that targeted over expression of AP-2y to 
the testis of male mice resulted in increased cell proliferation counter balanced by 
enhanced apoptosis in the epithelial structures of the seminal vesicles (Jager et al., 
2003). Differentiation was also impaired in these cells marked by the lack of androgen 
receptor expression. A more detailed analysis of AP-2y expression in human seminal 
vesicles revealed high AP-2y levels in immature undifferentiated germ foetal cells 
(Pauls et al 2005), and gradual down regulation of AP-2y was observed with increasing 
differentiation of foetal testis. Authors suggested that AP-2y expression might be 
required for the suppression of differentiation and the promotion of proliferation in 
germ cells (Pauls et al 2005). In support of this role, AP-2y expression is found in germ 
cell tumours which share characteristics with early germ cells (Hoei-Hansen et al., 2004 
and Pauls et al., 2005). 
1.4.2 AP -2 and skin epidermis 
Normal development of skin epidermis is first characterised by a single-layered surface 
ectoderm, which eventually forms the basal regenerating layer in developed skin. 
Subsequent commitment to stratification is dictated largely by the balance of p63 
transcription factor isoforms and results in multiple layers of supra-basal differentiated 
epithelial cells characterised by the expression of specific keratins (reviewed by Koster 
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et al., 2004a). Importantly, AP-2 family members have been implicated in the 
regulation of transcription from keratin promoters in cultured keratinocytes, outlining a 
role for these factors in differentiated cells of the skin (Leask et al., 1991; Magnaldo et 
al., 1993; Wanner et al., 1997; Chen et al., 1997; Dunn et al., 1998; Talbot et al., 1999; 
Maytin et al., 1999; Kaufman et al., 2002). Furthermore, frog embryos show a loss of 
epidermal character following injection of AP-2a anti-sense oligonucleotides (Luo et 
al., 2002). Recent work by Wang and colleagues has shown that, with the exception of 
AP-25, expression of all the AP-2 family members was observed in normal mouse skin 
epidermis. In particular, AP-2a was expressed at high levels in the supra-basal nuclei 
and to a lesser extent in the basal nuclei of skin epidermis, whereas high levels of AP-2y 
were restricted to basal nuclei (Wang et al., 2006). 
A conditional tfap2a null mouse, targeting AP-2a ablation to the skin epidermis 
resulted in hyperproliferation of the suprabasal cells caused in part by an increase in 
EGFR expression (Wang et al., 2006). The effect of AP-2a ablation was less dramatic 
in the basal cells of the epidermis where high levels of AP-2y were present, suggesting 
AP-2a independent mechanisms control proliferation in these cells. EGFR promoter 
occupancy by AP-2a in wildtype cultured primary keratinocytes but not keratinocytes 
null for AP-2a, suggested that AP-2a functions in the epidermis by repressing EGFR 
gene transcription as cells exit the basal layer and commit to terminal differentiation. 
In parallel to these findings for AP-2a, two recent studies have identified a role for AP- 
2y in earlier, p63-depencýia t events of epidermal morphogenesis. Studies in p63 null 
mice have shown that the transactivating (TA) isoforms of p63 are required for the 
commitment to initiate epithelial stratification in surface ectoderm (Koster et al., 2004a; 
Koster et al., 2004b). Subsequent work by Koster and colleagues showed, by 
Chromatin IP, that transcriptional activation of AP-2y by TAp63 was fundamental to 
this process (Koster et al., 2006). In the absence of AP-2y, TAp63 failed to induce 
Keratin 14 gene transcription, highlighting a role for AP-2y in the transcription of this 
early epidermal marker (Koster et al., 2006). As epidermis differentiates, the levels of 
AN p63 isoforms (forms without transactivation domains that act to inhibit transcription 
activation), increase with respect to TAp63 isoforms. This p63 isoform balance has 
been suggested to be important for commitment to terminal differentiation in epidermis 
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(Koster et al., 2004a). ONp63 was shown to inhibit AP-2y transcriptional activation, in 
a concentration dependent manner and this may be important for the loss of AP-2y 
expression observed in differentiated supra-basal cells of the epidermis (Koster et al., 
2006). A further level of complication has been revealed by the fact that AP-2 family 
members together with p63 are important in the maintenance of transcription from the 
p63 promoter, via an epidermis specific distal enhancer region (Antonini et al., 2006). 
Together these two studies suggest the presence of a possible control loop between AP- 
2 family members and p63. Based on these findings a role for AP-2 factors in 
epidermis is suggested in Figure 1.5. 
In summary AP-2a is important for the control of signalling and proliferation in 
differentiating supra-basal cells of the skin epidermis. Although the function of AP-2y 
requires further elaboration, its carefully controlled and restricted basal expression 
suggests it may be of some importance in the aetiology of the basal cell type. 
1.4.3 AP -2 and mammary morphogenesis. 
Two major tissue types constitute the mammary gland. Firstly, the stroma, which 
predom ately consists of adipocytes but also contains fibroblasts, vasculature and 
aemoatopo eic cells. The second compartment is the mammary epithelium, which 
forms the milk producing alveoli and associated ducts for milk transport. Following the 
initial embryonic stages of development these tissues undergo a sequence of hormonally 
controlled developmental stages termed puberty, pregnancy, lactation and regression or 
involution (Reviewed by Hennighausen & Robinson, 2001, Robinson, 2004 and 
Hennighausen & Robinson, 2005). These stages are summarised in Figure 1.6. The 
binding of ligands such as EGF, TGFcc and Amphiregulin to members of the epidermal 
growth factor receptor family (EGFR, ErbB2 and ErbB3), activates EGFR endogenous 
tyrosine kinase activity and further stimulates growth and branching of the epithelium in 
the virgin and pregnant mouse mammary gland (Sternlicht et al., 2006). 
AP-2 family members were first implicated in the control of growth and differentiation 
of cells of the mammary gland through early studies showing the association of AP-2a 
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Figure 1.5. A proposed role for AP-2 and p63 in the differentiation of skin epidermis. First 
expression of TA isoforms of p63 initiate the differentiation of the surface ectoderm and up-regulate AP- 
2y. AP-2y and p63 can then act together to maintain p63 transcription and thus commit the surface 
ectoderm to differentiate. As differentiation progresses the ratio of ANp63 isoforms increases with 
respect to TAp63 isoforms, perhaps inhibiting AP-2y and TAp63 expression and committing cells to 
terminally differentiate. An accompanying increase in AP-2a expression acts to repress EGFR 
expression and prevents proliferation in these differentiating cells. The time line of p63 expression was 
adapted from Koster et al., 2006 (E8.5 and E15.5 are d. p. c. and PO corresponds to birth). 
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Figure 1.6. Mammary gland development during embryogenesis, puberty, pregnancy, lactation and 
regression. Embryogenesis: The first stage of mammary development (reviewed by Robinson, 2004) 
occurs in the embryo where a small placode in the ectoderm develops into a bud. At the base of the bud, 
rapid epithelial proliferation leads to formation of an elongated single duct that grows towards a fat pad. 
Finally, mesenchyme derived structures form the nipple. Puberty: During puberty cyclical production 
of ovarian oestrogen and progesterone accelerate epithelial duct outgrowth. Terminal end buds (TEB), 
consisting of an outer layer of cap cell (myoepithelial progenitors) and an inner layer of body cells 
(luminal progenitors) are rapidly cycling and facilitate ductal outgrowth. In the mature gland ductal side 
branches form and disappear with each oestrogen cycle. Pregnancy: At pregnancy placental lactogens, 
prolactin, and progesterone stimulate cell proliferation, alveolar bud (AB) formation and alveolar 
expansion. Lactation: During lactation luminal cells of mature alveoli synthesise milk (characterised by 
the expression of milk genes and milk fat production), which is transported through the ducts to the nipple 
for feeding. Regression or Involution: Upon cessation of feeding, apoptosis occurs in the secretory 
epithelium and the surround stroma is remodelled to replace apoptosed cells. Finally, a cyclical 
production of ovarian oestrogen and progesterone returns. This diagram is based on information 
reviewed by Hennighausen and Robinson (Hennighausen & Robinson, 2001; Hennighausen & Robinson, 
2005). 
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and AP-2y expression with breast carcinoma (discussed in detail in Section 1.5, Bosher 
et al., 1995; Turner et al., 1998). Subsequent work by Zhang and colleagues, displayed 
in Figure 1.7 A, has shown that AP-2a, AP-2ß and AP-2y share similar temporal 
expression patterns during mouse mammary gland morphogenesis (Zhang et al., 2003). 
Furthermore, immunohistochemical analysis has shown that the expression of AP-2a 
and AP-2y is restricted to the epithelial compartment of the mouse mammary gland. In 
the developing structures of the terminal end buds during puberty, AP-2y showed the 
strongest staining in the highly proliferative outer layer of cap cells and additional AP- 
2y staining was observed in discrete cells within the area containing body cells. A 
reciprocal pattern was observed for AP-2a, with the strongest staining in all of the body 
cells and a weaker, sparser pattern of staining in the outer layer of cap cells (Zhang et 
al., 2003). Consistent with this pattern, Zhang and colleagues observed strong AP-2y 
staining in myoepithelial cells (cap cell derivatives) and some weaker staining in 
luminal cells (body cell derivatives) of mature virgin mouse mammary ducts. In 
contrast, AP-2a was seen in both cell types. A similar pattern of expression was also 
seen in the alveolar tissue of pregnant mice (Zhang et al., 2003). 
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Subsequent studies looking at AP-2a and AP-2y staining mature Lin human mammary 
ducts tend to support the findings in mouse. In particular, work from our lab (shown in 
Figure 1.7 B) and others shows strong myoepithelial AP-2y staining with additional 
weaker luminal staining (Hurst, personal communication and Hoei-Hansen et al., 2004). 
However, work by redrichs and colleagues showed more restricted staining: AP-2a 
stained only the luminal cells of mature human mammary ducts while AP-2y staining 
was present only in discrete cells within the myoepithelial layer (Friedrichs et al 2005). 
All of these studies demonstrated the AP-2 family member specificity of the antibodies 
used for immunohistochemistry. Therefore, the slight differences between the data from 
redrichs and colleagues compared to others might reflect a difference in antibody 
avidity. 
Unfortunately, gene knockout studies, in mice described in the previous sections could 
not provide a direct analysis of the role of AP-2 factors in breast development, due to 
the perinatal death caused by the severe embryological phenotypes. However, separate 
transgenic mouse studies targeted AP-2a or AP-2y over expression to the mouse 
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Figure 1.7. Expression of AP-2 family members in the mammary gland. (A) Figure from Zhang el 
al., 2003. An RNase protection analysis of AP-2 family members during various stages of mouse 
mammary gland maturation (as indicated V, virgin; Preg, pregnant; Lact, lactation; Reg, regression or 
involution). (B) Immunohistochemical analyses of AP-2y protein levels in transverse sections of normal 
adult human mammary tissue. Inset: Enlargement of a single duct shows strong staining of AP-2y in 
myoepithilial cells (arrow head) of the outer (basal) layer. A weaker staining in some of the luminal 
epithelial cells (arrow), the inner layer of the duct lining is also observed. Staining is absent from the 
surrounding stroma. (Helen Hurst, personal communication). 
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mammary gland, using a transgene under the control of the long terminal repeat of the 
mouse mammary tumour virus (Zhang et al., 2003; Jäger et al., 2003). 
In AP-2a over expressing mice, the initial embryonic stages of development were 
unaffected and during puberty the outgrowth and branching of ducts, which occurs in 
response to oestrogen (See Figure 1.6), appeared normal (Zhang et al., 2003). 
However, the ductal network of AP-2a over expressing pregnant mice was slightly 
sparser and with fewer alveolar buds. Alveolar bud development was also impaired. 
The buds failed to undergo expansion and showed abnormal morphology. Despite these 
abnormalities these mice were able to produce milk and to nurse their young, indicating 
that the differentiation required for lactation occurs in the presence of AP-2a over 
expression. A closer examination revealed a significant decrease in the number of 
proliferating cells of the AP-2a over expressing transgenic epithelial tissue during 
pregnancy, coupled with an increase in apoptosis (Zhang et al., 2003). This implies that 
loss or reduction of AP-2a expression in alveolar bud development is required for 
proliferation of these structures during normal pregnancy, despite some level of AP-2a 
expression being maintained until the end of pregnancy (Figure 1.4). 
Interestingly, a similar study targeting AP-2y over expression to the mammary gland 
revealed different results (Jäger et al., 2003). Similar to AP-2a over expression in 
mice, the embryonic and puberty stages of development were unaffected. But 
contrastingly, in AP-2y over expressing pregnant mice, the ductal network and number 
of alveolar buds appeared similar to those of wild type mice. However, at later stages of 
pregnancy, these alveolar buds failed to develop into mature alveoli in AP-2y over 
expressing mice and these mice were unable to nurse their young. A closer examination 
revealed that impaired alveolar development was due to hyperproliferation of cells 
within these structures, counterbalanced by enhanced apoptosis. Analysis of 
differentiation markers (Whey Acidic Protein and 0-casein) showed that the forced 
expression of AP-2y prevented these cells form terminally differentiating. This implies 
that loss or reduction of AP-2y expression in later stages of alveolar bud development is 
required for cessation of proliferation and for terminal differentiation. 
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In summary, these studies emphasise the apparent opposite effects of the two family 
members on cell proliferation in the mammary gland. Forced AP-2a expression inhibits 
epidermal proliferation in developing alveolar buds whereas forced AP-2y expression 
appears to promote proliferation in the same structures. Based on these observations, it 
is reasonable to consider AP-2 family members may also play a role in the balance of 
proliferation and differentiation of TEBs, developing structures in which they are also 
expressed. Indeed, recent unpublished work by Hubert Schorle and colleagues 
examining the phenotype of targeted ablation of AP-2y to mammary epithelial tissue 
supports this hypothesis (Helen Hurst, personal communication). In tfap2c null 
mammary glands a severe impairment in ductal elongation was observed during puberty 
despite the presence of TEB structures. 
It is important to stress that despite the hyperproliferative effect observed in AP-2y over 
expressing mice, no mammary tumourigenesis was observed, but the observed epithelial 
hyperplasia is thought to be a typical initiating event in breast tumourigenesis 
(Beckmann et al., 1997). The authors postulated that overcoming the pro-apoptotic 
mechanisms in these cells, a common occurrence during tumourigenesis (section 1.4), 
might permit tumours to form in these animals. 
Indeed both AP-2a and AP-2y have been implicated in tumourigenesis and their 
proposed roles in human cancers reflect their apparently opposing roles in post- 
embryonic mammalian development. AP-2a expression suppresses proliferation and 
promotes differentiation and therefore is often lost in cancer. Contrastingly, AP-2y 
expression has often been found in tumours, and although further research is necessary, 
evidence suggests AP-2y might be driving proliferation and suppressing differentiation 
in these tumours. Before the association of AP-2 and cancer is discussed, I will first 
provide a brief introduction into the common mechanisms that are thought to promote 
carcinogenesis in humans. Particular attention is placed on the regulation of cell 
proliferation in which AP-2 factors have been suggested to play a role. 
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1.5 Human Cancer 
The evolution of cancer is a considerably complex process, since specific interactions 
between tumour cells and host tissues are necessary for tumour angiogenesis, tissue 
invasion, and metastasis. Yet, despite the existence of many forms of cancer it has been 
suggested that relatively few essential alterations are common to most if not all 
tumours, shown in Figure 1.8 (reviewed by Hanahan & Weinberg, 2000). 
Figure 1.8 The Hallmarks of Cancer (from Hanahan & Weinberg 2000). Hanahan and Weinberg 
have suggested that all human cancers are a symptom of six essential alterations in cell physiology that 
collectively dictate tumour progression. 
Over expression or inappropriate activation of growth promoting signals, by so-called 
oncogenes is significant in promoting a cancerous state. Cell surface receptors that 
normally relay extra cellular growth stimulatory signals into the cell are oncogenic 
targets for deregulation in cancer. For example, receptor over expression, such as 
occurs for ErbB2 in mammary carcinomas (Slamon et al., 1998) enable a cancer cell to 
become over-responsive to ambient levels of growth factor that might not normally 
trigger cell proliferation. Equally, mutations in growth factors receptors can alter them 
to become constitutively activated in the absence of ligands. 
A second important event is insensitivity to anti-growth signals. Within a normal 
developed tissue the potential of a cell to proliferate is held in check by the absence of 
growth signals, via soluble growth inhibitors or inhibitors present on the surfaces of 
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contacting cells and in the extra cellular matrix. Cells can be held in a quiescent state 
and are prevented from cell cycle entr _cýr they can undergo terminal 
differentiation into 
as state where they permanentl , loose t ere ' otential to proliferate. Most of the 
machinery that facilitates a response to ant tröwth signals in a normal cell is associated 
with the mitotic cell cycle; in particular these pathways tend to converge on transition 
from G1 phase to S phase (shown in Figure 1.9. ). Disruption of this pathway can render 
cells insensitive to anti-growth signals that normally operate at this checkpoint and thus 
unleash the activity of E2F transcription factors and allow inappropriate cell 
proliferation. Mutations in the INK4a family of Cyclin Depen ant Kinase Inhibitors 
(CDKIs) are commonly observed in many cancer types and are thought to be important 
early events in transformation. In virus-mediated cancers, viral proteins bind and 
sequester specific proteins in this pathway, including p53 and Rb, inhibiting normal 
function and allowing unchecked proliferation of the host cell. The key transcription 
factors in this pathway are themselves prime targets for mutation given that their 
structures consist of very specific domains related to their functions, such as DNA 
binding, transcription regulation and dimerisation. The function of RB can become 
disrupted through genetic mutations that render it unable to interact with E2F. 
Mutations have been described in p53 and are common to all types of cancer cells. It a 
normal cell p53 becomes stabilised in response to upstream kinases that are activated by 
DNA damage in the cell (see Figure 1.9. ). This in turn leads to cell cycle arrest and 
apoptosis via the transcriptional. activation of the CDKI, p21 and additional pro- 
apoptotic genes. Mutations in p53 render cells unresponsive to DNA damage signals 
which in turn will exacerbate the cancer phenotype. 
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Figure 1.9. Overview of the control of cell cycle progression from GI phase to S phase. Central to 
the progression from GI phase to S phase of the cell cycle is the control of phosphorylation of 
Retinoblastoma Protein (Rb). In its hypophosphorylated state, Rb and its associated HDAC repressor 
complex bind to the E2F-DPI transcription factors, inhibiting downstream transcription of E2F target 
genes required for DNA synthesis and subsequent cell cycle phases. In response to upstream signals, the 
Cyclin Dependant Kinases (CDKs) and their associated Cyclin proteins sequentially phosphorylate Rb. In 
turn this leads to dissociation of the RB repressor complex permitting the transcription of E2F target 
genes and thus promoting cell cycle progression. Cyclin/CDK complexes are regulated at the level of 
transcription by the Myc transcription factor, or via the inhibition of their activity by upstream INK4 or 
Kip/Cip families of CDKIs, shown in green. TGFO signalling, DNA damage, contact inhibition and 
replicative senescence all act to inhibit cell cycle progression by inducing members of the INK4 or 
Kip/Cip families of CDKIs. TGF3 also inhibits the transcription of cdc25A, a phosphatase required for 
CDK activation. Growth factor withdrawal can activate GSK-3p, which in turn phosphorylates cyclinD, 
leading to its rapid ubiquitination and proteosomal degradation (Reviewed by Sherr & Roberts 1999; 
Caldon et a!., 2006). Solid lines indicate direct interactions, Dashed lines indicated indirect interactions 
and crooked lines indicate transcriptional interactions. Kinases are shown in Red, CKI in Green and 
transcription factors in blue. 
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1.6 AP-2 and Cancer 
1.6.1. AP 2a and Melanoma 
Loss of AP-2a function has been shown to be an important molecular event in 
melanoma progression. Work in melanoma cell lines has suggested that loss of AP-2a 
increases metastatic potential in part through the transcriptional up regulation of 
MUC18, MMP-2, and PAR-1 genes (Reviewed in Bar-Eli, 2001), proteins that are 
known to promote tumour cell adhesion to endothelial cells in blood vessels and support 
migration to metastatic sites (Jean et al., 1998; Tellez et al., 2003a; Tellez et al., 
2003b). A reduction in c-KIT expression is also correlated with the loss of AP-2a, thus 
rendering cells more resistant to apoptosis (Huang et al., 1998). Three independent 
studies examining AP-2a expression in melanomas from patients have shown that loss 
of nuclear AP-2a expression is associated with malign nt transformation and 
progression of melanoma as well as being a predictor poor patient prognosis 
(Karjalainen et al., 1998; Berger et al., 2005; Zhuang et al., 2 7). 
1.6.2. AP 2a and prostate cancer 
A similar role for AP-2a has been suggested in prostate carcinoma. AP-2a is expressed 
in normal differentiating prostate epithelium but expression is lost early in prostate 
cancer development (Ruiz et al., 2001). Interestingly, forced AP-2a expression in AP- 
2-negative prostate cancer cell lines, caused reduced tumourigenicity and was correlated 
with down regulation of the growth promoting VEGF (Ruiz et al., 2004). This study 
suggested that AP-2a can repress VEGF gene transcription via direct interaction with 
its promoter (Ruiz et al., 2004). Interestingly, work by others in keratinocytes 
implicates AP-2a in the transcriptional activation of VEGF (Gille et al., 1997; 
Brenneisen et al., 2003). This highlights the importance of cellular context in the 
regulation of AP-2 target genes. 
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1.6.3 AP 2a and ovarian cancer 
Over expression of AP-2a in AP-2-negative ovarian cancer cells, caused reduced cell 
proliferation, invasion and tumourigenicity when assessed following injection in nude 
mice (Sumigama et al., 2004). This is in agreement with a tumour suppressing role for 
AP-2a. However, this was inconsistent with the examination of AP-2a expression in 
ovarian tumours, where low cytoplasmic expression accompanied by high nuclear 
expression predicted poor patient prognosis (Anttila et al., 2000). The inconsistency 
may be due to the antibody used in this study, which failed to discriminate between AP- 
2a and AP-2y family members. 
1.6.4 AP 2a and colon cancers 
AP-2a expression has also been inversely correlated with colon carcinoma grade 
(Ropponen et al., 2001). Recently, the expression of AP-2a in AP-2-negative colon 
cancer cells was shown to suppress their tumourigenicity when assessed following 
injection in nude mice (Schwartz et al., 2007). In the same study, RNAi mediated 
silencing of endogenous AP-2a in AP-2a-positive colon cancer cells, was shown to 
increase migration in invasion assays. The transcriptional regulation of E-cadherin and 
MMP-9, by AP-2a, via direct interaction with their promoters, was implicated in the 
observed AP-2a depe ant phenotypes (Schwartz et al., 2007). 
1.6.4 AP 2a and Gliomas 
In addition to the examples described above, expression of AP-2a in gliomas associated 
with MMP-2 and VEGF expression has been inversely correlated with glioma grade 
(Ropponen et al., 2001). 
Broadly, in the examples described above, the reduction or loss of nuclear AP-2a 
expression in tumours appears to be correlated with increased proliferation, increased 
disease progression and poor patient prognosis. 
. 
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1.6.5 AP 2y and cancer 
In contrast to AP-2a, high levels of AP-2y have often been found in tumours and 
although further research is necessary AP-2y in some cases (9 been correlated with 
increased disease progression. High levels of AP-2y are associated with testicular 
cancer (Hoei-Hansen et al., 2004), germ cell tumours (Hoei-Hansen et al., 2004; Pauls 
et al., 2005), advanced stages of ovarian cancer (Anttila et al., 2000) and certain stages 
of melanoma (Nyormoi & Bar-Eli, 2003). A recent study advocated the detection of 
AP-2y expression as a useful diagnostic tool in the detection of testicular cancer (Hoei- 
Hansen et al., 2005). 
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1.7. AP-2 and Breast Cancer 
In addition to the aberrant AP-2 expression associated with the cancers described above, 
AP-2 proteins were originally linked to carcinogenesis via their association with breast 
carcinoma. 
1.7.1 Breast Cancer 
Breast cancer causes the premature death of more than 14,000 women a year in the UK. 
About 10% of these cases are thought to result from a hereditary predisposition to the 
disease, caused by mutations in genes including BRCA1, BRCA2 and CHEK2 thus 
leading to the malfunction of DNA damage checkpoints (Wooster & Weber, 2003). 
The remaining 90% of cases are sporadic. Clinical evidence suggests that breast cancer 
starts with atypical epithelial hyperplasia, followed by ductal carcinoma in situ (DCIS) 
and then invasive carcinomas leading to metastatic tumours (Beckmann et al., 1997). 
Figure 1.10 illustrates the typical mammary gland histology at these stages. The most 
important markers discovered to date in breast cancer are the hormone receptors: 
oestrogen receptor (ERa) and progesterone receptor (PrR) and the receptor tyrosine 
kinase ErbB2 (or Her2) expressed in 75-80% and 15-20% respectively, of all cases. 
These proteins are intrinsically liked to the aetiology of these tumours and importantly 
are amenable targets for therapeutic intervention. Selective oestrogen receptor 
modulators (SERMs) bind oestrogen receptor and exert anti-oestrogen activity in breast 
tumour tissue. ERa positive patients generally respond well to SERMs and therefore 
have a good survival prognosis, although prolonged treatment is often associated with 
the recurrence of hormone independent tumours and therefore resistance to therapy. ' 
Aromatase inhibitors are used in conjunction with SERMs to inhibit local oestrogen 
synthesis and can help reduce resistance to therapy. In contrast, ErbB2 over expression 
in breast cancer correlates with aggressive disease and poor patient prognosis (Slamon 
et al., 1998; Siegel et al., 1999). ErbB2 positive breast tumours are often ERa negative 
and therefore resistant to treatment with SERMs. Recent developments have shown that 
these tumours may respond to ErbB2 directed monoclonal antibody therapy (reviewed 
by Cleator et al., 2007) and it is hoped that this treatment will lead to improved 
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Normal Breast Tissue 
Ductal Carcinoma In Situ (DCIS) 
Primary Invasive Breast Carcinoma 
Figure 1.10. Typical stages of breast cancer. The top panel shows the typical morphology of normal 
human breast tissue (described in detail in section 1.4.3). Clinical evidence suggests that breast cancer 
starts with atypical epithelial hyperplasia, followed by ductal carcinoma in situ (DCIS) shown in the 
middle panel indicated by an arrow and then primary invasive carcinoma (bottom panel) characterised by 
a loss of recognisable morphology. Images show immunohistochemical analysis of AP-2y protein levels 
in transverse sections of adult human mammary tissue. AP-2y staining corresponds to myoepithelial and 
luminal epithelial cells within the normal mammary gland, in DCIS and in primary invasive carcinoma 
(Helen Hurst, personal communication). 
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prognosis of patients with ErbB2 positive tumours. 
Seminal work by Perou and colleagues showed that the molecular profiling of breast 
cancers, using gene expression microarrays, can further classify tumour subtypes based 
on global gene expression patterns (Perou et al., 2000). An unsupervised hierarchical 
clustering analysis based on an intrinsic set of genes showing high variability between 
matched tumour/normal pairs from breast cancer patients, identified five distinct 
subgroups based on their gene expression profiles (Perou et al., 2000, Sorlie et at., 
2001; Sorlie et al., 2003). The data from experiments by Sorlie and colleagues is 
displayed in Figure 1.11. 
As anticipated, a major discrimination was seen between tumours that expressed high 
ESR1 (ER(x) and tumours that had low or negative expression for this factor. ERBB2 
expressing tumours were also clustered together. Interestingly, these and additional 
clusters reflected the anatomical origins of tumours, based on their similarity in 
expression to normal mammary epithelial cells. The largest cluster of tumours showed 
luminal epithelial cell like expression profiles. These further subdivided into "Luminal 
A" and "Luminal B" based on differences in expression profile. Luminal subtypes were 
generally ESRI expressing tumours and therefore represented good prognosis although 
prognosis was worse for the "Luminal B" tumours. The "Normal" cluster of tumours 
showed similarity to adipose-enriched and basal mammary epithelial cells and 
represented a medium patient prognosis. A final group of breast tumours termed 
"basal" showed similarity in expression to basal mammary epithelial cells, based on 
their expression of cytokeratins 5/6 and 17. These have also been called "triple- 
negative" tumours, due to the absence of ESR1, PGRJ (PgR) and ERBB2 expression 
and additional validation studies showed they represent very poor patient prognosis due 
to the lack of expression of known targets for therapeutic intervention (van de Rijn et 
al., 2002; reviewed by Cleator et al., 2007). Further analysis of the gene expression 
profile of these basal like tumours has revealed that they share similarities to BRCA1 
mutated familial breast cancers implicating BRCA1 dysfunction in the aetiology of this 
subtype. 
Importantly, identifying new and distinct subgroups of breast tumours, which show 
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Figure 1.11. Hierarchical clustering of breast-cancer samples on basis of microarray gene 
expression data (Figure from Sortie et a/., 2003). Heat map of all samples clustered according to 
intrinsic gene set (534 genes) used for analysis (A) and dendrogram (B) shows segregation of breast 
cancers into five major subgroups, including a tightly clustered basal-like cluster. Red colouration for a 
given gene (listed vertically along right hand side of heat map) denotes relative up-regulation of 
expression, and green colouration, relative down-regulation in tumours compared to normal controls. 
Heat maps of gene clusters define the ERBB2 (C), luminal subtype B (D), basal-like (E), normal breast- 
like (F), and luminal subtype A (G) subgroups of breast cancer. 
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homogeneity in transcriptional programs, suggests common mechanisms which might 
initiate and sustain breast tumourigenesis. These studies have proved useful in 
hypothesis generation and are currently the focus of intense research in order to identify 
useful markers for clinical diagnosis and novel targets for therapeutic intervention. 
1.7.2. AP -2 and ERBB2: cell line studies 
AP-2 transcription factors were first linked to breast cancer when they were shown to be 
involved in the deregulation of ERBB2 transcription (Hollywood & Hurst, 1993). In 
most breast cancers over expression of ErbB2 is due to gene amplification. However, 
single copies also have transforming potential (Hurst, 2001). Both AP-2a and AP-2y 
family members have been shown to activate transcription from the ERBB2 promoter 
and the closely related ERBB3 promoter in vitro and AP-2y, in particular, was expressed 
in all mammary tumour cell lines over expressing ErbB2 (Skinner & Hurst, 1993, 
Bosher et al., 1995, Bosher et al., 1996). Functional AP-2 consensus binding sites have 
been found in the ERBB2 proximal promoter, an enhancer element located in the first 
intron and recently a distal enhancer region (Hollywood & Hurst, 1993; Vernimmen, et 
al. 2003, Perissi, et al. 2000, Newman, et al. 2000; Delacroix et al., 2005). ChIP 
studies in our lab have shown that activation of ERBB2 transcription is associated with 
an increase in AP-2y occupancy in the ERBB2 intronic enhancer region in vivo (Helen 
Hurst, Personal communication). AP-2 occupancy has also been observed at the distal 
enhancer region of the ERBB2 promoter, although the authors used an antibody that 
failed to discriminate between AP-2a, AP-20 and AP-2y family members (Delacroix et 
al., 2005). 
1.7.3. AP-2, ErbB2 and ERa: cell line studies 
AP-2 family members have also been implicated in the interplay between ErbB2 and 
ERa in breast carcinoma. ErbB2 and ERa show an inverse correlation in breast cancer, 
that is, when ErbB2 is over expressed, ERa signalling pathways are down regulated. 
Conversely, when ERa is activated by oestrogen, ErbB2 levels are reduced. This 
repression can be relieved using anti-oestrogens such as Tamoxifen or Fasolodex 
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(ICI182,780) (Bates & Hurst, 1997; Perissi, et al. 2000; Orso et al., 2004). The 
promoter of human ERBB2 does not however contain a binding site for ERa, therefore, 
the oestrogenic suppression must be mediated through another indirect mechanism. 
Indeed, the oestrogenic regulation of ERBB2 expression was mapped to the AP-2 
consensus binding sites and additional transcription factor binding sites in the ERBB2 
intronic enhancer element and over expression of AP-2y but not AP-2a was shown to 
overcome the repressive effects of oestrogen (Bates & Hurst, 1997; Newman et al., 
2000; Perissi, et al., 2000). Interestingly, following oestrogen treatment in hormonally 
manipulated ERa expressing breast cancer cell lines, AP-2y mRNA levels were 
increased whereas AP-2a levels decreased (Orso et al., 2004). ChIP analysis of the 
endogenous AP-2y promoter region observed ERa occupancy in response to oestrogen 
(Orso et al., 2004), indicating that the balance of AP-2 family members in response to 
oestrogen may allow AP-2 proteins to mediate some oestrogenic responses, such as 
ERRB2 repression. Indeed, following oestrogen treatment in hormonally manipulated 
MCF-7 cells, ERRB2 mRNA down regulation is accompanied by a decrease in AP-2y 
occupancy of the ERBB2 enhancer region, and concurrently, a reduction in the AP-2 
associated transcriptional machinery, CITED2 and CBP/p300 (Helen Hurst, personal 
communication). 
Of additional interest is the ability of AP-2y to maintain ERa transcription (reviewed in 
Hilger-Eversheim et al., 2000). In vitro reporter assays have shown that AP-2y and AP- 
2a can activate ERa transcription via interaction with AP-2 consensus sites within the 
untranslated region of exon 1 of the ERa promoter (DeConinck et al., 1995; McPherson 
& Weigel, 1999). Adenovirus mediated over expression of AP-2a or AP-2y was also 
shown to induce the formation of HS1, a DNase I hypersensitive site found in all ERa 
expressing breast cancer cell lines and tumours over the ESR1 locus (Schuur, et al. 
2001). However, although this result confirms the ability of AP-2 family members to 
remodel chromatin structure at the ERa locus, the expression of AP-2y in ERa negative 
cell lines did not yield a detectable increase in ERa transcript levels. This was 
postulated to be due to other more potent repressive mechanisms acting on the ERa 
promoter (Schuur, et al. 2001). Although the role of AP-2 family members in ERa 
regulation requires further evidence, these data suggest the presence of a possible 
control loop between these factors. 
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1.7.4. AP -2 and ErbB2 and ERa: human breast cancer 
Immunohistochemical and gene expression microarray studies performed in parallel to 
the cell line studies described above have looked at the relationship between AP-2, ERa 
and ErbB2 in tumours from breast cancer patients. AP-2a and AP-2y were found to be 
expressed at high levels in 17-35% and 84% of cases respectively and, in tumours co- 
expressing AP-2a and AP-2y, a positive correlation with ErbB2 status was also shown 
(Turner et al., 1998). Two separate studies (Turner, et al. 1998; Gee, et al. 1999) 
showed a direct correlation between AP-2a expression and ERa expression, in primary 
breast cancer and in invasive ductal carcinoma. Expression profiling studies, in 
agreement with these data, have shown that when TFAP2A expression is recorded it was 
in ERa positive breast tumours rather than ERa negative tumours (p<0.004, Wang et 
al., 2005 and p<0.00092, Sotiriou et al., 2006). AP-2a and ERa co-expression might 
reflect a tumour cell origin as both are predominantly expressed in luminal epithelia of 
normal breast. Additionally it might be related to the potential control loop between 
these factors. Immunohistochemical studies examining AP-2a only in clinical breast 
tumour samples showed a negative correlation with ErbB2 status but a positive 
correlation with staining for the universal cell cycle inhibitor p21WAF1/CIP1 and a 
lower rate of proliferation (Gee et al., 1999). AP-2a was also reduced in level from 
normal breast through to DCIS and primary invasive cancers. Others have shown that 
reduced nuclear AP-2a staining was associated with more aggressive breast cancers 
(Pellikainen et al 2002) and TFAP2A mRNA expression was inversely correlated with 
increased tumour grade (p<0.01, Sotiriou et al., 2006). In summary, these studies 
indicate AP-2a expression in breast cancer is associated with favourable prognostic 
markers, namely ERa expression and ErbB2 negativity and reduced proliferation. 
Considered together with observations of AP-2a expression in normal breast (Zhang et 
al., 2003), these data further suggest that AP-2a expression observed in breast tumours 
may be an attempt by the cells to arrest their growth and terminally differentiate. AP- 
2a may therefore be acting in a tumour suppressive role, consistent with the observation 
that its expression is reduced with advancing stages of breast cancer and also with its 
suggested role in other cancer types. The loss of AP-2 expression in invasive breast 
cancer has been significantly correlated with hypermethylation of a CpG island in exon 
1 of AP-2a gene. Hypermethylation of this region does not occur in normal breast 
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epithelium and occurred in only 16% of DCIS lesions, but was present in 75% of 
primary invasive breast tumours. Tumours unmethylated for this region expressed AP- 
2a protein, whereas tumours with hypermethylation showed considerable loss, 
describing a mechanism of suppression of AP-2a expression in vivo (Douglas et al., 
2004). 
An increasing body of evidence suggests that AP-2y expression might play an opposite 
role to that of AP-2a in breast carcinomas. Although AP-2y over expressing transgenic 
mice did not develop tumours, epithelial hyperplasia was observed, implicating AP-2y 
in the promotion of proliferation. Studies in ErbB2/AP-2y over expressing transgenic 
mice support a role for AP-2y expression in the promotion of tumour proliferation 
(Jäger et al., 2005). Whilst a small reduction in the overall number of tumours was 
observed in AP-2y/ErbB2 transgenic mice, an increased proportion of advanced stage 
carcinomas were seen. Closer examination revealed AP-2y expression was significantly 
correlated with increased proliferation rates in all stages of mouse mammary carcinoma. 
Indeed, a recent study has shown that elevated levels of AP-2y in advanced primary 
breast tumours correlate with reduced patient survival. Additionally, the relationship 
between AP-2y expression and ERa or ErbB2 expression was also explored in this 
series of advanced primary invasive tumours (Helen Hurst, personal communication). 
A wide range of AP-2y expression levels were found across the samples with a highly 
statistically significant correlation between high levels of staining and shortened 
survival, shown in Figure 1.12. (A). These data are supported by a second clinical study 
where a similar link between high levels of TFAP2C mRNA and reduced disease-free 
survival was observed (Zhoa et al., 2003). Additionally, TFAP2C mRNA expression 
has been associated with advancing clinical grade in gene expression profiling studies 
(p<0.002, Sotiriou et al., 2006). 
Figure 1.12. (B), shows high AP-2y was also linked to poor patient prognosis in patients 
positive for ERa expression, a typically good prognosis group due to their 
responsiveness to hormone therapy (Helen Hurst, personal communication). This 
suggests that one of the consequences of high level AP-2y expression in tumours may 
be an increased propensity towards resistance to anti-oestrogen therapy. As described 
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earlier, AP-2y transcription is activated by oestrogen bound ERoc and anti-oestrogen 
abrogates this ERoc mediated transcriptional activation (Orso et al., 2004). Based on 
these observations a reduction in AP-2y levels might be expected in ERa positive 
tumours undergoing anti oestrogen therapy. High AP-2y expression therefore represents 
a challenge to this mechanism and thus implicates AP-2y expression in the aetiology of 
anti-oestrogen resistance. A number of microarray studies have shown that TFAP2C 
mRNA is also expressed in ERa negative tumours and that this expression in general is 
higher in these tumours compared to ERa positive tumours (p<0.002, van de Vijver, et 
al., 2002; p<0.005, Gruvberger et al., 2001 and p<0.00012, Sotiriou et al., 2006). 
High AP-2y expression was also linked to poor patient prognosis in patients negative for 
ErbB2 expression, Figure 1.12. (C). No significant prognostic outcome was contributed 
by high AP-2y in patients positive for ErbB2 expression, since these patients already 
represented a poor prognosis subgroup (Helen Hurst, personal communication). 
In summary, this immunohistochemical -analysis (Figure 1.12), links high AP-2y 
expression to poor survival, both independently and in the context of the generally 
considered indicators of good prognosis: namely ERa expression and ErbB2 negativity. 
These findings indicate that AP-2y may be a useful prognostic indicator in breast cancer 
and the AP-2y regulation of target genes other than ERRB2 and ERa must also be 
important. Additionally, the poor prognosis in high AP-2y expressing, ERa positive 
tumours casually links AP-2y expression with resistance to hormone therapy. A 
reasonable hypothesis, given the consequences of AP-2y over expression in normal 
mouse mammary glands (Jäger et al., 2003) and mouse ErbB2/AP-2y over expressing 
mammary gland tumours (Jäger et al., 2005) is that AP-2 may promote proliferation in 
human breast carcinomas. Interestingly, the AP-2y genomic locus, 20g13.2, is 
frequently amplified in breast cancer cell lines and breast carcinoma suggesting, a 
possible mechanism for this aberrant expression (Williamson et al., 1996), providing 
further evidence that high AP-2y might be important in the aetiology of this disease. 
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Figure 1.12. Correlation between AP-2 expression and poor prognosis in advanced primary breast 
tumours. A series of 75 patients with primary invasive breast cancer showed a range of intensity of 
nuclear AP-2y immunostaining across the samples. In a cohort of 75 patients who presented with 
advanced primary tumours and were treated with surgery followed by anti-oestrogen therapy. Each 
sample was assigned a histopathology score (H-score) from 1-300 based on the intensity of the staining 
and the percentage of tumour cells stained. A statistically defined cut-off point, the median (H-score > 
120), was used to define "positivity" for subsequent analysis. (A) For all patients, higher AP-2y 
expression correlated with shortened survival time with clear curve separation after 20 months 
(p=0.0009). (B) For all ERa positive patients, higher AP-2y expression correlated with shortened survival 
time (p=0.0055). (C) For all ErbB2 negative patients, higher AP-21 expression correlated with shortened 
survival time (p=0.0002). (Helen Hurst, personal communication). 
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1.7.5. AP -2 and cell proliferation and apoptosis with reference 
to breast cancer. 
In addition to the complex interplay between AP-2 family members, ERa and ErbB2 
additional studies in cell lines have implicated AP-2 family members in the regulation 
of cell proliferation and apoptosis. 
One possible mechanism that could explain the proposed role for AP-2a as a tumour 
suppressor in breast cancer is through its induction of growth arrest and apoptosis. 
Initial work by Zeng and colleagues showed that exogenous AP2a expression in HepG2 
hepatoblastoma cells and SW480 colon carcinom cells inhibited their growth and this 
growth inhibition was accompanied by activatio 21WAF1/CIP1 expression (Zeng et 
al., 1997). The authors went on to show that AP-2a activated transcription from a p21 
promoter reporter construct and this activity depended on sites within the proximal 
promoter region (Zeng et al., 1997). CDKNIA encodes for p21, a member of the CDKI 
family (described in section 1.5). Since its discovery as a transcriptional target of p53 
and a key mediator of p53 dependent cell cycle arrest (el-Deiry et al., 1993), p21 has 
been the focus of intense study (reviewed in Sherr & Roberts, 1999; Gartel & 
Radhakrishnan, 2005; Caldon et al., 2006). It has been characterised as a negative 
regulator of cell cycle progression, in part through its ability to inhibit the activity of 
cyclin/cdk2 complexes during G1 phase of the cell cycle thus stalling cells at the G1/S 
transition (see Figure 1.9). Additional functions of p21 include its ability to interfere 
with DNA replication by inhibiting PCNA and, in contrast to these other function t is 
also required for the stabilisation of Cyclin/CDK complexes. 
A separate study has suggested that the ability of AP-2a to activate CDKN1A 
transcription is depen t on a direct interaction with p53, although the results require 
cautious interpretation (McPherson et al., 2002). AP-2a and AP-2y were shown to 
interact with p53 in vitro using yeast two hybrid and GST pull-down assays. The 
authors then showed a very small amount of endogenous AP-2 activity could be 
immunoprecipitated using a p53 specific antibody in MCF-7 cells. AP-2 activity was 
measured using DNA binding assays and controlled using an AP-2 antibody, but the 
antibody used cannot discriminate between AP-2a, AP-2(3 and AP-2y. The AP-2 
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activity in these assays was attributed to AP-2a, however AP-2y is the predominant 
family member expressed in MCF-7 cells whereas AP-2a levels are barely detectable 
(see Results Figure 3.1). In order to confirm an interaction between endogenous AP-2a 
and/or AP-2y and p53, and indeed the functional relevance of this interaction, these 
experiments need to be revisited with appropriate immunological reagents in alternative 
cell lines. 
Cell growth inhibition accompanied by p21 up regulation was also observed in colon 
carcinoma cells following adenovirus mediated over expression of AP-2a compared to 
the over expression of a LacZ control virus (Wajapeyee & Somasundaram, 2003). This 
growth arrest was dramatically reduced in HCT116 p21-/- cells compared to the 
wildtype counterparts suggesting that activation of CDKN1A transcription by AP-2a 
was essential for this arrest. In support of the data described above, p21 induction was 
shown to be enhanced by p53 as measured following AP-2a over-expression in 
HCT1 16 p53-/- cells compared to the HCT1 16 wildtype cells. However, p21 was still 
induced by AP-2a in HCT116 p534- cells, and the level of cell cycle arrest was 
equivalent to the wildtype cells. These data suggest therefore that AP-2a can activate 
p21 independently of p53, although cooperation with p53, similarly to previous findings 
(McPherson et al., 2002), might slightly enhance this activation. Importantly, these cell 
line studies complement the in vivo data described above which correlate expression of 
AP-2a in the mouse mammary gland and in human breast cancers to the cessation of 
proliferation and an up regulation of p21 (Zhang et al., 2003; Gee et al., 1999). 
As well as cell cycle arrest, Wajapeyee and Somasundaram also observed an induction 
of apoptosis in AP-2a over expressing cells (Wajapeyee & Somasundaram, 2003). AP- 
2a over expression was also correlated to increased sensitivity to chemotherapeutic 
drugs in breast and colon cancer cell lines (Wajapeyee et at., 2003; Wajapeyee et al., 
2005). Also, apoptosis in response to cisplatin (a DNA damaging agent), and taxol (an 
inhibitor of microtubule depolymerisation) in colon carcinoma cells was accompanied 
by an increase in AP-2a levels. This apoptotic response was shown to be inhibited by 
siRNA mediated AP-2a silencing, suggesting that AP-2a expression is intrinsic to the 
chemosensitivity of these cells (Wajapeyee et at., 2003; Wajapeyee et al., 2005). 
Recent work has shown that AP-2a can mediate apoptosis through the transcriptional 
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repression of the anti-apoptotic protein Bcl-2 in colon carcinoma cells (Wajapeyee et 
al., 2006). Apoptosis in AP-2a over expressing cells was accompanied by exogenous 
AP-2a occupancy of the proximal promoter region of BCL2. Exogenous expression of 
Bcl-2 inhibited AP-2a induced apoptosis suggesting that BCL2 repression is the 
principal mechanism for mediation of apoptosis by AP-2a (Wajapeyee et al., 2006). 
These data contrast with the observations of AP-2 in TNFa induced apoptosis in breast 
carcinoma cells that express both AP-2a and AP-2y (Nyormoi et al., 2001). TNFa 
induced apoptosis was accompanied by a decrease in levels of AP-2, detected using the 
non discriminating AP-2 antibody. Furthermore, it was suggested that caspase mediated 
cleavage of AP-2 (which resulted in loss of its transcriptional activity) was critical for 
this TNFct induced apoptotic pathway (Nyormoi et al., 2001). The differences in the 
roles for AP-2 in these studies may reflect mechanistic differences in the intrinsic 
apoptotic pathways activated by chemotherapy or TNFa. Equally, Wajapeyee and 
colleagues concentrated on the AP-2a family member whereas the other studies did not 
discriminate between family members. Additional studies are required to further 
elucidate the role of specific family members with respect apoptosis. Although a role 
for AP-2a expression in the induction of apoptosis is clearly supported in vivo by the 
enhanced cell death observed in AP-2a over expressing mouse mammary glands 
(Zhang et al., 2003). Targeting AP-2y over expression to the mammary gland also 
resulted in increased apoptosis (Jäger et al., 2003). Interestingly work in our laboratory 
by Jamie Meredith, has shown that adenovirus forced over expression of AP-2y in the 
AP-2 negative normal breast epithelial cell line (MTSV1.7neo) resulted in increased cell 
death, although the mechanism behind this phenotype could not be identified (Meredith 
J, 2006). 
In mammary carcinoma cell lines, 5' regulatory sequences for TGFa have been shown 
to be positively regulated by AP-2 in luciferase reporter assays (Wang et al., 1997, Gille 
et al., 1997, and Kim & Rho, 2002). Expression of TGFa is known to be growth 
promoting in mammary gland development and mammary neoplasia, its effects largely 
exerted via EGFR signalling (reviewed by Sternlicht et al., 2006). Interestingly, 
convincing evidence exists showing a role for AP-2 in EGFR family member 
transcription (described above), although a role in TGFa transcriptional regulation 
requires further analysis. 
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In vitro reporter assays also implicate AP-2a in the activation of transcription 
from the 
IGFBP5 promoter via AP-2 DNA recognition sites (Duan & Clemmons, 1995; Erclik 
& 
Mitchell, 2005). Interestingly, over expression of AP-2y targeted to the mouse 
mammary gland was accompanied by induction of IGFBP5 (Jager et al., 2003). 
Reports have suggested that IGFBP5 might be involved in the induction of apoptosis in 
alveolar cells during postlactational mammary gland involution (reviewed in Beattie et 
al., 2006). Indeed, enforced expression of AP-2y was associated with enhanced 
apoptosis and it was suggested that this may have been induced via transcriptional 
activation of IGFBP5 by AP-2y. Work in our lab supports this and using ChIP assays it 
has been shown that AP-2y is bound to the IGFBP5 promoter in MCF-7 cells (Karsten 
Friedrich, personal communication), although a functional role of IGFPB5 with regards 
to breast cancer requires further clarification. 
In summary, the cell line studies described above do not always provide a clear picture 
of the role of AP-2 proteins in breast cancer. Some general threads however can be 
drawn together. In support of a tumour suppressor-like role for AP-2a, it has been 
shown to up-regulate CDKNIA transcription and repress transcription of the anti- 
apoptotic gene BCL2. It is reasonable to consider that AP-2a and AP-2y might share 
some overlapping functions in relation to breast cancer and breast development, indeed 
they are both expressed in luminal and myoepithelial cells albeit at varying levels 
(Zhang et al., 2003) and over expression of both AP-2a and AP-2y has been associated 
with enhanced apoptosis. 
The molecular mechanisms behind the association of high AP-2y expression and 
increased breast tumour progression leading to poor patient prognosis remain elusive, as 
does the transcriptional program initiated by AP-2y in the promotion of cell 
proliferation and inhibition of differentiation in breast tissues during development. AP- 
2y expression is clearly associated with the regulation of ERBB2 and ERoc in breast 
cancer cell lines, however high levels of AP-2y predict poor prognosis independently of 
these factors in patients with advanced primary invasive breast carcinomas, suggesting 
other molecular mechanisms may be involved. In order to try to define the additional 
pathways activated by AP-2y specifically in breast cancer, the research presented in this 
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thesis aims to use Affymetrix GeneChip high-density oligonucleotide microarrays to 
define AP-2y dependant changes in gene expression in breast epithelial cells. 
1.8. AP-2 and Gene Expression Profiling 
Gene expression profiling using microarrays is fast becoming an established technology 
since its conception more than 10 years ago, pioneered by Brown and colleagues who 
established cDNA microarrays (Schena et al., 1995) and Affymetrix (Santa Clara, 
California, USA) who have built a considerable business around their oligonucleotide 
microarray technology. A microarray is an array of nucleotide features, representing 
tens of thousands of known genes and uncharacterised partial gene sequences, 
immobilised to a solid substrate. Labelled nucleic acid material derived from an RNA 
sample of interest can be hybridised to the nucleotide features. The amount of label 
detected at each feature corresponds to the level of each specific RNA message 
expressed in the sample. This technology enables thousands of nucleic acid 
hybridisation events to be investigated in a single experiment. 
The major challenge, in terms of AP-2 expression profiling in breast cancer, has been to 
determine the best strategy to derive two RNA populations to compare to identify AP-2 
regulated genes. Initial efforts concentrated on comparing cells with low AP-2 
expression with derivatives engineered to express AP-2y at levels similar to those 
observed in over-expressing breast tumour lines. This approach identified some 
interesting genes potentially regulated by AP-2 (Helen Hurst, personal communication). 
However, it is likely that the overexpression of AP-2y in a null line may not effectively 
activate all the key genes since DNA methylation and epigenetic chromatin 
modification will silence many genes in a manner that might not be reversed by over 
expression of AP-2y alone. Tissues derived from knockout mice have been used to 
examine expression profiles due to AP-2a (Werling & Schorle, 2002), but this has so 
far not been possible for AP-2y due to the early embryological death of the null mice. 
Expression profiles of wild type and AP-2a null mouse embryo fibroblasts were 
disappointingly similar (Helen Hurst, Personal communication), probably because AP-2 
factors are not significantly expressed in fibroblasts. 
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Importantly, the ability of short interfering RNA (siRNA) to mediate sequence-specific 
gene silencing in mammalian cells (Elbashir et al., 2001) opens up the possibility of 
circumventing the majority of these problems by knocking down AP-2y expression in 
AP-2y over expressing breast tumour lines. 
1.9. Short Interfering RNA (siRNA) 
The biological process of RNA interference (RNAi) was first discovered by Fire and 
colleagues who showed that the injection of long dsRNA species into C. elegans led to 
sequence-specific degradation of the corresponding mRNAs (Fire et al., 1998). This 
process was subsequently found to be conserved across eukaryotes and has greatly 
influenced our understanding of gene regulation in animals, plants and many fungi 
(Reviewed in Dykxhoorn et al., 2003). However, initially this process could not be 
applied to mammalian cells, as the introduction of long dsRNAs (>30 nucleotides) were 
known to elicit an interferon response (Minks et al., 1979). 
The interferon system is an innate antiviral immune response, which can be triggered by 
dsRNA, a common viral replicative intermediate (reviewed in Samuel et al., 2001). The 
response is mediated by the JAK-STAT signalling cascade and culminates in the 
induction of interferon-stimulated genes. These include 2'-5' Oligoadenylate Synthase, 
which in turn activates RNase L and triggers global degradation of mRNA, and the 
protein kinase, PKR, which can phosphorylate the translation initiation factor eIF2 
leading to a global inhibition of mRNA translation. The ultimate aim of this response is 
to prevent viral multiplication but in the process it can affect growth and cause damage 
to the host cell. 
The discovery that long dsRNA enabled the effective silencing of gene expression by 
presenting various short, 19-23 nucleotide, RNA cleavage fragments to the target 
mRNA was exploited by Elbashir and colleagues. They showed that direct introduction 
of these short RNAs into mammalian cells, could cause target mRNA degradation 
without triggering the interferon response (Elbashir et al., 2001). They went on to show 
that these short interfering RNAs (siRNAs) allowed the study of gene-specific 
phenotypes in mammalian cultured cells (Harborth et al., 2001). Since these early 
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experiments more about the mechanism of RNAi has been ascertained. It is thought to 
occur by one of two pathways in the cell, summarised in Figure 1.13: the siRNA 
pathway or the micro RNA pathway. 
MicroRNAs are endogenous 22 nucleotide RNAs that elicit either translational 
repression or mRNA cleavage (reviewed in Bartel, 2004). Typically encoded in non- 
protein coding regions of plant and animal genomes, microRNAs are emerging as an 
important post-transcriptional gene silencing mechanism in eukaryotes and have been 
shown to, amongst other processes, regulate neuronal patterning in nematodes (Johnston 
& Hobert, 2003) and modulate haematopoietic lineage differentiation in mammals 
(Chen et al., 2004). A third mechanism of transcriptional gene silencing via RNAi has 
been observed. In fission yeast, expressed genes can be direct targets of RNAi 
dependent heterochromatin formation (Schramke & Allshire, 2003). It has also been 
shown that siRNA induced transcriptional gene silencing can occur in mammalian cells 
(reviewed in Kawasaki et al., 2005). siRNAs targeted to CpG islands within a gene 
promoter can induce RNA-directed DNA methylation. 
It is important to stress the differences between the siRNA and microRNA processes. 
siRNAs are thought to require a 100% identity with the targeted transcript to cause 
mRNA degradation; a single base pair change has been shown to abolish ability of an 
siRNA to bind and degrade its specific target (Brummelkamp et al., 2002a). On the 
other hand microRNAs tolerate more sequence diversity and therefore can silence 
related sequences, primarily by translational repression, leading to loss of protein levels 
while mRNA levels are maintained (reviewed in Bartel, 2004). 
1.9.1 Short Interfering RNA Delivery 
Two main methods have developed to utilise RNAi via the siRNA pathway in 
mammalian cells. Firstly, siRNAs have been introduced into mammalian cells by 
transient transfection of synthetic double-stranded RNA (Elbashir et al., 2001). The 
major drawback of this method is the transient nature of the silencing effect. This 
becomes important when trying to reduce the level of proteins with a long half-life or 
when an RNAi specific phenotype only appears after an extended period of time 
69 
THE siRNA PATHWAY 
ATP 
Dicw 
ADP + P, 
P 
sRNA Alplex 
n 
siRNA-"eon complex (siRNP) 
p 
r 
-) RISC 
ATP 
RISC rirtwl: `in 
ADP " P, 
1 siRNA modatctl target rocogrtiliOn 
mRNA 0 
m7G-' \j 
\" I \ý 
1 -HNA cleavage 
m7G-/\JA. 
/A ' 
THE miRNA PATHWAY 
H. tfpvi prga ts&., 
(el 
Dicer 
mA J 
mo complex fmiRNP IMIRNP} 
j ý4. ix)yrýi; yt 
mRNA 
m7G 
TramL912x1, ti '1'1 tarn 
Figure 1.13. The proposed mechanisms of RNA interference in mammalian cells (Adapted From 
Dykxhoorn et a!., 2003). The siRNA pathway. Long double-stranded RNA is cleaved by the 
endoribonuclease Dicer, into siRNAs in an ATP-dependent reaction. siRNAs are then incorporated into 
the RNA-inducing silencing complex (RISC). The siRNA duplex is unwound in an ATP dependant 
manner. The single-stranded antisense strand guides RISC to messenger RNA that has a complementary 
sequence, resulting in the endonucleolytic cleavage of the target mRNA. The miRNA pathway. The 
endoribonuclease Drosha first processes the endogenous pre-miRNA transcripts into 70-nucleotide 
hairpin pre-miRNAs inside the nucleus. Once exported to the cytoplasm Dicer then cleaves these 
precursors to produce single stranded 22 nucleotide miRNA. These are incorporated into a 
ribonucleoprotein complex and are guided to messenger RNA with a partial complementary sequence and 
result in a repression of mRNA translation via obstruction of the translational machinery. 
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(Reviewed in Huppi et al., 2005). To overcome these problems siRNA expression 
vectors have been developed that can be stably introduced into cells either as selectable 
plasmids or as viral vectors (Brummelkamp et al., 2002a; Brummelkamp et al., 2002b; 
Paddison et al., 2002). These vectors utilise the RNA polymerase III promoters of the 
H1 or U6 genes to produce a short RNA hairpin. The loop of the hairpin is then cleaved 
by the Dicer endonuclease in the cell, to give a functional siRNA as shown in Figure 
1.14. 
I: GAGAAG[TCUCCCAGUCAG UUAA UCiAGAAGULtiCCCAUUCAGUU 
UUACUCUUCAGAGGGUCAGL'C A0 AG 
10 
VUACUCUUCAGAGGGUCAGUC 
Figure 1.14. shRNA produced by shRNA expression vectors is cleaved by the Dicer endonuclease in 
the cell to give a functional siRNA. 
1.9.2 Short Interfering RNA and Off Target Effects 
It is critical that the siRNAs chosen for RNAi experiments are designed to give the 
highest likelihood of generating an effective and specific silencing. The basic criteria 
outlined by Tuschl and colleagues suggested: searching the open reading frame of the 
target sequence for 23 nucleotide motifs AA(N19)Tr (approx. 50% GC content). It was 
emphasised that selected sequences should be subject to BLAST analysis. against EST 
libraries to ensure that only one gene is targeted (Tuschl et al., 1999). More recently 
there have been reports that specific nucleotide combinations produce more effective 
siRNAs, although the mechanistic significance of these findings has not been 
established (Reynolds et al., 2004; Ui-Tei et al., 2004). 
Despite the reported sequence-specific nature of the siRNA-mediated RNA interference 
many reports have highlighted the potential for non-specific effects. Two forms of off- 
target effects are proposed to exist: sequence-specific and sequence-independent. 
Firstly, a sequence-specific effect of degradation of mRNA species other than the target, 
due to cross-hybridisation has been reported. Systematic studies using microarrays 
showed that similarities as low as 11 contiguous bases could cause off-target effects 
(Jackson et al., 2003). However, a similar study exploring the same question saw no 
such effects (Chi et al., 2003). Other postulated sequence-specific effects include: the 
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binding to cellular proteins in a sequence-specific manner via an RNA aptamer effect, 
effecting protein function (Shi et al., 1999) and inhibition of mRNA translation through 
a micro RNA effect (Doench et al., 2003). Also, unexpectedly, it has been reported in 
the literature that both shRNA vectors and transiently transfected siRNAs can cause 
sequence-independent responses in cells via the interferon and PKR pathways described 
in section 1.9. (Sledz et al., 2003; Sledz et al., 2004; Bridge et al., 2003; Persengiev et 
al., 2004). Genome wide studies have shown that these off-target effects can be 
minimised in a concentration dependant manner (Semizarov et al., 2003; Persengiev et 
al., 2004). Also interferon induction can be monitored by looking for changes in 
interferon-stimulated genes during siRNA experiments (Sledz et al., 2003; Sledz et al., 
2004; Bridge et al., 2003). It has been suggested that using a number of different 
siRNA sequences targeting the same gene should provide further control for the 
specificity of any observed knockdown effect (Downward et al., 2004). Also, it has 
been suggested that the inclusion of non-silencing siRNAs as a further control for off- 
target effects is imperative (Huppi et al., 2005). These latter could contain either a 
base-pair change from the target, or target a non-mammalian sequence. 
1.10. Aims of this study 
In order to establish which cellular pathways have become activated by AP-2y in breast 
cancer this project aims to generate an AP-2y dependant expression profile using 
oligonucleotide microarrays and RNA interference technologies. This study will 
particularly concentrate on the AP-2y family member, a protein that has been linked 
with tumour progression and poor prognosis in patients. My aim was to do this in the 
following ways: 
" Establish a robust system for the selective knock-down of AP-2y using RNAi 
technology, including the identification of a number of distinct targeting 
sequences. 
" Initial work to focus on the MCF-7 mammary carcinoma cell line, chosen as it 
exclusively expresses AP-2y at high levels. Upon RNAi mediated depletion of 
AP-2y in MCF-7 cells, effectively all AP-2 activity would be removed from the 
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cells thus avoiding a further level of complication that might be encountered in 
other cell lines where AP-2a and AP-2y are expressed together. MCF-7 cells 
also express high levels of ERa together with AP-2y, a combination best thought 
to reflect the clinical data showing high levels of AP-2y correlated with poor 
patient prognosis in ERa positive primary breast carcinomas. 
" Use Affymetrix GeneChip microarrays to compare the wild type over- 
expressing lines with derivatives "knocked down" for AP-2y expression, 
ultimately identifying genes whose expression levels changed significantly in 
the knock down derivatives. 
" Validate selected genes in MCF-7 cells and, where possible, additional 
mammary cell lines (using real time PCR, Western blotting and ChIP). 
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CHAPTER 2: MATERIALS AND METHODS 
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2.1. Cell Culture 
2.1.2. Mammary Lines 
Cell lines were cultured as described in Table 2.1. All cells were regularly passaged to 
maintain exponential growth. In addition to mammary cell lines, the non AP-2y 
expressing HEPG2 hepatic carcinoma cell line was also used in this study and 
maintained in DMEM with 10% Foetal Calf Serum at 10% CO2. All cells were 
regularly screened for Mycoplasma sp. contamination. 
Cell Line Description Media 
MCF-7 Mammary Carcinoma 
DMEM, 10% Foetal Calf Serum, 10pg/ml 
Insulin. 
ZR75-1 Mammary Carcinoma RPMI, 10% Foetal Calf Serum. 
T47D Mammary Carcinoma DMEM, 10% Foetal Calf Serum. 
DMEM: HAMS F12 (1: 1), 5% Horse Serum, 
MCF10A 
Immortalised Normal 10µg/ml Insulin, 5 tg/ml Hydrocortisone, 
Mammary Epithelial Cells l00ng/ml Cholera Toxin, 20ng/ml Epidermal 
Growth Factor. 
Mammary Carcinoma. Stably 
MCF-7 EcoR expressing mouse retroviral As parental Line. 500µg/ml neomycin (G418) 
receptor, EcoR. 
Table 2.1. List of cell lines and cell culture conditions. MCF-7, T47D, and MCF1OA were grown in 
10% CO2 at 37°C. ZR75-1 were grown in 5% CO2 at 37°C. MCF-7 EcoR cell lines were kindly provided 
by Dr Subham Basu. 
2.1.3 Phoenix (qNX) Ecotropic Cells 
Phoenix ecotropic cells are a high titre, helper virus free, retrovirus producing line based 
D 
on 293T cells (Pear et al., 1993). Phoenix cells stably carry a M/loney Gag-Pol (Gag 
Pol-IRES-Lyt2) construct under the control of an RSV promoter and separately the 
Iv Joney ecotropic envelope gene driven by a CMV promoter. Phoenix cells were 
grown in DMEM supplemented with 10% foetal calf serum in 10% CO2 at 37°C. 
Phoenix cells were regularly passaged to maintain exponential growth. 
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2.2. RNA Interference 
2.2.1. siRNA Selection 
Initially sequences specific to AP-2y were selected for the generation of siRNA 
oligonucleotides based on published suggestions (Tuschl et al., 1999). Additional 
sequences specific to AP-2y were based on published patterns (Reynolds et al., 2004; 
Ui-Tei et al., 2004). BLAST searches were performed to verify the AP-2y specificity. A 
non-specific random sequence was used for a non-silencing control (Qiagen) These 
siRNA target sequences are detailed in Table 2.2. Four additional sequences specific to 
AP-2y were ordered from Dharmacon and are detailed in are detailed in Table 2.3. 
Target Name Target Sequence 5' - 3' 
AP-2y_1 AATGAGATGGCAGCTAGGAAG 
AP-2y2 GCGGCCCAGCAACTGTGTAAA 
AP-2y AP-2y-3 CCACACTGGAGTCGCCGAATA 
AP-2y4 GCTCATGTGACTCTCCTGACA 
AP-2y-5 CTGCACGATCAGACAGTCATT 
Mismatch1 TGAGATGGCAGCTAAGAAG 
AP-2y Mismatch Mismatch! GGCCGAGCAACTGTGTAAA 
Mismatch3 ACACTGGAGTCACCGAATA 
Non Silencing Control 
siRNA 
- AATTCTCCGAACGTGTCACGT 
Table 2.2. siRNA Target Sequences. The non-specific random sequence (Qiagen) was used for a non- 
silencing control for transient transfection. Those labelled mismatch have single base changes 
(underlined) compared to AP-2y-l, AP-2y_2 and AP-2y_3, therefore should not knock down the AP-2y 
target mRNA and were only used as non-silencing controls in pRetroSuper vectors (Figure 3.1). 
Catalogue Number Name Target Sequence 5' - 3' 
J-005238-05 #05 AACCGATAATGTCAAGTACGA 
J-005238-06 #06 GGACACTGGAGTCGCCGAATA 
J-005238-07 #07 TAGTAAACCAGTGGCAGAATA 
J-005238-08 #08 TTGGACAAGATTGGGTTGAAT 
Table 2.3. AP-2y siRNA targeting sequences from Dm con. The #06 sequence is identical to AP- 
2y_2 shown in Table 2.2. 
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2.2.2. Transient Transfection of siRNA oligonucleotides 
siRNAs were obtained from Qiagen or Dharmacon. Synthetic siRNAs consisted of a 
duplex with two 19-nucleotide RNA stands, each containing a two nucleotide overh f! idlj 
on the 3' end. The 21-nucleotide target sequences beginning with AA had dTdTJ 
overhangs on both strands and those startinglother bases (XY) had a dTdT on the sense 
strand and dXdY overhangs on the antisense strand. siRNAs were diluted in the 
manufacturer's buffer and annealed by a1 minute incubation at 90°C followed a 60 
minute incubation at 37°C, before storage at -20 °C. 
MCF-7 and ZR75-1 cells at 30 - 40 % confluency were transfected in six well plates 
using Oligofectamine as per the manufacturer's instructions (Invitrogen). Briefly the 
siRNA was diluted in DMEM to a volume of l85µ1. At the same time 3x1 of 
Oligofectamine reagent was diluted in 12 µl of DMEM, and allowed to equilibrate for. 
5-10 minutes. The diluted transfection reagent was then addedhe diluted siRNA, 
mixed by inversion and incubated at room temperature for 20 minutes. Following two 
washes of cells in DMEM, 800µ1 of DMEM was added per well. The transfection 
complexes were then added to the cells and incubated at 37 °C. Four hours later 500µl of 
3x Complete Medium (DMEM + 30% FCS + 30pg/ml Insulin) was added per well, and 
AP-2y knock down was assayed at time points thereafter. All the siRNA concentrations 
referred to in this report represent the final siRNA concentration in a lml, the volume in 
which transfection complexes were incubated on the cells for 4 hours. 
MCF1OA cells at 30 - 40 % confluency were transfected in six well plates using 
Interferin as per the manufacturer's instructions (PolyPlus). Briefly, the siRNA was 
diluted in DMEM: HAMS F12 (1: 1) to a volume of 200µ1.8p. 1 of Interferin transfection 
reagent was added to the diluted siRNA and incubated at room temperature for 15 
minutes. The transfection mix was then aliquoted onto the cells which were 
supplemented with 2m1 of their normal complete media and AP-2y knock down was 
assayed at time points thereafter. 
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2.2.3. Short Hairpin RNA Vector Construction 
Short hairpin RNA expressing constructs were based on the pRetroSuper vector and 
details are shown in Figure 2.1. (Brummelkamp et al., 2002a, 2002b). pRetroSuper 
constructs were made for AP-2y using the AP-2y_1, AP-2y_2 or AP-2y_3 target 
sequences and the corresponding mismatch non-silencing control constructs 
(mismatchl, mismatch2 or mismatch3). The correct sequence of inserts was confirmed 
before use. The resulting siRNAs were identical to the RNA oligonucleotides used for 
transient transfection. 
stn -ý, 
`ý fllol 
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wl Nn 
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0 AP-2y shRNA_I 
5'GATCCCC IGAG. A r(G(1CAGC'I'A(i(1AA(jTTCAAGAGAC'I "I'CC'I'AGCTGCCATCTCATTTTTGGAAA 3' 
5'AGCTTTTCCAAAAA'I'GAGATGGCAGCTAGGAAGTCTCTTGAACTTCCTAGCTGCC'A I CI ('AGGG 3' 
AP-2y shRNA_2 
5'GAT000CGGCCCA(iCAACTG FG I AAATTCAAGAGAI II ACACAG ITGUI (i(i(iUCTTITTGGAAA 3' 
5'AGCTVITCCAAAAA(', (G('('('AG('AA('"1'(, FG IA\: \TCTCTTGAATTTACACAGTTG('"I'(GGGC('GGG 3' 
AP-2y shRNA_3 
5'GAT000CA('A(' I GGAG1'C(i('C'(IAA f. ATTCAAGAGA IAII ('(I(iCGAC I C(' \G I (; LTITITGGAAA 3' 
5'AGCTTTTCCAAAAA: ICAC"TG(iAGTCG('('(TAA I ATCTCTTGAA IATTCGGCGAC"I C('A(l I (I I GGG 3' 
Figure 2.1. The pRetroSuper vector for expression of short interfering RNA. Custom 
oligonucleotide pairs were annealed then ligated into the BglII/HindIlI sites of the vector. Each inserted 
region contained a 19nt sequence derived from the target sequence, separated by a short spacer from the 
reverse complement of the same 19nt sequence. The H1 promoter transcribes a short RNA hairpin, which 
is cleaved to give a siRNA. In order to make the mismatch shRNA controls, Oligos were designed to 
contain the appropriate base changes within the 19nt target sequences (see underlined in Table 2.2). 
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2.2.4. Generation of shRNA Stable Lines 
2.2.4.1. Via Transfection 
AP-2y targeting constructs (shRNA1, shRNA2 or shRNA3), corresponding mismatch 
non-silencing control constructs (mismatchl, mismatch2 or mismatch3) and an empty 
pRetroSuper vector were linearised using the Sapl restriction endonu as ' before 
transfection. All cell lines wer transfected using FuGENE 6 following the 
manufacturer's instructions. Forty Ei t hours after transfection, cells were split one in 
three into selection medium containing 2.5µg/ml puromycin. Media was changed every 
2-3 days, and cells were maintained until all cells in the untransfected control had died 
(approximately 2 weeks). Single colonies of sufficient cell numbers were transferred 
onto 96-well plates using cloning cylinders. Single cell clones were then expanded and 
Western blots were performed to determine the knock down efficiency of each 
individual clone. 
2.2.4.2. Via Retroviral Transduction 
Ecotropic retroviral supernatants were produced by transfection of pRetroSuper 
constructs into phoenix packaging cells using Fugene 6 (Roche Molecular 
Biochemicals). Phoenix cells were split into selection medium containing 21tg/ml 
puromycin 48 hours following transfection and surviving cells were pooled for the long- 
term stable production of retrovirus. A day prior to the harvest of retroviral 
supernatants the media was changed to media without puromycin. The following day 
the virus-containing medium was removed from the Phoenix cells and passed through a 
0.45µm filter. Supernatants were then concentrated for virus particles using Centriplus 
(YM-100) centrifugal filter devices. An initial volume of 20m1 virus containing 
supernatant was applied to the filter device and centrifuged using a swinging-bucket 
rotor adapter at 2,500g for one and half hours. A final volume of 4ml virus containing 
supernatant was then snap-frozen in liquid nitrogen and stored at -80°C. The viral 
supernatant was used for infection of cells after addition of 5pglml polybrene. Cells at 
30 - 40 % confluency on 6cm plates were incubated with 2 ml of viral supernatant. 
After 6 hours incubation cells were allowed to recover for 24 hr with fresh medium. 
Infected cells were selected with puromycin 2.5. tg/ml and single colonies expanded as 
described above. 
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2.3. Western Blotting 
2.3.1. Whole Cell Extracts 
Cells were washed twice with ice-cold PBS and lysed on the plate in Urea whole cell 
extract buffer (8M Urea, 1M Thiourea, 0.5% CHAPS, 24mM Spermine, 50mM DTT). 
Extracts were collected using cell scrapers. The approximate protein content of each 
extract was determined using the Bradford Assay (Biorad Reagent) and a BSA standard 
curve ranging from 0- 20µg/ul. Typically 5µg of whole cell extracts were used in SDS 
PAGE. 
2.3.2. Concentration of tissue culture supernatant for secreted 
IGFBP3 detection 
Conditioned supernatants were briefly centrifuged at 4°C, to remove cell material and 
then 5x concentrated using Centriplus (YM-10) centrifugal filter devices. An initial 
volume of 2m1 conditioned supernatant was applied to the filter device and centrifuged 
at using a swinging-bucket rotor adapter at 2,500g for approximately one and half hours 
at to a final volume of 400µl. 10µl of this 5x concentrated supernatant was used in SDS 
PAGE. 
2.3.3. SDS PAGE and Western Blotting 
Samples were separated on a 6-12% SDS PAGE gels (National Diagnostics) prepared 
with a BioRad Mini Protean system. Full range molecular weight Rainbow Markers 
(Amersham) were loaded to allow size determination of detected proteins. Separated 
proteins were transferred onto a nitrocellulose membrane (Amersham) using a semi-dry 
blotting apparatus (Biorad). The membrane was blocked (5% Marvel 0.1% Tween-20 
in PBS) for an hour at room temperature. The primary antibody was diluted in blocking 
solution and incubated with the membrane for an hour at room temperature. Three 10- 
minute washes with blocking solution, removed excess primary antibody before 
incubation with the appropriate secondary (1 hour at room temperature). The 
membranes were washed in blocking solution twice and a further 3 times in PBS / 0.1% 
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Tween-20 to remove excess secondary antibody and Marvel. Supersignal WestFemto 
reagents (Pierce) were used for chemiluminescence and the membrane was exposed to 
Kodak BMR autoradiograph film. Where necessary, membranes were then stripped for 
15 minutes at 55°C in strip buffer (1M Tris HCl pH6.7,2% SDS, 100mM ß- 
Mercaptoethanol), re-blocked for 1 hour at RT and finally re-probed for Ku-70 as a 
loading control. A summary of the antibodies used and the appropriate dilutions is 
shown in Table 2.4. 
2.4. Immunofluorescence 
Coverslips were cleaned in 40% concentrated HCl / 60% ethanol for 30 minutes, then 
washed three times in distilled water and stored in 70% ethanol. One coverslip was 
placed in each well of a6 well plate, and 3x105 cells were plated for analyses 24 hours 
later. Cells were washed twice in PBS then fixed in 4% paraformaldehyde solution for 
20 minutes at room temperature. Cells were permeablised in 0.1% TritonX 100, PBS for 
5 minutes at 4°C. The Kiaa1324 antibody was diluted 1: 500 in PBS and added to the 
plated cells for 30 minutes at room temperature. Three 10-minute washes with PBS 
removed excess primary antibody. Goat anti-rabbit 564nm Alexaflour conjugate was 
diluted 1: 1000 in 5% heat inactivated goat serum PBS and incubated with the plated 
cells for 30 minutes in the dark. Three 10-minute washes with PBS followed to remove 
the excess secondary antibody. 20µg/m14'6-diamidino-2-phenylindole, dilactate (DAPI, 
Molecular Probes) in PBS was added to the cells, incubated at room temperature for 5 
minutes and washed twice with PBS. Stained cells were then put on glass slides using 
Permafluor mounting medium (Thermo Shandon). The slides were left in the dark 
overnight at 4°C to let the mounting medium set. Photos were taken with an Olympus 
BX51 with a 20x objective. 
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Antigen Animal origin Source Dilution 
AP-2y (6E4/4) Mouse Helen Hurst 1: 1000 
AP-2a (3B5) Mouse Santa Cruz 1: 1000 
BAX (N20) Rabbit Santa Cruz 1: 500 
CITED2 (MRG1) Mouse Santa Cruz 1: 500 
CITED4 (KH104) Mouse S. Bhattacharya 1: 500 
CBP (A-22) Rabbit Santa Cruz 1: 500 
CDK2 Mouse Santa Cruz 1: 500 
CDK4(DCS156) Mouse Cell Signalling 1: 1000 
CDK6 (DCS83) Mouse Cell Signalling 1: 1000 
Cyclin D1 (DCS6) Mouse Cell Signalling 1: 1000 
Cyclin D3 (DCS22) Mouse Cell Signalling 1: 1000 
Cyclin E2 (HE12) Mouse Santa Cruz 1: 1000 
ERa (HC-20) Rabbit Santa Cruz 1: 500 
IGFBP3 (#06108) Rabbit Upstate 1: 200 
Inhibin PA Mouse R&D systems 1: 10 
Keratin 8 (35ßH11) Mouse DAKO 1: 1000 
Keratin 18 (DC 10 Mouse DAKO 1: 1000 
Kiaa1324 Rabbit L. Deng 1: 1000 
Ku-70 (C19) Goat Santa Cruz 1: 1000 
Myc (9E10) Mouse Santa Cruz 1: 500 
p21 (DCS60) Mouse Cell Signalling 1: 1000 
p27 (# 2552) Rabbit Cell Signalling 1: 1000 
p53 (DOl) Mouse Santa Cruz 1: 1000 
p300 (N-15) Rabbit Santa Cruz 1: 500 
phospho-p27 (thr 187) (213 10137) Mouse Invitrogen 1: 1000 
phospho-Rb (ser807/811) Rabbit Cell Signalling 1: 1000 
phospho-Rb (ser795) Rabbit Cell Signalling 1: 1000 
SP1 (PEP2) Rabbit Santa Cruz 1: 500 
STAT-1 (C136) Mouse Santa Cruz 1: 1000 
Transgelin (ab14106) Rabbit Abcam 1: 1000 
HRP linked Mouse IgG - Amersham Pharmacia 1: 2500 
HRP linked Rabbit IgG - Amersham Pharmacia 1: 2500 
HRP linked Goat IgG - Santa Cruz 1: 2500 
Table 2.4. List of antibodies and their dilutions for western blotting. 
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2.5. Flow Cytometry 
Flow cytometry analysis was performed with the assistance of Derek Davies and 
colleagues at the CRUK FACS Laboratory, London Research Institute, Lincoln's Inn 
Fields. 
2.5.2. Bromodeoxyuridine Staining 
Cells were treated with 10µM BrdU for 8 hours. Cells were removed using trypsin, 
washed with PBS, and the pellet was resuspended in ice cold 70% ethanol to fix the 
cells. Ethanol was discarded after centrifugation at 2000rpm and cells were treated with 
2M HCl for 30 minutes at room temperature. Cells were then washed twice in PBS then 
once in PBS / 0.1% BSA 0.1% Tween-20. Anti-BrdU antibody (Becton Dickinson) was 
added directly to the cell pellet and incubated in the dark, for 20 minutes at room 
temperature. Cells were then washed twice in PBS / 0.1% BSA 0.1% Tween-20. FITC- 
conjugated rabbit anti-mouse F(ab')2 fragments (DAKO) were incubated for 20 minutes 
at room temperature in the dark, followed by one wash in PBS. Treatment with l00µ1 of 
RNase (100gg/ml) for 5 minutes at room temperature ensured only DNA would be 
stained. Propidium Iodide (PI) (50gg/ml) was then added to the cells and left for 15 
minutes at room temperature. Flow cytometry was performed using a FACS Calibur 
(Becton Dickinson). Fluorochromes were excited by a 488nm laser and fluorescence 
was collected between 515 and 545nm for FITC and above 580nm for PI. Forward and 
right angle scatter was used to define the cellular population and pulse processing of the 
PI signal was used to distinguish true G2 cells from G1 doublets. 
2.5.3. Propidium Iodide staining for Sub-G1 apoptosis analysis 
Cells were removed using trypsin, washed with PBS, and the pellet was resuspended in 
ice cold 70% ethanol to fix the cells. The media was collected to capture any floating 
cells for the analysis. Ethanol was discarded after, centrifugation at 2000rpm and cells 
were washed twice with phosphate citrate buffer (0.2M Na2HPO4 / 0.1M Citric acid). 
Treatment with 100µl of RNase (100gg/ml) for 5 minutes at room temperature ensured 
only DNA would be stained. PI (50 tg/ml) was then added to the cells and left for 15 
minutes at room temperature. Flow cytometry was performed as out lined in 2.5.2. 
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2.5.4. Propidium Iodide staining for Cell Cycle analysis 
An identical procedure as the PI staining for Sub-G1 apoptosis analysis was followed 
but omitting the phosphate citrate buffer washes. Flow cytometry was performed as out 
lined in 2.5.2. 
2.6. RNA extraction 
Cells were washed twice with ice cold PBS. In each well of a six well plate 250µ1 
TRIZOL reagent (Invitrogen) was added to the cells and incubated for 5 minutes at 
room temperature. TRIZOL extracts were collected using cell scrapers. 50µl chloroform 
was added per 250µ1 TRIZOL, vortexed for 15 seconds, and then incubated for 2-3 
minutes at room temperature. Samples were then centrifuged at 12,000g for 15 minutes 
at 4°C and the aqueous upper phase was transferred to a new microfuge tube. An equal 
volume of 70% ethanol was added and mixed by pipetting. The mixture was applied to 
an RNeasy Mini column (QIAGEN) then centrifuged for 15 seconds at 8000g. RNA 
clean up was followed using the manufactures instructions, including the DNAse I 
digestion step. The RNA concentration was estimated by spectrophotometer and 
formaldehyde-MOPS denaturing agarose gel electrophoresis was then used to assess 
RNA quality. 
2.7. Gene Expression Microarrays 
2.7.1. The Affymetrix GeneChip 
All experiments were performed using Human Genome U133 Plus 2.0 high-density 
oligonucleotide arrays (Affymetrix, url). Oligonucleotides of 25 base pairs in length are 
used to probe nwssage levels in the samples. Each gene of interest is represented by a 
set of oligonucleotides comprised of 11 probe pairs. Each probe pair is composed of a 
perfect match (PM) probe against a section of the mRNA molecule of interest, and a 
mismatch (MM) probe that is created by changing the middle (13th) base of the PM 
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with the intention of measuring non-specific binding. The HG-U133-Plus2 array 
contains 54,000 probe sets, representing an estimated 47,000 human transcripts. 
2.7.2. Target Preparation, Microarray Hybridisation, Staining 
and Scanning 
High quality RNA from each sample was used to prepare biotinylated target RNA, 
according to the manufacturer's recommendations (Affymetrix, url). An overview of 
this procedure is shown in Figure 2.2. Briefly, 8µg of total RNA was used to generate 
first-strand cDNA by using a T7-linked oligo(dT) primer. After second-strand synthesis, 
in vitro transcription was performed with biotinylated UTP and CTP, resulting in 
approximately 100-fold amplification of RNA. This labelled cRNA target was 
quantified then fragmented before preparation of the hybridisation cocktail. Spike in 
controls were added to fragmented cRNA (15µg per HG-Ul33Plus2 array), before 
overnight hybridisation. Arrays were then washed and stained with streptavidin- 
phycoerythrin, before being scanned on an Affymetrix GeneChip 3000 scanner. After 
scanning, array images were assessed by eye to confirm scanner alignment, the absence 
of significant bubbles or scratches on the chip surface, and the absence of slides with 
very high background (scanning and image analysis was performed by Tracy Chaplin, 
Institute of Cancer, Charterhouse Square). 
2.7.3. Data Analysis 
Data analysis was performed using BioConductor (Gentleman et al., 2004) and 
Genespring (Genespring GX 7.3, Agilent Technologies) software. BioConductor is an 
open development software project, providing access to a wide range of statistical and 
graphical approaches for the analysis of genomic data. It works through the R open 
source programming language (Ihaka and Gentleman, 1996). Data was processed from 
the *. CEL file format which contains information on background values and perfect 
match and mismatch intensities. Data processing was done using "affy" (Gautier et al., 
2004) and "simpleaffy" (Wilson & Miller, 2005) packages in BioConductor. 
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One-Cycle Target Labeling 
(for 1-15 pg total RNA or 0.2-2 pg mRNA) 
Approximate 
Products 
Total RNA Sample ExperimentTime Used 
11 " 5' 11111111111 AAAAA 3' 
Poly-A RNA Poly-A RNA 
PolyA RNA Controls 
Control Kit Control addition 
T7 - Oligo(dT) Primer 
1St strand 3' TTTTT - 5' 1.5 hours 
cDNA synthesis 
5' 1111111111 AAAAA 3' 
One-Cycle 3' II TTTTT - 5' 
cDNA 
Synthesis 
Kit 2nd strand 2 hours 
cDNA synthesis 
5' UCJ LI IJ LUULI L' AAAAA - 3' 
3'IlC 1UU[0flL]UTTTTT-5' 
Sample 
Cleanup Cleanup of double-stranded cDNA 0.5 hours 
Module 
" Biotin labeling of antisense cRNA 
Biotinylated 
/ Ribonucleotide overnight 
Labeling Kit "0. 
3.1 1111 U*U U*U U 5. 
Sample 
Cleanup of biotinylated cRNA + 0.5 hours 
Cleanup 
Module Fragmentation + 1 hour 
Hybridization Hybridization controls 
Control Kit 
" 
Hybridization 16 hours 
40 Streptavidin-phycoeryt hrin 
Biotinylated anti-strept avidin 
antibody 
Washing/Staining + 1.5 hours 
Scanning 4 < 12 minutes 
liiii; E. " ml- 
Legend 
RNA UL1UL DNA ý T7 promoter 0- Biotin U'- Pseudouridine 
Figure 2.2 Affymetrix GeneChip Eukaryotic Sample and Array Processing. A more detailed 
description of this procedure can be found in Section 3: Eukaryotic Sample and Array Processing of the 
GeneChip Expression Analysis Technical Manual (Affymetrix, ur! ). 
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2.7.3.1. Quality Control 
In order to ensure the arrays fulfilled a series of Affymetrix recommended quality 
control metrics (described in detail in the Data Analysis Fundamentals Manual, 
Affymetrix, 
Ouri) 
the raw data were pre-processed using the "simpleaffy" BioConductor 
package. Simpleaffy uses the Affymetrix MAS 5.0 array processing algorithms 
(described in detail below in section 2.7.3) to provide access to these metrics. 
Average background 
The average background is the level of signal detected by the scanner surrounding the 
signal from the specific features. No Affymetrix guidelines are suggested for average 
background only that the values are similar and typically in the range of 20 to 100. Any 
arrays with unusually high background would be discarded from this analysis following 
the visual inspection. 
Scale factor 
Before the data from different arrays can be compared a global normalisation method 
needs to be conducted in order to minimise variation between arrays. Variation is 
caused by biological and experimental factors throughout the microarray protocol, 
starting from the sample preparation and ending with data acquisition. The scaling or 
normalisation factors should be comparable among arrays. A large discrepancy scale 
factors (3 fold or greater) may indicate significant assay variability or sample 
degradation leading to poor quality data. 
3' to 5' ratios for p-actin and GAPDH. 
ß-actin and GAPDH are used to assess RNA sample and assay quality. Specifically, the 
intensities of the 3' probe sets for ß-actin and GAPDH are compared to the intensities of 
the corresponding 5' probe sets. The ratio of the 3' probe, set to the 5' probe set is 
should generally be no more than 3 for the targets prepared using the one cycle target 
labelling procedure described in Figure 2.2. A high 3' to 5' ratio indicates degraded 
RNA or inefficient transcription of cDNA or biotinylated cRNA. 
In addition to the "simpleaffy" quality control measures described above, target cRNA 
quality was also assessed using the array-by-array cRNA digestion plot produced using 
the "affy" BioConductor plotAffyRNAdeg function. This averages individual probe 
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intensities by their location in each probe set, following a scaling transformation an 
average can then be taken over all probe sets on the array. A side-by-side plots of these 
averages, then illustrates any global patterns of 5' to 3' probe intensity. Any 
abnormally low levels of 3' intensity would illustrate a degraded RNA or inefficient 
transcription of cDNA or biotinylated cRNA. 
2.7.3.2. Data Correction, Normalisation and Transformation 
After careful consideration of the quality control measures described above the 
correction, normalisation and transformation of raw array data took place, following a 
four-step process of Background Correction, Normalisation, Perfect Match(PM)/ 
Mismatch (MM) Correction and Summarisation. The data analysis was performed 
using the "affy" BioConductor package using the expresso function. In order to 
establish the most appropriate method for the microarray experiments performed in this 
study, the Affymetrix recommended mass method (Affymetrix was assessed along 
with variations of the Robust Multi-array Average (RMA) process (Irizarry et al., 
2003), specifically altering Background Correction and PM/MM Correction steps. The 
detail of each method used is described below. 
Background correction 
Background correction is the process of correcting probe intensities on an array by 
subtracting the background level of signal detected by the scanner. The following 
approaches were assessed. 
" none - no background correction. 
" rma - Developed by Irizarry and colleagues, this correction uses a model that 
assumes observed intensity is the sum of an exponential signal component and a 
linear noise component. PM probe intensities are corrected using a global model for 
the distribution of probe intensities (Irizarry et al., 2003). 
" masS - This is the method recommended by. Affymetrix (Affymetrix url where a 
chip is broken into subgrids, and background is calculated for each reg'onbased on 
the lowest 2% of probe intensities. For each region, a weighted average background 
value is calculated using the distances of the probe location and the areas 
surrounding the probes of the different regions. Individual probe intensity is then 
adjusted based upon the average background for each region. 
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Normalisation Methods 
Normalisation is the process of removing non-biological variability between arrays. All 
global normalisation methods work on the assumption that there is no variability 
between different microarrays. 
quantiles - Developed by Bolstad and colleagues (Bolstad et al., 2003), quantiles aims 
to give each chip the same empirical distribution. The method assumes that there is an 
underlying common distribution of intensities across the different experimental 
samples. The principle of the quantiles algorithm is to sort the probe intensities into 
ranks of similar intensity across all the microarrays. A median intensity for each rank is 
then calculated and reattributed to the all the probesets in the originating rank. 
mass - Developed by Affymetrix mas5 uses a global scaling factor in order to normalise 
the data between each microarray. A scaling factor is calculated based on the average of 
all the intensities, after removing the intensities in the lowest 2% and highest 2%. This 
factor is then used to correct the intensities across all the probe sets on all the arrays. 
Perfect Match / Mismatch Correction 
PM correction is the process of adjusting PM intensities based on information from the 
MM intensity values. 
pmonly - No PM/MM correction was performed and only PM values were used for 
analyses. It is widely reported that MM probesets may be detecting signal as well as 
non-specific binding and therefore including the MM parameter will contribute to the 
overall noise in the data analysis (Naef et al., 2002; Irizarry et al., 2003). 
mass - Recommended by Affymetrix, in this method an ideal MM value is subtracted 
from the PM intensity value, always leaving a positive value. An "artificial" mismatch 
value is computed when the MM intensity is greater than or equal to the PM and results 
in a PM-MM that is close to zero. 
Summarisation Method 
In order to combine the pre-processed probe intensities together in order to compute a 
single expression measure for each probe set on the array, a summarisation method was 
employed 
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medianpolish - Described by Irizarry and colleagues (Irizarry et al., 2003), median 
polish uses a multi chip linear model fitted to the data from each probe set and the result 
value is in log2 scale. 
mass - Recommended by Affymetrix uses a robust average using 1-step Tukey bi- 
weight on log2 scale. 
2.6.3.1 Differential Gene Expression 
Filtering 
Expression profiling experiments are interested in identifying genes that change their 
expression between two groups. Therefore, it is important to first to filter the data to 
include only those probe sets that change in expression. A commonly used method is to 
filter genes based on the fold change between the test and reference groups. However, 
when filtering on fold change there is a risk of ignoring genes that change significantly 
but are below the arbitrary fold change threshold. A more biologically sensitive method 
is to order genes from low to high standard deviation, in order to identify the most 
variable genes across the conditions analysed. The top 2500 probe sets with highest 
variance can then be used in clustering and statistical testing. 
Hierarchical Clustering 
Hierarchical clustering analysis allows the monitoring of overall patterns of gene 
expression between the normalised arrays, and uses standard statistical algorithms to 
arrange the genes according to a similarity in gene expression patters. The hierarchical 
clustering was performed using GeneSpring, based on the approach used by Eisen and 
colleagues (Eisen et al., 1998). The hierarchical clustering analysis aimed to produce a 
map of results where probe sets were grouped together based on similarities in their 
patterns of normalised expression all of the microarrays. The similarity or dissimilarity 
between a pair of objects in the data set was found by evaluating a distance measure and 
assuming a normal distribution of gene expression values, it is appropriate to use the 
Pearson correlation coefficient, which calculates the similarity measure based on a 
linear model. The objects are then grouped into a hierarchical cluster tree (dendrogram) 
by linking newly formed clusters. The same algorithms can then be applied to cluster 
the experimental samples for similarities in her overall patterns of gene expression. 
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Hierarchical clustering analysis wa prefo ed on the normalised and filtered gene 
expression data. 
Statistical Analyses 
This process involves the identification of efe entially expressed genes between 
different experimental conditions. The Welch's t-test was applied on filtered data using 
the one way ANOVA setting in GeneSpring. This is a parametric test that works on the 
assumption that microarray data are normally distributed. Another common assumption 
of parametric statistical analyses, such as Student's t-test, is that the variability of a gene 
is constant across treatment types. This is difficult to assess for microarray data so it is 
safest to assume that variance may differ between treatment and control. Welch's t-test 
corrects for difference in variability, and does not detect it, therefore is more suitable for 
microarray data differential gene expression analysis. In a conjunction with this test a 
False Discovery Rate (FDR) multiple test correction was applied across the significant 
genes using GeneSpring. Multiple testing corrections adjust p-values to correct for 
occurrence of false positives. False positives are genes that are identified as significant 
changes following statistical tests, when their true state is unchanged. A False 
Discovery Rate of 5% (p-value <0.05) on an array of 54,000 reporters would mean that 
on any size gene list, 2700 genes would be expect to be false leads. The Benjamini and 
Hochberg FDR correction was applied across the significant genes (Benjamini & 
Hochberg, 1995). This test reduces the number of false positives without enriching the 
number of false negatives which can be the case for other types of correction 
(Benjamini & Hochberg, 1995). Briefly, the p-values are ranked from the smallest to 
the largest. The largest p-value remains as standard. The second largest p-value is 
multiplied by the total number of genes in the gene list of differentially expressed genes 
divided by its rank. The same approach is repeated with the second largest p-value and 
so on, until no gene is found to be significant. The resulting FDR corrected values 
mean that a FDR of 5% (FDR corrected p-value <0.05) on a gene list of 500 would 
expect 25 to be false leads, regardless of the number of reporters on the array. 
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2.7.4. Gene Ontology 
2.7.4.1. Introduction to Gene Ontology 
Developed by the Gene Ontology Project, Gene Ontology (GO) is a controlled 
vocabulary to describe gene and gene pr duct attributes in any organism (Ashburner et 
al., 2000; The Gene Ontology project ur In particular, each gene is assigned a term 
based on its Molecular Function (e. g. DNA Binding Transcription Factor), Biological 
Process (e. g. Regulation of Transcription from RNA polymerase II promoter), and 
Cellular Component (e. g. Nucleus). The annotations are a mixture of those that are 
manually assigned, based on primary and review literature and some automatically 
assigned based on predicted gene functions. Each GO term is additionally assigned a 
code based on the strength of the associated evidence and more than one term can be 
assigned to each gene. It should be noted that the value of GO is limited by the quality 
of the associated research that is used to define each annotation. GO terms are 
organised into a hierarchical structure, an example for AP-2y is shown in Figure 2.3. A 
GO path is where a GO term is connected to several other GO terms higher in the GO 
hierarchy. An added level of complication is that these paths intersect or split and also 
several paths may lead to an individual gene. 
GO: 0008150 : biological_process [141300] 
'GO: 0065007 : biological regulation [20429] 
, GO: 0050789 : regulation of biological process [18593] 
'00: 0050794 : regulation of cellular process [ 14845] 
L*GO: 0031323 : regulation of cellular metabolic process [9642] 
'-GO: 0019219 : regulation of nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process [8738] 
'-IGO: 0045449 : regulation of transcription [8305] 
LsGO: 0006355 : regulation of transcription, DNA- 
dependent[6764] 
"GO: 0006357 : regulation of transcription from 
RNA polymerase II promoter [ 1747] 
Figure 2.3. Biological Process Gene Ontology Hierarchy for TFAP2C. In brackets is the total number 
of genes assigned the particular GO term. 
In order to assess any patterns in groups of genes within a differential gene expression 
data set, data can be sorted into broad functional groups based on their assigned 
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Biological Process GO terms. This can be done by hand which offers the advantage of 
deciding the most appropriate terms for each gene where two or more differing terms 
are described. Or this analysis can be automated. For automated analysis the GOSTAT 
and Panther web based interfaces were used. 
The GOstat interface 
This analysis was conducted using the GOstat interface developed by Beissbarth and 
Speed (GOstat url; Beissbarth & Speed 2004), in order to establish with statistical 
confidence which GO terms were over-represented or under-represented in a list of 
significantly regulated transcripts. Briefly, for all of the transcripts analysed, GOstat 
determines the associated annotated GO terms and all branches on their connection 
path. The program then counts the number of appearances of each GO term for the 
transcripts in the list being analysed, as well as in a reference list. For each GO term, a 
Chi2 p-value is calculated representing the probability that the observed numbers of 
counts could have resulted from randomly distributing this GO term between the tested 
and the reference lists. 
The PANTHER classification system 
The PANTHER classification system is very similar to the Gene Ontology system, 
based on interconnecting hierarchies of terms, but great] abbreviated and simplified 
(NE et al, 2005; PANTHER Classification System, url). This facilitates automated 
high-throughput analyses and accessible graphical outputs. In order to establish with 
statistical confidence which PANTHER Biological Process annotations were over- 
represented or under represented in a list of significantly regulated transcripts, they can 
be compared to all of the PANTHER Biological Process represented by all of the 25431 
genes within the NCBI Refseq Database. Similarly to the GOstat program described 
above, this allows an objective and statistically controlled measure of enriched GO 
terms from with the data set. 
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2.8. Quantitative PCR 
2.8.1. Reverse transcription reaction 
A microgram of total RNA was used to generate cDNA. Reverse transcription reactions 
were performed using sterile plastic ware throughout and aerosol filter tips to reduce 
contamination. All materials were from Applied Biosystems. The reactions were 
prepared on ice as follows, 1µg total RNA, 5.5mM MgC12,2.5mM dNTP mix, 2.5µM 
Random Hexamers, RNase Inhibitor (0.4U/µl), MultiScribe Reverse Transcriptase 
(1.25U/µl) and RNAse free water to make the reaction volume up to 50µl. Samples 
were then transferred to a thermocycler and reactions incubated at 25°C for 10 minutes, 
48°C for 30 minutes followed by 95°C for 5 minutes to inactivate the enzyme. After the 
RT reaction one can assume that 1µg of total RNA corresponds to 1µg of cDNA. 
2.8.2. Quantitative "Real Time" PCR reaction 
Pre-designed transcript specific primer-probe sets for use in for "real time" PCR 
reactions were purchased from Applied Biosystems, the details of these are outlined in 
Table 2.5. Briefly, a probe binds the DNA between the two primers and is dye labelled 
at the 5' end whose fluorescence is controlled by a quencher at the 3'. As the reaction 
proceeds, the dye is cleaved from the probe and thus released from the quencher. 
Therefore as the reaction progresses the fluorescent emission from the dye increases 
allowing accurate quantification of the target sequence. PCR reactions (25µ1) were 
prepared in triplicate on a 96-well plate using 15ng cDNA per reaction. 2X Universal 
PCR master mix (Applied Biosystems) was combined with the primer-probe mix to 
minimise pipetting error between each well of the plate. In addition to the samples, a no 
template control was included to look at DNA contamination of the samples and a no 
reverse transcriptase control was included to control for potential genomic DNA 
contamination in the RNA extraction. This consisted of an equivalent amount of a 
reverse transcriptase reaction in which the reverse transcriptase was omitted. In order to 
assess the efficiency of the PCR reaction and to allow relative quantification, a standard 
curve was run alongside the samples. The standard curve used four separate dilutions of 
cDNA per reaction and was prepared in triplicate; 25ng, 6.25ng,. 1.5625ng and 0.39ng. 
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The PCR reaction was carried out on the 7700 Sequence Detection System (Applied 
Biosystems) using the following program as standard: 50°C for 2 minutes (AmpErase 
UNG step), 95°C for 10 minutes to activate the AmpliTaq Gold, then 40 cycles of 95°C 
for 15 seconds, 60°C for 1 minute. 
Transcript Assay ID 
Probe Dye 
Layer 
GAPDH 4319413E VIC 
TFAP2C Hs00231476_ml FAM 
TIMP2 Hs00234278_ml FAM 
PERP Hs00751717_s 1 FAM 
SPDEF Hs00171942_ml FAM 
DKKI Hs00183740_ml FAM 
IGFBP3 Hs00181211_ml FAM 
CXCL12 Hs00171022_ml FAM 
INHBA Hs00170130_ml FAM 
KIAA1324 Hs00331399_ml FAM 
CELSR2 Hs00154903_ml FAM 
TGLN Hs00162558_ml FAM 
Table 2.5. Details of primer-probe sets used in qPCR analyses. All PCR reactions were analysed by 
agarose gel electrophoresis to ensure the presence of a single product under standard PCR conditions. 
Results were initially analysed using the Sequence Detection software version 1.9.1. 
(Applied Biosystems). The amplification plots were observed in both linear and semi- 
log plots, with the background corrected and the threshold cycles determined. Following 
this the standard curve was plotted showing the slope (PCR efficiency) and the 
correlation coefficient. A slope of -3.3 relates a 100% efficient PCR reaction, a ten fold 
increase in PCR product every 3.3 cycles. The PCR efficiency was considered 
satisfactory above 98% and only if all the samples fell within the points of the standard 
curve. Data was analysed according to the Standard Curve Method for relative 
quantification (Applied Biosystems(url). Standard curves were prepared for both the 
target (e. g. AP-2y) and the endogenou reference (e. g. GAPDII. For each experimental 
sample, the relative quantity of target and endogenous reference levels was determined 
from the appropriate standard curve. The target amount was then divided by the 
endogenous reference amount to obtain a normalised target value. The transfection 
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control sample was used as a calibrator and each of the normalised target values was 
divided by the calibrator normalised target value to generate the relative expression 
levels. Triplicate samples were used to generate standard errors. 
The OAS1 real time PCR reactiontI erformed using a SYBR green PCR reaction to 
detect PCR products, in an identical manner as the qPCR described for ChIP (see 
section 2.9.3), the data normalised to endogenous reference levels as described 
above. The primers used for OAS1 amplification were 5'- 
AGGTGGTAAAGGGTGGCTCC-3' and 5'-ACAACCAGGTCAGCGTCAGAT-3' 
(Bridge et al., 2003). 
2.9 Chromatin ImmunoPrecipitation Assays 
All of the ChIP assays presented in this thesis were performed in collaboration with 
Karsten Friedrich, who performed the chromatin preparation and IPs. 
2.9.1. Preparation of soluble chromatin 
Cells were analysed at approximately 70-80% confluency on a 15cm plate. Chromatin 
was cross-linked by the addition of formaldehyde to a final concentration of 1% and 
incubated at 37°C for 10 minutes. Cross-linking was stopped by the addition of glycine 
to a final concentration of 0.125M and incubated at RT for 5 minutes with gentle 
rocking. Cells were washed twice with ice cold PBS then detached using a cell scraper 
in 5ml PBS with Complete Proteinase Inhibitors (Roche) and pelleted at 3,000g for 5 
minutes at 4°C. The supernatant was removed and the resultant cell pellet was gently 
resuspended in 3m1 (for 3 plates) of cell lysis buffer (5mM PIPES pH 8.0,85mM KCI, 
0.5% NP40, and Complete Proteinase Inhibitors). Cell lysis was performed on ice for 
10 minutes and followed by centrifugation to pellet the crude nuclei fraction (5,000g for 
5 minutes, 4 °C). The pellet from 3 plates was resuspended in S00µ1 of nuclei lysis 
buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HC1 pH 8.1) and incubated for 10 minutes 
at 0-4 °C (care was taken to prevent SDS precipitation). The chromatin was sheared to 
an average length of 500bp by sonication. This was achieved using a 10 second pulse 
followed by a 30 second rest for a total of 24 cycles at 30% amplitude on the Sonics 
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Vibracell VCX500 using a 0.3cm tip. Sonications were performed on ice and a multiple 
tipped probe allowed simultaneous sonication of up to four microfuge tubes, 
maximising the homogeneity of sonication between experimental conditions. After 
sonication, debris was pelleted by centrifugation at 14,000g for 10 minutes at 10°C and 
the supernatant transferred to a clean tube. At this point chromatin could be snap frozen 
in liquid nitrogen and stored at -80°C for several months. Typically, 3-4 plates 
(15cm) 
yielded enough chromatin to perform 10 IP reactions including the controls. 
2.9.2. Immuno Precipitation 
Chromatin was diluted approximately 2.5 fold in IP buffer (0.5 % Titron X100,2 mM 
EDTA, 20 mM Tris-HC1 pH 8.1,100 mM NaCl, plus protease inhibitors) before being 
bulk pre-cleared using of 50% (w/v) blocked Protein A Sepharose (PSA), in order to 
reduce the level of background in IPs. 
To block the PSA beads two washes, followed by a2 hour gentle rotation at 4°C, in a 
2X volume of IP buffer with 0.1 mg/ml sonicated herring sperm DNA (Sigma B8894) 
and 0.2 mg/ml BSA (Invitrogen 15634-017) was conducted, followed by a final wash in 
lx IP buffer prior to use. 5O0µ1 of 50% (w/v) blocked PSA beads were added to the 
1250µ1 of diluted chromatin (50µl of beads per IP reaction) and incubated by gentle 
rotation at 4°C for 1 hour. PSA was removed by centrifugation at 2,000g for 3 minutes 
and the supernatant transferred to a clean tube. 
For the ChIP experiments documented in this thesis looking at the differences in 
promoter occupancy between AP-2y expressing and non-expressing cell lines, it was 
important to ensure that the amount of starting chromatin was kept consistent between 
experimental conditions. Therefore, at this stage a 125µl aliquot of the pre-cleared 
chromatin was taken for DNA isolation and quantification. 
DNA isolation was performed using Chelex 100 beads based on the protocol described 
by Nelson and colleagues (Nelson et at., 2006). The DNA from this aliquot was 
precipitated in 2.5 volumes of ethanol and then washed in 70% ethanol. The dissolved 
pellet was then resuspended in 100µ1 of a 10% (w/v) Chelex 100 suspension and boiled 
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for 10 minutes. After cooling, 1µl of proteinase K (10 mg/ml) was added and incubated 
on a thermal mixer at 55°C for 30minus (1000rpm). Samples were boiled for a further 
10 minutes to inactivate the protenase K and then centrifuged at 12,000g for 1 minute 
(4°C). The DNA supernatant (approximately 80µl) was then transferred to a new tube. 
A further 120µl of water was added to the Chelex beads, vortex mixed and then 
centrifuged at 12,000g for 1 minute (4°C). The 120µ1 supernatant was then pooled with 
the previous supernatant and the DNA concentration calculated using a 
spectrophotometer. This sample was kept on ice and used as the total input chromatin. 
An equivalent amounts of chromatin as determined by DNA concentration were then 
aliquoted for each IP reaction. A no antibody control was included as a background 
comparator for IP experiments and in addition a mock sample was set up containing no 
chromatin to give an indication of DNA contamination during the reaction. The details 
of the antibodies using in ChIP are outlined in Table 2.6. The amounts of each specific 
antibody were empirically determined by Karsten Friedrich. IP reactions were 
incubated over night at 4°C with gentle mixing. 
Antibody Animal Origin Amount of Antibody Source (Cat#) 
AP-2y (KF3) Rabbit l0µ1 Lab Reagent 
p300 (N-15) Rabbit 5µl Santa Cruz (sc-584) 
Acetylated-H4 Rabbit 141 Upstate (06-866) 
Table 2.6 Antibodies used in ChIP assays in this study. Amount (t1) corresponds to the volume of 
antibody added to a tenth of the chromatin extracted from 3-4,70-80% confluent, 15cm plates of MCF-7 
cells (Approximately 5µg of antibody per 106 cells). 
The immune complexes were collected by adding 50 µl of blocked 50 % (w/v) PSA to 
each sample and incubating on a rotating platform at 4°C for 1 hr. The PSA beads were 
pelleted by centrifugation at 2,000g for 3 minutes at RT and the supernatant discarded. 
PSA beads were washed for three minutes on a rotating platform using 1 ml of wash 
solution and then centrifuged for 3 minutes at 2,000g at RT using the following wash 
conditions: 
" Wash One: 2 mM EDTA , 20 mM Tris-HC1 [pH 8.0], 0.1 % SDS, 1% Titron X100, 
150 mM NaCl 
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" Wash Two: 2 mM EDTA, 20 mM Tris-HCl [pH 8.0], 0.1 % SDS,, 1 % Titron 
X100, 
500 mM NaCl 
" Wash, Three: 1 mM EDTA , 10 mM 
Tris-HC1 [pH 8.0], 1% NP-40,1 % 
Deoxycholate, 0.25 M LiCI 
" TE wash repeated twice: 1 mM EDTA , 10 mM 
Tris-HC1 [pH 8.0], 
After the centrifugation, as much of the remaining TE as possible was removed without 
disrupting the PSA beads. The antibody/chromatin complexes were eluted from the 
PSA by adding 150µl elution buffer (1% SDS, 50mM NaHCO3) and shaking at 
1000rpm for at least 30minutes at RT. Elutes were centrifuged at 14,000g for 1 minute 
to pellet PSA and supernatant was removed to a clean tube. DNA was then isolated 
using Chelex 100 beads as described above and 51l was used per reaction in a 
quantitative real time PCR reaction described below. 
2.9.3. Quantitative PCR for ChIP 
Quantitative "real time" PCR for ChIP was performed using promoter specific primer 
pairs and measured using the fluorescent SYBR Green dye as a detector. Briefly, 
SYBR Green intercalates into double-stranded DNA and produces a fluorescent signal. 
The intensity of the signal is proportional to the amount of dsDNA present in the 
reaction. Therefore, at each step of the PCR reaction, the signal intensity increases as 
the amount of specific product increases. 
Promoter specific primer pairs, except where stated were designed using the Primer 
Express 3.0 software (Applied Biosystems, (9 following recommended guidelines. In 
order to optimise the PCR reaction, a titration of primer concentration was performed. 
Combinations of the final primer concentrations: 5OnM, 300nM, 900nM, were assessed 
for each primer pair under standard PCR conditions. All PCR products were visualised 
by agarose gel electrophoresis in order to confirm the presence of a specific product. 
Details of the primers used in ChIP are shown in Table 2.7 
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Final 
Genomic Amplicon 
Primer Pairs 5' - 3' Primer Reference 
Region Location Concentrations 
GTGGCTCTGATTGGCTTTCTG 50nM Kaeser & 
-2290 -2185 CTGAAAACAGGCAGCCCAAG 300nM Iggo, 2001 
TTGTATATCAGGGCCGCGCT 300nM Shan et al., 
-21 +44 CGAATCCGCGCCCAGCTC 300nM 2003 
CDKNIA 
Promoter 
TGGCCCCTCTGTGAAAACAT 300nM 
-4005 -3931 This Study TTCCTGTTCCTGGCTCTAACAAC 300nM 
TGATCTGAGTTAGGTCACCAGACTTC 300nM 
-935 -864 This Study TCCCCACATAGCCCGTATACA 9006M 
Chrl satellite CATCGATGGAAATGAAAGGAGTC 300rM Jiang et 
Sat2 
repeat ACCATTGGATGATTGCAGTCAA 300nM al., 2004 
Table 2.7. The detail of the primers used for SYBR Green Quantitative PCR for analysis of ChIP 
elutes. Amplicon Location are relative to the start of transcription. 
PCR reactions (25µl) were prepared in triplicate on a 96-well plate using 5p1 of eluted 
DNA per reaction. 2X SYBR green aster mix (Applied Biosystems) was combined 
with the primers to the indicated concretion Table 2. In addition to the samples, a no 
template control was included to look at DNA contamination of the samples. In order 
to assess the efficiency of the PCR reaction and to allow relative quantification, a 
standard curve was run alongside the samples. The standard curve used four separate 
dilutions of input chromatin ind was prepared in triplicate; 1/100,1/500,1/2000 and 
1/5000. The PCR reaction wasland initial data analysis was carried out as described in 
Section 2.8. The relative quantities of each PCR reaction were calculated from the 
standard' dilution of input chromatin. The "no antibody control" quantity was then 
subtracted from the specific antibody quantity and expressed relative to the 1/1000 
dilution of the total input chromatin. 
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2.10. Luciferase Reporter assays 
2.10.1. Transient Transfection of Luciferase Reporter 
Constructs in HEPG2 cells. 
HEPG2 cells were seeded in 24-well plates at 1x 105 cells per well and were 
transfected in triplicate the following day using FuGENE 6 (Roche Molecular 
Biochemicals). Briefly, equal total amounts of plasmid DNA for triplicate reactions was 
aliquoted into tubes, 100µl media without serum was added to the DNA and Fugene 
was added at a ratio of 3: 1 (µl Fugene: pg DNA) and incubated at RT for 15 minutes. 
The reaction is then aliquoted onto the cells which were supplemented with media 
containing 10% FCS. To accurately show changes in luciferase reporter activity, cells 
were transfected with both the luciferase reporter construct and the phRG-TK Renilla 
plasmid (Promega). The phRG-TK Renilla utilises a constitutively expressing promoter 
to drive the expression of Renilla luciferase, therefore allowing luciferase levels to be 
normalised between reactions. After transfection cells were incubated for 48 hours 
before being assessed for luciferase reporter activity. Cells were washed twice with ice 
cold PBS, then lysed with l00pl passive lysis buffer (Promega) at RT for 15 minutes 
with shaking. Lysis buffer and cell debris was transferred to a clean microfuge tube and 
the debris was pelleted by centrifugation at 14,000g for 1 minute. 40gl of cleared 
lysates were aliqouted onto a 96-well plate. Luciferase levels were determined using 
Promega's dual luciferase kit according to the manufacturer's instructions on the 
Luminoskan Ascent (Thermo Labsystems) luminometer. 
2.10.2 Transient Transfection of Luciferase Reporter Constructs 
in MCF-7 cells in conjunction with siRNA transfections. 
MCF-7 cells were transfected with siRNAs in triplicate using six well plates as 
described in Section 2.2.2. Twenty four hours later a second transfection with both the 
luciferase reporter construct (1µg) and the phRG-TK Renilla plasmid (0.25µg) was 
carried out using FuGENE 6 in an identical manner to that described above. At 48 
hours, cells were passaged 1 in 2 and finally at 72 hours luciferase activity was assayed 
as described above except cells were lysed in 2O0µ1 of passive lysis buffer. 
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CHAPTER 3: RESULTS AP-27 RNA INTERFERENCE 
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3.1. Assessment of AP-2y expressing cell lines. 
With the aim to establish which cellular pathways have become activated in AP-2y 
expressing breast tumours we planned to determine the AP-2y dependent gene 
expression profile, initially in breast derived cell lines. It was decided to compare wild 
type over-expressing lines with derivatives "knocked down" for AP-2y expression using 
RNAi technology. 
In order to confirm the suitability of some known AP-2 expressing breast cell lines 
levels of AP-2a and AP-2y were assessed by western blot, shown in Figure 3.1. Table 
3.1 summarises this data together with the status of key breast cancer related proteins in 
these cell lines. Initial work focused on the MCF-7 mammary carcinoma cell line, 
chosen as it exclusively expresses AP-2y at high levels. Upon RNAi mediated depletion 
of AP-2y in MCF-7 cells all AP-2 would be removed from this cells thus avoiding a 
further level of complication that might be encountered in other cell lines where AP-2a 
and AP-2y are expressed together. MCF-7 cells also express high levels of ERa 
together with AP-2y, a combination best thought to reflect the clinical data showing 
high levels of AP-2y correlated with poor patient prognosis in ERa positive primary 
breast carcinomas. 
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Figure 3.1. AP-2y and AP-2a protein levels in a panel of breast cell lines. Whole Cell extracts 
(5pg/lane) were separated by SDS/PAGE and blotted to a membrane. Blots were probed with primary 
antibodies against AP-2y or AP-2a before being reprobed for Ku-70 as a 
loading control. A 
representative loading control is shown. See Materials and Methods 2.3 for antibody 
details. 
MCF-7 MCFIOA T47D ZR-75-1 
AP-2y +++ ++ +++ + 
AP-2a +/- ++ ++ +++ 
AP-2ß - nd nd +/- 
CITED2 ++ + + + 
CITED4 +++ +++ +++ + 
CBP ++ + ++ 
p300 ++ + ++ ++ 
ERa +++ - ++ ++ 
ERBB2 -/+ + + ++ 
p53 wt wt mut wt 
Table 3.1. Summary of AP-2 and cofactor expression data and in addition the status of key cancer 
related proteins in a panel of breast cell lines. Table summarises protein levels as determined by 
western blot, except for p53 where status as wildtype (wt) or mutant (mut) is indicated. Key: Negative (- 
), barely detectable (-/+), low expression (+), expression readily detectable (++), very high level of 
expression (+++), or not determined (nd). p53 status from Bartek et al., 1990. Others determined by 
Western Blot (Helen Hurst, personal communication). 
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3.2. Identification of AP-2y targeting siRNAs. 
Selection of AP-2y targeting sequences is described in the Materials and Methods, 
Section 2.2. Briefly sequences specific to AP-2y were selected for the generation of 
siRNA oligonucleotides based on published suggestions and BLAST searches were 
performed to verify the specificity. (Tuschl et al., 1999; Reynolds et al., 2004; Ui-Tei 
et al., 2004). Additional sequences specific to AP-2y were ordered from Dharmacon 
and consisted of four sequences recommended for use in SmartPool transfections (see 
Section 2.2). A non-specific random sequence was used for a non-silencing control 
(Qiagen). Figure 3.2 shows efficient knock down of AP-2y protein levels by three 
dsRNA oligonucleotide sequences after transient transfection in MCF-7 cells. 
For later work in this study sequences from Dharmacon were tested in transient 
transfections in MCF-7 cells. Figure 3.3 shows western blots of MCF-7 cells following 
transient transfection of AP-2y targeting siRNAs in order to assess the additional 
Dharmacon sequences and a SMARTPoo1 of the four Dharmacon sequences alongside 
two of the siRNAs already determined to be effective at AP-y silencing. AP-2y siRNA3 
and Dharmacon siRNA #06 target an identical region of the AP-2y mRNA and show an 
expected similar efficiency of knock down. Dharmacon siRNA #05 and #08 are not 
very efficient showing approximately 50% knockdown. Dharmacon siRNA #07 or the 
SMARTpool of #05, #06, #07 and #08 show knock down at levels equivalent to AP-2y 
siRNA2 and AP-2y siRNA3. 
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Figure 3.2 Reduction of AP-2y protein in MCF-7 cells with different siRNAs. MCF-7 cells were 
transfected with Transfection reagent only (Control), Non-silencing control siRNA or siRNA targeted to 
AP-2y: siRNA 1, siRNA2, siRNA3, siRNA4 or siRNA5 (Lanes 2-6). Cells were harvested at the 96 hours 
following transfection with 25nM of siRNA per well of a six well plate. Whole Cell extracts (10µg/lane) 
from MCF-7 cells were separated by SDS/PAGE and blotted to a membrane. Blots were probed with 
primary antibodies against AP-2y before being reprobed for Ku-70 as a loading control. 
rrrr r"r A- Ku70 
W'Gi f-- AP -2-1 
23 05 06 07 08 SP 
ý, °c®c AP-2: Dharmacon 
siRNA AP-2 
oc siRNA 
Figure 3.3 Reduction of AP-2y protein in MCF-7 cells with Dharmacon siRNAs. MCF-7 cells were 
transfected with Transfection reagent only (Control), Non-silencing control siRNA, siRNA targeted to 
AP-2y (siRNAI, siRNA2), individual Dharmacon AP-2y siRNAs (siRNAs 05-08) or a SMARTPool of 
siRNAs 05-08 (SP). Dharmacon siRNAs 05,06,07 and 08 correspond to Dharmacon product codes J- 
005238-05, J-005238-06, J-005238-07, and J-005238-08 respectively. Cells were harvested at the 96 
hours following transfection with 25nM of siRNA per well of a six well plate or for the Smart Pool 
6.25nM of each 6,7,8, and 9 to give a total of 25nM of siRNA per well of a six well plate. Whole Cell 
extracts (5pg/lane) from MCF-7 cells were separated by SDS/PAGF and blotted to a membrane. Blots 
were probed with primary antibodies against AP-2y before being reprobed for Ku-70 as a loading control. 
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3.3. shRNA Vectors to make stable AP-2y silenced lines. 
Effective AP-2y targeting sequences for use in RNA interference have been identified 
using transient transfections with siRNA duplexes (see Figures 3.2 and 3.3. ). These 
sequences were used to create AP-2y targeting pRetroSuper shRNA constructs along 
with control vectors containing a single base pair mismatch within the AP-2 targeting 
sequence. Details of vector construction and sequences are shown in the Materials and 
Methods 2.2. Figure 3.4 shows that the three AP-2y shRNA constructs were able to 
slightly reduce AP-2y levels in MCF-7 cell transient transfections compared to control 
vectors containing a single mismatch in the AP-2 targeting sequence. The degree of 
knock down is small, but it is thought that this reflects sub-optimal transfection 
efficiency and not the ability of these sequences to reduce AP-2y levels. Indeed, in 
parallel transfections with a pMIG-GFP expression construct (derived from the same 
vector back bone) showed only 20-30% transfection efficiency. Figure 3.5 shows that 
the three AP-2y targeting pRetroSuper shRNA constructs also reduced AP-2y 
transactivation from the 3xAP-2 luciferase reporter construct when cotransfected with 
AP-2y and CITED2 expression constructs in HepG2 cells, where the mismatch controls 
had no effect. Together these data suggested that the three shRNA constructs were able 
to reduce AP-2y levels and might be used to generate stable shRNA cell lines in MCF-7 
cells. 
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Figure 3.4. Transient transfection of AP-2y targeting shRNA constructs in MCF-7 cells. MCF-7 
cells were transfected as indicated and harvested 72 hours later. Whole Cell extracts (5. tg/lane) were 
separated by SDS/PAGE and blotted to a membrane. Blots were probed with primary antibodies against 
AP-2y and Ku-70 as a loading control. 
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Figure 3.5. Reduction of AP-2y transactivation of the 3xAP-2Luc reporter upon cotransfection of 
AP-2y targeting shRNA constructs. HepG2 cells were cotransfected with a 3xAP-2Luc reporter and the 
constructs indicated. (phRG-TK) was co-transfected in each experiment. Luciferase activity was assayed 
after 48 hours. Results (mean ± S. E. of three independent experiments) are presented as relative luciferase 
activity, corrected for Renilla luciferase activity. The reporter alone transfection value was set at 1. 
108 
_+++ 
_-++ 
---1 
MCF-7 cells were transfected with each of the three linearised constructs targeting AP- 
2y (shRNA1, shRNA2 or shRNA3), the corresponding mismatch non-silencing control 
constructs (mismatch!, mismatch2 or mismatch3) or the empty pRetroSuper vector. 
Stable colonies were selected for by continuous growth in puromycin-containing 
medium. Unexpectedly, we were unable to select any AP-2y shRNA stable puromycin 
resistant sub lines. Figure 3.6 shows microscope images of typical colonies from these 
experiments after 14 days of selection. Large colonies of over 100 cells in size 
developed in the control experiments whereas the AP-2y knockdown colonies were only 
5-15 cells in size and failed to thrive any further. Colonies from triplicate transfections 
were counted after 21 days under selection conditions. Figures 3.7 A&B show AP-2y 
targeting shRNA transfected cells formed significantly fewer colonies than the 
corresponding control or empty vector experiments. This data was consistent for the 
three independent targeting shRNA sequences. Furthermore, surviving single cell 
clones derived from the AP-2y targeting shRNA transfections showed no reduction in 
levels of AP-2 (Figure 3.7 C), indicating that although these cells have successfully 
integrated and expressed the puromycin resistance gene, but the AP-2y shRNA cassette 
was not expressed. 
As an alternative approach, ecotropic retroviruses engineered to express the same 
constructs were used to transduce MCF-7 EcoR cells. MCF-7 EcoR cells stably carry 
the mouse retroviral ecotropic receptor allowing transduction with mouse retroviruses 
(Materials and Methods 2.2). Although the retrovirus has the advantage of more 
efficiently transducing the cells, a similar pattern of reduced colony numbers in cells 
infected with the AP-2y shRNA retroviruses and subsequent failure of these colonies to 
thrive compared to the control infections, was observed. 
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Figure 3.6. Colony growth of MCF-7 cells stably expressing pRetroSuper constructs. MCF-7 were 
transfected with the shRNA constructs indicated. Untransfected cells were eliminated by continuous 
growth in puromycin-containing medium. Images show representative colonies of cells 14 days 
following selection. Large colonies of over 100 cells in size have grown in the control plates. The AP-2y 
knockdown colonies are only 5-15 cells in size and failed to grow any further. 
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The same plasmid constructs have also been used to try to stably reduce AP-2y in three 
further breast cell lines, MCFlOA, ZR75-1 and T47D, that express both AP-2a and AP- 
2y family members. MCF1OA cells were transfected with three linearised constructs 
targeting AP-2y (shRNAI, shRNA2 or shRNA3), corresponding mismatch non- 
silencing control constructs (mismatchl, mismatch2 or mismatch3) or an empty 
pRetroSuper vector. Stable colonies were selected for by continuous growth in 
puromycin-containing medium. Reduced colony numbers in cells transfected with 
shRNA constructs targeting AP-2y and subsequent failure of these colonies to thrive 
compared to the control infections was again observed (see Figure 3.8). Work by 
Charlotte Moss in the lab has shown colonies stably expressing AP-2y shRNA1 did not 
survive in ZR75-1 cells, however in T47D cells AP-2y shRNAI colonies survived and 
initially showed significant AP-2y knockdown (Figure 3.9. ). However, during passage 
the effectiveness of AP-2y knockdown progressively declined, suggesting that cells able 
to silence the AP-2y shRNA expression cassette had a selective advantage in culture 
(Helen Hurst, personal communication). 
A summary of the ability to stably reduce AP-2y levels in four different AP-2y 
expressing lines is shown in Table 3.2. These results were unexpected and imply that 
reducing the level of AP-2y in breast epithelial lines which express this factor to 
significant levels, (i. e. readily detectable by western blot Figure 3.1) forces them to 
arrest their growth. 
AP-2y 
shRNA1 
AP-2y 
shRNA2 
AP-2y 
shRNA3 
MCF-7 No No No 
MCF10A No No No 
ZR75-1 No nd nd 
T47D Yes nd nd 
Table 3.2. Table indicating survival of colonies stably expressing the AP-2y shRNA pRetrosuper 
constructs. Stable colonies were selected for by continuous growth in puromycin-containing medium. 
Failure of AP-2y shRNA stable colonies to form or survive was controlled by comparing colony 
formation in empty vector and mismatch control transfected cells. (nd = not determined). 
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Figure 3.7. AP-2y silencing results in reduced colony formation in MCF-7 cells. MCF-7 cells were 
transfected with the shRNA constructs indicated. Untransfected cells were eliminated by continuous 
growth in puromycin-containing medium and colonies were counted after 21 days under selection 
conditions. (A) Graphical representation of average colony numbers per plate (three plates per 
condition). (B) Representative experiment showing colonies stained with MTT. (C) Whole Cell extracts 
(5 tg/lane) from surviving colonies were separated by SDS/PAGE and blotted to a membrane. Blots were 
probed with primary antibodies against AP-2y and Ku-70 as a loading control. 
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Figure 3.8. AP-2y silencing results in reduced colony formation in MCFIOA cells. MCFIOA cells 
were transfected with the shRNA constructs indicated. Untransfected cells were eliminated by continuous 
growth in puromycin-containing medium and colonies were counted after 21 days under selection 
conditions. (A) Graphical representation of average colony numbers per plate (three plates per 
condition). (B) Representative experiment showing colonies stained with MTT. (C) Whole Cell extracts 
(IOgg/lane) from surviving colonies were separated by SDS/PAGE and blotted to a membrane. Blots 
were probed with primary antibodies against AP-2y and Ku-70 as a loading control. 
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Figure 3.9 Single colonies showing stable knockdown of AP-2y in T47D cells expressing the shRNA 
constructs. Western blot of extracts from T47D cells stably carrying pRetroSuper empty vector (pool), 
non-silencing Mismatch l construct (pool), and cells derived from two single colonies stably expressing 
AP-2y shRNAI. Whole Cell extracts (IOgg/lane) were separated by SDS/PAGE and blotted to a 
membrane. Blots were probed with primary antibodies against AP-2y before being reprobed for Ku-70 as 
a loading control. (Data kindly provided by Dr Charlotte Moss) 
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3.4. Synthetic siRNA oligonuleotides for transient 
knockdown of AP-2y. 
The observed effect on the growth of the cells stably expressing shRNA constructs 
targeting AP-2y made gene expression profiling impossible by this method, so transient 
knockdowns were pursued in MCF-7 cells. Transient knockdowns with synthetic 
siRNA oligonucleotides were also used to investigate how silencing AP-2y effects cell 
growth. The observed effects on cell growth might make it difficult to determine an 
AP-2y dependent gene expression profile as a proportion of the changes in gene 
expression observed upon AP-2y knockdown may be secondary to the altered cell cycle 
rather than due to a direct response to the altered AP-2y level. 
3.4.1. Optimisation of transient Synthetic siRNA transfections 
for knockdown of AP-27. 
Originally I planned to use double transfection experiments, that is cells transfected 
once then re-transfected 72 hours later after a1 in 3 split, using a 200nM concentration 
of siRNA, to achieve a longer-term knock down of AP-2'y. However, this approach 
served to highlight the limitations of RNAi. After the second transfection non-specific 
effects of siRNA transfection were observed and an interferon response was triggered in 
the cells. Figure 3.10 shows the efficient knockdown of AP-2y using this double 
transient transfection of AP-2y siRNA 1. Efficient knock down was achieved after 96 
hours, however this was accompanied by an increase in STAT1 levels at the 96 hour 
time point and thereafter. STAT1 is the major transcription factor central to the 
induction of an interferon response in mammalian cells and up-regulation of STAT1 
following siRNA transfection is indicative of such non-specific effects (Bridge et al., 
2003). Interestingly, a pilot gene expression microarray experiment comparing the 
expression profiles of the non-silencing control siRNA condition with AP-2y siRNA1 
using RNA harvested from the 96 hour time point clearly demonstrated an induction of 
additional interferon stimulated genes (see Table 3.3. ) 
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Figure 3.10. STAT-I induction in MCF-7 cells transfected with siRNAs. MCF-7 cells were 
transfected with Transfection reagent only (T), Non Silencing control siRNA (1) or siRNA I targeted to 
AP-2y (2). Cells were first transfected at time point 0 hours then re-transfected 72 hours later after aI in 
3 split. Cells were harvested at the indicated time points across this 120 hour period. Whole Cell extracts 
(10µg/lane) were separated by SDS/PAGE and blotted to a membrane. Blots were probed with primary 
antibodies against AP-2y or STAT-1 before being reprobed for Ku-70 as a loading control. 
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Probe ID 
Fold 
Change Name Description 
205483_s_at 2.350 G1P2 interferon, alpha-inducible protein (clone IFI-15K) 
203153_at 2.309 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 
221577_x_at 2.261 PLAB prostate differentiation factor 
201601_x_at 2.202 IFITM1 6-pyruvoyltetrahydropterin synthase 
214022_s_at 2.196 IFITM1 6-pyruvoyltetrahydropterin synthase 
212203_x_at 2.185 IFITM3 interferon induced transmembrane protein 2 (1-8D) 
205660_at 2.183 OASL 2'-5'-oligoadenylate synthetase-like 
202446_s_at 2.176 PLSCR1 phospholipid scrambiase 1 
205552_s_at 2.168 OAS1 2', 5'-oligoadenylate synthetase 1,40/46kDa 
203882_at 2.136 ISGF3G interferon-stimulated transcription factor 3, gamma 48kDa 
202869_at 2.133 OAS1 2', 5'-oligoadenylate synthetase 1,40/46kDa 
216231_s_at 2.115 B2M beta-2-microglobulin 
204341_at 2.114 TRIM16 tripartite motif-containing 16 
204415_at 2.112 G1P3 interferon, alpha-inducible protein (clone IFI-6-16) 
209140_x_at 2.111 HLA-B major histocompatibility complex, class I, B 
201315_x_at 2.110 IFITM2 interferon induced transmembrane protein 2 (1-8D) 
200887_s_at 2.110 STAT1 signal transducer and activator of transcription 1,91kDa 
Table 3.3. Interferon stimulated genes up-regulated 96 hours following a double transfection with 
AP-2y siRNA1 compared to non-silencing control siRNA. Biotin labelled cRNA from cells harvested 
at 96 hours following a double transfection with nonsilencing control siRNA or AP-2y siRNA1 was 
hybridised in duplicate onto Affymetrix U133A chips. (Sleds et al., 2003,2004; Bridge et al., 2003; 
Persengiev et al., 2004) 
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In order to avoid such an interferon response it was necessary to optimise the transient 
siRNA transfections. An interferon response was only triggered in the cells after the 
second transfection, therefore I removed the second transfection step and also aimed to 
reduce the concentration of siRNA transfected to the lowest effective concentration. 
Figure 3.11. shows AP-2y and STAT-1 protein levels 96 hours following a single 
transfection with 5nM to 200nM siRNAs. Efficient knockdown was achieved with 
siRNA concentrations as low as 5nM (80x less than early experiments). No STAT-1 
induction was seen at any concentration tested. Biological replicates siRNA1 and 
siRNA2 showed similar results. Figure 3.12. shows AP-2y and OAS1 relative mRNA 
levels, measured by real time PCR (Materials and Methods, Section 2.6), 96 hours 
following a single transfection with siRNAs. OAS I is an interferon induced gene that 
was also up-regulated in the pilot gene expression studies (Table 3.3). Again, efficient 
AP-2y knockdown was achieved with siRNA concentrations as low as 5nM. No, OAS 1 
induction was seen at any of the concentrations tested and replicates siRNA1 and 
siRNA2 showed similar results (see Figure 3.11). Taken together, data from Figures 
3.11 and 3.12 show effective silencing of AP-2y can be achieved using short-term 
transfections and without induction of the interferon pathway. 
There are several other non-specific effects that could be induced by siRNAs. Firstly 
the degradation of mRNA species other than the target, due to cross-hybridization. 
Secondly the binding to cellular proteins in a sequence-specific manner via an RNA 
aptamer effect (Shi et al., 1999). Finally a translational silencing through a micro RNA 
effect (Doench et al., 2003). Unlike the interferon response it is difficult to monitor 
these "off target" effects. However, it has been reported that they too can be minimised 
in a concentration dependant manner (Semizarov et al., 2003; Persengiev et al., 2004). 
Figure 3.12. shows the reduction of AP-2y mRNA levels, the primary target of dsRNA 
oligonucleotides AP-2y siRNA1 and AP-2y siRNA2. This supports a direct effect of the 
dsRNA oligonucleQtides on the AP-21 mRNA via a siRNA mechanism rather than a 
translational effect preventing production of the AP-2y protein via a microRNA 
mechanism. 
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In summary three effective AP-2y targeting sequences, AP-2y siRNA1, AP-2y siRNA2 
and AP-2y siRNA3 have been characterised. It was hoped that using siRNAs targeting 
distinct sequences within the AP-2y mRNA would provide biological replicates and 
control for "off target" effects. I planned to derive gene expression profiles comparing 
two control conditions (the nonsilencing control siRNA and cells treated with 
transfection reagent only) with the AP-2y targeting siRNAs (AP-2y siRNA1, AP-2y 
siRNA2 and AP-2y siRNA3). Data from Figures 3.11 and 3.12 showed that using a 
final concentration of 25nM of siRNA gave the most effective knockdown (greater than 
90% knockdown) in these transient transfection experiments and therefore this would 
used in subsequent experiments. Transfections performed under these conditions were 
also assessed using a 3' Alexa Fluor 488 labelled non-silencing control siRNA and 
observed via fluorescence microscopy. Fluorescence was reproducibly detected in 
greater than 90% of transfected cells reflecting the level of AP-2y knockdown observed 
following transfection with the AP-2y targeting siRNAs. 
3.5. Levels of the established AP-2 coactivators: 
CITED2, CITED4, CBP and p300 following AP-2y 
silencing in MCF-7 cells 
Work introduced in detail in section 1.2.2, has shown that AP-2 proteins can be co- 
activated by the recruitment of p300/CBP to their target genes and that this recruitment 
is mediated by the CITED adaptor proteins CITED2 and CITED4 (Bamforth et al., 
2001; Braganca et al., 2002; Braganca et al., 2003). As the abundance of each of these 
proteins is likely to influence the ability of AP-2 factors to activate their target genes, it 
was-important to assess if the level of these key co-activators was perturbed following 
AP-2y silencing in MCF-7 cells. Figure 3.13 shows the levels of CITED2, CITED4, 
CBP and p300 72 hours following AP-2y silencing in MCF-7 cells. Compared with the 
controls, no change in the level of CITED2 or CITED4 was observed for any of the AP- 
2y targeting siRNAs. However, a moderate increase in the abundance of both CBP and 
p300 was observed following AP-2y silencing. This was unexpected but may be* a 
consequence of the observed cell cycle phenotype. 
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Figure 3.11. Monitoring STAT-I induction over a range of siRNA concentrations. MCF-7 cells were 
transfected with siRNAs at the indicated concentrations. Cells were transfected once and harvested 96 
hours later. Whole Cell extracts (10µg/lane) from MCF-7 cells were separated by SDS/PAGE and blotted 
to a membrane. Blots were probed with primary antibodies against AP-2y or STAT-1 before being 
reprobed for Ku-70 as a loading control. (Control - Transfection reagent only) 
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Figure 3.12. Monitoring OAS I mRNA induction over a range of siRNA concentrations. MCF-7 
cells were transfected with siRNAs at the indicated concentrations. Cells were transfected once and 
total RNA harvested 96 hours later. Quantitative Taqman RT-PCR analysis of AP-2y and OASI mRNA 
levels was performed. Data were norn*ised to the GAPDH RNA levels. The transfection reagent only 
value was set at I to generate relative mRNA levels. The graph represents data averaged from three 
replicates f standard deviation. 
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Figure 3.13. Levels of AP-2 coactivators following AP-2y silencing in MCF-7 cells. Cells were 
transfected as indicated and harvested at 72 hours for western blot. Whole Cell extracts (5µg/lane) were 
separated by SDS/PAGE and blotted to a membrane. Blots were probed with primary antibodies against 
CITED2, CITED4, p300, CBP and Ku-70. 
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CHAPTER 4: - RESULTS AP-2y GENE EXPRESSION 
PROFILING 
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4.1. Array processing and quality control 
A more detailed description of the array procedure is given in Materials and Methods 
section 2.7. Briefly, total RNA was extracted from MCF-7 cells 96 hours following 
transfection with AP-2y targeting siRNAs (AP-2y siRNA1, AP-2y siRNA2 and AP-2y 
siRNA3), a non silencing control siRNA, and cells treated with transfection reagent 
alone. The RNA was treated with DNase to remove any genomic DNA contaminants 
and q was assessed via a formaldehyde-MOPS denaturing agarose gel. High yield 
bio final Yt cRNA (A260/A280 ratio between 1.8 and 2.1) was prepared for each 
expe ental sample and hybridised to Affymetrix HG-U133Plus2 arrays. The chips 
were scanned using the GeneArray Scanner 3000. After scanning, array images were 
assessed by eye to confirm scanner alignment, the absence of significant bubbles or 
scratches on the chip surface, and the absence of slides with very high background 
(scanning and image analysis was performed by Tracy Chaplin, Institute of Cancer, 
Charterhouse Square). Each experiment was performed in biological triplicates to allow 
appropriate statistical analysis. A summary of the array experiments is shown in Table 
4.1 
Raw data were analysed using the BioConductor statistical package (Gentleman et al., 
2004; BioConductor, url) as described in Materials and Methods 2.7. The raw data, 
acquired from the scanner, includes information on background intensity values, perfect 
match, (PM) and mismatch, (MM) values and is contained in *. CEL files. 
As well as visually assessing RNA quality before cRNA target preparation, information 
from the raw array data also provided a measure of the quality of hybridised material. 
Figure 4.1 shows an array-by-array cRNA digestion plot produced using the "affy" 
BioConductor plotAffyRNAdeg function (Gautier et al., 2004). This plot illustrates that 
no severe degradation of the targeted cRNA occurred, except for a small degree of 
degradation at the 3' of the molecule; importantly the plots are consistent for all fifteen 
samples. 
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I 
Experimental Condition 
7d 
cD 
:z 
F) 
K 
r. CD 
File Name Sample Type 
1 MCF7TC. CEL reference 
MCF-7 Transfection Reagent Alone 2 MCF7TC2. CEL reference 
3 MCF7TC3. CEL reference 
1 MCF7NS. CEL reference 
MCF-7 Non-Silencing siRNA 2 MCF7NS2. CEL reference 
3 MCF7NS3. CEL reference 
1 MCF7GB. CEL test 
MCF-7 AP-2y siRNAI 2 MCF7GB2. CEL test 
3 MCF7GB3. CEL test 
1 MCF7GE. CEL test 
MCF-7 AP-2y siRNA2 2 MCF7GE2. CEL test 
3 MCF7GE3. CEL test 
1 MCF7GF. CEL test 
MCF-7 AP-2y siRNA3 2 MCF7GF2. CEL test 
3 MCF7GF3. CEL test 
Table 4.1: Affymetrix gene expression profiling: experimental design. Table shows each 
experimental condition with details of replicates, CEL files and sample type. 
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Figure 4.1 An assessment of target cRNA quality. Side-by-side cRNA digestion plot produced using 
the "affy" BioConductor plotAffyRNAdeg function. Individual probes in a probe set were ordered by 
location relative to the 5' end of the targeted RNA molecules. Typically RNA degradation starts from the 
5' end of the molecule. Therefore probe intensities were expected to be systematically lowered at the 5' 
end compared to the 3' end. This plot analysed each array: probe intensities were averaged by location in 
the probe set, with an average then taken over all probe sets. Then side-by-side plots of these means 
exhibited the 5' to 3' trend and illustrate severity of target cRNA degradation. The plot illustrates that 
there was no severe degradation of the targeted cRNA except for a small degree of degradation at the 3' of 
the molecule, which is consistent in all the samples. 
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RNA digestion plot 
In order to ensure the arrays fulfil a series of Affymetrix recommended quality control 
metrics (described in detail in the Expression Analysis Fundamentals Manual, 
Affymetrix, url), raw data were pre-processed using "simpleaffy" BioConductor 
package. Simpleaffy uses the Affymetrix MAS 5.0 array analysis algorithms to provide 
access to these metrics (Wilson & Miller, 2005; Materials and Methods 2.7.3). Figure 
4.2 shows an array-by-array quality control plot generated using "simpleaffy" 
BioConductor plotQC function. This plot highlights variability in background across 
the fifteen arrays although all the background values falls within the Affymetrix 
suggested range of 20 to 100 (Affymetrix url)j Interestingly the background variability 
observed reflects batch-to-batch variation in the hybridisation process. Array 
hybridisations were performed in batches of five: the first replicate from each condition 
in one batch, the second replicate from each condition in another batch and the third 
replicate from each condition in a final batch. The batch-to-batch variation is 
highlighted in Table 4.2, which shows the average background for each set of five 
arrays hybridised together. 
Hybridisation Average Standard 
Batch Background Deviation 
First Replicates 64 6 
Second Replicates 77 7 
Third Replicates 91 9 
Table 4.2 shows the average background for each batch of five arrays hybridised together. First 
Replicates: MCF7TC. CEL, MCF7NS. CEL, MCF7B. CEL, MCF7E. CEL, MCF7F. CEL. Second 
Replicates: MCF7TC2. CEL, MCF7NS2. CEL, MCF7B2. CEL, MCF7E2. CEL, MCF7F2. CEL. Third 
Replicates: MCF7TC3. CEL, MCF7NS3. CEL, MCF7B3. CEL, MCF7E3. CEL, MCF7F3. CEL. 
It is thought that this variability in background, although slightly high, is within 
acceptable limits for this experimental design and importantly it occurs equally across 
the experimental conditions and therefore its effect will not impair or skew the 
following downstream data analysis towards a particular condition. Figure 4.2 also 
shows that this observed variability in background has no effect on % present value and 
mas5 scale factors which both remain within acceptable hounds. None of the arrays 
stand out as having high GAPDH or ß-actin 3'/5' ratios confirming the data in Figure 
4.1 showing no severe degradation of the targeted cRNA. 
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Figure 4.2 Affymetrix Quality Control Plot. Affymetrix recommended quality control metrics were 
produced using the "simpleaffy" BioConductor p! otQC function in order to assess the average 
background, scale factor, percentage of genes called present and 3' to 5' ratios for ß-actin and GAPDH. 
Each line represents a mass normalised array. For each line, top value % present call; bottom value, 
average background; circle, GAPDH ratio; triangle, beta actin ratio; line, scale factor. The shaded region 
represents the range where scale factors are within 3-fold of each other (centred around the mean). 
Although variability in background is observed across the arrays the % present value and mas5 scale 
factors remain with acceptable bounds. No arrays stand out as having high GAPDH and ß-actin ratios 
supporting the data in Figure 4.1 showing no severe degradation of the targeted cRNA. 
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4.2. Normalisation and transformation of Raw Array 
Data 
The aim of these analyses was to identif defer ntially expressed genes in MCF-7 cells 
that were transfected with AP-2y targeting si NAs compared to the control conditions. 
In order to minimise variation between arrays caused by biological and experimental 
factors it was important to perform appropriate data transformation and normalisation. 
The analysis of the normalisation and transformation of raw array data took place in a 
four-step process as described in Table 4.3. In order to establish the most appropriate 
method for normalisation and transformation of the raw data, different combinations of 
Background Correction, Normalisation, PM/MM Correction and Summarisation were 
assessed. The Affymetrix recommended mass method was assessed along with 
variations of the Robust Multi-array Average (RMA) process (Irizarry et al., 2003) 
using the quantile normalisation method and medianpolish summarisation, but altering 
the background correction and PM/MM Correction methods. 
Background Correction Normalisation PM/MM Correction Summarisation 
1 mass mass mass mass 
2 rma quantiles pmonly (none) medianpolish 
3 none quantiles pmonly (none) medianpolish 
4 mass quantiles pmonly (none) medianpolish 
5 none quantiles mass medianpolish 
6 mass quantiles mass medianpolish 
Table 4.3 Overview of the Bioconductor data analysis. Data analysis was performed using the "affy" 
BioConductor package using the expresso function in six indicated combinations for Background 
Correction, Normalisation, PM/MM Correction and Summarisation. Background corrections were 
performed using either the Affymetrix mass method (average background estimates from defined array 
regions), or the rma method (PM corrected values as described by (Irizarry et al., 2003)) or none (no 
background correction). Normalisation was performed using the Affymetrix recommended mass method 
or the quantile normalisation method. PM correction was applied either as pmonly, (using only the PM 
normalised values), or as mass (using the ideal mismatch method as suggested by Affymetrix). 
Summarisation analysis combined the pre-processed probe intensities together to compute an expression 
measure for each probe set on the array. Medianpolish was applied as described by (Irizarry et al., 2003) 
and mass using a robust average 1-step Tukey bi-weight on loge scale. 
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Figure 4.3 shows frequency histograms for the HG-U133Plus2 raw expression data and 
expression data processed by the six different methods outlined in Table 4.3. It 
is 
apparent from the frequency histograms of raw intensity values that variation between 
arrays is present. Box plots of all of the normalisation methods confirm that 
transformation of the data is such that the distribution of probe intensities for every 
array in the set of the fifteen arrays used in this experiment are the same and fit the same 
distribution (data not shown). However it is clear from the histograms that this 
distribution is not necessarily a normal distribution, which is an assumption for any 
downstream parametric statistical analysis. For example in histogram (1), the 
Affymetrix recommended mass method, gives an almost bell shaped curve which has a 
shoulder to the left of the median values. This is most likely due to the PM/MM 
correction. It is widely reported that MM may be detecting signal in addition to non- 
specific binding and therefore, including the MM parameter, contributes to the overall 
noise in the data analysis (Naef et al., 2002; Irizarry et al., 2003; Landis et al., 2004). 
Similar double peaked distributions are observed in histograms (5) and (6) where the 
mass PM/MM correction is also employed. Histograms (2), (3) and (4) show 
normalisation methods that considered PM values only but varied in the background 
correction method used. All three show smooth distributions, but (4) employing mass 
background correction is most similar to a normal distribution. Therefore it was 
considered that mass background correction, quantile normalisation, PM correction 
using PM values only (pmonly) and medianpolish summarisation method were the most 
effective processing steps for intra- and inter-array normalisation, and data processed 
this way would fulfil the assumptions made for parametric statistical analysis. Figure 
4.4 shows schematic presentations of the HG-U133plus2 raw and 
mass. quaniltes. pmonly. medianpolish normalised expression data. This confirms the 
data appears to be transformed in such a way that the distribution of probe intensities for 
every array in the set of the fifteen arrays used in this experiment are the same and the 
data resembles a normal distribution. 
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Figure 4.3. Frequency Histograms of the HG-U133PIus2 raw and normalised expression data. This 
Figure shows plots of the densities for probe intensities of the fifteen human arrays datasets, with their 
distributions before normalisation (Raw Intensities) and after normalisation using the methods outlined in 
Table 4.3 (1-6). Histograms were produced using the "affy" BioConductor Hist function. 
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Figure 4.4. Schematic presentations of the HG-U133plus2 raw and normalised expression data. The 
Figure shows plots of the densities for probe intensities of the fifteen human arrays datasets, with 
distribution before normalisation (A) and after normalisation using the mass, quantiles, pmonly and 
medianpolish methods (B) are also displayed. The distribution of the average expression measure is 
displayed using array by array box plots of raw data (C) and data after normalisation using the mass, 
quantiles, pmonly and medianpolish methods (D). Box plots array by array from left to right: 
MCF7GB. CEL. MCF7GB2. CEL, MCF7GB3. CEL, MCF7GE. CEL, MCF7GE2. CEL, MCF7GE3. CEL, 
MCF7GF. CEL MCF7GF2. CEL, MCF7GF3. CEL, MCF7NS. CEL, MCF7NS2. CEL, MCF7NS3. CEL, 
MCF7TC. CEL, MCF7TC2. CEL, and MCF7TC3. CEL. The data appears to be transformed in such a way 
that the distribution of probe intensities for every array in the set of the fifteen arrays used in this 
experiment are the same and fit a normal distribution. The plots were produced using the "affy" 
BioConductor hiss and boxplot functions. 
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4.3. Hierarchical Clustering Analysis 
Bioconductor normalised data were imported into the Genespring package (Genespring 
GX 7.3, Agilent Technologies) in order to allow a hierarchical clustering analysis to 
monitor overall patterns of gene expression between the normalised arrays (Materials 
and Methods 2.7.3; Eisen et al., 1998). Briefly, a hierarchical clustering analysis 
produces a map of results where probe sets are grout together based on similarities in 
their patterns of normalised expression across the fifteen arrays. As the processed data 
follows a normal distribution it is appropriate to use the Pearson correlation coefficient, 
which calculates the similarity measure based on a linear model. Because we are 
interested in genes that change their expression between the reference and test groups, 
data were filtered to include the 2500 probe sets with the highest variance across the 
fifteen arrays. The same algorithm was also applied to cluster the experimental samples 
for similarities in their overall patterns of gene expression. The resulting dendogr am and 
heat map is shown in Figure 4.5. Arrays hybridised with replicate samples representing 
the reference samples formed their own cluster, indicating that there is no major effect 
of non-silencing siRNA transfection on expression in this variable subset of' probe sets. 
Arrays hybridised with replicate samples representing the AP-2y siRNA transfected test 
samples also formed their own cluster separate from the reference samples, illustrating 
an effect of AP-2y siRNA transfection on expression these probe sets. Interestingly 
within this AP-2y siRNA cluster the replicates from each AP-2y targeting siRNA 
(siRNAI, siRNA2 and siRNA3) form their own sub-clusters together. Particularly 
noticeable was AP-2y siRNA2, which formed its own sub-cluster away from AP-2y 
siRNAI and AP-2y siRNA3 replicates. 
These differences in clustering between different AP-2y targeting siRNAs could he due 
to differences in efficiency of AP-2y silencing. Indeed, examination of the TEAP2C 
probesets showed differences in efficiency of silencing of AP-2y transcript levels 
between the siRNAs used. As shown in Figure 4.6, AP-2y siRNA2 silencing appears to 
have been more efficient than silencing from AP-2y siRNA 1 and AP-2y siRNA3 
replicates. 
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AP-2"y siRNA 1 REPLICATES 
AP-2"r siRNA 2 REPLICATES LOW AP-2"r siRNA 3 REPLICATES 
"IC" 
Figure 4.5. Cluster diagram showing 2500 most variable probes sets across the fifteen arrays. Each 
column represents a single array experiment, and each row represents a single probe set. Normalised 
gene expression values are shown for arrays hybridised with the samples indicated. Red squares represent 
high expression and green squares represent low expression as indicated on the scale at the bottom right. 
The colour bar represents the replicates from different conditions. The Heat map represents a hierarchical 
clustering analysis with a Pearson correlation similarity measure on 2500 probe sets with the highest 
variance across the 15 different arrays. The dendrogram (top) also indicates the clustering of arrays based 
on similarity of expression across the 2500 probe sets. 
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TRANSFECTION CONTROL REPLICATES 
NON SILIENCING siRNA REPLICATES 
AP-2! siRNA I REPLICATES 
AP-2ý! siRNA 2 REPLICATES Ný AP-2 siRNA 3 REPLICATES 
Figure 4.6. Cluster diagram showing AP-2y probes sets across the fifteen arrays. Each column 
represents a single array experiment, and each row represents a single probe set. Normalised gene 
expression values are shown for arrays hybridised with the samples indicated. Red squares represent high 
expression and green squares represent low expression as indicated on the scale at the bottom right. The 
colour bar represents the replicates from different conditions. The Heat map represents a hierarchical 
clustering analysis with a Pearson correlation similarity measure on 2500 probe sets with the highest 
variance across the 15 different arrays. The dendrogram (top) also indicates the clustering of arrays based 
on similarity of expression across the 2500 probe sets. Data adapted from Figure 4.5. 
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Differences in clustering between different AP-2y targeting siRNAs might also be due 
to sequence specific off-target effects of the siRNAs. Each AP-2y targeting siRNA 
might be directly silencing the transcripts of genes other than AP-2y, thus causing 
variations in clustering patterns. Optimisation experiments have served to reduce these 
potential sequence specific off-target effects (Figures 3.11 & 3.12), which have been 
shown to be minimised in a concentration dependant manner (Semizarov et al., 2003; 
Persengiev et al., 2004). Off-target effects have also been addressed in the experimental 
design, by including three distinct siRNA sequences targeting AP-2y. It was thought 
that treating all the AP-2y targeting siRNAs together as one variable, the test group (AP- 
2y targeting siRNAs: AP-2y siRNA1, AP-2y siRNA2 and AP-2y siRNA3) and 
conducting stringent statistical comparisons between this group and the reference group 
(non silencing control siRNA and cells treated with transfection reagent only) would 
address this phenomenon. Statistically significant changes would be those in agreement 
for all three AP-2y targeting siRNAs and any sequence-specific off-target gene 
expression changes (i. e. changes only occurring for a single AP-2y targeting sequence) 
would thus be eliminated from the final data set. 
4.4. Differential Gene Expression Analysis 
Bioconductor normalised data were imported into Genespring in order to allow 
statistical analyses to be carried out. As well as fitting a normal distribution, another 
assumption of statistical analyses, such as the widely used Student's t-test, is that the 
variability of a gene is constant across treatment types. However, in the absence of 
accurate diagnosis methods, it is safest to assume that variability may differ between 
our reference and test groups. As we have confirmed that our data fits a normal 
distribution, it is appropriate to conduct a Welch's t-test, this is a parametric analysis 
that corrects for difference in variability. 
As we are interested in identifying genes that change their expression between the 
reference and test groups, it was important first to filter the data to include only those 
probe sets that change in expression. We chose to order the list from low to high 
standard deviation. This would enable us to identify the genes that are changed the 
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most in expression across the fifteen arrays, and remove probe sets from the analysis 
that change very little. It was felt that this is more informative than filtering on fold 
change, for which there is a risk of ignoring genes that change significantly but are 
below the arbitrary fold change threshold. 
Genespring was used to calculate a Welch's t-test on the 2500 probe sets with highest 
variance across the fifteen arrays. A Benjamini and Hochberg False Discovery Rate 
(FDR) test (Benjamini & Hochberg, 1995) was also applied in order to identify the 
percentage of false positive genes that could have been included in the final lists of 
differentially expressed genes. Appendix 1 displays the 578 probe sets that changed 
their expression significantly (FDR corrected, p<0.05) between the reference (non 
silencing control siRNA and cells treated with transfection reagent only) and test (AP- 
2y targeting siRNAs: AP-2y siRNA1, AP-2y siRNA2 and AP-2y siRNA3) groups. 
4.5. AP-2y Gene Expression Profile Initial Observations 
Significant changes in gene expression were observed after silencing of AP-2y in MCF- 
7 cells and are summarised in Table 4.4. Many genes regulated in these experiments 
were represented by multiple probe sets therefore the actual number of genes regulated 
is indicated in brackets. A smaller subset of 300 probe sets (254 genes) regulated at a 
p<0.01 probability was used for subsequent Gene Ontology, Pathway Mapping and 
Transcription Factor Binding Site analysis as it was felt that this provided a more 
manageable data set and would provide more statistical relevance when conducting 
these large scale analyses. In the results presented in this thesis, probe sets were 
assigned to gene symbols and gene descriptions based on the January 2007 release of 
the HG-U133_Plus2 Affymetrix NetAffx Annotation files (Liu et al, 2003; Affymetrix 
url). 
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p<0.05 1 p<0.01 
Total probe sets (genes) differentially regulated 1 578 (469) 1300 (254) 
Total probe sets (genes) down regulated 1 389 (315) 1 225 (190) 
Total probe sets (genes) up-regulated 1 189 (154) 1 75 (64) 
Table 4.4. Significant changes in gene expression following AP-2y silencing. Changes observed in 
probe sets between the reference (non silencing control siRNA and cells treated with transfection reagent 
only) and test (AP-2y targeting siRNAs: AP-2y siRNA1, AP-2y siRNA2 and AP-2y siRNA3) groups at 
the indicated False Discovery Rate corrected p values. Number of genes represented is indicated in 
brackets. 
Encouragingly within these significant expression changes, probes sets specific to AP- 
2y are represented as illustrated in Figure 4.7. As expected, AP-2y transcript levels are 
down-regulated in response to AP-2y targeting siRNA in MCF-7 cells and this change 
was detected by both AP-2y HG-U133P1us2 hybridising probe sets (TFAP2C 
205286_at: Fold Change = -2.09, p=0.00439, TFAP2C 205287_s_at: Fold Change =- 
2.39, p=0.00646). These results compare favourably to the qPCR data presented in 
Figure 3.12. In MCF-7 cells transfected with 25nM of AP-2y targeting siRNA or non- 
silencing control RNA and harvested 96 hours later resulted in a fold down regulation 
of -3.5 and -3.3 for siRNAs 1 and 2 respectively. 
Also within the significant expression changes were genes previously suggested to be 
transcriptionally regulated by AP-2y or the family member AP-2a. As AP-2a and AP- 
2y has been shown to bind identical DNA recognition sequences in vitro (McPherson & 
Weigel, 1999), genes previously suggested to be regulated by AP-2a are thought to 
have some relevance to this AP-2y dependant data set. These changes are summarised 
in Figure 4.7. Significant down regulation of MT2A was supported by previous work 
(Mitchell et al., 1987), showing AP-2a dependent in vitro transcription from the human 
MT2A promoter in HeLa cells. Interestingly paralogs of MT2A (MTI F, MT111, and 
MT1X) were also significantly down-regulated following AP-2y knockdown in MCF-7 
cells suggesting a common mechanism for their transcriptional regulation. TGFet was 
also significantly regulated following AP-2y silencing. An increasing body of evidence 
suggests that AP-2a plays an important role in TGFa transcriptional activation (Gille et 
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al., 1997; Wang et al., 1997; Kim & Rho, 2002). Data from this study shows TGFa up- 
regulation following AP-2y silencing. This suggests AP-2y plays a contrasting role to 
AP-2a, and could be involved in the transcriptional repression of TGFa. In vitro 
reporter assays implicate AP-2a in the activation of transcpiption from the IGFBP5 
promoter via AP-2 DNA recognition sites (Duan & Clemmons, 1995; Erclik & 
Mitchell, 2005). Data from this study shows IGFBP5 up-regulation following AP-2y 
silencing; again suggesting AP-2y plays a different role, and could be involved in the 
transcriptional repression of IGFBP5. Work in our lab supports this hypothesis and 
using ChIP assays it has been shown that AP-2y is bound to the IGFBP5 promoter in 
MCF-7 cells (Karsten Friedrich, personal communication). AP-2 transcription factors 
have also been shown to be involved in the regulation of transcription from keratin 
promoters during epidermal differentiation (See Introduction 1.4.2 for details). 
Consistent with these observations, three keratin transcripts (KRT8, KRT81, KRT86) are 
significantly down-regulated following AP-2y silencing. 
A list of the top 30 most significantly changing probe sets is displayed in Figure 4.8. 
These include several genes that have been selected for follow up and will be discussed 
further in Results Section 4.9. 
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T-; ý7 PROBE ID GENE DESCRIPTION 
FAD 
CHANGE 
P VALUE 
. '05287 s at 
TFAP2C transcription factor AP-2 gamma -2.09 0.00439 
5286 at TFAP2C transcription factor AP-2 gamma -2.39 0.00646 
., 17165 x at 
MT1F metallothionein 1F (functional) -1.51 0.00934 
. '08581 x at 
MT1X metallothionein 1X -1.72 0.00916 _ 
. '06461 
x at MT1H metallothionein 1H -1.68 0.00793 
.' 
12185 x at MT2A metallothionein 2A -1.96 0.00511 
043267x-at MT1X metallothionein 1X -1.49 0.0485 x at ' 16568 KRT8 Keratin 8 -1.66 0.000383 _ ' 13711 at KRT81 keratin 81 -4.02 0.000275 15189 at KRT86 keratin 86 -2.12 0.00344 
d 
. '05016 at 
TGFA transforming growth factor, alpha 1.78 0.0074 i 
L' 11959 at IGFBPS insulin-like growth factor binding protein 5 218 0.00817 
=m 155599T sat - 
IGFBP5 insulin-like growth factor binding protein 5 1.46 0.0141 
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Figure 4.7. Significant changes in gene expression following AP-2y silencing related to AP-2 
biology. Changes observed in probe sets between the reference (non silencing control siRNA and cells 
treated with transfection reagent only) and test (AP-2y targeting siRNAs: AP-2y siRNAI, AP-2y siRNA2 
and AP-2y siRNA3) groups at the indicated False Discovery Rate corrected p values. A full list of 
significantly regulated probe sets together with normalised expression values, fold change values 
(between test and reference groups) and FDR corrected p values is contained in Appendix 1. 
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ý-j 11 PROBE ID GENE DESCRIPTION 
FOLD IP VALUE 
KIAA1324 KIAA1324 -2.57 8.43E-06 
PREX1 phosphatidykrasitol 3,4,5-trisphosphate- RAC exchanger 1 -1.89 8.43E-06 
CDH26 cadherin-like 26 2.07 8.43E-06 
C10ort116 chromosome 10 open reading frame 116 -2.53 1.09E-05 
EDG3 endothelial differentiation, sphingolipid G-PCR, 3 -2.49 1.09E-05 
DBF4 DBF4 homolog (S. cerevisiae) -2.08 1.09E-05 
PDK4 pyruvate dehydrogenase kinase, isozyme 4 1.96 1.09E-05 
ZNF117 Zinc finger protein 117 (HPF9) 2.01 1.09E-05 
BUB3 BUB3 budding uninhibited by benzimidazoles 3 homolog (yeast) -1.77 1.56E-05 
INHBA inhibin, beta A (activin A, activin AB alpha polypeptide) 1.97 1.56E-05 
PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 2.18 1.92E-05 
ELOVL6 ELOVL family member 6, elongation of long chain fatty acids -1.72 2.62E-05 
MSI2 musashi homolog 2 (Drosophila) -2.01 3.15E-05 
CALML5 calmoduln-like 5 -1.90 3.15E-05 
SPDEF SAM pointed domain containing ets transcription factor -2.24 3.76E-05 
RARRES3 retinoic acid receptor responder (tazarotene induced) 3 -2.06 3 76E-05 
STMN3 stathmin-like 3 -1.97 3.76E-05 
TMPO thymopoietin -1.78 3.76E-05 BAMBI BMP and activin membrane-bound inhibitor homolog (X. laevis) -2.10 4.41 E-05 
PSRC1 proline/senne-rich coiled-coil 1 -1.78 5.29E-05 CDC42EP5 CDC42 effector protein (Rho GTPase binding) 5 -2.16 5.36E-05 PBX1 Pre-B-cell leukemia transcription factor 1 -1.79 5.36E-05 
INHBA inhibin, beta A (activin A, active AB alpha polypeptide) 3.06 5.36E-05 
GPSM2 G-protein signalling modulator 2 (AGS3-like, C. elegans) -1.78 5.38E-05 
OIP5 Opa interacting protein 5 -1.72 5.38E-05 
ZNF616 Inc finger protein 616 1.87 5.38E-05 
PAPSS2 3'-phosphoadenosine 5'-phasphosulfate synthase 2 1.90 5.38E-05 
IGFBP3 insulin-Ike growth factor binding protein 3 2.30 5.38E-05 
RGS10 regulator of G-protein signalling 10 -1.75 5.90E-05 
IGFBP3 insulin-like growth factor binding protein 3 2.39 5.90E-05 
LOW HIGH 
Figure 4.8. The top thirty most significant changes in gene expression following AP-2y silencing in 
MCF-7 cells. Changes observed in probe sets between the reference (non silencing control siRNA and 
cells treated with transfection reagent only) and test (AP-2y targeting siRNAs: AP-2y siRNAI, AP-2y 
siRNA2 and AP-2y siRNA3) groups at the indicated False Discovery Rate corrected p values. A full list 
of significantly regulated probe sets together with normalised expression values, fold change values 
(between test and reference groups) and FDR corrected p values is contained in Appendix 1. 
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4.6. Analyses of Associated Gene Ontology Terms 
In order to interrogate the significant gene expression changes following AP-2y 
silencing in MCF-7 cells further, and to explore any patterns in groups of genes within 
the data set, additional analyses were conducted based on associated Biological Process 
Gene Ontology Terms (Ashburner et al., 2000; The Gene Ontology project, ctrl).; Gene 
Ontology Terms are organised in a hierarchical structure described in detail in Section 
2.7.3. Briefly, each gene can be assigned several associated Biological Process GO 
terms. A GO path is where a GO term is connected to several other GO terms higher in 
the GO hierarchy, for example: biological process --º cellular process - cellular 
physiological process - cell cycle. An added level of complication is that these paths 
intersect or split and also several paths may lead to an individual gene. This 
hierarchical and interconnected nature of GO terms can make the outputs of such 
analyses difficult to present graphically. For this reason three separate approaches were 
employed. 
4.6.1. Hand Curated Analysis of Biological Process Ontology 
Terms 
For an initial analysis, the AP-2y (p<0.01) data set was assigned GO terms extracted 
from the January 2007 release of the HG-U133_Plus2 Affymetrix NetAffx Annotation 
files (Liu et al, 2003; Affymetrix,; url). ''The data set was separated into up-regulated and 
down-regulated genes, then sorted into broad functional groups based on their assigned 
Biological Process GO terms. Each gene was assigned to a single GO term. This 
analysis was done by hand and appropriate terms were first decided based on the most 
likely biological function where two or more differing terms were described, a decision 
based on each GO term's associated evidence code. A suitable term higher up the GO 
path was then assigned to allow the genes to be grouped together into broad functional 
categories. This data is shown graphically in Figure 4.9. The pie chart represents 
expression changes for single transcripts (not probe sets) so as to avoid 
overrepresentation of functional classes where multiple probe sets representing one gene 
are significantly regulated. From this analysis it is clear that a large proportion of the 
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probe sets in the AP-2y data set have no known Biological Process GO term (24% of 
down-regulated genes and 2l % of up-regulated genes). Additionally a large number of 
genes down-regulated following AP-2y silencing are classified as being involved in the 
cell cycle, 34%% of down-regulated genes compared to just 3% of up-regulated genes. 
These are indicated by the "exploded" region of the pie chart in Figure 4.9. Genes 
assigned the functional categories of mRNA processing and Protein Biosynthesis were 
also represented within down-regulated changes and not the up-regulated changes. A 
larger number of genes assigned the functional categories of development and apoptosis 
were represented in the up-regulated changes compared to the down-regulated changes. 
4.6.2. GO STAT Analysis of Biological Process Ontology Terms 
A second separate analysis was conducted using the Gostat interface (GOstat, urrl; 
Beissbarth & Speed, 2004), in order to establish with statistical confidence which GO 
terms were over-represented or under-represented in our lists of significantly up- 
regulated and significantly down-regulated transcripts following AP-2y silencing in 
MCF-7 cells. This analysis assigned GO Biological Process terms based on the given 
Affymetrix HG-U133P1us2 identifiers then compared these to all of the GO terms 
represented by all of the genes on the Affymetrix HG-U 133P1us2 microarray. This 
allows an objective and statistically controlled measure of enriched GO terms from the 
data set. Table 4.5 shows a sub-set of 29 representative significant GO terms that were 
significantly enriched in our AP-2y data set compared to GO terms on the entire 
Affymetrix HG-U 133P1us2 microarray. It is clear for genes down-regulated following 
AP-2y silencing, GO terms are highly significantly over-represented in categories 
related to cell cycle. This is consistent with the analysis shown in Figure 4.9, although 
the functional categories are more precise. Additionally, for those genes up-regulated 
following AP-27 silencing GO terms are significantly over-represented in categories 
related to development, cell growth and apoptosis. This is also consistent with the 
analysis shown in Figure 4.9. 
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Cell Cycle - Regulation (10) 
(0) 
Q Cell Cycle - DNA replication 111 DNA repair (17) 
(0) 
Cell Cycle - Checkpoints (4) 
(0) 
Cell Cycle - Chromatin Organisation, 
Modification and Segregation (14) (0) 
Cell Cycle - Mitosis (21) (2) 
Regulation of Cell Proliferation 111 Growth (8) (5) 
Regulation of Transcription (10) (4) 
Miscellaneous (7) (3) 
Electron Transport (3) (1) 
Protein Modification (6) (3) 
Transport (7) (3) 
Carbohydrate Metabolism (3) (4) 
Miscellaneous metabolism (6) (1) 
Q mRNA Processing (2) (0) 
Q Protein Biosynthesis (8) (0) 
0 Apoptosis (0) (3) 
Cell Adhesion 111 Cell Communication (2) (4) 
Signal Transduction (10) (8) 
Development (5) (10) 
Figure 4.9. A functional classification of genes that are significantly down-regulated or up- 
regulated (p <0.01) following AP-2y silencing in MCF-7 cells. Pie charts represent the fraction of 
genes within functional categories as classified by their associated Gene Ontology Biological Process 
annotations. Each gene was assigned a single GO term. The numbers of genes are indicated adjacent to 
the pie chart or with the text (down-regulated genes in green and up-regulated in red). This pie chart 
represents expression changes for single transcripts (not probe sets) this is to avoid overrepresentation of 
functional classes where multiple probe sets representing one gene are significantly regulated. Gene 
ontology terms for each probe set were extracted using the Affymetrix NetAffx web interface (Liu et a!, 
2003, Affymetrix ur! ). 
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Table 4.5. A List of gene ontology biological process terms that were significantly enriched in our 
set of 254 transcripts found to be significantly regulated following AP-2y silencing in MCF-7 cells. 
Shown here is a sub-set of 29 representative significant GO annotations shown in bold type with their 
associated hierarchy indicated by arrows and indenting. Analysis was performed using the GOstat 
software (GOstat, url; Beissbarth & Speed 2004) which found GO terms that were statistically over- 
represented within the 254 genes regulated following AP-2y silencing in MCF-7 cells compared with the 
all of the genes represented on the Affymetrix HG-U133PIus2 microarray. The Group Count represents 
the number of genes from the AP-2y dataset represented within each GO term and the Total Count 
represents the number of genes from the entire Affymetrix HG-U133PIus2 microarray representedwithin 
each GO group. A statistical analysis of the functional annotations overrepresented in the AP-2y dataset 
with a Benjamini correction for multiple comparisons was used to calculate P-Value for each GO term. A 
P-Value cut off of less than 0.05 was used to filter insignificant GO terms. A more detailed description of 
the GOstat software can be found in the Materials and Methods 2.7.3. 
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Significant GO Biological Process Hits: Down Regulated 
Group 
Count 
Total 
Count 
P 
Value 
cellular process - cellular physiological process -+ cell cycle (GO: 0007049) 41 667 5.47E-48 
'-regulation of cell cycle (GO: 0051726) 19 438 2.11E-07 
L. regulation of progression through cell cycle (GO: 0000074) 19 435 2.11E-07 
'-amitotic cell cycle (GO: 0000278) 28 192 1.07E-24 
'-mitotic spindle organization and biogenesis (GO: 0007052) 4 11 3.13E-05 
'+M phase of mitotic cell cycle (GO: 0000087) 25 145 5.01E-24 
L+mitosis (GO: 0007067) 25 143 4.63E-24 
cellular process -º cellular physiological process -º cellular metabolism -º 
nucleobase, nucleoside, nucleotide and nucleic acid metabolism -º DNA 
metabolism (GO: 0006259) 
18 532 1.32E-05 
'-DNA replication (GO: 0006260) 12 142 1.50E-07 
'-'DNA-dependent DNA replication (GO: 0006261) 7 70 4.05E-05 
'-'DNArepair (GO: 0006281) 9 191 0.000577 
cellular process -º cellular physiological process -º cell organization and 
biogenesis -+ organelle organization and biogenesis (GO: 0006996) 
21 750 3.40E-07 
L. cytoskeleton organization and biogenesis (GO: 0007010) 16 322 4.55E-07 
ýmicrotubule-based process (GO: 0007017) 13 130 4.37E-09 
L-omicrotubule-based movement (GO: 0007018) 8 76 6.49E-06 
'-ºmicrotubule cytoskeleton organization and biogenesis 
(GO: 0000226) 7 51 6.26E-06 
"spindle organization and biogenesis (GO: 0007051) 6 18 2.11E-07 
cellular process -º cellular physiological process -+ chromosome 
gregation (GO: 0007059) 6 34 8.83E-06 
'sister chromatid segregation (G0: 0000ß 19) 4 24 0.000662 
cellular process -+ cellular physiological process -+ cell division 
GO( 0051301) 24 162 1.59E-21 
'-ºcytokinesis (GO: 0000910) 4 24 0.000662 
Significant GO Biological Process Hits: Up-regulated 
Group 
Count 
Total 
Count 
P 
Value 
development -+ organ development (GO: 0048513) 8 508 0.0128 
development _ morphogenesis (00: 0009653) 8 546 0.0131 
Dorgan morphogenesis (00: 0009887) 5 207 0.0 16 
"cellular morphogenesis -º regulation of cell size (GO: 0008361) 4 131 _ 0.0181 
L+cell growth (G0: 0016049) 4 131 0.0181 
response to stimulus -+ response to external stimulus (GO: 0009605) 6 459 0.039 
'-'response to wounding (00: 0009611) 6 354 0.0181 
cellular process --' cellular physiological process -º cell death (GO: 0008219) 7 551 0.0198 
'-ºapoptosis (G0: 0006915) 7 526 0.0183 
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4.6.3. PANTHER Classification System Analysis. 
The PANTHER classification system is very similar to the Gene Ontology system, 
based on interconnecting hierarchies of terms, but grea abbreviated and simplified 
(Mi et al, 2005; PANTHER Classification System url . 
This facilitates automated 
high-throughput analyses and accessible graphical outputs. For the results presented in 
this thesis, each Affymetrix ID from the AP-2y data set was assigned a NCBI RefSeq ID 
extracted from the January 2007 release of the HG-U133_Plus2 Affymetrix NetAffx 
Annotation files (Liu et al, 2003; Affymetrix, url). After accounting for a number of 
Affymetrix Ids that had no associated NCBI RefSeq ID and filtering to remove multiple 
representations of individual RefSeq Ids, the AP-2y data set were separated into 59 up- 
regulated and 176 down-regulated genes, then sorted using the PANTHER 
Classification System interface in to groups based on their assigned PANTHER 
Biological Process terms. The pie chart shown in Figure 4.10 represents the fraction of 
genes hits within functional categories against the total gene hits across all categories. 
In order to establish with statistical confidence which PANTHER Biological Process 
annotations were over-represented or under-represented in our lists of significantly up- 
regulated and significantly down-regulated transcripts, we compared them to all of the 
PANTHER Biological Process represented by all of the 25431 genes within the NCBI 
Refseq Database using the PANT Classification System interface (Mi et al, 2005; 
PANTHER Classification System url) Similarly to the GOstat program described 
above, this allows an objective a tistically controlled measure of enriched GO 
terms from with the data set. Table 4.6 shows PANTHER Biological Process terms that 
are significantly enriched in our AP-2y data set compared to terms represented within 
the NCBI Refseq Database. It is clear for those genes down-regulated following AP-2y 
silencing PANTHER Biological Process terms are highly significantly over-represented 
in categories related to cell cycle, consistent with the data obtained from the GOstat 
analysis (Table 4.5) and also reflected in the PANTHER Biological Process pie chart 
(Figure 4.10). Additionally, for genes up-regulated following AP-2y silencing, 
PANTHER Biological Process terms were significantly over-represented in categories 
including Signal transduction, Cell proliferation and differentiation and Growth factor 
homeostasis. 
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DOWN REGULATED 
TOTAL GENES # 176 
TOTAL PROCESS HITS # 287 
n 10 33 
8 
7 
2 
Category Name (Accession) 
Amino acid metabolism (BP00013) 
Apoptosis (BP00179) 
Biological process unclassified (BP00216) 
Carbohydrate metabolism (BP00001) 
Q Cell adhesion (BP00124) 
Cell cycle (BP00203) 
Cell proliferation and differentiation (BP00224) 
Cell structure and motility (BP00285) 
Coenzyme and prosthetic group metabolism (BP00081) 
Developmental processes (BP00193) 
Electron transport (BP00076) 
Q Homeostasis (BP00267) 
Immunity and defense (BP00148) 
Intracellular protein traffic (BP00125) 
Lipid, fatty acid and steroid metabolism (BP00019) 
Miscellaneous (BP00211) 
® Muscle contraction (BP00173) 
Q Neuronal activities (BP00166) 
Nitrogen metabolism (BP00090) 
Nucleoside, nucleotide and nucleic acid metabolism (BP00031) 
Q Oncogenesis (BP00281) 
Other metabolism (BP00289) 
Q Phosphate metabolism (BP00095) 
Q Protein metabolism and modification (BP00060) 
Protein targeting and localization (BP00137) 
9 Sensory perception (BP00182) 
" Signal transduction (BP00102) 
Q Sulfur metabolism (BP00101) 
" Transport (BP00141) 
Figure 4.10. A PANTHER functional classification of genes that are significantly down-regulated 
or up-regulated (p <0.01) following AP-2y silencing in MCF-7 cells. Pie charts represent the fraction 
of genes hits within functional categories, as classified by their associated PANTHER Biological Process 
annotations, against the total gene hits. This pie chart represents expression changes for single transcripts 
based on their associated gene symbol (not probe sets) this is to avoid overrepresentation of functional 
classes where multiple probe sets representing one gene are significantly regulated. Gene ontology terms 
for each probe set analysed using the PANTHER Classification System (Mi el a/, 2005, PAN"1'llEIR 
Classification System, ur/). 
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UP REGULATED 
TOTAL GENES # 59 
TOTAL PROCESS HITS # 124 
iS 11 
Down-regulated Biological Processes 
Process 
Hits From 
Reference 
List 
Process 
Hits From 
AP-2y data 
set 
Expected 
Ilits 
+1' P value 
Cell cycle 1009 44 6.98 + 2.43E-21 
"Mitosis 382 20 2.64 + 5.74E-10 
"Chromosome segregation 121 10 0.84 + 3.48E-06 
L-ºCytokinesis 115 7 0.8 + 3.62E-03 
'-Cell cycle control 418 14 2.89 + 2.33E-04 
L+DNA replication 155 9 1.07 + 2.45E-04 
Nucleoside, nucleotide and nucleic acid metabolism 3343 41 23.4 + 6.77E-03 
L, DNA metabolism 360 13 2.49 + 2.47E-04 
Biological process unclassified 11321 58 78.35 3.60E-02 
Up-regulated Biological Processes 
Process 
hits From 
Reference 
List 
Process 
Hits From 
AP-2y data 
set 
Expected +1- P value 
Signal transduction 3406 26 7.9 + 2.61E-07 
'-ýCell surface receptor mediated signal transduction 1638 12 3.8 + 4.78E-02 
Ls Cell communication 1213 12 2.81 + 2.75E-03 
Cell proliferation and differentiation 
ýy 
1028 10 2.38 + 3.68E-03 
Growth factor homeostasis 7 2 0.02 + 1.86E-02 
Biological process unclassified 11321 8 26.26 - 1.17E-05 
Table 4.6. A List of PANTHER Biological Process terms that were significantly enriched in our set 
of 254 transcripts found to be significantly regulated following AP-2y silencing in MCF-7 cells. 
Shown here is a sub-set of 14 significant PANTHER Biological Process annotations within their 
associated hierarchy indicated by indenting. Analysis was performed using the PANTHER Classification 
System (Mi et al, 2005; PANTHER Classification System, url). Pair wise analyses between the AP-2y 
dataset and genes within the NCBI Refseq Database (Reference List) were performed, using the binomial 
distribution function with a Benjamini correction for multiple comparisons, in order to identify genes with 
PANTHER Biological Process annotations statistically overrepresented or underrepresented within the 
AP-2y dataset. A P-Value cut off of less than 0.05 was used to filter insignificant terms. A more detailed 
description of the PANTHER Classification System can be found in the Materials and Methods 2.7.3. 
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4.7. Analysis of Cell Cycle Ontology Related Gene 
Expression Changes 
The data presented in Section 4.6 clearly illustrates that a large proportion of the 
significantly down-regulated genes are cell cycle related and also that these cell cycle 
related transcripts are significantly enriched in the AP-2y data set compared to the 
genome as a whole. In order to understand how down regulation of this cell cycle 
subset might be related to the observed failure to generate long-term stable 
AP-2y 
knockdowns (Table 3.2) these genes were interrogated further. This analysis was 
restricted to the genes assigned the cell cycle GO terms. An additional miscellaneous 
group included genes assigned the Regulation of Cell Proliferation /// Growth GO 
terms, some unclassified genes and AP-2y itself. 
In order to understand at what point in the cell cycle these genes might be regulated, 
each gene was compared to experimental data from Whitfield and colleagues (Whitfield 
et al., 2002; Whitfield et al., supplemental dat url This microarray study 
characterised the periodicity of gene expression a ording to cell cycle phase in 
chemically synchronised HeLa cells. Figure 4.11 shows the results of this comparison. 
Interestingly, a large number of genes within this data subset were shown by Whitfield 
and colleagues to display cell cycle periodicity of expression. It is reasonable to 
consider that many of the gene expression changes in this AP-2y data subset may have 
occurred as a consequence of a cell cycle perturbation as their expression is known to be 
intrinsic to the cell cycle. For the subset of genes that are known to show cell cycle 
periodicity the cell cycle phase or transition at which the expression was highest and 
lowest was also annotated in Figure 4.11 (extracted from Whitfield et al., 2002). With 
the exception of genes within the DNA Replication /// DNA Repair GO group, all the 
genes displaying cell cycle periodicity were known to show maximal expression at G2 
or G2/M and minimal expression at G1/S. All but one of these genes known to show 
cell cycle periodicity were down-regulated in response to AP-2y silencing in MCF-7 
cells and it could be postulated that their low expression in AP-2y silenced cells hints at 
a cell cycle perturbation at the GUS transition. However, genes within the DNA 
Replication /// DNA Repair GO group displaying cell cycle periodicity were known to 
show maximal expression at G1/S or S phase and minimal expression at G2 or G2/M. 
149 
These were also down-regulated in response to AP-2y silencing in MCF-7 cells and it 
could be postulated that their low expression in AP-2y silenced cells hints that the cell 
cycle perturbation occurred before the cells enter S-phase where expression would 
normally be expected to be high. Also consistent with this hypothesis is that a large 
proportion of the genes listed in Figure 4.11 have been shown to be transcriptionally 
regulated by E2F family members at the GUS transition (Ishida et al., 2001; Polager et 
al., 2002; Ren et al., 2002) These genes are annotated in the final column of Figure 
4.11. 
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4.8. Analysis of Associated Transcription Factor 
Binding Sites 
In order to explore whether any common regulatory elements existed within the list of 
significantly changed genes (p<0.01) observed following silencing of AP-2y in MCF-7 
cells, transcription factor binding site (TFBS) analysis were carried out. An initial 
analysis took advantage of data contained within the UCSC Genome Browser (UCSC 
Genome Browser, url; Kent el al., 2002), detailing transcription factor binding sites 
conserved between the human, mouse and rat genome alignments. Briefly, this consists 
of transcription factor binding matrices from the Transfac Matrix Database (Transfac 
Matrix Database (v7.0), url; Matys et al., 2003), considered to be conserved across the 
alignment only if the matrix similarity score meets a given threshold score for its 
binding matrix in all three species. Using this pre-calculated data, TFBS were searched 
for in the 2000 base pair region upstream of the start of transcription for transcripts 
associated with an Affymetrix ID. Table 4.7 lists the most represented TFBS observed 
within our list with their associated genes. The most represented TFBS are those for 
cell cycle related transcription factors, in particular binding sites for the E2F family are 
most represented upstream of transcripts within the AP-2y dataset. It should be noted 
that this TFBS analysis was very stringent. Firstly, it was looking for conservation 
between human, mouse and rat genomes, which may not be biologically appropriate for 
many of the genes represented within the human genome. Secondly, it includes a. 
statistical comparison that scores each TFBS on the probability (P<0.01) of the 
sequence occurring in the upstream regions of all NCBI RefSeq genes, this will filter 
out any commonly occurring elements. However, these constraints were considered 
necessary to produce a manageable and more meaningful dataset. Of particular interest 
to this study is the AP-2 consensus-binding sequence, SCCNNVRGB, represented by 
the Transfac Matrices V$AP2GAMMA_01 and V$AP2ALPHA_01. These AP-2 
consensus binding sites was experimentally derived using a PCR-assisted binding site 
selection and competitive gel shift assay (McPherson & Weigel, 1999). No conserved 
AP-2 TFBS were found using the analysis above, however this sequence occurs fairly 
frequently in the human genome especially within promoter sequences (Bajic et al., 
2004) and will therefore have been filtered out by the significance threshold constraints 
described above. 
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An additional, smaller scale analysis, focusing on the AP-2 consensus-binding site was 
conducted using the "HumanGenome9999" human promoter sequence data (9999bp up 
stream sequences of 21787 genes represented in the ENSEMBL database) imported into 
the Genespring package (Genespring GX 7.3, Agilent Technologies). A subset of 192 
genes out of the 254 represented in the AP-2y dataset was successfully mapped to the 
ENSEMBL promoter sequences. Searching for the AP-2 consensus binding sequence 
(SCCNNVRGB) in a -500 to +50 bp upstream region of these sequences showed that 
156 sequences contained one or more matches (82.1% of the 192 genes). However, the 
SCCNNVRGB consensus also matched more than once in the -500 to +50 region 
upstream of 80.3%'of the 21787 sequences contained in the ENSEMBL data set. The - 
100 to +50 and -200 to +50 regions were also interrogated, in order explore the effect of 
refining the promoter region analysed on the occurrence of the SCCNNVRGB 
consensus. The data from this analysis is summarised in Table 4.8 and the entire dataset 
is listed in Appendix 2. Overall, this analysis shows that there is no enrichment for the 
presence of AP-2 binding sites in promoter regions of genes within AP-2y data set. The 
analysis also highlights how common the AP-2 consensus sequence is in upstream 
sequences of genes, complementing the data from Bajic and colleagues (Bajic et al., 
2004). It is likely therefore, that constraints other than DNA sequence alone must confer 
AP-2 DNA binding specificity. This analysis is unfortunately insufficient for 
distinguishing between direct and indirect AP-2y targets within this data set. 
Region AP-2y Data set ENSEAMBL promoter data set 
Interrogated (192 genes) (21787 genes) 
-500 to + 50 82 80 
-200 to + 50 64 65 
. 100 to + 50 48 49 
Table 4.8. Percentage calls of one or more SCCNNVRGB consensus sequences in the indicated 
genomic region around the +1 start of transcription of genes within the AP-2y data set. Sequences 
were analysed using the "HumanGenome9999" human promoter sequence data (9999bp up stream 
sequences of 21787 genes represented in the ENSEMBL database) imported into the Genespring package 
(Genespring GX 7.3, Agilent Technologies). 
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4.9. Validation of Selected Affymetrix gene expression 
changes 
4.9.1. qPCR Validation 
In order to assess the reliability of the microarray gene expression profile generated 
following AP-2y silencing in MCF-7 cells, a selection of genes were carried forward for 
further analysis. Genes were chosen based on the magnitude and statistical significance 
of their microarray-derived gene expression values and their biological interest with 
respect to AP-2 and breast cancer. The expression changes for the majority of these 
genes were included in the top thirty most significant changes in gene expression 
following AP-2y silencing displayed in Figure 4.8. Figure 4.12 shows the qPCR 
validation of selected transcripts following AP-2y silencing with three independent AP- 
2y targeting siRNAs compared to controls assessed 96 hours following transfection. In 
an effort to examine the concordance between the qPCR data in Figure 4.12 and the 
primary data generated in the microarray experiment (Appendix 1), the two sets of 
values were compared graphically, as shown in Figure 4.13. These data fitted well to a 
line of best fit indicated by an R2 value of 0.86 and the plot illustrates a good correlation 
between microarray and qPCR derived gene expression (fold change) data. In general, 
the fold change was higher for the qPCR derived values compared to the microarray 
data, indicated by a gradient of 0.81. This level of correlation is consistent with other 
studies looking at qPCR and Affymetrix microarray gene expression data (Dallas et al., 
2005). 
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Figure 4.12. Validation of selected microarray gene expression changes by quantitative P('R 
analysis. MCF-7 cells were transfected as indicated and total RNA harvested 96 hours later. 
Quantitative Real Time PCR analysis of the indicated mRNA levels was performed. Details of the primer 
probe sets used for this analysis are shown in the Materials and Methods 2.8. Data were normalised to the 
GAPDH mRNA levels. The transfection reagent only value was set at I to generate relative mRNA levels 
for each transcript analysed. The graph represents data averaged from three P('R replicates 1 standard 
error. 
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Figure 4.12. Validation of selected microarray gene expression changes by quantitative PCR 
analysis. MCF-7 cells were transfected as indicated and total RNA harvested 96 hours later. 
Quantitative Real Time PCR analysis of the indicated mRNA levels was performed. Details of the primer 
probe sets used for this analysis are shown in the Materials and Methods 2.8. Data were normalised to the 
GAPDH mRNA levels. The transfection reagent only value was set at I to generate relative mRNA levels 
for each transcript analysed. The graph represents data averaged from three PCR replicates + standard 
error. 
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Figure 4.13 A comparison of fold change between microarray-derived and qPCR values for ten 
selected transcripts. In order to conduct this comparison fold change values for the qPCR data were 
calculated from the average of the control data (transfection reagent only and non-silencing control 
siRNA) versus the average of AP-2y siRNA data (AP-2y siRNAI, AP-2y siRNA2 and AP-2y siRNA3). 
These values were then plotted against microarray-derived fold change values from Appendix 1. Where 
more than one Affymetrix probe set was represented for a single gene the fold change was expressed as 
an average. A line of best fit was plotted in black along with a calculation of the gradient and the (R2) 
value showing how well the data fits to this line. 
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4.9.2. Western blot validation 
In order to determine whether any of the microarray gene expression changes could 
be 
confirmed at the functional level of protein abundance, western blot analyses were 
conducted. The selection of genes for validation in this case was largely governed 
by 
the availability of suitable commercial antibodies; therefore the data presented 
represents only those antibodies which gave appropriate, detectable signals. Figure 
4.14 
shows MCF-7 protein levels of Kiaa1324, Keratin 8, Keratin 18, Transgelin 
(TGLN), 
IGFBP3, and Inhibin PA (INHBA) analysed by western blot 96 hours 
following 
transfection with control and AP-2y targeting siRNAs. 
Although, no attempt was made to verify changes in the KRT8 transcript by qPCR, 
protein levels of Keratin 8 and the associated luminal keratin, Keratin 18 were analysed. 
Figure 4.14 (A) shows no change in Keratin 18 and perhaps a slight reduction in Keratin 
8 levels following AP-2y silencing in MCF-7 cells. This is consistent with the slight 
down regulation of the KRT8 transcript observed by microarray gene expression 
profiling following AP-2y silencing in MCF-7 cells. 
Figure 4.14 (A) shows a large increase in the protein levels of Transgelin observed 
following AP-2y silencing with each of the AP-2y targeting siRNAs (although less 
pronounced for siRNA_3) and again is in support of the observed increase at the mRNA 
level (Figure 4.12). Transgelin (also known as SM22a) is a 22kDa actin binding protein 
that was first discovered as an early marker for the early onset of cellular transformation 
(Shapland et al., 1993). 
Figure 4.14 (A) shows a consistent decrease in the protein levels of Kiaa1324 observed 
following AP-2y silencing with each of the AP-2y targeting siRNAs and thus supports 
the observed decrease at the mRNA level (Figure 4.12). This antibody was a kind gift of 
Lei Deng (University of Texas) and detects a specific band above the 105 kDa MW 
marker, consistent with the predicted 121 kDa MW. Kiaa1324 is a protein of unknown 
function, although it was discovered in a microarray study to be over expressed in 
endometrial carcinoma (Deng et al., 2005). In this study, Kiaa1324 was selected for 
further analysis as it was the most statistically significant down-regulated gene on the 
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microarray, following AP-2y silencing in MCF-7 cells (Figure 4.8) and was represented 
by multiple probes sets. In the study in endometrial carcinoma, Kiaa1324 was 
identified as a novel oestrogen regulated gene (Deng et al., 2005). In order to explore 
whether Kiaa1324 was similarly regulated in MCF-7 cells, changes in protein levels 
were monitored following 24 hours treatment with the anti-oestrogen, ICI182,780. 
Figure 4.14 (B) shows a reduction in the levels of Kiaa1324 protein following anti- 
oestrogen treatment suggesting that Kiaa1324 expression is modulated in response to 
oestrogen in this cell line. Immunofluoresence in wild type MCF-7 cells, shown in 
Figure 4.15 (C), shows a strong staining corresponding to the Kiaa1324 antibody at the 
cell membrane and discrete patches to one side of the nucleus. In an effort to 
understand the functional role of Kiaa1324, the protein sequence was interrogated using 
standard comparative proteomic web based tools. No homologous proteins of known 
function were revealed by a protein BLAST analysis (Altschul et al., 1997). However, 
in support the cell membrane compartmentalisation, protein BLAST analysis against 
known proteins (Non-redundant SwissProt sequences), showed that a discrete region of 
Kiaa1324, from amino acid 270 to 420, shares significant homology with a number of 
membrane bound receptors (Altschul et al., 1997), in particular regions containing 
conserved cysteine residues that are thought to be important for the formation of intra- 
chain disulphide bonds in the extra-cellular domains of several membrane bound 
receptors (Bateman et al., 2004). 
Figure 4.14 (B) also shows an increase in the protein levels of JGFPB3 observed 
following AP-2y silencing with each of the AP-2y targeting siRNAs and is in support of 
the observed increase at the mRNA level (Figure 4.12). A specific band between the 35 
kDa and 50 kDa markers is consistent with a glycosylated form of IGFPB3 shown by 
others to run at approximately 40 kDa (Harms & Chen, 2005). IGFBP3 regulation was 
also explored in ZR75-1 cells following AP-2y silencing. ZR-75-1 cells were 
transfected in an identical manner to MCF-7 cells. Figure 4.15 (A) shows the level of 
AP-2y knockdown achieved was approximately 80% when compared to the control 
experiment and this was accompanied by a two fold increase in the relative abundance 
of IGFPB3 mRNA for each of the AP-2y targeting siRNAs. 
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Figure 4.14 (C) shows very slight increase in the protein levels of Inhibin ßA observed 
following silencing with AP-2y siRNA_3, although the difference could largely be 
accounted for by inaccuracy in protein loading marked by a similar increase in the Ku70 
signal. This is inconsistent with, the observed increase at the mRNA level (Figure 4.12) 
and suggests that in this cell line additional posttranscriptional mechanisms act to 
maintain the level of this protein despite transcriptional changes. Inhibins are members 
of the TGF(3 super family. Work by others has shown that Activin A (the Inhibin (3A 
dimerising protein) can mediate growth inhibition and cell cycle arrest through 
regulation of Smad transcription factor phosphorylation in mammary carcinoma cell 
lines (Burdette et al., 2005). However, the negligible difference in Inhibin ßA protein 
level observed here suggests it is not responsible for growth abnormalities following 
AP-2y silencing in MCF-7 cells. 
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Figure 4.14. Validation of selected microarray gene expression changes by Western Blot analysis. 
MCF-7 cells were transfected as indicated and whole cell extracts harvested 96 hours later. (A & C) 
Whole Cell extracts (5. tg/lane) were separated by SDS/PAGE and blotted to a membrane. Blots were 
probed with primary antibodies against Ku-70, Kiaa1324, Keratin 8, Keratin 18, Transgelin, and Inhibin 
3A. Blots were striped and reprobed where necessary. (B) In order to analyse IGFBP3 protein levels, 
conditioned tissue culture supernatant was collected from MCF7 transfected as indicated. Supernatant 
was 5x concentrated using a Centricon Centrifugal concentrator Unit with a 10 kDa MW cut off. 10µl of 
5x concentrated supernatant was separated by SDS/PAGE and blotted to a membrane. Blots were then 
probed with primary antibodies IGFBP3, the asterisk shows a non-specific band that serves as a loading 
control. 
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Figure 4.15. (A) IGBFP3 mRNA up-regulation accompanies AP-27 silencing in ZR75.1 cells. ZR75- 
I cells were transfected as indicated and harvested 96 hours later. qPCR analysis of IGFBP3 mRNA 
levels was normalised to the GAPDH mRNA levels. The control value was set at I to generate relative 
mRNA levels (average of three PCR replicates ± standard error). Whole Cell extracts (5pg/lane) were 
separated by SDS/PAGE and blotted to a membrane. Blots were probed with primary antibodies against 
Ku-70, AP-2y. (B) Western blot showing the effect of 1C1182,780 anti-oestrogen treatment on 
Kiaa1324 levels in MCF-7 cells. MCF-7 cells were split one in two into ICI 182,780 (IOOnM) containing 
medium and harvested for western blot 24 h later. Whole Cell extracts (5pg/lane) were separated by 
SDS/PAGE and blotted to a membrane. Blots were probed with primary antibodies against Ku-70, AP-2y, 
and Kiaal324. (C) Immunofluoresence of Kiaa1324 in wild type MCF-7 cells. Strong Kiaa1324 
staining (Red) was observed at the cell membrane and to one side of the nucleus. DAPI staining (Blue) is 
localised to the nuclear compartment. Details of the lmmunofluoreTnce procedure are described in 
Section 2.4. 
U co) 
a 
LL 
m 
>a ßQ 
C 
O 
N 
b 
3 
3 
L 
1 
0 
4 Ku-70 
oG" 
4tiý 
OC 
165 
RED: Kiaa1324 
BLUE: DAPI 
CHAPTER 5: RESULTS AP-2y AND THE CELL CYCLE 
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Due to the inability to stably reduce AP-2y levels in various breast epithelial lines 
(summarised in Table 3.2) coupled with the observation that genes significantly down- 
regulated following transient AP-2y silencing were found to have GO Biological 
Process terms highly significantly over-represented in categories related to the cell cycle 
(Section 4.7), it was considered important to explore the affect AP-2y appears to have 
on cell proliferation. 
5.1. AP-2-y silencing affects cell proliferation. 
Initial observations in MCF-7 cells transiently transfected with AP-2y targeting siRNAs, 
suggested that reducing AP-2y levels in these cells was affecting cell proliferation. 
Figure 5.1 (A) shows that after 72 hours, the cells transiently transfected with AP-2y 
targeting siRNA_1 appeared fewer in number than those in the control experiments. 
Additionally, in cell counts performed on triplicate wells of AP-2y targeting siRNA_1 
and control experiments, reduced numbers of cells were observed in wells transfected 
with AP-2y targeting siRNA_1. This is shown graphically in Figure 5.1. (B). These 
early effects on cell proliferation appeared to be independent of cell death, as numbers 
of floating cells were not increased in AP-2y siRNA transfected cells. A SubG1 FACS 
cell cycle analysis was performed on cells transiently transfected with AP-2y targeting 
siRNA_1. Briefly this analysis, as well as analysing DNA content to give 4 cell cycle 
profile, also records the subG1 population of cells with fragmented genomic DNA, a 
typical phenotype of cell death (reviewed in Samejima & Earnshaw, 2005). Figure 5.1 
(D) revealed no increase in the SubG1 population after 72 hours and was consistent 
with our visual observations. Interestingly, an increase in the number of cells with a G1 
DNA content was observed, accompanied by a decrease in the proportion of cells in S 
phase. These data are indicative of a cell cycle perturbation at the GUS transition. 
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Figure 5.1. Transient AP-2y silencing in MCF-7 cells affects cell proliferation. (A) MCF-7 cells were 
transfected as indicated and observed microscopically 72 hours following transfection. (B) MCF-7 cells 
were transfected as indicated and counted at 24 hour intervals following transfection. Counts are 
averages (± standard error) from triplicate experiments in wells of six-well plates and were performed 
using a Coulter Counter (Beckman). (C) Western blot analysis demonstrating the AP-2y knock down 
efficiency 72 hours after transfection. Whole Cell extracts (51Lg/lane) were separated by SDS/PAGE and 
blotted to a membrane. Blots were probed with primary antibodies against AP-2y before being reprobed 
for Ku-70 as a loading control. (D) SubGl FACS analysis for DNA content on control cells and those 
transfected with an AP-2y targeting siRNA and harvested at 72 hours following transfection. 
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5.2. AP-2y silencing affects cell cycle at the G1/S 
transition. 
A more detailed cell cycle analysis was performed 72 h after transfection to further 
characterise the observed proliferation differences. These experiments were performed 
in triplicate and the effects of the three independent AP-2y targeting siRNAs were 
examined. Additionally, cells were passaged at the 48-hour time point following 
transfection. This was to ensure that any observed differences in cell cycle profiling 
were not due to the cells in the control plates being more confluent than the AP-2y 
knock down plates leading to contact inhibition of growth becoming an extra variable in 
these experiments. A one in two passage ensured that cells remained sub-confluent at 
the time of harvest and therefore the population consisted of mostly cycling cells. 
Figure 5.2 (A) displays the cell cycle profiles of cells 72 hours following transfection 
with the three independent AP-2y targeting siRNAs. A significant increase in G1 
population (p<0.0.1) was observed for each AP-2y targeting siRNA compared to the 
control G1 populations. Additionally, a moderate but significant decrease in the 
proportion of cells in S phase (p<0.0.1) was observed for each AP-2y targeting siRNA 
compared to the control S phase populations. No differences were observed between 
transfection control populations and cells transfected with a non-silencing siRNA. An 
additional analysis looking at S-phase activity of the cell population following transient 
transfection with AP-2y targeting siRNA_3 is shown in Figure 5.2 (B). To provide a 
snapshot of the fraction of cells actively synthesising DNA, S-phase activity was 
measured by labelling transfected cell cultures with BrdU for a 20 minute period 
immediately prior to harvest (Materials and Methods 2.5). A significant reduction in 
the fraction of cells actively undergoing S phase is seen in cells transfected with AP-2y 
targeting siRNA_3 compared to the control populations. The percentage of cells 
actively undergoing DNA synthesis was also consistent with the proportion of cells with 
S Phase DNA content shown in Figure 5.2 (A), this indicated that any cell cycle 
abnormality was occurring before the cells enter S-phase. Together these data suggest 
that cells transfected with AP-2y targeting siRNAs were undergoing a partial cell cycle 
arrest at the Gl/S transition. 
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Figure 5.2. MCF-7 cells transiently transfected with AP-2y targeting siRNAs show altered cell cycle 
distribution. (A) PI FACS analysis for DNA content performed 72 h after transfection. Cells were 
transfected as indicated, split I in 2 at 48 h, then harvested for cell cycle analysis 24 h later. (B) FACS 
analysis for BrDU incorparation performed 72 h after transfection. Cells were transfected as indicated, 
split I in 2 at 48 h, then harvested for cell cycle analysis at 72 h. Cells were labeled for BrDU for 20 
mins before harvest. (C) Western blot analysis demonstrating the AP-2y knock down efficiency 72 hours 
after transfection. Whole Cell extracts (5pg/lane) were separated by SDS/PAGE and blotted to a 
membrane. Blots were probed with primary antibodies against AP-2y before being reprobed for Ku-70 as 
a loading control. Averages from triplicate experiments are shown (± standard error). * p<0.0I compared 
to controls. 
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These phenotypic observations also complement the changes observed in the gene 
expression profile following AP-2y knock down. A detailed analysis of the cell cycle 
associated subset of genes showed that the majority of these were known to display cell 
cycle periodicity (Whitfield et al., 2002), almost all showing their lowest expression at 
G1 or S phase (Figure 4.11), and it is reasonable to consider that many of these changes 
my have occurred as a consequence of the cell cycle arrest. However, it should be noted 
that RNA for the microarray analysis was harvested at a later time point, 96 hours 
following transfection and therefore cells were approaching confluency at the time of 
harvest. It is expected that some differences in cell cycle related transcripts or proteins 
might be observed at the different time points, but it is clear that both the gene 
expression profile and the FACS cell cycle analysis point towards an effect on GUS 
transition following AP-2y silencing. 
In order to understand the mechanism whereby AP-2y silencing mediates this cell cycle 
arrest, the expression of cell cycle regulatory molecules were analysed by western blot 
72 h after transfection with AP-2y targeting siRNAs. Cells were passaged at the 48- 
hour time point following transfection to ensure cycling cells at the time of harvest. 
Figure 5.3 (A) shows that little or no change in the levels of cyclin Dl, cyclin D3 and 
the cyclin dependent kinases, cdk2, cdk4, and cdk6 was observed following AP-2y 
silencing. Slight differences in protein levels observed in the bottom section of Figure 
JvICA MS ' uy ýM 5.3 (A), particularly apparent in lane 2, are largely due to inaccuracieg in protein J vcls.. 
(when compared to the Ku-70 loading control). The levels of cyclinE2 are moderately 
increased following AP-2y silencing, although this difference appears exaggerated due 
lVoCßýýSIý"t'ttý 
to the loading i naa ei 'n lane 2 (Figure 5.3 (A)). One of the principle cellular 
targets for cyclin/cdk complexes in cell cycle regulatio is the retinoblastoma family of 
pocket proteins. Western blot analysis in Figure 5. (B) using antibodies specific to 
phosphorylated forms of Rb protein, showed a reduction in detected levels following 
AP-2y silencing. This indicates that cyclin/cdk activity was reduced following AP-2y 
silencing, leading to hypophosphorylation of Rb. A consequence of reduced Rb 
phosphorylation is the formation of stable Rb/E2F complexes which leads to the 
repression of E2F target genes. Many known transcriptional targets of E2F family 
members (Ishida et al., 2001; Polager et al., 2002; Ren et al., 2002). were shown to be 
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down-regulated in the gene expression profiling experiments following AP-2y silencing 
in MCF-7 cells (Figure 4.11), consistent with an increase in Rb/E2F complex stability. 
To assess whether up-regulation of Cyclin Dependent Kinase Inhibitor expression was 
associated with these cell cycle changes, levels of p15, p21 and p27 proteins were also 
analysed. Levels of p15 were barely detectable by western blot in control and AP-2y 
silenced cells (data not shown). p16 was not assessed as it is not expressed in this cell 
line (Ragione et al., 1996). However, an increase in p21 and p27 levels, as determined 
by western blot, was observed for each AP-2y targeting siRNA. The increase in p27 
levels is accompanied by a decrease in p27 phosphorylation at Thr187 (Figure 5.3). In 
cycling cells, p27 is phosphorylated by CyclinE/CDK2 kinase activity and targeted for 
proteolysis (Sheaff et al., 1997). It is reasonable to consider therefore, that the increase 
in p27 levels following AP-2y silencing could be largely due to a reduction in signalling 
activity promoting p27 proteolysis. An induction of p21 is of particular interest to this 
study as AP-2a has been implicated in the activation of CDKN1A transcription (Zeng et 
at., 1997; McPherson et at., 2002). It was tempting to speculate that AP-2y might play 
an opposing role in CDKNIA transcriptional regulation, repressing transcription in wild 
type MCF-7 cells with AP-2y silencing relieving this repression, leading to p21 
activation and hence a reduction in Cyclin/CDK kinase activity leading to the observed 
cell cycle perturbation. 
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Figure 5.3. Elevated p21 levels following AP-2y silencing in MCF-7 cells. (A-C) Cells were 
transfected as indicated, split I in 2 at 48 h, then harvested at 72 hours for western blot. Whole Cell 
extracts (5pg/lane) were separated by SDSIPAGE and blotted to a membrane. Blots were probed with 
primary antibodies against Ku-70, Cyclin D1, Cyclin D3, cdk4, cdk6, cyclinE2, cdk2, p27, p21, phospho 
p27 (Thr 187) and phosphor RB (Ser 807/811 and Ser 795). Blots were striped and reprobed where 
necessary. (D) CDKNIA levels observed on gene expression microarrays 96 hours following transient 
transfection with AP-2y targeting siRNAs in MCF-7 cells. 
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However, no significant gene expression change had been noted on the microarray for 
the CDKNIA (p2l) transcript following AP-2y silencing. Figure 5.3 (D) shows a heat 
map of normalised expression values for the CDKNIA probe set, 202284_at. The levels 
of CDKNIA in the control wells were already very high and although a slight increase 
in CDKNIA gene expression was seen for the AP-2y siRNA transfected conditions, this 
difference is minimal. Discrepancies between the data in Figures 5.3 (C) and (D) could 
be due to the RNA for the microarrays being harvested at a later time point. The gene 
expression profile was performed at 96 hours following transfection when cells were 
approaching 100% confluency at the time of harvest while the western blot analysis was 
performed at 72 hours following transfection and on sub-confluent cells. Indeed, levels 
of p21 are known to be induced when cells reach high densities and contact inhibition 
occurs and this might account for the high CDKNIA levels observed by microarray in 
the control cells which minimised differences seen after AP-2 silencing (Macleod et al., 
1995; Erhardt & Pittman, 1998). Equally, changes in p21 level could actually he 
occurring at the posttranscriptional level (Coleman et al.. 2003; Cerda et al., 2006). 
5.3. AP-2y silencing is accompanied by elevated p21 
mRNA and protein levels. 
In order to further elucidate the observed changes in p21 level, MCF-7 cells were 
transfected with AP-2y targeting siRNAs and, following a one in three passage at 48hrs, 
both RNA and whole cell extracts were harvested at 72 and 96 hours. This was to 
ensure the cells were sub-confluent at the times of harvest. Figure 5.4 shows that using 
these transfection conditions elevated p21 mRNA (A) and protein (B) were observed at 
both time points. Additionally, Figure 5.4 (B) shows that the p2l protein level has 
increased in the control extracts harvested at 96 hours compared to those extracts 
harvested at 72 hours, suggesting that cell density is also a factor in regulation of p21 
levels in MCF-7 cells. Changes in the amount of both p21 mRNA and p2l protein 
imply that its regulation occurs at the level of transcription upon AP-2y silencing. 
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Figure 5.4. Elevated p2l mRNA and protein are observed following transient transfection with AP- 
2y targeting siRNAs in cycling MCF-7 cells. Cells were passaged at the 48-hour time point following 
transfection and harvested at 72 and 96 hours. (A) Quantitative PCR analysis of CDKNIA mRNA levels. 
Data were normalised to GAPDH mRNA levels and the transfection reagent only (control) values, at 72 
and 96 hours, were set at I to generate relative mRNA levels. The graph represents data averaged from 
three PCR replicates, t standard error. (B) Whole Cell extracts (5pg/lane) were separated by SDS/PAGE 
and blotted to a membrane. Blots were probed with primary antibodies against Ku-70, p2l and AP-2y. 
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5.4. AP-2a and p53 protein levels show little change 
following AP-2y silencing. 
As both AP-2a and p53 had previously been shown to play an important role in the 
transcriptional activation of CDKN1A (McPherson et at., 2002), changes in AP-2a or 
p53 protein levels were assessed following AP-2y knockdown in MCF-7 cells. Figure 
5.5 (A) shows no increase in AP-2a, which remained at barely detectable levels 
following AP-2y silencing, implying that changes in AP-2a levels were not involved in 
CDKNIA up-regulation in these cells. Figure 5.5 (A) also shows no significant changes 
in levels of p53, except for a slight difference for AP-2y siRNA_2 transfected cells. 
In an effort to verify this slight increase in p53 levels following AP-2y siRNA_2 
silencing, an additional Dharmacon smart pool of AP-2y targeting siRNAs was 
evaluated alongside our existing set of AP-2y targeting siRNAs. AP-2y siRNAs from 
Dharmacon were evaluated individually and as a pool (at the same final concentration) 
compared to AP-2y siRNAs 2 and 3 (see Results 3.2). Figure 5.5 (B) shows the level of 
AP-2y knockdown achieved for each siRNA and the resulting p21 and p53 protein 
levels. Encouragingly, the induction of p21 following AP-2y silencing with, the 
Dharmacon siRNAs was comparable to the effect observed with those designed s. 
However, two of the siRNAs from the smart pool (#05 and #08) showed inefficient AP- 
2y knock down and this was accompanied with a reduced induction of p21 levels. 
Interestingly, the smart pool was only as effective as the most effective individual 
siRNA (#07), suggesting that knockdown in the smart pool experiment could have been 
due to the #07 siRNA alone. At a medium exposure (30 seconds) it was difficult to 
determine any differences in p53 levels following AP-2y knockdown, however 
following a brief exposure (2 seconds), a very slight increase in p53 levels 
accompanying AP-2y knockdown was revealed and this increase was observed for all 
the siRNAs transfected. 
In order to put these slight changes in p53 level in to context we felt it was important to 
compare them to the changes in p53 levels following DNA damage stress. MCF-7 cells 
have been shown by others to express wild type p53 and exhibit an intact DNA damage 
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response pathway (Bartek et al., 1990). Figure 5.6 (A) shows that 24 hours following 
treatment with cisplatin to induce DNA damage, p53 levels were increased in a dose- 
dependant manner. This is consistent with the well-documented stabilisation of p53 
following DNA damage (Reviewed by Fei & El-Deiry, 2003) and was accompanied by 
an induction of p21 and BAX protein levels, known p53 transcriptional targets in 
response to DNA damage (el-Deiry et al., 1993; Miyashita & Reed 1995; Fei & El- 
Deiry, 2003). This confirms that the wild type p53 protein in our MCF-7 cells behaved 
predictably following DNA damage stress, and rules out any p53 anomalies in our cells. 
The increase in p53 levels seen following AP-2y silencing (Figure 5.5 (B) Lanes 3-9) is 
modest compared to the stabilisation of p53 observed in cisplatin treated MCF-7 cells, 
even atýd the 1µM cisplatin concentration (Figure 5.6 (A) Lane 2) and is inconsistent 
with the observed magnitude of p21 induction. Together these data suggest that this 
very small increase in p53 is not the major mechanism of p21 induction following AP- 
2y silencing. Interestingly, an increase in AP-2a levels and a decrease in AP-2y levels 
were also observed following cisplatin treatment (Figure 5.6 (B)). However, the change 
for 2y is modest, with the apparent reduction in the last lane largely due to 
ca in protein levels(loading (when compared to the Ku-70 signal Figure 5.6 
(B)). 
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Figure 5.5. Assessment of AP-2a and p53 protein levels 72 hours following AP-2y silencing in 
MCF-7 cells. (A) Western showing knock down with AP2y siRNA I, 2 and 3. (B) Comparison of AP2y 
siRNA 2 and 3 and with Dharmacon AP-2y sequences 05,06,07,08 and the "Smart Pool" (SP). A total 
concentration of 25nM siRNAs was transfected for each experiment. Whole Cell extracts (5pg/lane) 
were separated by SDS/PAGE and blotted to a membrane. Blots were probed with primary antibodies 
against Ku-70, p21, AP-2a, p53 and AP-2y, blots were striped and reprobed where necessary. 
*Represents films that have undergone a very brief exposure approximately 2 seconds. 
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Figure 5.6. Cisplatin mediated DNA damage in MCF-7 cells leads to a stablilisation of p53 and 
activation of p53 target genes p21 and BAX (A) and modest changes in AP-2 family members (B). 
MCF-7 cells were treated with cisplatin and harvested 24 hours later. Whole ('ell extracts (Slit; /lane) were 
separated by SDS/PAGE and blotted to a membrane. Blots were probed with primary antibodies against 
Ku-70, p21, AP-2a BAX p53 and AP-2y, blots were striped and reprobed where necessary. *Represents 
films that have undergone a very brief exposure approximately 2 seconds. 
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5.5. Myc, ERa and SP1 protein levels show little change 
following AP-2y silencing. 
As well as AP-2a and p53, it was considered important to assess the changes in other 
proteins regulated by AP-2 family members, which have also been shown to play an 
important role in the transcriptional regulation of CDKN1A. One such protein, c-Myc 
has been shown to negatively regulate CDKN1A transcription, through interaction with 
proximal SP1 sites or via initiator elements down-stream of the start of transcription 
(reviewed in Gartel & Radhakrishnan 2005). Myc has also been suggested to be under 
negative control by AP-2 family member, AP-2a (Gaubatz et al., 1995). Because of 
these findings it was important to assess the contribution of Myc to these observations. 
Figure 5.7 shows there was no or little change in Myc levels following AP-2y silencing 
in MCF-7 cells and suggests that it is not regulated by AP-2y in this cell line. 
Additionally, AP-2y has been shown to maintain ERa transcription in breast cancer cell 
lines (reviewed in Hilger-Eversheim et al., 2000). In order to assess the contribution of 
ERa to the observed cell cycle changes, levels were assessed by western blot. However, 
Figure 5.7 shows that ERa does not contribute to cell cycle regulation following AP-2y 
silencing in MCF-7 cells. Finally, many factors have been shown to modulate the 
expression of CDKNIA via interaction with the six SP1 sites in the 100bp proximal to 
the start of transcription (reviewed in Gartel & Radhakrishnan 2005). Changes in SP1 
protein levels were also unaffected following AP-2y silencing in MCF-7 cells (Figure 
5.7). 
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Figure 5.7 Assessment of Myc, SPI, and ERa protein levels 72 hours following AP-2y silencing in 
MCF-7 cells. Whole Cell extracts (5pg/lane) were separated by SDS/PAGE and blotted to a membrane. 
Blots were probed with primary antibodies against Ku-70, Myc, SPI and ERa, blots were striped and 
reprobed where necessary. 
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5.6. AP-2y expression represses a CDKN1 A promoter 
reporter construct 
In order to examine the possible effect of AP-2y over expression on CDKN/. 1 
transcription, luciferase reporter assays were conducted to assess CDKNIA promoter 
activity in AP-2 non-expressing HepG2 cells. Genomic sequences from -2325 to +8 
relative to the start of transcription of the CDKNJA gene have been shown to be 
important for the regulation of transcription and have been previously cloned into a 
luciferase reporter vector (el-Deiry et al., 1993). Initially, the reporter construct alone 
was transfected at different amounts. Figure 5.8 (A) shows that good levels of basal 
luciferase expression were achieved when transfecting lug of reporter, therefore this 
amount was used in co-transfection studies with an AP-2y expression construct. The 
results in Figure 5.8 (B) show that basal luciferase activity from this construct was 
reduced in a dose-dependant manner following co-transfection with an AP-2'1 
expression construct. These data suggest that AP-? y is able to repress CI)KNIA 
promoter activity in HepG2 cells. However, the observed effects on luciferase activity 
are not necessarily due to direct effects of' AP-2y on the C'DKNIA promoter, and could 
he due to indirect regulation via other downstream targets of" AP-2y or via sequestration 
of factors away from the reporter construct. 
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Figure 5.8. AP-2y repressed basal activity from the CDKN/A promoter in HepC2 cells. The AP-2 
non-expressing cell line, HepG2 was transiently transfected with 0.25,0.5 and I. O tg of the -2325\ f8 
CDKNIA luciferase reporter construct (A) or I. Opg of the -2325\+8 ('DKNIA luciterase reporter 
construct and the indicated amounts of the AP-2y expression construct (B). A renilla luciferase construct 
(phRG-TK) was co-transfected in each experiment and the differences in DNA amount were compensated 
for using a promoterless Luciferase construct (A) or pcDNA3 plasmid (ß). Forty-eight hours following 
transfection cells were assayed for luciferase activity. Results (mean i S. E. of three independent 
experiments) are presented as relative luciferase activity, corrected for Renilla luciferase activity. ('ells 
transfected with the CDKNIA promoter luciferase reporter alone (B) were set at 100%. See materials and 
methods for plasmid details. 
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5.7. ChIP reveals occupancy of the CDKN1A promoter 
by endogenous AP-2y 
To understand whether AP-2y played a direct role in CDKN1A transcriptional regulation 
in MCF-7 cells, the CDKNIA promoter region was analysed for AP-2y DNA binding 
sites. The generic AP-2a and AP-2y consensus-binding sequence SCCNNVRGB 
(McPherson & Weigel, 1999) was searched for in the -4020 to +185 region of the 
CDKN1A promoter and occurs at several sites across this region, the exact locations are 
shown in Figure 5.9. However, it should be noted that this TFBS occurs frequently in 
the human genome (see Section 4.8 for details). 
In order to determine whether AP-2y played a direct role in CDKN1A transcriptional 
regulation in MCF-7 cells, Chromatin ImmunoPrecipitation (ChIP) accompanied by 
quantitative PCR (see Materials and Methods 2.9) was employed to investigate AP-2y 
occupancy on the endogenous CDKNIA promoter. All of the ChIP data presented in 
this thesis was generated in collaboration with Karsten F edri h. Briefly, cells were 
passaged (1 in 2) 24 hours before use in ChIP assays to ensure cells were cycling. The 
cells were crosslinked with 1% formaldehyde for 10 minutes and chromatin was 
sheared by sonication to an average size of 500bp. Immunoprecipitation reactions were 
carried out overnight using predetermined amounts of antibody and then washed with 
optimised wash conditions. Following immunoprecipitation, nd the DNA was 
extracted using Chelex beads. A "no antibody control" was treate the same manner 
as the other samples and used to determine the background level to which the qPCR 
data were normalised. Four sets of qPCR primers were designed and evaluated for their 
ability to specifically amplify regions across the CDKN1A promoter (see Material and 
Methods 2.9: Table 2.7) Figure 5.10 (A) shows the location of primers relative to 
known regulatory regions across the CDKNIA promoter and summarises the data in 
Figure 5.9. Primer set'-4005 / -3931 was 'designed across a 'region of high species 
conservation, with potential AP-2 binding sites. Primer set -2290 / -2185 was designed 
against a region flanking the classical p53 binding site (Kaeser & Iggo 2002), also a 
region previously shown to be occupied by AP-2a (Mcpherson et al., 2002). The primer 
set -935 / -864 was designed across a region with potential AP-2 binding sites binding 
sites and finally, the -21 / +44 primers were designed across a region encompassing the 
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start of transcription. This region encompassed several potential AP-2 binding sites and 
a region previously described to be important for transcriptional activation by AP-2a 
(Zeng et al., 1997). These sets of four primers were sufficiently spaced across the p21 
promoter region that they would not amplify overlapping chromatin fragments, 
considering the chromatin was sheared to an average size of 500bp. In addition to these 
p21 promoter specific sequences, primers were designed within a centromeric region 
consisting of satellite repeat (SAT2) sequences (Jiang et al., 2004). This region of 
constitutive heterochromatin on Chromosome 1 was used as a negative control to 
determine the specificity of the antibodies. Binding would be expected to be absent in 
this region for the factors examined in this study. In addition to examining AP-2y 
occupancy across these regions, I also thought it would be informative to examine the 
occupancy of the known AP-2y co-factor, p300, and also to examine the acetylation 
status of the H4 histone protein, a marker of active chromatin. 
Figure 5.10 (B) shows the relative enrichment of CDKNIA promoter specific sequences 
measured in AP-2y, p300 and acH4 ChIP elutes. None of the antibodies used in these 
ChIP experiments were enriched for amplification from the SAT2 heterochromatin 
region implying that the activity observed at the CDKN1A locus was specific for each 
protein target. Interestingly these data showed that AP-2y occupancy within the 
CDKNIA endogenous promoter region was confined to the region amplified by the -21 / 
+44 primer set. AP-2y did not occupy any of regions amplified by the other primer sets 
further upstream and in particular it was not found associated near the classical p53 
binding site amplified by primer set -2290 / -2185. It is intriguing that AP-2y 
occupancy was associated with p300 occupancy across the CDKNIA promoter, p300 
also showing greatest enrichment near the region amplified by the -21 / +44 primer set. 
Although p300 is a known co-factor of AP-2y, recruited through CITED adapter 
proteins, it has previously only been described in the context of AP-2 transcriptional 
activation and it is somewhat surprising that p300 is also associated with AP-2y when it 
is potentially mediating transcriptional repression. Strikingly, the AP-2y and p300 
occupied region amplified by the -21 / +44 primer set shows a reduction in ac114 is 
when compared to the acH4 occupancy near regions amplified by the -2290 / -2185 and 
-935 / -864 regions, suggesting that the, -21 / +44 region is less accessible to the general 
transcription machinery than the regions upstream. 
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-4030 -4020 -4010 -4000 -3990 -3980 -3970 -3960 
ATCTCAGTTTGCCCATTAATATTATAGGTCTGGCCCCTCTGTGAAAACATGCCCAGCGGCAAGGCCAACAAGCTGGGGGATGTTGTTA 
TAGAGTCAAACGGGTAATTATAATATCCAGACCGGGGAGACACTTTTGTACGGGTCGCCGTTCCGGTTGTTCGACCCCCTACAACAAT 
`ß r) 3Bß0 3870 +90 -3930 -3920 
GAGCCAGGAACAGGAAGACCATCCAGGTTGGTAACACTGATGCTGAGGGGAGGCTCATACTGGCTGATGCGCTCTGTTACGTGCACAC 
CTCGGTCCTTGTCCTTCTGGTAGGTCCAACCATTGTGACTACGACTCCCCTCCGAGTATGACCGACTACGCGAGACAATGCACGTGTG 
-3850 -3840 -3830 -3820 -3810 -3800 -3790 -37H'() 
ATTTAACCCGAAGGTCATCCTCAATGCCACCACCTTAACAGGTGTCATAGATGTAGCTTTGGGGTCAGGTGCCACTGGGGTCTTTACC 
TAAATTGGGCTTCCAGTAGGAGTTACGGTGGTGGAATTGTCCACAGTATCTACATCGAAACCCCAGTCCACGGTGACCCCAGAAATGG 
3770 -3760 -3750 -3740 -3730 -37_20 -3710 -3700 -; 
(', O 
AATTCATCCTGGCTCTGGAACAAGCTCTTCGAGGCCAGCATTGAAACAGGGGACCGTGTCTGGAGGATGCCTCTCTTCAAACATTGTA 
TTAAGTAGGACCGAGACCTTGTTCGAGAAGCTCCGGTCGTAACTTTGTCCCCTGGCACAGACCTCCTACGGAGAGAAGTTTGTAACAT 
-3680 -3610 -3660 -3650 -3640 -3630 -3620 - 
3610 -3600 
CAAGACAGGTTGTAGATTGCCAGCTGGCTGATGTTAACAACATTGGAAAATATAGATCTGCGGGAGCATGTACATCTGCGGCATTCCT 
GTTCTGTCCAACATCTAACGGTCGACCGACTACAATTGTTGTAACCTTTTATATCTAGACGCCCTCGTACATGTAGACGCCGTAAGGA 
-3590 -3580 -3570 -3560 -3550 -3540 -3530 -3520 
GAAAGAATTCGTGACTCATCCTAAGTGGGCACATTTAGACATAGCAGGTGTGATGACCAACAAAGATGAGGTTCCCTATCTATGGAAA 
CTTTCTTAAGCACTGAGTAGGATTCACCCGTGTAAATCTGTATCGTCCACACTACTGGTTGTTTCTACTCCAAGGGATAGATACCTTT 
-3500 -3490 -3480 -3470 -3460 -3450 -3440 -3430 
GGCATGACCGGGAGGCCCACAAGGACTCTCATAGAGTTCTTACTTCGTTTCAGTCAAGACAATGCTTAGTTCAGATACTCAAAAATGT 
CCGTACTGGCCCTCCGGGTGTTCCTGAGAGTATCTCAAGAATGAAGCAAAGTCAGTTCTGTTACGAATCAAGTCTATGAGTTTTTACA 
-3410 -: 1; 10 -3390 -33H; --- -ý- , 
CTTCACTCTATCTTAAATTGGACAGTTGAAGTTAAAAGGTTTTTGAATGAATGGATGAAAATATTTTAAAGGAGGCAATTTATATTTA 
GAAGTGAGATAGAATTTAACCTGTCAACTTCAATTTTCCAAAAACTTACTTACCTACTTTTATAAAATTTCCTCCGTTAAATATAAAT 
-3330 -3320 -3310 -3300 -3250 
AAAATGTAGAACACAATGAAATTTTTATGCCTTGATTTTTTTTTCATTTTACACAAAGATTTATATATTTTTTTTTTGAGACGGAGTC 
TTTTACATCTTGTGTTACTTTAAAAATACGGAACTAAAAAAAAAGTAAAATGTGTTTCTAAATATATAAAAAAAAAACTCTGCCTCAG 
-3240 -3230 -3220 -3210 -3200 -3190 -3180 
-3170 -3160 
TCACTCTGTCACCCAGGCTGGAGTGCAGGTGGCATGATCTCAGCTCACTGCAACCTCCGCCTCCTAGGTTCAAGCGATTCTCCCACCT 
AGTGAGACAGTGGGTCCGACCTCACGTCCACCGTACTAGAGTCGAGTGACGTTGGAGGCGGAGGATCCAAGTTCGCTAAGAGGGTGGA 
-315C 3140 -3130 -312C 31,10 -,. .. -3097 -sH, O 
CAGCCACCTGAATACCTGGGACTACAGGTGCCCACCACCATGCCCGGCTGATTTTTGTATTTTTAATGGAGACGGGGTTTCACCATAT 
GTCGGTGGACTTATGGACCCTGATGTCCACGGGTGGTGGTACGGGCCGACTAAAAACATAAAAATTACCTCTGCCCCAAAGTGGTATA 
-3060 -3050 -3040 -3030 30.0 150') 29ý(, 
TGGCCAGGCTGGTCTCAAAACTCCTGACCCTGTGATCTGCCCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTAAGCCACCACG 
ACCGGTCCGACCAGAGTTTTGAGGACTGGGACACTAGACGGGCGGAGCCGGAGGGTTTCACGACCCTAATGTCCGCATTCGGTGGTGC 
-2970 -2960 -2950 -2940 -2930 -2920 -2910 -: "+0 () 
CCCGGCCAGTATATATTTTTAATTGAGAAGCAAAATTGTACTTCAGATTTGTGATGCTAGGAACATGAGCAAACTGAAAATTACTAAC 
GGGCCGGTCATATATAAAAATTAACTCTTCGTTTTAACATGAAGTCTAAACACTACGATCCTTGTACTCGTTTGACTTTTAATGATTG 
-: 9,90 -2880 -2870 -2860 -2850 -2830 , NCf, . tp) 
CACTTGTCAGAAACAATAAATCCAACTTTTTGTGCAAAAAAAAAAATACAAATATTAGCTGGGCATGGTGGTGCATGCCTGTAATCCC 
GTGAACAGTCTTTGTTATTTAGGTTGAAAAACACGTTTTTTTTTTTATGTTTATAATCGACCCGTACCACCACGTACGGACATTAGGG 
X800 `C -2780 -2770 -2760 -: 740 1;, . 1720 
AGCTACTCGGGAGGCTGAGGCAGAATTGCTTGAACCTGGGAGGCGGAGACTGCAGTGAGCTGAGATTGTGCCACTGCTGACTTTGTCT 
TCGATGAGCCCTCCGACTCCGTCTTAACGAACTTGGACCCTCCGCCTCTGACGTCACTCGACTCTAACACGGTGACGACTGAAACAGA 
-2710 -2700 -2690 -2680 -2670 -2660 ., "h -39 4u 
CAAAAAACAAAACAAAACAAAAAAACAAAATGAAAACAAAAAGCCAGGGCTGCCTCTGCTCAATAATGTTCTATCTTTGTTCCGCCTC 
GTTTTTTGTTTTGTTTTGTTTTTTTGTTTTACTTTTGTTTTTCGGTCCCGACGGAGACGAGTTATTACAAGATAGAAACAAGGCGGAG 
-2.620 -2610 -2600 -2590 -. 3I50 00, 
TTCTCTGGGGTCTCACTTCTTGGGAGCCTGTGTGAAGGTGAATTCCTCTGAAAGCTGACTGCCCCTATTTGGGACTCCCCAGTCTCTT 
AAGAGACCCCAGAGTGAAGAACCCTCGGACACACTTCCACTTAAGGAGACTTTCGACTGACGGGGATAAACCCTGAGGGGTCAGAGAA 
-2530 -25-0 - 510 00 490 480 4 /) 4r, i) 
TCTGAGAAATGGTGACATTGTTCCCAGCACTTCCTCTCCCTTCCTAGGCAGCTTCTGCAGCCACCACTGAGCCTTCCTCACATCCTCC 
AGACTCTTTACCACTGTAACAAGGGTCGTGAAGGAGAGGGAAGGATCCGTCGAAGACGTCGGTGGTGACTCGGAAGGAGTGTAGGAGG 
-2450 -2440 -2430 -2420 -2410 -2400 -2390 -o io 
TTCTTCAGGCTTGGGCTTTCCACCTTTCACCATTCCCCTACCCCATGCTGCTCCACCGCACTCTGGGGAGGGGGCTGGACTGGGCACT 
AAGAAGTCCGAACCCGAAAGGTGGAAAGTGGTAAGGGGATGGGGTACGACGAGGTGGCGTGAGACCCCTCCCCCGACCTGACCCGTGA 
-2360 -2350 -2340 -2330 -2320 -2310 -2300 -2290 -,:, fiu 
-2260 -2250 -2240 -2230 -: 22u `: `1O 
-2180 --1 170 -2IE, () -71`, 0 -: '14(, -: '1 (i) I. '', 
AGGTGAGGAAGGGGATGGTAGGAGACAGGAGACCTCTAAAGACCCCAGGTAAACCTTAGCCTGTTACTCTGAACAGGGTATGTGATCT 
TCCACTCCTTCCCCTACCATCCTCTGTCCTCTGGAGATTTCTGGGGTCCATTTGGAATCGGACAATGAGACTTGTCCCATACACTAGA 
'090 080 -2070 -() 1) , >(( , 0. °( 
GCCAGCAGATCCTTGCGACAGGGCTGGGATCTGATGCATGTGTGCTTGTGTGAGTGTGTGCTGGGAGTCAGATTCTGTGTGTGACTTT 
CGGTCGTCTAGGAACGCTGTCCCGACCCTAGACTACGTACACACGAACACACTCACACACGACCCTCAGTCTAAGACACACACTGAAA 
-201() -2000 -1990 -1980 -1870 -196)) -19')O 11.47 1,0, 
TAACAGCCTGCTCCCTTGCCTTTTTCAGGGCAGAAGTCCTCCCTTAGAGTGTGTCTGGGTACACATTCAAGTGCATGGTTGCAAACTT 
ATTGTCGGACGAGGGAACGGAAAAAGTCCCGTCTTCAGGAGGGAATCTCACACAGACCCATGTGTAAGTTCACGTACCAACGTTTGAA 
-1920 -1910 -1900 -1890 -1880 -187) -IH60 -18 71) 181)) 
TTTTTTTTAAAGCACTGAATAGTACTAGACACTTAGTAGGTACTTAAGAAATATTGAATGTCGTGGTGGTGGTGAGCTAGAAGTTATA 
AAAAAAAATTTCGTGACTTATCATGATCTGTGAATCATCCATGAATTCTTTATAACTTACAGCACCACCACCACTCGATCTTCAATAT 
-1830 -1820 -1910 - IprO -1179 -1781) -17-1() 17, t 
AAAAAAATTCTTTCCCAAAAACAACAACAAAAAGAATTATTTCATTGTGAAGCTCAGTACCACAAAAATTTAAATAATTCATTACAAG 
TTTTTTTAAGAAAGGGTTTTTGTTGTTGTTTTTCTTAATAAAGTAACACTTCGAGTCATGGTGTTTTTAAATTTATTAAGTAATGTTC 
-1/40 -1-1 30 ': 0 - 1'71 0- 170O - 1(4(1 1 1() 
CCTTTATTAAAAAAAATTTTCTCCCCAAAGTAAACAGACAGACAATGTCTAGTCTATTTGAAATGCCTGAAAGCAGAGGGGCTTCAAG 
GGAAATAATTTTTTTTAAAAGAGGGGTTTCATTTGTCTGTCTGTTACAGATCAGATAAACTTTACGGACTTTCGTCTCCCCGAAGTTC 
185 
-1650 -1640 -1630 -1620 -1610 -1600 -, 1 -1" , 
GCAGTGGGAGAAGGTGCCTGTCCTCTGCTGGACATTTGACAACCAGCCCTTTGGATGGTTTGGATGTATAGGAGCGAAGGTGCAGACA 
CGTCACCCTCTTCCACGGACAGGAGACGACCTGTAAACTGTTGGTCGGGAAACCTACCAAACCTACATATCCTCGCTTCCACGTCTGT 
-1570 -1560 -1550 -1540 -1530 -1520 -1510 -1500 -1 
GCAGTGGGGCTTAGAGTGGGGTCCTGAGGCTGTGCCGTGGCCTTTCTGGGGTTTAGCCACAATCCTGGCCTGACTCCAGGGCGAGGCA 
CGTCACCCCGAATCTCACCCCAGGACTCCGACACGGCACCGGAAAGACCCCAAATCGGTGTTAGGACCGGACTGAGGTCCCGCTCCGT 
1470 -1460 -1450 -1440 -14 141 
GGCCAAGGGGGTCTGCTACTGTGTCCTCCCACCCCTACCTGGGCTCCCATCCCCACAGCAGAGGAGAAAGAAGCCTGTCCTCCCCGAG 
CCGGTTCCCCCAGACGATGACACAGGAGGGTGGGGATGGACCCGAGGGTAGGGGTGTCGTCTCCTCTTTCTTCGGACAGGAGGGGCTC 
-1380 -1370 -1360 -'_35J -1 ? i0 -13 
GTCAGCTGCGTTAGAGGAAGAAGACTGGGCATGTCTGGGCAGAGATTTCCAGACTCTGAGCAGCCTGAGATGTCAGTAATTGTAGCTG 
CAGTCGACGCAATCTCCTTCTTCTGACCCGTACAGACCCGTCTCTAAAGGTCTGAGACTCGTCGGACTCTACAGTCATTAACATCGAC 
-1300 -1290 -1280 -1270 -1260 -1250 -1740 -I: '31 
CTCCAAGCCTGGGTTCTGTTTTTTAGTGGGATTTCTGTTCAGATGAACAATCCATCCTCTGCAATTTTTTAAAAGCAAAACTGCAAAT 
GAGGTTCGGACCCAAGACAAAAAATCACCCTAAAGACAAGTCTACTTGTTAGGTAGGAGACGTTAAAAAATTTTCGTTTTGACGTTTA 
-1210 -1200 -1190 -1180 -11.70 -1160 -1) 0 -1)41 
GTTTCAGGCACAGAAAGGAGGCAAAGGTGAAGTCCAGGGGAGGTCAGGGGTGTGAGGTAGATGGGAGCGGATAGACACATCACTCATT 
CAAAGTCCGTGTCTTTCCTCCGTTTCCACTTCAGGTCCCCTCCAGTCCCCACACTCCATCTACCCTCGCCTATCTGTGTAGTGAGTAA 
-1130 -11-10 -1110 -1100 -1090 -1080 -: 0ý0 -1r)%f) -1"'f, 
TCTGTGTCTGTCAGAAGAACCAGTAGACACTTCCAGAATTGTCCTTTATTTATGTCATCTCCATAAACCATCTGCAAATGAGGGTTAT 
AGACACAGACAGTCTTCTTGGTCATCTGTGAAGGTCTTAACAGGAAATAAATACAGTAGAGGTATTTGGTAGACGTTTACTCCCAATA 
-104C -1030 -1020 -1010 -1000 -990 -980 -1+ 7r) -9F, 0 
TTGGCATTTTTGTCATTTTGGAGCCACAGAAATAAAGGATGACAAGCAGAGAGCCCCGGGCAGGAGGCAAAAGTCCTGTGTTCCAACT 
AACCGTAAAAACAGTAAAACCTCGGTGTCTTTATTTCCTACTGTTCGTCTCTCGGGGCCCGTCCTCCGTTTTCAGGACACAAGGTTGA 
-950 94 (' .n PýC -910 -500 
ATAGTCATTTCTTTGCTGCATGATCTGAGTTAGGTCACCAGACTTCTCTGAGCCCCAGTTTCCCCAGCAGTGTATACGGGCTATGTGG 
TATCAGTAAAGAAACGACGTACTAGACTCAATCCAGTGGTCTGAAGAGACTCGGGGTCAAAGGGGTCGTCACATATGCCCGATACACC 
-860 -850 x0 ý0 H0P, 10 
GGAGTATTCAGGAGACAGACAACTCACTCGTCAAATCCTCCCCTTCCTGGCCAACAAAGCTGCTGCAACCACAGGGATTTCTTCTGTT 
CCTCATAAGTCCTCTGTCTGTTGAGTGAGCAGTTTAGGAGGGGAAGGACCGGTTGTTTCGACGACGTTGGTGTCCCTAAAGAAGACAA 
-770 -760 -750 -740 -730 -7.. 0 -71O , r, rj 
CAGGTGAGTGTAGGGTGTAGGGAGATTGGTTCAATGTCCAATTCTTCTGTTTCCCTGGAGATCAGGTTGCCCTTTTTTGGTAGTCTCT 
GTCCACTCACATCCCACATCCCTCTAACCAAGTTACAGGTTAAGAAGACAAAGGGACCTCTAGTCCAACGGGAAAAAACCATCAGAGA 
-690 -680 -670 -660 -650 -640 -630 - F, 'O _ 61 
CCAATTCCCTCCTTCCCGGAAGCATGTGACAATCAACAACTTTGTATACTTAAGTTCAGTGGACCTCAATTTCCTCATCTGTGAAATA 
GGTTAAGGGAGGAAGGGCCTTCGTACACTGTTAGTTGTTGAAACATATGAATTCAAGTCACCTGGAGTTAAAGGAGTAGACACTTTAT 
-600 -590 -580 -5'70 -560 -, -530 
AACGGGACTGAAAAATCATTCTGGCCTCAAGATGCTTTGTTGGGGTGTCTAGGTGCTCCAGGTGCTTCTGGGAGAGGTGACCTAGTGA 
TTGCCCTGACTTTTTAGTAAGACCGGAGTTCTACGAAACAACCCCACAGATCCACGAGGTCCACGAAGACCCTCTCCACTGGATCACT 
-510 -500 -490 -480 -470 -4J, 0-4, ) 44 
GGGATCAGTGGGAATAGAGGTGATATTGTGGGGCTTTTCTGGAAATTGCAGAGAGGTGCATCGTTTTTATAATTTATGAATTTTTATG 
CCCTAGTCACCCTTATCTCCACTATAACACCCCGAAAAGACCTTTAACGTCTCTCCACGTAGCAAAAATATTAAATACTTAAAAATAC 
-420 -410 -400 -390 -380 -370 -;: r, 
TATTAATGTCATCCTCCTGATCTTTTCAGCTGCATTGGGTAAATCCTTGCCTGCCAGAGTGGGTCAGCGGTGAGCCAGAAAGGGGGCT 
ATAATTACAGTAGGAGGACTAGAAAAGTCGACGTAACCCATTTAGGAACGGACGGTCTCACCCAGTCGCCACTCGGTCTTTCCCCCGA 
-330 3ý0 - 1) ) -300 -: 1,0 HO 270 
CATTCTAACAGTGCTGTGTCCTCCTGGAGAGTGCCAACTCATTCTCCAAGTAAAAAAAGCCAGATTTGTGGCTCACTTCGTGGGGAAA 
GTAAGATTGTCACGACACAGGAGGACCTCTCACGGTTGAGTAAGAGGTTCATTTTTTTCGGTCTAAACACCGAGTGAAGCACCCCTTT 
-250 -_^. 30 -220 -210 -''j'i -)0(- LHOO 
TGTGTCCAGCGCACCAACGCAGGCGAGGGACTGGGGGAGGAGGGAAGTGCCCTCCTGCAGCACGCGAGGTTCCGGGACCGGCTGGCCT 
ACACAGGTCGCGTGGTTGCGTCCGCTCCCTGACCCCCTCCTCCCTTCACGGGAGGACGTCGTGCGCTCCAAGGCCCTGGCCGACCGGA 
-160 -150 -140 -130 -100 -110 
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Figure 5.9 CDKNIA promoter region. The CDKN IA promoter from positions -4020 to + 185 is shown 
with potential AP-2 binding sites based on the SCCNNVRGB consensus (McPherson & Weigel, 1999) 
highlighted in yellow. p53 binding sites are highlighted in green and SPI sites highlighted in blue. 
Sequences transcribed into mRNA are marked in red, indicated by the +I position. p53 sites described 
previously by (Kaeser & Iggo, 2002). Quantitative PCR Primers used to amplify regions for ChIP assays 
are in bold and underlined. 
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Figure 5.10 ChIP assay showing endogenous AP-2y and p300 occupancy and acll4 levels across the 
CDKNIA promoter region. (A) Shows summarises the location of key regulatory elements across the 
CDKNIA promoter in relation to the primers used for the quantitative PCR. (B) ChIP assay for AP-2y, 
p300 and AcH4 in wild type MCF-7 cells. Cells were passaged (I in 2) 24 hours before use in ChIP 
assays to ensure cells were cycling. Results were normalised to a no antibody control and expressed 
relative to a 1/1000 dilution of the total input chromatin. . 
Chromatin samples were analysed by qPCR 
using -4005 / -3931, -2290 / -2185, -935 / -864, and -21/+44 CDKNIA promoter specific primers and 
SAT2 heterochromatin specific primer. Data were averaged from three PC'R replicates. ± standard error. 
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5.8. ChIP reveals a role for AP-2y in the direct 
repression of CDKN1 A transcription. 
In order to explore whether AP-2y silencing in MCF-7 cells was accompanied by 
changes in AP-2y and p300 occupancy or H4 acetylation across the -21 / +44 region, 
ChIP assays were conducted in cells transfected with AP-2y targeting siRNAs. Figure 
5.11 (A) shows the relative enrichment of the -21 / +44 CDKNIA promoter specific 
sequence measured in AP-2y, p300 and acH4 ChIP elutes in cells transfected with a non 
silencing control siRNA or the AP-2y targeting siRNA_3. The level of the p21 mRNA 
and protein up-regulation was also assessed 72 hours following AP-2y knockdown and 
is shown in Figure 5.11 (B). The observed reduction in AP-2y promoter occupancy in 
Figure 5.11 (A) is consistent with the reduction in total AP-2y protein levels determined 
by western (Figure 5.11 (B)) following AP-2y silencing. This suggests that chromatin- 
associated AP-2y is degraded at a similar rate to total AP-2y in silenced MCF-7 cells. 
It is intriguing that the decrease in AP-2y occupancy is associated with a slight decrease 
in p300 occupancy. Strikingly, a two fold increase in H4 acetylation accompanies the 
observed decrease in AP-2y occupancy. This correlates with activation of transcription 
from the CDKN1A promoter as measured by an increase in CDKNIA mRNA levels 
Figure 5.11 (B). Together these data suggest that a reduction in AP-2y occupancy at the 
CDKN1A promoter is associated with CDKN1A gene activation and highlights the role 
of AP-2y in the repression of transcription from this promoter. In appears 
counterintuitive that p300 levels should fall when H4 acetylation increases across this 
region of the CDKN1A promoter, however loss `of' AP-2y (and p300) may be 
accompanied by recruitment of alternative HATs, or modification of HATs at this site. 
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Figure 5.11 ChIP assay showing the effect of AP-21 knockdown on endogenous AP-2y and p300 
occupancy and acH4 levels at the -21/+44 CDKNIA promoter region. MCF-7 cells were transfected 
with a non silencing control siRNA or AP-2y siRNA 3, split 1 in 2 at 48 h, then harvested for use in 
ChIP, qPCR or western blot 24 h later. (A) ChIP assay for AP-2y, p300 and Ac114. Results were 
normalised to a no antibody control and expressed relative to a 1/1000 dilution of the total input 
chromatin. Chromatin samples were analysed by qPCR using the -21/+44 primers, data averaged from 
three PCR replicates, ± standard error. (B) p21 mRNA and protein levels 72 hours following AP-2y 
silencing in MCF-7 cells. CDKNIA levels were analysed by qPCR and normalised to GAPDI! mRNA 
levels. The transfection reagent alone (control) value was set at 1 to generate relative mRNA levels. The 
graph represents data averaged from three PCR replicates, t standard error. Whole Cell extracts 
(5µg/lane) were separated by SDS/PAGE and blotted to a membrane. Blots were probed with primary 
antibodies against Ku-70, p21, and AP-2y. 
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Figure 5.11 ChIP assay showing the effect of AP-2y knockdown on endogenous AP-2y and p300 
occupancy and acH4 levels at the -21/+44 ('DKNIA promoter region. MCF-7 cells were transfccted 
with a non silencing control siRNA or AP-2y siRNA 3, split I in 2 at 48 h, then harvested for use in 
ChIP, qPCR or western blot 24 h later. (A) ChIP assay for AP-2y, p300 and Ac114. Results were 
normalised to a no antibody control and expressed relative to a 1/1000 dilution 01' the total input 
chromatin. Chromatin samples were analysed by qPCR using the -21/+44 primers, data averaged from 
three PCR replicates, ± standard error. (B) p2l mRNA and protein levels 72 hours following AI'-3y 
silencing in MCF-7 cells. CDKN/A levels were analysed by qPCR and normalised to c; A! 'U!! mRNA 
levels. The transfection reagent alone (control) value was set at I to generate relative mRNA levels. I he 
graph represents data averaged from three PCR replicates, i standard error. Whole ('ell extracts 
(5pg/lane) were separated by SDS/PAGE and blotted to a membrane. Blots were probed with primary 
antibodies against Ku-70, p21, and AP-2y. 
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Considering these findings it was felt that it was important to assess the role of anti- 
oestrogen treatment in MCF-7 cells in the context of AP-2y mediated transcriptional 
repression of CDKNIA. Previous work in our lab has shown that MCF-7 cells respond 
to oestrogen and undergo cell cycle arrest in the presence of ERa agonist ICI182,780. 
Additionally ERa regulates AP-2y transcription in MCF-7 cells and treatment with 
ICI182,780 reduces AP-2y expression (Orso et al., 2004). Therefore treatment of MCF- 
7 cells with ICI182,780 might be considered as a drug-induced silencing of AP-2y and 
should also result in loss of AP-2y occupancy from the CDKN1A locus and an increase 
in p21 levels. To explore whether ICI182,780 treatment in MCF-7 cells was 
accompanied by changes in AP-2y occupancy across the -21 / +44 region of CDKNIA, 
ChIP assays were conducted in cells harvested following 24 hours treatment with 
lOOnM ICI182,780. Figure 5.12 (A) shows a reduction in the relative enrichment of the 
-21 / +44 CDKNIA region in AP-2y ChIP elutes following ICI182,780 treatment. This 
change is consistent with the reduction in AP-2y protein levels observed following 
ICI182,780 treatment, shown in Figure 5.12 (B) and was accompanied by an up- 
regulation of p21 mRNA and protein levels also shown in Figure 5.12 (B). Figure 5.12 
(B) also shows that levels of AP-2a do not change after ICI182,780 treatment and 
importantly a decrease in phosphorylation of RB is observed confirming these cells are 
undergoing cell cycle arrest. These data suggest that AP-2y is important in the 
transcriptional modulation of CDKNIA expression in response to anti-oestrogen 
treatment. 
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Figure 5.12 ChIP assay showing the effect of 1C1182,780 anti-oestrogen treatment on endogenous 
AP-2y occupancy at the -21/+44 CDKNIA promoter region. MCP-7 cells were split one in two into 
ICI 182,780 (100nM) containing medium and harvested for use in Chi P, gPCR or western blot 24 h later. 
(A) ChIP assay for AP-2y, p300 and AcH4. Results were normalised to a no antibody control and 
expressed relative to a 1/1000 dilution of the total input chromatin. Chromatin samples were analysed by 
qPCR using the -21/+44 primers, data averaged from three PCR replicates, f standard error. (11) p21 
mRNA and protein levels following 1C1182,780 anti-oestrogen treatment in MCI -7 cells. c'I)F N/A 
levels were analysed by qPCR and normalised to GAPD/f mRNA levels. The translection reagent alone 
(control) value was set at I to generate relative mRNA levels. The graph represents data averaged from 
three PCR replicates, f standard error. Whole Cell extracts (5pg/lane) were separated by Slri/PAGI": and 
blotted to a membrane. Blots were probed with primary antibodies against Ku-70, p2 I, and AP-2y, AP-2u 
and phospho Rb (ser 795). 
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5.9. Reporter assays identify the CDKN1A proximal 
promoter is important for regulation by AP-2y. 
The data from these ChIP experiments show that AP-2y is associated with the CDKN1A 
endogenous promoter only near the region amplified by the -21 / +44 primer set and not 
near regions amplified by the other primer sets further upstream. However this does not 
imply AP-2y interacts with the promoter between the -21 / +44 primer pair, but only 
within the proximity of this region. The resolution of the ChIP is dictated by the 500bp 
average size at which the chromatin has been sheared by sonication. 
To narrow down which region of the CDKNIA promoter was mediating the repression 
by AP-2y, a series of 5' promoter deletion mutants of the CDKN1A promoter cloned 
into a luciferase reporter construct were evaluated in MCF-7 cells silenced for AP-2y. 
Details of these 5' promoter deletion mutants are summarised in Figure 5.13 (A). These 
constructs have been described previously by Datto and colleagues (Datto et al., 1995). 
A time line of the experimental procedure is displayed in Figure 5.13 (C). Briefly, 
MCF-7 cells were first transfected with reagent only, a non-silencing control or AP-2y 
targeting siRNA_2. At 24 hours a second transfection with CDKNIA promoter 
luciferase reporter constructs was conducted, at 48 hours cells were passaged 1 in 2 and 
finally at 72 hours luciferase activity was assayed. The data in Figure 5.13 (B) shows 
that following AP-2y silencing in MCF-7 cells an increase in luciferase activity is 
observed for all of the 5' promoter deletion mutants. These data suggest that the region 
from -111 to +8 relative to the start of transcription of the CDKNIA gene is sufficient 
for repression by AP-2y in the MCF-7 cells transfected with reagent only or the non 
silencing control siRNA and this repression can be relieved upon AP-2y silencing. All 
of the 5' promoter deletion mutants of the CDKN1A showed a similar pattern of activity 
to the full length reporter, although, the absolute level of activity was lower for the 
shorter constructs. It has been suggested by others (Maclaren et al., 2003) that this may 
be due to the fact the 5' promoter deletion mutants all lack the p53 binding region of the 
of the promoter and this region may account for a large component of promoter activity. 
However, some of the effect could also be due to differences in the constructs used as 
the 5' promoter deletion mutants are in a pGL2 (Promega) background where as the - 
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2325\+8 CDKNIA luciferase reporter construct was created by cloning the Firefly 
Luciferase gene CDKNIA promoter into a pBluescript background (pWWP-luc, el- 
Deiry et al., 1993). 
In an effort to narrow down which region of the CDKNIA promoter was mediating the 
repression by AP-2y further, an additional series of minimal -74/+20 CDKN1A 
luciferase reporter constructs was evaluated, consisting of 10 base pair substitutions 
across the *SP1 sites and flanking sequences. These constructs have been described 
previously by Datto and colleagues (Datto et al., 1995). Transfections were performed 
in an identical manner as those described in Figure 5.13 and a time line of the 
experimental procedure is displayed in Figure 5.14 (C). 
The data in Figure 5.14 (B) show that following AP-2y silencing in MCF-7 cells an 
increase in luciferase activity is observed for the WT -74/+20 promoter. These data 
suggest that the region from -74 to +20 relative to the start of transcription of the 
CDKNIA gene is sufficient for repression by AP-2y in the MCF-7 cells transfected with 
reagent only or the non silencing control siRNA and this repression can be relieved 
upon AP-2y silencing. All of the substitution mutants of the -74/+20 CDKNIA 
promoter showed a similar pattern of activity to the full length reporter, although the 
absolute level of activity varied. Constructs Mut#2, Mut#3, Mut#4, Mut#5 and Mut#6 
show reduced basal levels of luciferase activity in the control experiments compared to 
the WT -74/+20 promoter control experiments. Upon AP-2y silencing, the luciferase 
activity was also lower for the mutants than the WT -74/+20 promoter experiment, 
although the fold increase in activation remained fairly similar. This suggests the 
sequences substituted in these five mutants are important for activation of transcription 
from this promoter. Indeed, these substitutions all affect known SPI binding sites that 
are required for this activity (Datto et al., 1995). Substitution mutant Mut#1 showed an 
increase in basal levels of luciferase activity in the control experiments compared to the 
WT -74/+20 promoter control experiments, although the magnitude of activation upon 
AP-2y silencing, again, remained fairly similar. 
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Figure 5.13. MCF-7 cells transfected with reagent only or non-silencing control siRNAs were able 
to repress transcription from a minimal -111/+8 ('DKNJA luciferase reporter construct and this 
repression was relieved upon AP-2y silencing. MCF-7 cells were first transfected with reagent only, it 
non-silencing control or AP-2y targeting siRNA_2, at 24 hours a second transti ction with the indicated 
CDKN 1A promoter luciferase reporter constructs was conducted (A), at 48 hours cells were passaged I in 
2 and finally at 72 hours luciferase activity was assayed (B). A renilla luciferase construct (phRG- lK) 
was co-transfected in each experiment. Results (mean i S. F. of three independent experiments) are 
presented as relative luciferase activity, corrected for Renilla luciferase activity. A time line of the 
experimental procedure is displayed (C). 
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Figure 5.14. Transactivation of the -74/+20 CDKNIA luciferase reporter constructs following Al'-2y 
silencing in MCF-7 cells. MCF-7 cells were first transfected with reagent only, it non-silencing control 
or AP-2y targeting siRNA_2, at 24 hours a second transfection with the indicated -74/ 120 ('I )K NIA 
promoter luciferase reporter construct was conducted, at 48 hours cells were passaged I in 2 and finally at 
72 hours luciferase activity was assayed (B). A renilla luciferase construct (phRG-TK) was co-transtected 
in each experiment. Results (mean i S. E. of three independent experiments) are presented as relative 
luciferase units (RLU), corrected for Renilla luciferase activity. The sequence of the -74/ 120 ('I )KNI A 
luciferase reporter is displayed in (A). A time line of the experimental procedure is displayed (C). 
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5.10. AP-2y mutants lacking residues required for SUMO 
modification do not represses a CDKN1A promoter 
reporter construct. 
Previous work in our lab has shown that AP-2(x, AP-20 and AP-2y can interact with the 
SUMO conjugating enzyme UBC9. This interaction results in SUMO conjugation at the 
conserved lysine residue (lys 10) in the N-terminal region of AP-2, and was shown to 
reduce the ability of AP-2 to activate transcription when analysed in reporter gene 
assays (Eloranta et al., 2002). Previous experiments, shown in Figure 5.8 (A&B), 
suggested that AP-2y was able to repress CDKNIA promoter activity in HepG2 cells. In 
order to explore whether SUMO modification can facilitate CDKNIA transcriptional 
repression by AP-2y, a series of mutant AP-2y constructs were assessed for their ability 
to repress transcription from the -2325 to +8 CDKN1A promoter reporter. These 
mutant of ct the potential for SUMO modification of AP-2y and details of these 
constructs are outlined in Figure 5.15 (A). Constructs were generated by Jyrki Eloranta. 
The K1OR-AP-2y, described previously by Eloranta and colleagues, is mutated at the 
target lysine residue for SUMO modification and is unable to be SUMO modified 
(Eloranta et al., 2002). The Flag-AN10-AP-2y substitutes a Flag tag for the first 10 N- 
terminal amino acids. It is therefore also missing the target lysine residue for SUMO 
modificatio and is unable to be SUMO modified (Eloranta el al., 2002). In order to 
assess th aff t of artificial SUMO conjugation on AP-2y activity, two forms of AP-2y 
were generated that have the 10 N-terminal amino acids replaced with a consensus 
SUMO peptide corresponding to either SUMO1 or SUM03. Only the effect of 
SUM03 was assessed as SUM02 and SUM03 are almost identical and have been 
shown to function in the same manner (Reviewed by Hay, 2005). 
Figure 5.15 (B) shows that basal luciferase activity from this construct was reduced 
following co-transfection with a wild-type AP-2y expression construct, reproducing 
previous results in Figure 5.8 (B). Co-transfection of the CDKN1A promoter reporter 
with a wild-type AP-2a expression construct was accompanied by an increase in 
luciferase activity. This is in support of data from others, who have shown AP-2a can 
activate CDKN1A transcription (Zeng et al., 1997; McPherson et al., 2002). 
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Interestingly, co-transfection of the CDKN1A promoter reporter with the KIOR-AP-2y 
mutant construct was also accompanied by an increase in luciferase activity. This 
suggests that SUMO modification at lysine 10 of AP-2y is important for mediating its 
transcriptional repression at the CDKNIA promoter. Indeed this mutation appears to 
modulate the activity of AP-2y within this assay from repressor to activator. Co- 
transfection of the CDKNIA promoter reporter with the Flag-AN10-AP-2y mutant 
construct resulted in luciferase levels similar to those observed in cells transfected with 
reporter only. Again this suggests residues within the substituted region of AP-2y, a 
region including the SUMO modification target lysine, are important for mediating its 
transcriptional repression at the CDKN1A promoter. Interestingly, in contrast to 
reporter co-transfections with the K1OR-AP-2y, no additional increase in CDKNIA 
promoter reporter activity above basal levels was observed following co-transfection 
with the Flag-AN10-AP-2y mutant. This suggests that residues required for this 
additional activity are absent from this construct. Both of the constitutively SUMO 
modified forms of AP-2y (SUMO1-ON10-AP-2y and SUMO3-AN10-AP-2y) reduce 
luciferase activity over and above that of wild-type AP-2y when co-transfected with the 
CDKN1A promoter reporter. This shows that artificial conjugation of SUMO to AP-2y 
can repress CDKNIA promoter activity in HepG2 cells. - 
Together these transient transfection studies indicate that SUMO modification of AP-2y 
mediates its ability to repress CDKN1A promoter activity in HepG2 cells. However, the 
observed effects on luciferase activity are not necessarily due to direct effects of AP-2y 
and its mutant forms on the CDKN1A promoter, and they could be due to indirect 
regulation via differential sequestration of factors away from the reporter construct by 
AP-2y or its mutants. 
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Figure 5.16. The effect of mutant forms of AP-2y on basal activity from the (7)KA'IA promoter in 
HepC2 cells. (A) Shows mutant firms of AP-2y in the pcDNA3 vector. KI OR AI'-2y and I I' At ; -AN 10 
AP-2y are resistant to SUMO modification and Sl1MOI and SIJMO2 . AN 10 AP-2y constructs are 
constitutively SUMO modified. (B) The AP-2 non-expressing cell line, Ilcp(i2 was transiently 
transfected with I. O tg of the -2325\+8 ('DKNIA luciferase reporter construct and O. iltg of the indicated 
AP-2y expression construct or an AP-2a expression construct. A renilla luciterase construct (phR(; - 1K) 
was co-transfected in each experiment and the differences in DNA amount were compensated tiºr using it 
pcDNA3 plasmid. Forty-eight hours following transfection cells were assayed for lucit'erase activity. 
Results (mean ± S. D. of three independent experiments) are presented as relative luciferase activity, 
corrected for Renilla luciferase activity. Cells transfected with the COMA promoter luciferase reporter 
alone were set at 100°rä. 
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5.11. AP-2 silencing in MCF10A and ZR-75-1 cells. 
A role for AP-2y in the transcriptional regulation of CDKN1A in other breast cancer 
derived cell lines was also assessed. Attempts to stably reduce AP-2y levels in 
MCF1OA and ZR-75-1 cell lines were also unsuccessful (summarised in Table 3.2) and 
therefore it was postulated that AP-2y may play a role in proliferation in these cell lines. 
Levels of p21 protein were assessed following AP-2y silencing in these cell lines and 
the results are shown if Figure 5.17. 
MCF1OA cells proved difficult to transfect when compared to other cell lines. 
Optimisation experiments showed (not shown) that some AP-2y silencing could be 
achieved using 5nM final concentration of siRNA and 8µl of Interferin transfection 
reagent (PolyPlus). Cells were split one in two 48 hours following transfection and 
harvested at 72 hours. Figure 5.17 (A) shows the level of AP-2y knockdown achieved 
were approximately 50% when compared to the control experiment and this was 
accompanied by a slight increase in p21 and p27 protein levels. A moderate reduction 
in Rb phosphorylation was also observed and no change in AP-2a levels was seen. 
These data imply that AP-2y knockdown in these cells also effects cell cycle regulation 
and possibly through regulation of p21 by a similar mechanism to that observed in 
MCF-7 cells. Transfections performed using these conditions in MCF1OA cells were 
also assessed using a 3' Alexa Fluor 488 labelled non-silencing control siRNA and 
observed via fluorescence microscopy. Fluorescence was reproducibly detected in 50- 
60% of transfected cells reflecting the level of AP-2y knockdown observed following 
transfection with the AP-2y targeting siRNAs. 
ZR-75-1 cells were transfected in an identical manner to MCF-7 cells. Figure 5.17 (B) 
shows the level of AP-2y knockdown achieved were approximately 90% when 
compared to the control experiment and this was accompanied by a slight increase in 
p21 but not p27 protein levels. No change in Rb phosphorylation or AP-2a levels was 
observed. These data imply that AP-2y knockdown in ZR-75-1 cells may also effect 
p21 regulation but downstream effects on Rb phosphorylation are not apparent. 
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Figure 5.17. Changes in cell cycle proteins following silencing of AP-2y in MCFIOA (A) and ZR-75- 
I (B) cells. Cells were transfected as indicated, passaged at the 48-hour time point following translection 
and harvested at 72 hours. Whole Cell extracts (5µg/lane) were separated by SUS/PAGl": and blotted to a 
membrane. Blots were probed with primary antibodies against Ku-70, AP-2y, Al'-2. t, p21, p27 and 
Phospho RB (Ser 795). Blots were striped and reprobed where necessary. 
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CHAPTER 6: DISCUSSION 
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High levels of the developmentally regulated transcription factor, AP-2y have been 
correlated to poor survival in breast cancer. This correlation occurs independently and 
in the context of the generally considered indicators of good prognosis: namely ERa 
expression and ErbB2 negativity. Interestingly, AP-2y has been previously described as 
a ligand activated target gene of ERa. AP-2y expression in these tumours therefore, 
might represent an opposition to anti-oestrogen therapy. This study aimed to 
understand which pathways are activated in AP-2y expressing breast cancer cells and 
how they might contribute to poor patient prognosis. 
Several lines of evidence based on the expression of AP-2 family members during 
development suggest that expression of these proteins might act at a checkpoint 
between proliferation and differentiation. 
1. In regenerating skin epidermis AP-2a expression is required to inhibit 
proliferation via EGFR transcriptional repression as cells exit the basal layer. 
Without AP-2a, subrabasal cells fail to differentiate and exhibit 
hyperproliferation (Wang et al., 2006). 
2. In gonocyte development AP-2y expression is high in early proliferating germ 
cells and must be lost in order for the cells to differentiate. Forced AP-2y 
expression in these cells results in hyperproliferation and prevents differentiation 
(Jager et al., 2003; Pauls et al 2005). 
3. In the developing mammary gland, targeted over-expression of AP-2a results in 
inhibition of epithelial proliferation in developing alveolar buds but 
differentiation is not impaired (Zhang et al., 2003). However, over-expression of 
AP-2y results in a hyperproliferation and a failure of the alveolar buds to 
differentiate into their lactating derivatives (Jager et al., 2003). 
4. In early embryogenesis, AP-2y expression is required for the proliferation of cells 
derived from the trophoectoderm (Auman et al., 2002; Werling & Schorle, 2002). 
Overall this evidence suggests that AP-2a expression is required for inhibition of 
proliferation. Indeed, previous studies have correlated high AP-2a expression with 
reduced proliferation and good prognosis in breast cancer patients, whereas loss or 
reduction of AP-2a expression has been associated with disease progression. 
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Conversely, AP-2y expression appears to be required for proliferation to occur. This 
coordinated control of proliferation and differentiation by AP-2 family members is 
desirable during development and organogenesis, but aberrant expression of these 
proteins might lead to hyperplasia, a proliferative and undifferentiated state that could 
contribute to the promotion of cancer growth in adults. 
When considered together the in vitro studies do not always provide a clear picture of 
the molecular mechanisms underlying a role for AP-2 proteins in breast cancer. In 
general, evidence exists in support of a tumour suppressor-like role for AP-20C. AP-2a 
can facilitate inhibition of proliferation by the transcriptional repression EGFR, in the 
case of skin epidermis, and the activation of CDKNIA transcription and repression of 
BCL2 transcription by AP-2a has also been shown in various cells lines. The molecular 
mechanisms behind the association of high AP-2y expression and increased breast 
tumour progression leading to poor patient prognosis remain elusive, as does the 
transcriptional program initiated by AP-2y in the promotion of cell growth and 
inhibition of differentiation in breast tissues during development. AP-2y expression is 
clearly associated with the regulation of ERBB2 and ERot in breast cancer cell lines, 
however high levels of AP-2y predict poor prognosis independently of these factors in 
patients with advanced primary invasive breast carcinomas, suggesting other molecular 
mechanisms may be involved. 
In order to try to define the additional pathways activated by AP-2y specifically, in 
breast cancer, the research presented in this thesis aimed to use Affymetrix GcncChip 
high-density oligonucleotide microarrays to define AP-2y dependant changes in gene 
expression in breast epithelial cells. 
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6.1. A Role for AP-2y in the control of proliferation in 
MCF-7 cells. 
Although the primary aim of this study was to generate an AP-2y dependant gene 
expression profile following RNAi mediated AP-2y silencing in MCF-7 cells, it soon 
became apparent that depleting AP-2y levelefected the growth of these cells. 
Initial experiments used shRNA constructs to try to establish derivatives of the MCF-7 
cells with stably reduced AP-2y levels. Intriguingly, when carrying AP-2y knockdown 
constructs MCF-7 cells produced reduced colony numbers after antibiotic selection and 
these colonies subsequently failed to thrive (Figure 3.7. ). These results implied that 
lack of AP-2y expression in these lines perturbs their normal growth. With the aim of 
generating material for gene expression profiling and to further analyse potential 
abnormalities in proliferation, transient transfection conditions for lipofection-mediated 
delivery of siRNA were carefully optimised with respect to off-target effects (see 
Figures 3.11 and 3.12 for details). 
In early experiments, shown in Figure 5.1, a reduction in the number of cells was 
observed following transient AP-2y silencing. These early effects on cell proliferation 
appeared to be independent of cell death, as neither the number of floating cells, nor the 
SubGl population were increased in AP-2y siRNA transfected cells. However, an 
increase in the number of cells with a G1 DNA content was observed and accompanied 
by a decrease in the proportion of cells in S phase. A more detailed cell cycle analysis, 
shown in Figure 5.2, was performed with the three independent AP-2y targeting siRNAs 
compared to control conditions and confirmed a significant increase in G1 population 
(p<0.0.1) and a moderate but significant decrease in the proportion of cells in S phase 
(p<0.0.1) in MCF-7 cells depleted for AP-2y. A significant reduction in the fraction of 
cells actively undergoing S phase was also seen in cells transfected with AP-2y targeting 
siRNAs compared to the control populations. Together these data suggest that cells 
transfected with AP-2y targeting siRNAs were undergoing a partial cell cycle arrest at 
the GUS transition. 
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These results provide compelling evidence that AP-2y expression is required in MCF-7 
cells in order for them to proliferate and that siRNA mediated silencing of AP-2y in 
these cells inhibits their growth by inducing cell cycle arrest at the G1/S transition. 
6.2. AP-2y dependant mechanisms for the control of 
proliferation in MCF-7 cells. 
6.2.1. AP-2y silencing in MCF-7 cells results in a cell cycle 
related gene expression profile. 
Amongst the transcripts significantly regulated following AP-2y silencing in MCF-7 
cells were a subset of transcripts related to cell cycle. Using two different publicly 
available GO databases, the transcripts from the AP-2y dataset were assigned GO or 
Panther biological process terms and then organised into related groups (Figure 4.9 and 
4.10). In particular, both of these methods identified biological process terms highly 
significantly over-represented within the down-regulated genes in categories related to 
cell cycle (Tables 4.5 and 4.6). 
A more detailed analysis of this subset of cell cycle regulated genes showed the 
majority of these are known to display cell cycle periodicity (Whitfield et al., 2002), 
almost all showing their lowest expression at G1 or S phase, again consistent with a 
perturbation at the G1/S transition (Figure 5.2). It is reasonable to consider that many 
of these changes may have occurred as a consequence of the cell cycle arrest and 
therefore may not be direct targets of AP-2y. Consistent with this hypothcsis was that 
many of these genes are known to be transcriptionally regulated by E2F family 
members at the G1/S transition (Figure 4.11) and therefore AP-2y may have a role in the 
regulation of genes upstream of this protein. The analysis of conserved TFBS within 
this data set supports this hypothesis. The most represented TFBS <2Kb upstream of 
transcripts within the AP-2y dataset, were those for cell cycle related transcription factor 
families E2F and FOXO (Table 4.7). 1 
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An additional TFBS analysis, focusing on the AP-2 consensus-binding site upstream of 
the genes significantly regulated following AP-2y silencing, was performed in order to 
'discriminate between potential direct transcriptional targets for AP-2y and indirect 
targets. No enrichment for the presence of the AP-2 consensus sequence was observed 
in promoter regions of genes within the AP-2y data set compared to a similar region 
upstream of a set of 21787 genes (Table 4.8). The analysis highlighted how common 
the AP-2 consensus sequence is in upstream sequences of genes, and supports other 
studies which showed similar findings looking at a smaller set of promoters (Bajic et 
al., 2004). Such computational genomics approaches to identify DNA regulatory 
elements should be interpreted with caution, especially when considering degenerate 
sequences that are common in GC-rich regions such as the AP-2 TFBS. It is likely, that 
constraints other than DNA sequence alone must confer the efficacy of these sites in 
vivo. In general the specific chromatin architecture that regulates the accessibility of 
TFBS within promoters or enhancers has been shown to be important (review in Li et 
al., 2007). Also, interactions with other sequence-specific transcription factors binding 
within the vicinity of AP-2 binding sites may be important. 
Shortly after establishing the findings of this study, Jin and colleagues addressed the 
ate question for E2F1 using a more complex computational approach (Jin et al., 2006). 
Of particular interest to this study was their analysis of E2F1 and AP-2 TFBS co- 
localisation. Using a small set of known E2F1 target promoters, the authors found AP-2 
TFBS within the vicinity of 55% of functional E2F1 sites, compared to E2FI sites in 
non-E2F target promoters. However the next most common association, E2F1 and 
NFAT TFBSs, was only enriched in 10% of functional E2F1 sites compared to the 
control promoters. In light of this second association, it seems debatable whether 
association of E2F1 and P-2 TFBS in likely to have a functional consequence. Both 
E2F and AP-2 bind GC-rich TFBS. Functional E2F binding sites might be associated 
with GC-rich promoter regions where there would be an increased likelihood of chance 
occurrence of the AP-2 TFBS. Subsequent ChIP-chip experiments were performed on 
E2F target promoters in order to address the functional consequence of this association 
in vivo. ChIP-chip combines Chromatin IPs with microarray analysis (chip), where 
DNA enriched in the IPs is labelled and hybridised to microarrays containing tiled 
promoter sequences. The level of hybridisation over sequences enriched by a control 
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antibody can be directly related to occupancy of a factor at the promoter region to which 
it hybridises. Interestingly, it was shown that AP-2 ChIPs were enriched for E2F target 
promoters containing co-localisation of E2F1 and AP-2 TFBS. These results should be 
cautiously interpreted. Previous work in our lab has shown that the AP-2 antibody used 
in this ChIP has a high level of non-specific activity as determi using primers 
against a heteiChromatic (x-satellite region (Karsten Frederic 
1 
Personal 
Communication), and therefore perhaps it would have been useful to include similar 
controls in this study alongside known AP-2 target promoters to a provide positive 
control for binding. Little regard was given to the biological relevance of these findings 
and unfortunately the authors used the non discriminating AP-2 antibody. Although the 
potential association of AP-2 family members and regulation of E2F1 target genes is 
interesting, in light of AP-2 mediated regulation of p21 (see below), these findings 
remain to be more convincingly established. 
6.2.2. AP 2y silencing in MCF-7 cells results in an up-regulation 
of the cyclin dependant kinase inhibitor p21. 
In parallel to the microarray experiments, changes in cell cycle regulators known to be Wlir 
important at the G1 transition were observed byVestern following AP-2y silencing in 
MCF-7 cells in order to delineate a mechanism for the cell cycle arrest (Figure 5.2). 
The most notable was an up-regulation of the CDKI, p21, observed for each AP-2y 
targeting siRNA. As explained in Section 1.5, CDKIs like p21 exert their activity by 
inhibiting the kinase activity of Cyclin/CDK complexes. Indeed, a reduction in 
Cyclin/CDK activity was observed following AP-2y silencing, marked by a reduction in 
phosphorylation of both Rb and p27. Changes in the levels of Cyclin and CDK proteins 
have also been shown to contribute to altered activity of Cyclin/CDK complexes. For 
example, the levels of cyclin D and CDK4/6 are transcriptionally activated by Myc in 
response to growth signalling (Reviewed by Pelengaris et al., 2002). However, there 
was little or no change in expression levels of Cyclin D1, Cyclin D3 and CDK2, CDK4, 
and CDK6 or indeed of Myc itself following AP-2y silencing in MCF-7 cells (Figure 
5.3 and Figure 5.7), suggesting that changes in the overall levels of these proteins were 
not responsible for the observed altered activity of Cyclin/CDK complexes. 
208 
In addition to an up-regulation of p21 following AP-2y silencing in MCF-7 cells, a 
moderate increase in the protein levels of p27 and cyclin E was observed. The increase 
in p27 levels was accompanied by a decrease in p27 phosphorylation at serl47. This 
suggests that the increase in p27 level could be largely due to a reduction in 
cyclinE/CDK2 activity which would, in normal cycling cells, promote p27 proteolysis 
(Sheaff et al., 1997). The moderate increase in levels of Cyclin E2 however, can not be 
so easily explained, although this difference appears exaggerated due to the loading 
1'%VASkWUWj' I)º inac s. However, 1cycle arrest occurred in spite of the moderate increase] cyclin E 
levels, suggesting that cyclin E up-regulation is not sufficient to override anti- 
proliferative mechanisms associated with AP-2y silencing in MCF-7 cells. 
In addition to the proteins described above an increase in both CBP and p300 protein 
levels were observed following AP-2y silencing in MCF-7 cells (Figure 3.13). The 
mechanisms behind these observations clearly require further investigation; however the 
observed increases are likely be related to the involvement of these proteins at the G1/S 
transition. As well as their characterised role in the coactivation of positive and 
negative cell cycle regulating transcription factors including, p53, Myc, RB and E2F, 
CBP/p300 also play additional less well understood roles in the regulation of the cell 
cycle. A recent study has shown cells negative for p300 show defects at the G1/S 
transition and in particular, the HAT independent activity of p300 is required for orderly 
GUS transition. In early G1, p300 specifically has been shown to associate with hypo- 
phosphorylated RB and inhibit Cyclin/CDK6 dependant RB phosphorylation (Iycr et 
al., 2007). However, at the GUS boundary p300 and possibly CBP have been 
suggested to associate with RB and augment RB phosphorylation (Iyer et al., 2007). 
Furthermore both p300 and CBP are phosphorylated in a cell cycle dependent manner 
although the functional consequences are unclear (reviewed in Goodman & Smolik, 
2000). Considering these observations, is it unclear how an increase in p300 or CBP 
following AP-2y silencing might contribute to the observed cell cycle arrest in MCF-7 
cells particularly in the context of p21 up-regulation. 
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6.2.2.1. Can p21 activation alone explain the cell cycle perturbation 
at the GUS transition? 
Overall evidence strongly supports that the cell cycle perturbation at the GUS transition 
in AP-2y silenced cells is largely due to the up-regulation in p21 levels. Indeed a 
decrease in the kinase activity of Cyclin/CDK complexes, a functional consequence of 
p21 induction, is marked by a reduction in phosphorylation of Rb and p27. Of the other 
cell cycle regulators studied, changes in cyclin E cannot explain a cell cycle arrest and 
p27 induction could largely be explained by posttranscriptional mechanisms caused by a 
cell cycle arrest. We cannot rule out the involvement of additional pathways regulated 
by AP-2y silencing in MCF-7 cells that were not explored in this study or indeed that 
AP-2y is normally required for the transcription of E2F target genes that were down- 
regulated>nollowing AP-2y silencing (discussed above). 
In support of cell cycle arrest being caused by p21 induction alone, gene expression 
changes observed upon AP-2y silencing in MCF-7 cells showed remarkable overlap 
with other studies observing gene expression changes following exogenous p21 
expression in unrelated cell lines. In particular, in human fibrosarcoma cells 
approximately 45% of the genes down-regulated upon p21 induction (Chang et al., 
2000) were also down-regulated following AP-2y silencing in MCF-7 cells in my 
experiments. Additionally, in human ovarian carcinoma cells approximately 47% of 
genes differentially regulated upon expression of exogenous p21 (Wu et al., 2002) were 
also significantly regulated following AP-2y silencing in MCF-7 cells. The details of 
these analyses are shown in Table 6.1. Clearly a number of E2F target genes (indicated 
by an underline in Table 6.1) are included in these overlapping gene lists. This is 
consistent with the idea that a major contributing factor leading to the down-regulation 
of E2F targets is the up-regulation of p21 following AP-2y silencing in MCF-7, and not 
the direct regulation of E2F target genes by AP-2 family members (Jin et al., 2006). 
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Table 6.1. Gene expression changes following AP-2y silencing show overlap with those occurring 
following exogenous p21 expression. Significant gene expression changes following AP-2y silencing in 
MCF-7 cells (p<0.05) were examined for overlapping genes within two studies exploring gene expression 
changes following exogenous p2l expression in unrelated cell lines. The percentage overlap is expressed 
along with the list of up (red) and down (green) regulated genes showing overlap. Genes were also 
annotated as known E2F targets (underlined) based on findings from the literature (Ren el al., 2002; 
Polager et al., 2002, Cam et al., 2004). 
In order to confirm whether the growth arrest caused by AP-2y silencing in MCF-7 cells 
was dependant only on p21 induction, future experiments could examine the effect on 
cell cycle following co-transfection of AP-2y and p2l siRNAs. If p21 induction 
following AP-2y silencing in MCF-7 cells is the only mechanism by which cell cycle 
arrest is mediated, silencing of p21 should prevent this growth arrest. however, 
transient co-transfection of two different siRNAs can be technically difficult. 
Experiments in our lab trying to reduce AP-2a and AP-2y levels in cell lines where they 
are both expressed have shown that when combined, one siRNA can he more effective 
that the other, despite each showing good knockdown when transfected individually. 
This suggests that the silencing machinery is more efficient at incorporating some 
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siRNA sequences than others and this is perhaps due to favourable structural 
characteristics. 
6.2.2.2. Does p21 up-regulation occur at the level of transcription 
following AP-2y silencing in MCF-7 cells? 
Before exploring the potential role for AP-2y in CDKNIA transcriptional repression, it 
was necessary to determine whether p21 was regulated at the level of transcription. It 
was perplexing that if this were the case, no significant gene expression change was 
observed on the microarray for the CDKNIA transcript following AP-2y silencing in 
MCF-7 cells. However, a closer examination of normalised expression values for the 
CDKN1A probe set in Figure 5.3 (D), showed that the levels of CDKNIA mRNA in the 
control experiments were already high and, although a slight increase in CDKNIA gene 
expression was seen for the AP-2y siRNA transfected conditions, this difference was 
minimal and not significant (p<0.05). I considered whether the discrepancies between 
p21 protein levels as detected by western (Figure 5.3) and those detected on the 
microarray might be due to differences in experimental set up. In particular, the gene 
expression profile was performed at 96 hours following siRNA transfection and the 
cells were approaching 100% confluency at the time of harvest while the western blot 
analysis was performed at 72 hours following transfection and on sub-confluent cells. 
p21 levels are known to be induced when cells reach high densities and contact 
inhibition occurs (Macleod et al., 1995; Erhardt & Pittman, 1998) and perhaps in the 
microarray experiment differences in p21 mRNA level were less pronounced due to p21 
already being above basal levels in the control (reference) samples. In order to test this 
hypothesis, p21 mRNA and protein levels were analysed in AP-2y silenced MCP-7 
cells, following a one in three passage at 48hrs, to ensure that cells were sub-confluent 
when harvested at 72 and 96 hours (Figure 5.5. ). Here, elevated p21 mRNA and protein 
were observed in MCF-7 silenced cells, at both time points suggesting that p21 up. 
regulation does indeed occur at the level of transcription in MCF-7 cells. Furthermore, 
the level of induction of p21 mRNA shows a good correlation with the observed 
increase in p21 protein. Interestingly, p21 protein levels increased in the control extracts 
harvested at 96 hours compared to those harvested at 72 hours. This suggests that as 
cells increase in density on the plate contact inhibition contributes to p21 regulation in 
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MCF-7 cells and supports the explanation for the failure to detect this change in the 
microarray data. 
Although the microarray gene expression changes were predominantly cell cycle related 
(Figure 4.9 and 4.10) and closer analysis of the cell cycle subset. clearly points to a cell 
cycle arrest at the G1/S transition (Figure 4.11), with hindsight it may have been more 
appropriate to have performed the experiments at a slightly earlier time point, or on sub- 
confluent cells. However, due to the high cost of gene expression profiling experiments 
it was felt that there was little value in revisiting these experiments in this cell line. 
In summary, the change seen in cell cycle gene expression and proliferation in AP-2y 
silenced MCF-7 cell can largely be explained by the up-regulation of the ( 
` 
p21, 
although we have not ruled out the potential involvement of other pathways. This up- 
regulation occurs at the protein and mRNA level and therefore suggests p21 may be 
regulated at the level of transcription. This was of particular interest to this study as 
work by others had already described AP-2a as an important activator of transcription 
at the CDKN1A promoter (Zeng et al., 1997; McPherson et al., 2002). We hypothesised 
that AP-2y could be acting in an opposing role in CDKNIA transcriptional regulation. 
This suggests that in normal cycling MCF-7 cells AP-2y is absolutely required to 
repress CDKN1A transcription and upon AP-2y silencing this repression is relieved, 
leading to p21 activation and growth arrest. 
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6.2.3. AP-2y dependant transcriptional repression of CDKN1A - 
a mechanism for the control of proliferation by AP 2y in MCF-7 
cells. 
Initial experiments suggested that exogenous AP-2y was able to repress basal luciferase 
activity from the -2325 +8 CDKNIA reporter construct (Figure 5.8. B). In order to 
examine whether endogenous AP-2y was associated with the CDKNIA promoter in 
vivo, AP-2y occupancy was determined using ChIP. ChIP assays were conducted in 
cycling wt MCF-7 where p21 is maintained at basal levels and enrichment at four 
discrete CDKNIA promoter specific qPCR amplicons was explored (Figure 5.10 A&B). 
Importantly, enrichment for the CDKN1A promoter region amplified by the -21 / +44 
primer set was observed in AP-2y ChIP. This provides strong in vivo evidence that 
endogenous AP-2y is recruited to the CDKNIA promoter region and implicates AP-2y in 
the repression of transcription from this promoter. Interestingly, enrichment of the 
regions amplified by the other primer sets further upstream in the CDKN1A, promoter 
was not observed in AP-2y ChIP. This indicates that endogenous AP-2y in not recruited 
to the region near the classical p53 binding site amplified by primer set -2290 / -2185 
which has been suggested for AP-2 family member, AP-2a (Mcpherson et al., 2002). 
AP-2y occupancy was also associated with p300 occupancy; the greatest enrichment 
was observed for the region amplified by the -21 / +44, primer set in p300 ChIP and not 
amplicons upstream. Although p300 is a known co-factor of AP-2y, recruited through 
CITED adapter proteins, it has previously only been described in the context of AP-2 
transcriptional activation and it is intriguing that p300 is associated with AP-2y when it 
is mediating transcriptional repression. This suggests that the HAT activity of p300 
must be altered or repressed. Strikingly the acH4 ChIP shows a lower enrichment for 
the -21 / +44 amplicon compared to the upstream amplified regions -2290 / -2185 and - 
935 / -864. This suggests that in cycling MCF-7 cells the -21 / +44 region associated 
with AP-2y occupancy, is in a more condensed chromatin state than the regions 
upstream and perhaps less accessible to the general transcription machinery. 
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In order to determine whether AP-2y occupancy of the CDKNIA promoter was in fact 
mediating transcriptional repression, changes in AP-2y and p300 occupancy or 114 
acetylation across the -21 / +44 region were examined following AP-2y silencing in 
MCF-7 cells (Figure 5.11. A&B). An expected reduction in AP-2y promoter occupancy 
was marked by a reduction in enrichment for -21 / +44 amplicon in the AP-2y ChIP, 
following AP-2y silencing in MCF-7 cells. Furthermore, a two fold increase in 
enrichment for the acH4 ChIP indicates that increased histone acetylation accompanies 
the observed decrease in AP-2y occupancy. Increased histone acetylation correlates 
with activation of transcription from the CDKN1A promoter following AP-2y silencing 
in MCF-7 cells, and suggests that an increased HAT activity is important for 
destabilising the chromatin in this region and allowing the access of the general 
transcription machinery to the DNA. Interestingly a two fold decrease in enrichment for 
the p300 ChIP indicates that decreased p300 occupancy accompanies AP-2y silencing. 
Together these data show that a reduction in AP-2y occupancy at the CDKNIA promoter 
is associated with CDKN1A transcriptional activation and provide strong evidence for a 
role of AP-2y in the repression of transcription form this promoter. However, many 
questions remain unanswered. 
These experiments do not conclusively demonstrate that p300 and AP-2y arc bound 
together in the same complex, although an in vivo interaction has been shown 
previously, and requires the presence of CITED2 (Braganca et al., 2003). Originally 
these ChIP experiments aimed to examine the occupancy of CITED2 alongside AP-2y 
and p300. However problems with batch to batch variation in the commercial CITED2 
antibody precluded such an analysis. The presence of CITED2 would support the 
coexistence of AP-2y and p300 in the same complex. Although it is known that p300 is 
associated with other factors in this region, such as SP1 (Xiao et al., 2000). Ultimately 
in order to confirm the co-occupancy of these factors sequential ChIP (re-ChIP) 
experiments could be attempted in the future. 
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6.2.3.1 Why does a reduction in p300 occupancy accompany 
CDKN1A transcriptional activation following AP-2y silencing and 
how does this relate to histone acetylation? 
The observed reduction in p300 occupancy that accompanies CDKNIA transcriptional 
activation following AP-2y silencing appears to be in conflict with the increased levels 
of histone acetylation. 
One explanation is that alternative HATs, recruited by activators such as SP1, are 
involved in CDKNIA transcriptional activation following AP-2y silencing. However, it 
is likely that the p300 remaining, following AP-2y silencing is associated with SP1 co- 
activation (Xiao et al., 2000). 
It is interesting that a very slight increase in p53 levels is observed following AP-2y 
silencing (discussed in detail below). Future experiments should explore whether an 
increase in p53 occupancy in the p53 binding region (-2290 / -2185) of the CDKNIA 
promoter also occurs. An associated increase in p300, a known p53 coactivator, at this 
region would be expected to contribute to the observed increase hi stone 'acetylation at 
the -21 / +44 region, as the close proximity of the p53 binding region and core promoter 
region is thought to be responsible for p53 mediated transcriptional activation in vivo 
(Kaeser & Iggo, 2004). 
Finally, the observed decrease in p300 enrichment following AP-2y silencing could be 
explained by an increase in p300 HAT activity. In addition to the transcription factor 
targeted HAT activity by catalytically active p300, work by Black and colleagues has 
shown that autoacetylation mediated dissociation of p300 from chromatin, is required 
for ordered PIC assembly (Black et al., 2006). This could lead to a more transient 
association of p300 with chromatin in the actively transcribing CDKNIA promoter and 
therefore the overall enrichment by p300 in ChIP might be reduced compared to that of 
the repressed promoter, where an inactive p300 (discussed below) more stably 
associated with chromatin. 
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6.2.3.1 How does AP-2y repress transcription at the p21 promoter? 
It is intriguing that AP-2y and p300 promoter occupancy are observed when AP-2y is 
mediating transcriptional repression of the CDKNIA promoter. 
Indeed studies by others have shown p300 promoter occupancy in the context of 
transcriptional repression in vivo. The formation of a chromatin bound p53-p300-E6 
complex was shown to require the presence of p300 in order to repressed CDKNIA 
transcription in vivo and was correlated with reduced acetylation of both histone H4 and 
p53 (Thomas, & Chiang, 2005). This implies co-activating properties of p300 can be 
altered or counteracted by additional proteins. 
SUMO modified forms of p300 have been shown to recruit HDAC6 in vitro and repress 
transcription (Girdwood et al., 2003). Equally, conformational changes in p300 
following its association with other transcription factors may be important in regulating 
its activity (Dial et al., 2003). The basal catalytic activity of p300 is known to be 
stimulated by acetylation of several key lysine residues within an activation loop motif 
(Thompson et al., 2004). It has been suggested that deacetlyases such as HDACs might 
associate with p300 to keep it in a catalytically inactive state, or counteract its catalytic 
activity (Pugh et al., 2006). In support of this hypothesis, a recent study has shown that 
p300 can acetylate HDAC1 and inhibit its histone deacetylase activity leading to 
transcription activation (Qiu et al., 2006). This suggests that HAT and HDAC 
complexes may occur concurrently on promoters and can regulate each other's activity. 
Indeed, several lines of evidence support the association of HDAC activity with basal 
levels of p21 transcription. Small molecule inhibitors of HDACs including 
Suberoylanilide hydroxamic acid (SAHA) and'trichostatin A (TSA) can induce p21 
from the CDKNIA promoter in MCF7 cells. Using reporter assays, this activity has been 
shown to require a minimal region of the proximal p21 promoter containing the six SP1 
sites (see Figure 5.14. for details) (Huang et al., 2000; Varshochi et al., 2005). Mutation 
of any of the SP1 sites reduced the activation of p21 transcription following treatment 
with HDAC inhibitors, suggesting that SP1 binding is important in activation of 
transcription in this proximal region. RNAi studies have also provided evidence for 
specific HDAC activity. For example, treatment with HDAC1, 'but not HDAC3 
targeting siRNAs in MCF7 cells induced p21 levels (Varshochi et al., 2005). A 
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separate study showed siRNA knockdown of HDAC2, but not HDAC1 enhanced p53 
mediated induction of p21 and caused a cell cycle arrest in MCF7 cells (Harms & Chen, 
2007). 
Interestingly, comparisons can also be drawn between the observations described above 
for HDAC inhibitors and those observed in this study investigating the activity of a 
series of CDKN1A promoter reporter constructs following AP-2y silencing in MCF-7 
cells. Although the data from ChIP experiments show that AP-2y is associated with the 
proximal region of CDKN1A in vivo (by enrichment of the -21 / +44 amplicon), 
additional luciferase reporter assays defined a minimal region from -74 to +20 relative 
to the start of transcription of the CDKNIA promoter as sufficient for repression by AP- 
2y in the MCF-7 cells (Figures 5.11 & 5.14). As AP-2y is associated with a region of 
the p21 promoter suggested to be repressed by HDACs, the AP-2y mediated repression 
of transcription in this region could therefore involve the recruitment of HDACs or 
modulation of HDAC activity. Additionally, in a manner similar to the activation of 
p21 transcription following treatment with HDAC inhibitors, mutation of any of the 4 
SP1 sites within the -74 to +20 promoter was also shown to reduce the activation of p21 
transcription following AP-2y silencing in MCF-7 cells (Figure 5.14). This suggests 
that the activity of the p21 promoter following AP-2y silencing is largely mediated by 
SP1. 
6.2.3.2 Does AP-2y mediate its repression via interaction with AP-2 
consensus binding sites in the p21 promoter? 
The experiments presented in this study were insufficient to identify a specific binding 
sequence for AP-2 within the CDKN1A promoter. However a minimal +74 to +20 
promoter region was shown to be sufficient for AP-2y mediated repression. This does 
not include any consensus binding sites, as defined by the SCCNNVRGB consensus 
(McPherson & Weigel, 1999). Additionally sequences that contributed to AP-2a 
activation of CDKNA1 in vitro are upstream of this minimal region (Zeng et al., 1997). 
Therefore, it is possible that AP-2y might bind sequences alternative to the consensus 
within the +74 to +20 region. Future experiments could use electromobility shift assays 
(EMSA) to determine whether AP-2y proteins can directly bind this DNA region in 
vitro. Alternatively, AP-2y could facilitate its transcriptional repression through direct 
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interaction with other transcription factors that bind DNA within this region. A prime 
candidate would be SP1. Many other transcriptional regulators of p21 have been shown 
to exert their effects through the interaction with SP1 and not a direct interaction with 
the DNA in this region, these include Myc and HBx protein (reviewed in Gartel & 
Radhakrishnan, 2005). Indeed, evidence suggests that SP1 and AP-2 family members 
may interact to regulate transcription. AP2a and SP-1 have been shown to cooperate to 
activate the KISS1 transcription in vitro (Mitchell et al., 2006). A potential AP-2y-SP1 
interaction could be explored in MCF-7 cells via coiP or sequential ChIP. 
6.2.3.3 Can Modulation of AP-2y by SUMO proteins alter its 
transcriptional potential? 
Previous work in our lab has shown that AP-2a, AP-20 and AP-2y can interact with the 
SUMO conjugating enzyme UBC9. This interaction results in SUMO conjugation at 
the conserved lysine residue (lys 10) in the N-terminal region of AP-2, and was shown 
to reduce the ability of AP-2 to activate transcription when analysed in reporter gene 
assays (Eloranta et al., 2002). However, until this study, the effect of SUMO 
modification of AP-2y had not been explored in the context of a promoter that was a 
known target for AP-2y mediated transcriptional repression. It order to examine 
whether SUMO modification could facilitate CDKNIA transcriptional repression by 
AP-2y a series of mutant AP-2y constructs were assessed for their ability to repress 
transcription from the -2325 to +8 CDKN1A promoter reporter Figure 5.15 (A&B). 
Interestingly, co-transfection of the CDKNIA promoter reporter with the K1OR-AP-2y 
or ON10-AP-2y non-SUMO-modifiable mutant constructs did not lead to repression of 
luciferase activity, in contrast to the repression observed with wildtype AP-2y. These 
data suggest that SUMO modification at lysine 10 of AP-2y is important for mediating 
its transcriptional repression at the CDKN1A promoter., Constitutive SUMO-modified 
forms of AP-2y reduced luciferase activity over and above that of wild-type AP-2y 
when co-transfected with the CDKN1A promoter reporter. This shows that artificial 
conjugation of SUMO to the AP-2y N-terminus can repress CDKNIA promoter activity 
in HepG2 cells. 
a 
219 
Together these transient transfection studies indicate that SUMO modification of AP-2y 
mediates its ability to repress CDKN1A promoter activity in HepG2 cells in vitro and 
highlight the potential for SUMO modification of AP-2y to mediate transcriptional 
repression in vivo. However, the presence of SUMO modification of AP-2y needs to be 
demonstrated at the CDKNIA promoter in MCF-7 cells. This could be explored by 
performing ChIP for SUMO at the CDKNIA proximal promoter region. Alternatively, 
the effect of siRNA-mediated silencing of UBC9 on p21 expression could be used to 
determine the involvement of SUMO modification in transcriptional repression of the 
CDKNIA promoter. If, in the absence of active UBC9, endogenous AP-2y is no longer 
recruited to the CDKNIA promoter, this would be strong evidence implicating SUMO- 
modified AP-2y in the repression of this gene in vivo. 
SUMO modification of AP-2y might facilitate the recruitment of HDAC repressor 
complexes, as has been proposed for other factors including p300 and Elk-1, and thus 
enhance the recruitment of AP-2y associated complexes into repressive nuclear domains 
such as PML bodies (Girdwood, et al. 2003; Yang & Sharrocks et al., 2004). Another 
unanswered question is how the SUMO modification of AP-2y is regulated? In this 
context it is interesting that p300 SUMO modification has been reported to be inhibited 
by p21 protein. An interaction between p21 and the SUMO modification domain of 
p300 was hypothesised to prevent SUMO modification resulting in enhanced p300 
activation in vitro (Snowden et al., 2000). 
6.2.3.4. Do changes in AP-2a or p53 contribute to p21 up-regulation 
following AP-2y silencing in MCF-7 cells? 
As both AP-2a and p53 had previously been shown to play a role in the transcriptional 
activation of CDKN1A (McPherson et al., 2002; Wajapeyee & Somasundaram, 2003), 
changes in AP-2a or p53 protein levels were assessed following AP-2y knock down in 
MCF-7 cells. No increase in AP-2a was observed following AP-2y silencing; indeed 
AP-2a remained at barely detectable levels (Figure 5.5. A). However, there was a 
suggestion that p53 might increase slightly following AP-2y silencing (Figure 5.5. A). 
Subsequent experiments, using additional AP-2y targeting siRNAs, revealed a very 
slight increase in p53 levels accompanying AP-2y knockdown (Figure 5.5. B). In order 
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to put these slight changes in p53 level in to context we compared them to the changes 
in p53 levels following DNA damage stress (Figure 5.6. A). This showed that the wild 
type p53 protein in our MCF-7 cells behaved predictably following DNA damage stress 
and rules out any p53 anomalies in our cells. The increase in p53 levels seen following 
AP-2y silencing (Figure 5.5 (B) Lanes 3-9) was very slight compared to the stabilisation 
of p53 observed in cisplatin treated MCF-7 cells, even at the low 1µM cisplatin 
concentration (Figure 5.6 (A) Lane 2) and was inconsistent with the magnitude of p21 
induction. Together these data suggested that the fairly small increase in p53 is not the 
major mechanism of p21 induction following AP-2y silencing, although it may 
contribute to p21 activation. 
Shortly after establishing these findings, work by Stabach and colleagues (Stabach et 
al., 2006) showed a similar two fold p21 induction at the mRNA level 72 hours 
following AP-2y knockdown in MCF-7 cells, in support of our findings. However, this 
AP-2y knock down was accompanied by a substantial increase in p53 protein levels 
shown in Figure 6.1. The primary aim of this study by Stabach and colleagues was to 
follow up previous findings that suggested AP-2 family members could interact with 
p53 in vitro, and the suggestion that AP-2a and p53 could cooperate to activate 
CDKNIA transcription (McPherson et al., 2002; Wajapeyee & Somasundaram, 2003). 
Indeed, Stabach and colleagues confirmed an interaction of exogenous AP-2a and p53 
in vivo by co-IP (Stabach et al., 2006). In contrast to previous findings by Wajapeyee & 
Somasundaram, Stabach and colleagues showed that AP-26 activation of a CDKNIA 
reporter construct was entirely dependant on the expression of p53. These discrepancies 
aside, Stabach and colleagues suggested using ChIP that occupancy by exogenous AP- 
2a near the -2250 p53 regulatory region only occurred in HCT116 wt cells and not in 
HCT1 16 p53 (-/-) derivatives, again supporting their hypothesis that p53 is required for 
AP-2a coactivation of p21. These results should be cautiously interpreted as previous 
work in our lab has shown that the antibody used in this ChIP has a high level of non- 
specific activity, and no control for non-specific activity was reported in this study 
(Stabach et al., 2006). In addition to a role for AP-2a in the activation of CDKNIA 
transcription, Stabach and colleagues suggested that exogenous AP-2a expression was 
able to reduce p53 protein stability in cyclohexamide chase experiments. They 
hypothesised that AP-2y might have a similar role in destabilising p53 and that the 
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observed increase in p53 protein levels following AP-2y knock down in MCF-7 cells 
(shown in Figure 6.1) was due to stabilisation of p53. Closer examination of these data 
shows that these differences are also reflected in the Actin loading control blot and 
suggests that the majority of this difference could be accounted for by increased protein 
loading in the AP-2y knockdown well. 
In summary, a role for p53 in the regulation of CDKN1A transcription by AP-2 family 
members remains uncertain. What is clear is that AP-2a can activate CDKNIA 
transcription either by proximal promoter sites (Zeng et al., 1997) or possibly via an 
interaction with p53 at upstream p53 sites (Stabach et al., 2006) and this activation was 
shown to be reduced or abolished in the absence of p53 (Wajapeyee & Somasundaram, 
2003; Stabach et al., 2006). Perhaps in conflict with these findings exogenous AP-2a 
can also reduce the stability of p53 (Stabach et al., 2006). The findings presented in this 
thesis show that endogenous AP-2y can repress CDKNIA transcription by interacting 
with a proximal promoter region in vivo but not at the p53 binding sites in upstream 
regions. AP-2y silencing in MCF-7 cell relieves this transcriptional repression and is 
accompanied by a very slight increase in p53 levels. The significance of this slight 
increase in p53 following AP-2y silencing requires further analysis. Evidence suggests 
that the p53 binding region of the CDKN1A promoter accounts for a large component of 
the luciferase activity in MCF-7 cells following AP-2y silencing (Figure 5.13. ). 
Therefore, it is possible that p53 contributes to the induction of CDKN1A following AP- 
2y silencing. 
It is interesting to note that the only cell line in which we successfully derived stable 
AP-2y silenced colonies was the p53-defective T47D cell line (Table 3.2). All of the 
other cell lines studied are wild type for p53 and exhibit a p21 induction following AP- 
2y silencing. In future experiments it will be interesting to see if p21 is induced 
following transient AP-2y silencing in T47D. It would be hypothesised that p21 
induction would be absent or reduced due to defective p53 activity and thus explaining 
the derivation of stable AP-2y silenced colonies in the T47D cell line. The lack of cell 
cycle arrest in T47D cells makes them a useful tool for future expression profiling 
experiments. Experiments could explore resultant gene expression profiles following 
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the silencing of AP-2a and AP-2y both individually and together, 
in order to more 
clearly identify non-cell cycle related AP-2y targets. 
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Figure 6.1. AP-2y silencing in MCF-7 cells is accompanied by an up-regulation of p21 mRNA and 
p53 protein from Stabach et a/., 2006. A similar two fold p21 induction at the mRNA level 72 hours 
following AP-2y knockdown in MCF-7 cells, in support of our findings. However, the AP-2y knock 
down is also accompanied by a substantial increase p53 protein levels. Closer examination of these data 
shows that these differences are also reflected in the Actin loading control blot and suggests that the 
majority of this difference could be accounted for by increased protein loading in the AP-2y knockdown 
well. 
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6.2.3.5 A Model for AP-2y mediated repression of p21 in MCF-7 cells 
Based on the findings in this study and the evidence discussed above a model for the 
repression of CDKN1A transcription by AP-2y and the subsequent activation of 
CDKN1A transcription following AP-2y silencing can be proposed, shown in Figure 6.2. 
There are clearly some gaps in this proposed model, the important one being the 
discovery of an AP-2y associated HDAC. It would also be of interest to explore the role 
of AP-2a which is known to activate CDKNIA transcription. AP-2a and AP-2y can 
heterodimerise in vitro and perhaps in a cell line in which they are both expressed the 
balance of these factors might be important in the propensity of p21 to be activated or 
repressed. Indeed, p21 induction has been demonstrated following AP-2y silencing in 
ZR-75-1 cells and MCF1OA cells where both AP-2y and AP-2a are expressed at high 
levels (Figures 3.1 and 5.17). During the preparation of this thesis, preliminary work in 
the lab has shown that AP-2y promoter occupancy is associated with HDAC1 and 
HDAC2, marked by the enrichment of the -21 / +44 CDKN1A promoter amplicon in 
HDAC1 and HDAC2 ChIPs. Studies are currently underway to confirm their 
involvement in the AP-2y mediated repression of CDKN1A transcription by 
demonstrating that either or both HDACs are lost from the promoter after AP-2y 
silencing (Karsten Friedrich, personal communication). 
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Figure 6.2. A model for AP-2y mediated transcriptional repression at the CDKNIA promoter. 
(A) Repression. AP-2y is recruited to the promoter by an undefined TFBS or via an interaction with SP I. 
In this repressed state AP-2y is associated with p300 which is probably recruited via CITED proteins. 
AP-2y may also recruit an undefined HDAC, via SUMO modification of its conserved N-terminal lysine 
residues, which then counteracts or inactivates the HAT activity of p300. In this state chromatin remains 
inaccessible to other activating factors, which is marked by a lowered level of histone acetylation. 
(A) Activation. Following AP-2y silencing in MCF-7 cells, AP-2y is depleted from the ('DKNIA 
promoter. In turn the associated HDAC activity is lost. The remaining p300, in association with SPI and 
perhaps p53, is now active at its associated HAT activity leads to increased Histone acetylation, the 
resulting chromatin remodelling increases the accessibility to the general transcription machinery and 
transcription is activated. 
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6.3 What is the functional significance of repression of 
the CDKN1A transcription by AP-2y and the associated 
regulation of proliferation 
The results in this study show that in order for MCF-7 cells to proliferate, 
AP-2y 
expression is required in order to mediate repression of CDKNIA transcription. 
This is 
supported by data from ZR751 and MCF10A that show p21 induction following AP-2y 
silencing suggesting that this mechanism may be relevant in other AP-2y expressing 
cells. These findings directly support other developmental studies showing a 
requirement for AP-2y expression for the normal proliferation of trophoblasts, early 
germ cells, and normal breast epithelial cells at different stages of development 
(Jager et 
al., 2003; Pauls et al 2005; Auman et al., 2002; Werling & Schorle, 2002). It may be 
that in developmental programmes AP-2y mediated repression of CDKN1A transcription 
is also required to allow proliferation to continue. For example in TEB structures of the 
mammary gland AP-2y expression in cap cells might prevent cell cycle arrest as 
epithelial ducts develop through the surrounding stroma. This study might also provide 
a molecular mechanism behind the association of high AP-2y expression and increased 
breast tumour progression leading to poor patient prognosis. AP-2y expression might 
represent increased insensitivity to anti-growth signals. Repression of CDKNIA 
transcription by AP-2y might lead to failure of cells to arrest via CDKN1A up-regulation 
in response to anti-proliferative cues, leading to unchecked cell proliferation. 
Equally, repression of CDKNIA transcription by AP-2y might also represent a challenge 
to growth arrest in response to DNA damage stress. It is interesting that following 
Cisplatin treatment of MCF-7 cells in this study, AP-2? levels were slightly reduced 
(Figure 5.6. B). This suggests the presence of a mechanism to down-regulate AP-2y in 
response to DNA damage stress. 
High AP-2y expression has been linked to poor patient prognosis in patients positive for 
ERa expression. In these patients AP-2y expression represents a challenge to anti- 
oestrogen therapy as AP-2y (a ligand activated target gene of ER(X (Orso et al., 2004)) 
would be expected to be down-regulated by anti-oestrogens. Indeed, poor patient 
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prognosis in this subset of ERa positive tumours might be due to failed ERa regulation 
of TFAPC transcription. The prevailing levels of AP-2y in these tumours might lead to 
failure of cells to arrest via CDKN1A induction following anti-oestrogen treatment 
contributing to enhanced proliferation and poor patient prognosis. 
Work presented in this thesis shows that ERa can indeed mediate some of its 
proliferative effects in MCF-7 cells via AP-2y dependant transcriptional regulation of 
CDKNIA. ICI182,780 anti-oestrogen treatment in MCF-7 cells was accompanied by a 
decrease in AP-2y occupancy across the -21 / +44 region of CDKNIA promoter (Figure 
5.12. A). This change was consistent with the reduction in AP-2y protein levels 
observed following ICI182,780 treatment and was accompanied by an up-regulation of 
p21 mRNA and protein levels and a reduction in RB phosphorylation (Figure 5.12. B). 
These results were interesting in the light of findings by Varshochi and colleagues. The 
authors used ChIP to show that ICI182,780 treatment of MCF-7 cells could induce 
CDKN1A transcription through the release of ERa and HDAC1 association with SP1 at 
the CDKNIA proximal promoter in vivo (Varshochi et al., 2005). These data suggest 
that a dual level of transcriptional control occurs following ICI182,780 treatment of 
MCF-7 cells. Firstly, the antagonism of ligand activated ERa transcription of TFAP2C 
leads to a reduction in AP-2y levels and a concurrent reduction in AP-2y occupancy of 
the CDKNIA proximal promoter leading to CDKN1A up-regulation. Secondly, the 
ICI182,780 mediated disruption of an ERa-SP1-HDAC1 complex at the CDKNIA 
proximal promoter leads to release of HDAC1 repression and CDKNIA up-regulation. 
Interestingly, work in our lab exploring cell line models of anti-oestrogen resistance, 
has shown that, although wt MCF-7 cells down-regulate AP-2y in response to anti- 
oestrogen treatment, Tamoxifen-resistant derivatives express normal levels of AP-2y. 
As these cells now cycle in the presence of Tamoxifen, it is interesting to speculate that 
part of the adaptation process has been the re-expression of AP-2y allowing the cells to 
effectively repress p21 expression and re-enter the cell cycle. In order to determine 
whether AP-2y expression in these cell lines might represent a general mechanism of 
anti-oestrogen resistance, work is currently underway to explore whether AP-2y is 
down-regulated in response to acute levels of anti-oestrogens in other ERa positive cell 
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lines (ZR75-1, T47D) and whether their resistant derivatives also re-express AP-2y to 
allow their re-entry into the cell cycle via repression of CDKNIA. 
As well as being associated with increased proliferation in developmental studies, 
enhanced apoptosis was also observed in cells with forced over-expression of AP-2y 
(Jager et al., 2003; Meredith, 2006). No significant increase in apoptosis was observed 
following AP-2y silencing in MCF-7 cells. Developmental data suggest that in order to 
sustain AP-2y expression in cells, normal apoptotic pathways must be bypassed or 
silenced. Sustained expression of AP-2y in the immortal MCF-7 cell line might 
therefore represent insensitivity to any potential pro-apoptotic effects of AP-2y. 
Therefore, induction of apoptosis would not be an expected consequence of AP-2y 
silencing in MCF-7 cells and these experiments cannot rule out an involvement for AP- 
2y in the normal regulation of apoptosis. Interestingly, -that treatment of MCF-7 cells 
with cisplatin results in an up-regulation of AP-2a and moderate down-regulation of 
AP-2y (Figure 5.6. B). An up-regulation of AP-2a is consistent with findings from 
others who showed that AP-2a expression is required for transcriptional repression of 
BCL2 during chemotherapy mediated apoptosis in colon carcinoma cells (Wajapeyee et 
al., 2006), and suggests a similar mechanism in MCF-7 cells. The moderate AP-2y 
down-regulation following cisplatin treatment in MCF-7 cells might also have 
consequences for apopiosis, although if this were the case it would be in conflict with 
data relating to forced over-expression of AP-2y to enhance apoptosis. It would be 
interesting to explore whether the response to chemotherapy-induced apoptosis is 
altered in cells silenced for AP-2y compared to their wild type counterparts. 
6.4 Other Potential Targets for AP-2y regulation 
As well as revealing a role AP-2y in the regulation of the cell cycle (discussed above), 
the transcription profiling experiments presented in this thesis have also identified 
changes in the abundance of additional transcripts following AP-2y silencing in MCF-7 
cells. A number of these changes were validated using qPCR, and where, possible 
western blots were used to test if these translated into 'changes at the protein level 
(Section 4.9). 
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6.4.1. SPDEF (SAM Pointed 
_Domain . containing _Ets transcription Factor) 
A significant down-regulation of the SPDEF transcript following AP-2y silencing in 
MCF-7 cells was verified using qPCR (Figure 4.12). Although, further investigations 
are required to validate this change by western blot, it is interesting that several AP-2 
TFBS were found in the -500 to +50 bp relative to the start of SPDEF transcription, 
implicating AP-2y in the activation of transcription from this promoter (Appendix 2). 
High levels of SPDEF transcript have been detected in a large proportion of human 
breast cancers, where SPDEF expression has been related to invasive potential 
(Feldman et al., 2003). In particular, SPDEF has been shown to enhance migration and 
invasion in normal and tumourigenic breast epithelial cell lines (Gunawardane et al., 
2005). Interestingly, SQSTMI (Sequestosome 1), a previously described transcriptional 
target of SPDEF was also identified within the gene expression changes following AP- 
2y silencing in MCF-7 cells (244804_at: Fold Change = 1.74, p Value = 0.00492). 
Unfortunately, very little is known about additional transcriptional targets of SPDEF 
and it was not possible to identify further potential SPDEF transcriptional effects within 
the AP-2y microarray data. These observations lead to the speculation that AP-2y 
expression might be important for the regulation of invasion and migration of cells 
during normal breast development and carcinogenesis. 
6.4.2. TIMP2 (Tissue Inhibitor of MetalloProteinases 2) 
In support of a role for AP-2y in the regulation of invasion is the qPCR verification of 
the significant up-regulation of the TIMP2 transcript following AP-2y silencing in 
MCF-7 cells (Figure 4.12). Again, further investigations are required to validate this 
change at the functional level and indeed any involvement for AP-2y in TIMP2 
regulation. TIMPs have been shown to irreversibly inhibit the activity of matrix 
metalloproteinases (MMPs). The activity of MMPs is associated with many types of 
cancer and is thought to be important for the` degradation of connective tissue 
contributing to invasion by facilitating tumour cell migration (reviewed in Overall & 
Kleifeld, 2006). Therefore the down-regulation of TIMP2 in AP-2y expressing cells 
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suggests that these cells might be more capable of MMP mediated degradation of 
connective tissue required for invasion. 
6.4.5. TGLN (Transgelin) 
The up-regulation of the TGLN transcript following AP-2y silencing in MCF-7 cells was 
verified by qPCR and western blot (Figure 4.12 and Figure 4.14). Again, further 
investigations are required to validate this change at the functional level and indeed an 
for AP-2y in TGLN regulation. Transgelin is a 22kDa actin binding protein that was first 
discovered as an early marker that was lost during the onset of cellular transformation 
(Shapland et al., 1993) Indeed, Transgelin expression is frequently down-regulated in 
colon and breast tumour tissue (Shields et al., 2002). A recent study has shown that 
Transgelin is able to repress MMP-9 gene expression, via modulation of ERK signalling 
in colon carcinoma cells (Nair et al., 2006), although no change was observed for the 
MMP-9 transcript following AP-2y silencing in MCF-7 cell in this study. 
6.4.3. Kiaa 1324 
A significant down-regulation of the KIAA1324 transcript following AP-2y silencing in 
MCF-7 cells was verified by qPCR and western blot (Figure 4.12 and Figure 4.14). 
This protein has no known function, but was selected for further analysis in this study as 
it was the most statistically significant down-regulated gene on the microarray, 
following AP-2y silencing in MCF-7 cells (Figure 4.8) and was represented by multiple 
probes sets. Subsequent immunofluorescence revealed kiaa1324 was localised to the 
membrane in MCF-7 and was regulated by oestrogens, supporting observations by 
others (Deng et al., 2005). The AP-2 TFBS analysis presented in this study (Appendix 
2) revealed several AP-2 sites within the region -500 to +50 bp relative to the start of 
Kiaa1324 transcription. During the preparation of this thesis, enrichment of a -180 I- 
129 KIAA1324 promoter specific amplicon was observed in AP-2y antibody ChIP elutes 
from MCF-7 cells, implicating AP-2y in the direct regulation of KIAA1324 transcription 
(Karsten Friedrich, personal communication). Kiaa1324 protein was also detected in 
other breast carcinoma cell lines where AP-2y was expressed, including ZR751 and 
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T47D, however Kiaa1324 protein was absent from the normal MCF1OA cell line 
suggesting mechanisms other than AP-2 control its expression in this cell line (data not 
shown). AP-2y silencing in these cell lines should be explored with respect to Kiaa1324 
expression in order. to see if AP-2y can also regulate KIAA1324 transcription in these 
additional tumour cell lines. Future work should also examine the relationship between 
AP-2y expression and Kiaa1324 via immunohistochemistry in human breast tumours 
and, in order to identify a functional role for Kiaa1324, the effect of siRNA mediated 
Kiaa1324 silencing in MCF-7 cells could be explored with respect to tumourigenic 
character such as cell proliferation, apoptosis and migration. 
6.4.4. IGFBP3 (Insulin-like Growth Factor Binding Protein 3) 
The up-regulation of the IGFBP3 transcript following AP-2y silencing in MCF-7 cells 
was verified by qPCR and western blot (Figure 4.12 and Figure 4.14). Interestingly, a 
two fold increase in the relative abundance of IGFPB3 mRNA was also observed 
following AP-2y silencing in ZR75-1 cells (Figure 4.15), suggesting that the 
mechanisms of IGFBP3 up-regulation following AP-2y silencing are similar in MCF-7 
and ZR75-1 cells. Several AP-2 TFBS were found in the -500 to +50 bp relative to the 
start of IGFPB3 transcription (Appendix 2), implicating AP-2y in the repression of 
transcription from this promoter. Future ChIP experiments will be important in 
verifying such an interaction but it is interesting that others have identified IGFBP3 as a 
potential target for AP-2c activation (Wajapeyee et al., 2005). The functional 
significance of IGFBP3 up-regulation following AP-2y silencing in these AP-2 
expressing cell lines is unclear. IGFBP3 expression can both mediate anti-proliferative 
signalling and apoptosis in breast cancer cell lines (reviewed in Cohen, 2006). Studies 
examining forced expression of IGFP3 in mouse models of prostate cancer have showed 
that IGFBP3 can act in two distinct modes to mediate a dramatic suppression of tumour 
development (Silha et al., 2006). Firstly, this can be indirectly mediated by IGFBP3 
through complex formation with IGFs, preventing IGFs from activating IGF receptors 
and inhibiting cell survival signalling. Alternatively, IGFBP3 suppression of tumour 
development can be mediated directly through IGF-independent mechanism (reviewed 
in Cohen, 2006). Evidence exists for IGF-independent mechanisms in MCF-7 cells. 
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Recombinant IGFBP3 has been shown to stimulate phosphorylation of the exogenously 
expressed cell surface receptor TGF-RI, although the initiating mechanism remains 
unclear, this was accompanied by an increase in Smad transcription factor 
phosphorylation (Fanayan et al., 2002). Although not explored with reference to 
IGFBP3, TGF-ß signalling can lead to growth inhibition via Smad mediated activation 
of target genes such as CDKNIA. Work presented in this thesis, demonstrated that a 
mutation in the region of the CDKN1A promoter previously shown to be critical for 
reporter activity after TGFß signalling (Datto et al., 1995) did not effect CDKN1A 
reporter activity following AP-2y silencing (mut#3, Figure 5.14), suggesting that 
increased TGFß signalling is not involved in the up-regulation of CDKN1A, following 
AP-2y silencing. These data suggest that if IGFBP3 up-regulation following AP-2y 
silencing is exerting any anti-proliferative effects in MCF-7 cells, these are not 
mediated through any of previously described mechanisms. I4BP3 has also been 
shown to activate apoptosis in breast cancer cell lines, however this mechanism is less 
well understood (Reviewed in Cohen, 2006). Although, no significant increase in 
apoptosis was observed following AP-2y silencing in MCF-7 cells, it maybe that the 
normal mechanisms of IGFBP3-mediated apoptosis are not functional in this cell line. 
It is interesting that proteins suggested to activate apoptosis, both IGFBP3 and the 
related protein IGFBP5, are potential targets for down-regulation by AP-2y in breast 
cancer cell lines. Although more work is required to establish the functional relevance 
of these observations this suggests that in some contexts AP-2y can repress apoptotic 
mechanisms. 
6.5 Concluding Remarks 
Presented within this thesis is a large scale microarray analysis conducted in order to 
identify potential AP-2y regulated genes. As well as a large proportion of cell cycle 
regulated genes down-regulated in response to AP-2y silencing, additional transcripts 
involved in the regulation of apoptosis, invasion and developmental pathways were also 
identified. The functional relevance of these AP-2y dependant regulated targets requires 
further investigation, although they implicate AP-2y expression in regulation of 
pathways additional to proliferation. 
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Also in this study we have shown that in order for MCF-7 cells to proliferate, AP-2y 
expression is required to mediate repression of CDKN1A transcription. This provides 
the first evidence for a molecular mechanism behind the requirement for AP-2y 
expression in the normal proliferation required in developing tissues. Importantly AP- 
2y mediated repression of CDKNIA transcription may also be important for the control 
of proliferation in beast cancers. Evidence suggests that breast cancer cell lines can 
provide good models in which to identify molecular events that are likely to be 
important in human breast cancers (Zhu et al., 2006). Therefore, the correlation of high 
AP-2y expression and poor prognosis in patients with breast cancer might be due to 
failure of cells to arrest via CDKN1A up-regulation in response to anti-proliferative 
cues, leading to unchecked cell proliferation. 
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APPENDIX 1 
Appendix 1 displays the 578 probe sets that changed their expression significantly (FDR corrected, p 
value <0.05) between the reference (non silencing control siRNA and cells treated with transfection 
reagent only) and test (AP-2y targeting siRNAs: AP-2y siRNAI, AP-2y siRNA2 and AP-2y siRNA3) 
groups. The table displays the Affymetrix Probe Set ID, Gene Symbol, Gene Name, Fold Change (test 
vs. reference) and the associated statistical significance. 
Probe Set ID Gene Symbol 
Gene Name 
Fold 
Change p value 
232306_at CDH26 cadherin-like 26 2.07 8.43E-06 
224925_at PREX1 phosphatidylinositol trisphosphate-dependent RAC -1.89 8.43E-06 
exchanger1 
221874_at KIAA1324 KIAA1 324 -2.57 8.43E-06 
235408_x_at ZNF117 Zinc finger protein 117 (HPF9) 2.01 1.09E-05 
225207_at PDK4 pyruvate dehydrogenase kinase, isozyme 4 1.96 1.09E-05 
228176_at EDG3 endothelial differentiation, sphingolipid G-protein-coupled -2.49 1.09E-05 
receptor, 3 
204244_s_at DBF4 DBF4 homolog (S. cerevisiae) -2.08 1.09E-05 
203571_s_at C10orf116 chromosome 10 open reading frame 116 -2.53 1.09E-05 
210511 sat INHBA inhibin, beta A (activin A, activin AB alpha polypeptide) 1.97 1.56E-05 
201458_s at BUB3 BUB3 budding uninhibited by benzimidazoles 3 homolog -1.77 1.56E-05 
203060_s_at PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 2.18 1.92E-05 
210868_s_at ELOVL6 ELOVL family member 6, elongation of long chain fatty -1.72 2.62E-05 
acids (FEN1/Elo2, SUR4/Elo3-like, yeast) 
243010_at MSI2 musashi homolog 2 (Drosophila) -2.01 3.15E-05 
220414_at CALMLS calmodulin-like 5 -1.90 3.15E-05 
209754_s_at TMPO thymopoietin -1.78 3.76E-05 
222557_at STMN3 stathmin-like 3 -1.97 3.76E-05 
220192_x_at SPDEF SAM pointed domain containing ets transcription factor -2.24 3.76E-05 
204070_at RARRES3 retinoic acid receptor responder (tazarotene induced) 3 -2.06 3.76E-05 
203304_at BAMBI BMP and activin membrane-bound inhibitor -2.10 4.41 E-05 
201896_s_at PSRC1 proline/serine-rich coiled-coil 1 -1.78 5.29E-05 
227140_at INHBA inhibin, beta A (activin A, activin AB alpha polypeptide) 3.06 5.36E-05 
212148_at PBX1 Pre-B-cell leukemia transcription factor 1 -1.79 5.36E-05 
227850_x_at CDC42EP5 CDC42 effector protein (Rho GTPase binding) 5 -2.16 5.36E-05 
239007_at ZNF616 zinc finger protein 616 1.87 5.38E-05 
203058_s_at PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 1.90 5.38E-05 
212143_s at IGFBP3 insulin-like growth factor binding protein 3 2.30 5.38E-05 
213599_at 01P5 Opa Interacting protein 5 -1.72 5.38E-05 
205240_at GPSM2 G-protein signalling modulator 2 (AGS3-like, C. elegans) -1.78 5.38E-05 
210095_s_at IGFBP3 insulin-like growth factor binding protein 3 2.39 5.90E-05 
204319_s_at RGS10 regulator of G-protein signalling 10 -1.75 5.90E-05 
210297_s_at MSMB microseminoprotein, beta- -2.11 6.39E-05 
209291_at ID4 Inhibitor of DNA binding 4 2.28 6.57E-05 
201830_s_at NETZ neuroepithelial cell transforming gene 1 -1.85 6.57E-05 
207076_s_at ASS1 argininosuccinate synthetase 1 -2.30 6.57E-05 
227099_s_at LOC387763 hypothetical LOC387763 '' 2.88 7.45E-05 
226248_s_at KIAA1324 KIAA1 324 -2.55 7.62E-05 
224734_at HMGB1 high-mobility group box 1 -1.95 7.62E-05 
242245 at SYDE2 Synapse defective 1, Rho GTPase, homolog 2 (C. elegans) -2.25 7.98E-05 
213906_at 
, 
MYBL1 v-myb myeloblastosis viral oncogene homolog (avian)-like 1 -2.00 7.98E-05 
209301_at CA2 carbonic anhydrase li -2.53 7.98E-05 
204602_at 
, 
DKK1 dickkopf homolog 1 (Xenopus laevis) -1.85 9.42E-05 
217744_s_at PERP PERP, TP53 apoptosis effector 1.81 0.000106 
201829_at NETZ neuroepithelial cell transforming gene 1 -1.79 0.000106 
219918_s_at ASPM asp (abnormal spindle)-like, microcephaly associated -2.10 0.000106 
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205380_at 
204709_s_at 
229305_at 
218542_at 
202870_s at 
228729_at 
212314_at 
213253_at 
204886_at 
221258_s_at 
228273_at 
204033_at 
228597_at 
209684_at 
211080_s_at 
211708_s_at 
218755_at 
224909_s_at 
209343_at 
242138_at 
202183_s at 
240633_at 
235564_at 
201292_at 
201456_s_at 
204446_s_at 
240572 s_at 
219004_s_at 
203554_x_at 
219540_at 
213711 at 
219294_at 
212958_x_at 
236641_at 
225710_at 
235775_at 
1554614_a_at 
207695_s_at 
202766_s_at 
237435_at 
213664_at 
206204_at 
227452_at 
204141 at 
218683_at 
216568_x_at 
1555758_a_at 
213154_s_at 
221726_at 
203343_at 
225687 at 
243349_at 
204641_at 
209714_s_at 
231855_at 
201897_s at 
224719_s_at 
202565_s_at 
206364_at 
PDZK1 
KIF23 
MLFIIP 
CEP55 
CDC20 
CCNB1 
KIAA0746 
SMC2L1 
PLK4 
KIFI8A 
TRIP13 
C21orf45 
RIN2 
NEK2 
SCD 
KI F20A 
PREX1 
EFHD1 
DLX1 
KIF22 
DOK7 
ZNF117 
TOP2A 
BUB3 
ALOX5 
LOC374443 
C21orf45 
PTTG1 
ZNF267 
KRT81 
CENPO 
PAM 
KIF14 
TMTC2 
PTBP2 
IGSF1 
FBN1 
SLC1A1 
GRB14 
LOC146795 
TUBB2A 
PTBP2 
KRT8 
CDKN3 
BICD2 
RPL22 
UGDH 
FAM83D 
KIAA1324 
NEK2 
CDKN3 
KIAA1524 
CKS1 B 
C12orf57 
SVIL 
KIF14 
PDZ domain containing 1 -2.59 
kinesin family member 23 " -1.84 
MLF1 Interacting protein -1.79 
centrosomal protein 55kDa -2.03 
CDC20 cell division cycle 20 homolog (S. cerevisiae) -2.04 
cyclin B1 
KIAA0746 protein 
SMC2 structural maintenance of chromosomes 2-like 1 
(yeast) 
polo-like kinase 4 (Drosophila) 
kinesin family member 18A /// kinesin family member 18A 
Transcribed locus 
thyroid hormone receptor interactor 13 
chromosome 21 open reading frame 45 
Ras and Rab interactor 2 
NIMA (never In mitosis gene a)-related kinase 2 
stearoyl-CoA desaturase (delta-9-desaturase) 
kinesin family member 20A 
phosphatidylinositol 3,4,5-trisphosphate-dependent RAC 
exchanger l 
EF-hand domain family, member D1 
distal-less homeobox 1 
kinesin family member 22 
docking protein 7 
Zinc finger protein 117 (HPF9) 
topoisomerase (DNA) II alpha 170kDa 
BUB3 budding uninhibited by benzimidazoles 3 
arachidonate 5-lipoxygenase 
CLR pseudogene 
chromosome 21 open reading frame 45 
pituitary tumor-transforming 1 
zinc finger protein 267 
keratin 81 
centromere protein 0 
peptidylglycine alpha-amidating monooxygenase 
kinesin family member 14 
CDNA FLJ34013 fis, clone FCBBF2002111 
transmembrane and tetratricopeptide repeat containing 2 
polypyrimidine tract binding protein 2 
immunoglobulin superfamily, member 1 
fibrillin 1 
Transcribed locus 
solute carrier family 1 (neuronal/epithelial high aff inity 
glutamate transporter, system Xag), member 1 
growth factor receptor-bound protein 14 
Hypothetical protein LOCI 46795 
tubulin, beta 2A 
polypyrimidine tract binding protein 2. 
Keratin 81 
cyclin-dependent kinase inhibitor 3 (CDK2-associated dual 
specificity phosphatase) 
bicaudal D homolog 2 (Drosophila) 
ribosomal protein L22 
UDP-glucose dehydrogenase 
family with sequence similarity 83, member D 
KIAA1324 
NIMA (never in mitosis gene a)-related kinase 2 
cyclin-dependent kinase inhibitor 3 (CDK2-associated dual 
specificity phosphatase) 
KIAA1524 
CDC28 protein kinase regulatory subunit 1B 
chromosome 12 open reading frame 57 
supervillin 
_ kinesin family member 14 
"2.10 
1.83 
-1.87 
-1.66 
-1.87 
-2.38 
-1.86 
-1.85 
1.87 
-1.73 
0.000109 
0.000113 
0.000125 
0.000125 
0.000125 
0.000143 
0.000158 
0.000158 
0.000158 
0.000158 
0.000158 
0.000163 
0.000166 
0.000167 
0.00017 
-1.72 0.000178 
-2.26 0.000187 
-1.98 0.000193 
-1.79 0.000195 
-1.72 0.000195 
-1.86 0.000198 
-1.68 0.000225 
2.01 0.000228 
-2.28 0.000228 
-1.90 0.000228 
1.70 0.000238 
-1.81 0.000245 
-1.68 0.000246 
-2.02 0.000254 
1.70 0.000275 
-4.02 0.000275 
-1.99 0.000275 
1.66 0.000276 
-1.86 0.000276 
-1.68 0.000276 
2.02 0.000303 
-1.63 0.000312 
1.73 0.000314 
1.71 0.000314 
-1.86 0.00032 
-1.77 0.000339 
1.90 0.00034 
1.77 0.000354 
2.23 0.000358 
-1.64 0.000382 
-1.66 0.000383 
-2.23 0.000392 
1.68 0.000408 
-1.67 0.000424 
-1.90 0.000452 
-1.87 0.000455 
-2.08 0.000502 
-2.14.0.000505 
-2.25 0.000505 
-1.63 0.000516 
-2.00 0.000532 
-1.90 0.000532 
1.75 0.000573 
-1.94 0.000574 
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230165_at SGOL2 shugoshin-like 2 (S. pombe) -1.69 0.000594 
219306_at KIF15 kinesin family member 15 -1.63 0.000616 
209715_at CBX5 chromobox homolog 5 (HPI alpha homolog, Drosophila) -1.87 0.000638 
219529_at CLIC3 chloride Intracellular channel 3 -1.82 0.000742 
219032_x_at OPN3 opsin 3 (encephalopsin, panopsin) 1.96 0.000751 
207430_s_at MSMB microseminoprotein, beta- -2.17 0.00077 
206115_at EGR3 early growth response 3 -1.91 0.000777 
211812 a at B3GALNTI beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside -1.72 0.000777 
blood group) 
229964_at C9orf152 chromosome 9 open reading frame 152 -1.63 0.000792 
203276_at LMNB1 lamin B1 -2.12 0.000814 
223374_s_at B3GALNTI beta- 1,3-N-acetylgalactosaminyltransferase 1 (globoside -1.90 0.000946 
blood group) 
229309_at --- Beta-1 adrenergic receptor mRNA, 3' UTR 1.90 0.00101 
232155_at KIAA1618 KIAA1618 -1.59 0.00101 
227165_at C13orf3 chromosome 13 open reading frame 3 -1.64 0.00103 
204058_at ME1 Malic enzyme 1, NADP(+)-dependent, cytosolic 1.74 0.00112 
209581 at HRASLS3 HRAS-like suppressor 3 -1.77 0.00112 
214710_s at CCNBI cyclin 131 -2.10 0.00112 
211513_s_at OGFR opioid growth factor receptor 1.64 0.00113 
205110_s_at FGF13 fibroblast growth factor 13 1.78 0.00115 
202705_at CCNB2 cyclin B2 -1.93 0.00117 
228574_at TMTC2 transmembrane and tetratricopeptide repeat containing 2 1.77 0.0012 
212281_s_at TMEM97 transmembrane protein 97 -1.74 0.0012 
228323_at CASC5 cancer susceptibility candidate 5 -1.63 0.00122 
213682_at NUP50 nucleoporin 5OkDa -1.67 0.00123 
222039_at SLC35EI solute carrier family 35, member El -1.73 0.00126 
226936_at C6orf 173 chromosome 6 open reading frame 173 -1.80 0.00126 
211162_x_at SCD stearoyl-CoA desaturase (delta-9-desaturase) -1.65 0.00131 
231894_at SARS Seryl-tRNA synthetase -1.74 0.00131 
232278_s_at DEPDC1 DEP domain containing 1 -1.67 0.00131 
225297_at CCDC5 coiled-coil domain containing 5 (spindle associated) -1.71 0.00131 211379_x_at B3GALNT1 beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside -1.81 0.00131 blood group) 
203856_at VRK1 vaccinia related kinase 1 -1.72 0.00147 
226980_at DEPDC1B DEP domain containing 1B -1.72 0.00147 224944_at TMPO thymopoietin -1.73 0.00148 
203418_at CCNA2 cyclin A2 -1.95 0.00149 
209366_x_at CYB5A cytochrome b5 type A (microsomal) -1.64 0.00151 210052_s_at TPX2 TPX2, microtubule-associated, homolog (Xenopus laevis) ' -1.82 0.00152 235456_at --- CDNA clone IMAGE: 4819084 1.69 0.00156 
204128_s_at RFC3 replication factor C (activator 1) 3,38kDa -1.95 0.00156 201663_s_at SMC4 structural maintenance of chromosomes 4 -1.80 0.00159 210983_s_at MCM7 MCM7 minichromosome maintenance deficient 7 -1.73 0.00164 208712_at CCND1 cyclin D1 -1.77 0.00164 213931_at ID2 inhibitor of DNA binding 25 1.80 0.00167 
202336_s_at PAM peptidylglycine alpha-amidating monooxygenase 1.69 0.00169 
204727_at WDHD1 WD repeat and HMG-box DNA binding protein 1 -1.66 0.00169 202489_s_at FXYD3 FXYD domain containing ion transport regulator 3 -2.12 0.00171 
204235_s_at GULP1 GULP, engulfment adaptor PTB domain containing 1 1.73 0.00177 
209172_s_at CENPF centromere protein F. 350/400ka (mitosin) -1.72 0.00177 204962_s_at CENPA centromere protein A -1.89 0.00177 219555_s_at CENPN centromere protein N -1.57 0.00188 209373_at MALL mal, T-cell differentiation protein-like 2.31 0.00192 
238756_at GAS2L3 Growth arrest-specific 2 like 3 -1.62 0.00193 213624_at SMPDL3A sphingomyelin phosphodiesterase, acid-like 3A -1.58 0.00194 
201525_at APOD apolipoprotein D -2.06 0.00194 204237_at GULPI GULP, engulfment adaptor PTB domain containing 1 1.68 0.00195 
222699_s_at PLEKHF2 pleckstrin homology domain containing, family F (with -1.59 0.00198 FYVE domain) member 2 237160_at CCDC83 coiled-coil domain containing 83 -1.73 0.00199 207843_x_at CYBSA cytochrome b5 type A (microsomal) -1.65 0.00206 201368_at ZFP36L2 zinc finger protein 36, C311 type-like 2 -1.66 0.00222 209408_at KIF2C kinesin family member 2C -1.58 0.00226 
254 
201540_at 
209774_x_at 
235113_at 
203764_at 
208988_at 
226140_s_at 
228286_at 
205003_at 
201664_at 
204822_at 
208808_s_at 
1552619_a_at 
203967_at 
223839_s_at 
204127_at 
210299_s_at 
204444_at 
218640_s_at 
202954_at 
215189_at 
202625_at 
1554696_s_at 
203210_s_at 
218723_s at 
224866_at 
235425_at 
228281_at 
227350_at 
223381 at 
203217_s_at 
222608_s_at 
203640_at 
205909_at 
213088_s at 
235419_at 
205287_s_at 
FHL1 
CXCL2 
PPIL5 
DLG7 
FBXL11 
OTUDI 
FU40869 
DOCK4 
SMC4 
TTK 
HMGB2 
ANLN 
CDC6 
RFC3 
FHL1 
KIF11 
PLEKHF2 
PAK3 
KRT86 
LYN 
TYMS 
RFC5 
RGC32 
MLSTD2 
SGOL2 
FU25416 
HELLS 
CDCA1 
ST3GAL5 
ANLN 
MBNL2 
POLE2 
DNAJC9 
ERRFII 
TFAP2C 
229551_x_at ZNF367 
205234_at SLC16A4 
228242_at --- 
216237_s_at MCM5 
1554768_a_at 
212112_s_at 
222077_s_at 
209104_s-at 
MAD2L1 
STX12 
RACGAP1 
NOLA2 
244804_at 
210028_s_at 
218726_at 
228640_at 
213008_at 
212185_x_at 
203362_s_at 
203887_s_at 
217996_at 
213092_x_at 
230360_at 
202859_x_at 
222848_at 
205339_at 
SQSTM1 
ORC3L 
DKFZp762E 
1312 
KIAA1794 
MT2A 
MAD2L1 
THBD 
PHLDA1 
DNAJC9. 
GLDN 
IL8 
CENPK 
STIL 
- 
four and a half LIM domains 1 
chemokine (C-X-C motif) ligand 2 
peptidylprolyl Isomerase (cyclophilin)-like 5 
discs, large homolog 7 (Drosophila) 
F-box and leucine-rich repeat protein 11 
OTU domain containing 1 
hypothetical protein FLJ40869 
dedicator of cytokinesis 4 
structural maintenance of chromosomes 4 
TTK protein kinase 
high-mobility group box 2 
anillin, actin binding protein 
CDC6 cell division cycle 6 homolog (S. cerevisiae) 
PRO1933 
replication factor C (activator 1) 3,38kDa 
four and a half LIM domains 1 
kinesin family member 11 
pleckstrin homology domain containing, family F (with 
FYVE domain) member 2 
p21 (CDKN1A)-activated kinase 3 
keratin 86 
v-yes-1 Yamaguchi sarcoma viral related oncogene 
homolog 
thymidylate synthetase 
replication factor C (activator 1). 5,36.5kDa 
response gene to complement 32 
male sterility domain containing 2 
shugoshin-like 2 (S. pombe) 
hypothetical protein FU25416 
Helicase, lymphoid-specific 
cell division cycle associated 1 
ST3 beta-galactoside alpha-2,3-sialyltransterase 5 
anillin, actin binding protein 
muscleblind-like 2 (Drosophila) 
polymerase (DNA directed), epsilon 2 (p59 subunit) 
DnaJ (Hsp40) homolog, subfamily C, member 9 
ERBB receptor feedback inhibitor 1 
transcription factor AP-2 gamma (activating enhancer 
binding protein 2 gamma) 
zinc finger protein 367 
solute carrier family 16, member 4 (monocarboxylic acid 
transporter 5) 
MCM5 minichromosome maintenance deficient 5, cell 
division cycle 46 (S. cerevisiae) 
MAD2 mitotic arrest deficient-like 1 (yeast) 
syntaxin 12 
Rac GTPase activating protein 1 
nucleolar protein family A, member 2 (H/ACA small 
nucleolar RNPs) 
Sequestosome 1 
origin recognition complex, subunit 3-like (yeast) 
hypothetical protein DKFZp762E1312 . 
2.10 
2.47 
-1.62 
-2.16 
1.67 
1.65 
-1.67 
1.89 
-1.96 
-1.88 
-1.93 
-1.71 
-1.67 
-1.70 
-1.77 
2.07 
-2.17 
-1.70 
-1.77 
-2.12 
1.62 
-1.68 
-1.61 
1.75 
-1.54 
-1.54 
-1.73 
-1.71 
-2.00 
1.55 
-1.77 
-1.56 
-1.65 
-1.62 
1.62 
-2.09 
0.00235 
0.00236 
0.0024 
0.00245 
0.00249 
0.00257 
0.00257 
0.00283 
0.00283 
0.0029 
0.0029 
0.0029 
0.00296 
0.00305 
0.00323 
0.00328 
0.00329 
0.00337 
0.00344 
0.00344 
0.0036 
0.0036 
0.0036 
0.00378 
0.00398 
0.00399 
0.00401 
0.00402 
0.00413 
0.00422 
0.00423 
0.00429 
0.00433 
0.00433 
0.00439 
0.00439 
-1.95 0.0044 
-2.23 0.00454 
-1.60 0.00462 
-1.69 0.00487 
-2.24 
1.74 
-1.71 
-1.55 
, 1.74 
-1.53 
-1.51 
0.00487 
0.00488 
0.00489 
0.00489 
0.00492 
0.00504 
0.00508 
CDNA clone IMAGE: 4800096 1.63 0.00509 
KIAA1794 -1.57 0.00509 
metallothionein 2A -1.96 0.00511 
MAD2 mitotic arrest deficient-like 1 (yeast) -2.07 0.00511 
thrombomodulin 1.68 0.00518 
pleckstrin homology-like domain, family A, member 1 1.81 0.00531 
DnaJ (Hsp40) homolog, subfamily C, member 9 -1.69 0.00531 
gliomedin 1.75 0.00541 
Interleukin 8 1.87 0.00544 
centromere protein K -1.88 0.00545, 
SCIJTALI interrupting locus -1.60 0.00552 
255 
227180_at ELOVL7 ELOVL family member 7, elongation of long chain fatty -1.49 
0.00552 
202095 a at BIRC5 
acids (yeast) 
baculoviral IAP repeat-containing 5 (survivin) -1.54 0.00552 
230964 at FREM2 FRASI related extracellular matrix protein 2 -1.76 
0.0057 
_ 
at 204092 s AURKA aurora kinase A -1.85 
0.00572 
_ _ 
s at 201041 DUSP1 dual specificity phosphatase 1 
1.54 0.00601 
_ 204146_at RAD51AP1 RAD51 associated protein 1 -1.92 
0.00601 
218990_s at SPRR3 small proline-rich protein 3 
2.88 0.0061 
203209_at RFC5 replication factor C (activator 1) 5,36.5kDa -1.66 
0.00611 
207165_at HMMR hyaluronan-mediated motility receptor (RHAMM) -1.87 0.00617 
225834_at LOC652689 hypothetical protein LOC652689 -2.11 0.00625 
204472_at GEM GTP binding protein overexpressed in skeletal muscle 2.60 0.00629 
201739_at SGK serum/glucocorticoid regulated kinase 1.81 0.00635 
203022_at RNASEH2A ribonuclease H2, subunit A -1.59 0.00635 
at 219148 PBK PDZ binding kinase -2.43 
0.00635 
_ 242560 at FANCD2 Fanconi anemia, complementation group D2 -1.61 
0.00635 
216598_s_at CCL2 chemokine (C-C motif) ligand 2 1.50 0.00637 
211623_s_at FBL fibrillarin -1.54 0.00642 
218875_s at FBX05 F-box protein 5 -1.64 0.00643 
201539_s_at FHL1 four and a half LIM domains 1 1.56 0.00645 
204204_at SLC31A2 solute carrier family 31 (copper transporters), member 2 1.56 0.00646 
205286_at TFAP2C transcription factor AP-2 gamma (activating enhancer -2.39 0.00646 
binding protein 2 gamma) 
224788_at ARF6 ADP-ribosylation factor 6 -1.52 0.00646 
209464_at AURKB aurora kinase B -1.52 0.00684 
202413_s_at USP1 ubiquitin specific peptidase 1 -1.52 0.00691 
226456_at C16orf75 chromosome 16 open reading frame 75 -1.57 0.00692 
218883_s_at MLF1IP MLF1 interacting protein -1.89 0.00695 
201563_at SORD sorbitol dehydrogenase -1.55 0.00702 
227196_at RHPN2 rhophilin, Rho GTPase binding protein 2 -2.03 0.00702 
213226_at CCNA2 cyclin A2 -1.89 0.00702 
228033_at E2F7 E2F transcription factor 7 -1.49 0.00705 
218662_s_at HCAP-G chromosome condensation protein G -1.66 0.00721 
212021_s_at MK167 antigen identified by monoclonal antibody Ki-67 -1.61 0.00723 
223229_at UBE2T ubiquitin-conjugating enzyme E2T (putative) -1.70 0.00724 
204240_s_at SMC2 structural maintenance of chromosomes 2 -1.77 0.00736 
205694_at TYRP1 tyrosinase-related protein 1 1.55 0.0074 
205016_at TGFA transforming growth factor, alpha 1.78 0.0074 
236224_at RIT1 Ras-like without CAAX 1 1.51 0.00751 
205394_at CHEK1 CHK1 checkpoint homolog (S. pombe) -1.63 0.00752 
204256_at ELOVL6 ELOVL family member 6, elongation of long chain fatty -1.58 0.00761 
acids (FEN1/Elo2, SUR4/Elo3-like, yeast) 
218039_at NUSAP1 nucleolar and spindle associated protein 1 . 1.89 0.00772 
204112_s_at HNMT histamine N-methyltransferase -1.70 0.00772 
205807_s_at TUFT1 tuftelin 1 1.90 0.00775 
242338_at TMEM64 transmembrane protein 64 -1.55 0.00775 
218009. s-at PRC1 protein regulator of cytokinesis 1 -1.97 0.00775 
205393_s_at CHEK1 CHK1 checkpoint homolog (S. pombe) -1.73 0.00781 
204510_at CDC7 CDC7 cell division cycle 7 (S. cerevisiae) -1.55 0.00786 
206461_x_at MT1 H metallothionein 1H -1.68 0.00793 
211959_at IGFBP5 insulin-like growth factor binding protein 5 2.18 0.00817 
219471 at C13orf18 chromosome 13 open reading frame 18 1.56 0.00817 
202567_at SNRPD3 small nuclear ribonucleoprotein D3 polypeptide 18kDa -1.51 0.00817 
203214_x_at CDC2 cell division cycle 2, G1 to S and G2 to M -2.03 0.00817 
232238_at ASPM asp (abnormal spindle)-like, microcephaly associated -1.63 0.00817 
214505_s_at FHL1 four and a half LIM domains 1 1.51 0.00826 
218807_at VAV3 vav 3 oncogene -1.70 0.00826 
205053_at PRIM1 primase, polypeptide 1,49kDa ' -1.60 0.00826 
220651_s_at MCM10 MCM10 minichromosome maintenance deficient 10 -1.57 0.00826 
204542_at ST6GALNA ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1.3)-N- -1.64 0.00827 C2 acetylgalactosaminide alpha-2,6-sialyltransferase 2 
1559060_a_at KIAA1961 KIAA1961 gene 1.77 0.00836 
219978_s_at NUSAPI nucleolar and spindle associated protein 1 -1.66 0.00836 
222118_at CENPN centromere protein N, _ -1.55 
0.00839 
256 
229256 at PGM2L1 phosphoglucomutase 2-like 1 1.89 
0.0143 
226621_at »- --- 
1.77 0.0143 
201504_s_at TSN translin -1.51 0.0143 
203432_at TMPO thymopoietin -1.48 0.0143 
214042_s_at RPL22 ribosomal protein L22 -1.52 0.0143 
231981_at PRLR Prolactin receptor -1.74 0.0143 
218768_at NUP107 nucleoporin 107kDa -1.49 0.0143 
235178_x_at ESCO2 establishment of cohesion 1 homolog 2 (S. cerevisiae) -1.63 0.0143 
1553984_s_at DTVMK deoxythymidylate kinase (thymidylate kinase) -1.45 0.0143 
219000 s at DCC1 defective In sister chromatid cohesion homolog 1 -1.53 0.0143 
226790 at MORN2 MORN repeat containing 2 2.17 0.0146 
241652_x at LIN7A Lin-7 homolog A (C. elegans) 1.48 0.0146 
201202_at PCNA proliferating cell nuclear antigen -1.55 0.0146 
218294_s_at NUP50 nucleoporin 50kDa -1.57 0.0146 
204105 s at NRCAM neuronal cell adhesion molecule -1.50 0.0146 
206206 at MPHOSPH9 M-phase phosphoprotein 9 -1.51 0.0146 
231121_at HPS3 Hermansky-Pudlak syndrome 3 -1.49 0.0146 
236223_s_at RIT1 Ras-like without CAAX 1 1.51 0.0147 
204825 at MELK maternal embryonic leucine zipper kinase -1.55 0.0147 
205018_s_at MBNL2 muscleblind-like 2 (Drosophila) -1.49 0.0147 
201324_at EMP1 epithelial membrane protein 1 -1.51 0.0147 
221667_s_at HSPB8 heat shock 22kDa protein 8 1.74 0.0148 
204162_at KNTC2 kinetochore associated 2 -1.94 0.0151 
226189_at ITGB8 integrin, beta 8 2.37 0.0152 
224764_at ARHGAP21 Rho GTPase activating protein 21 1.49 0.0152 
224989_at --- Full-length cDNA clone CSODE011Y020 of Placenta -1.53 0.0153 
224830_at NUDT21 nucleoside diphosphate linked moiety X-type motif 21 -1.47 0.0154 
220840_s at C1orf 112 chromosome 1 open reading frame 112 -1.53 0.0155 
218806_s_at VAV3 vav 3 oncogene -1.62 0.0159 
212022_s_at MKI67 antigen identified by monoclonal antibody Ki-67 -1.59 0.0159 
232654_s_at UGT1 A6 UDP glucuronosyltransferase 1 family, polypeptide A6 1.48 0.0163 
209270_at LAMB3 laminin, beta 3 1.53 0.0163 
225706_at GLCCII glucocorticoid induced transcript 1 1.58 0.0163 
218117_at RBX1 ring-box 1 -1.48 0.0165 
218349_s_at ZWILCH Zwilch, kinetochore associated, homolog (Drosophila) -1.56 0.0169 
202267 at LAMC2 laminin, gamma 2 1.44 0.0173 
219493_at SHCBP1 SHC SH2-domain binding protein 1 -1.78. 0.0173 
209687_at CXCL12 chqmokine (C-X-C motif) ligand 12 -1.47 0.0173 
228468_at MASTL microtubule associated serine/threonine kinase-like -1.51 0.0175 
1562836_at --- CDNA FLJ11653 fis, clone HEMBA1004538 -1.45 0.0176 
1554168_a_at SH3KBP1 SH3-domain kinase binding protein 1 1.45 0.0178 
212141_at MCM4 MCM4 minichromosome maintenance deficient 4 -1.50 0.0178 
223556 at HELLS helicase, lymphoid-specific -1.61 0.0178 
223758_s_at GTF2H2 general transcription factor IIH, polypeptide 2,44kDa -1.49 0.0178 
209676_at TFPI tissue factor pathway inhibitor (lipoprotein-associated 1.63 0.0179 
coagulation Inhibitor) 
206316_s_at KNTC1 kinetochore associated 1 -1.46 0.0179 
211712_s_at ANXA9 annexin A9 /// annexin A9 -1.52 0.0179 
205590 at RASGRP1 RAS guanyl releasing protein 1 (calcium and DAG- 1.84 0.0181 
regulated) 
217678_at SLC7A1 1 solute carrier family 7, (cationic amino acid transporter, y+ 1.54 0.0184 
system) member 11 
203404_at ARMCX2 armadillo repeat containing, X-linked 2 1.69 0.0185 
209187_at DR1 down-regulator of transcription 1, TBP-binding (negative -1.52 ' 0.0185 
cofactor 2) 
222740_at ATAD2 ATPase family, AAA domain containing 2 -1.64 0.0186 
200934_at DEK DEK oncogene (DNA binding) -1.44 0.0187 
225486 at TMEM18 transmembrane protein 18 -1.45 0.0188 237968_at ARL6IP2 ADP-ribosylation factor-like 6 Interacting protein 2 -1.48 0.0189 
227003_at RAB28 RAB28, member RAS oncogene family -1.50 0.0193 202903_at LSM5 LSM5 homolog, U6 small nuclear RNA associated -1.53 0.0197 
221563_at DUSP10 dual specificity phosphatase 10 1.49 0.0198 
222680_s_at DTL denticleless homolog (Drosophila) 
" -1.47 
0.0198 
1554314_at C6orf 141 chromosome 6 open reading frame 141 1.52 0.0201 
258 
220083_x_at UCHL5 ubiquitin carboxyl-terminal hydrolase L5 -1.54 0.0201 
200831 s_at SCD stearoyl-CoA desaturase (delta-9-desaturase) -1.60 0.0201 
203176_s_at TFAM transcription factor A, mitochondrial -1.46 0.0206 
223700 at MND1 meiotic nuclear divisions 1 homolog (S. cerevisiae) -1.71 0.0206 
218585_s_at DTL denticleless homolog (Drosophila) -1.45 0.0206 
1557765_at LOC643401 hypothetical protein LOC643401 1.49 0.0207 
227525_at GLCCI1 glucocorticoid induced transcript 1 1.57 ; 0.0207 
242836_at ATP1 B3 ATPase, Na+/K+ transporting, beta 3 polypeptide 1.61 0.0207 
202219_at SLC6A8 solute carrier family 6, member 8 1.55 0.0208 
227998_at S100A16 S100 calcium binding protein A16 -1.72 0.0212 
225700_at GLCCI1 glucocorticoid Induced transcript 1 1.43 0.0214 
228401 at ATAD2 ATPase family, AAA domain containing 2 -1.44 0.0215 
215913_s_at GULP1 GULP, engulfment adaptor PTB domain containing 1 1.49 0.0216 
226320_at THOC4 THO complex 4 -1.61 0.0216 
202107_s_at MCM2 MCM2 minichromosome maintenance deficient 2, -1.64 0.0216 
220060_s_at C12orf48 chromosome 12 open reading frame 48 -1.52 0.0216 
215780_s_at SET SET translocation (myeloid leukemia-associated) -1.46 0.0217 
204768_s_at FEN1 flap structure-specific endonuclease 1 -1.50 0.0217 
203665 at HMOX1 heure oxygenase (decycling) 1 2.01 0.0219 
209084_s_at RAB28 RAB28, member RAS oncogene family -1.51 0.0219 
228834_at TOB1 transducer of ERBB2,1 -1.45 0.0224 
209337_at PSIP1 PC4 and SFRS1 interacting protein 1 -1.55 0.0227 
214507_s_at EXOSC2 exosome component 2 -1.45 0.023 
221970_s_at NOL11 nucleolar protein 11 -1.56 0.0232 
222872_x_at OBFC2A oligonucleotide%oligosaccharide-binding fold containing 2A 1.59 0.0235 
200832_s_at SCD stearoyl-CoA desaturase (delta-9-desaturase) -1.56 0.0236 
238736_at REV3L REV3-like, catalytic subunit of DNA polymerase zeta 1.43 0.0237 
222921_s at HEY2 hairy/enhancer-of-split related with YRPW motif 2 -1.48 0.0237 
229744_at SSFA2 Sperm specific antigen 2 -1.56 0.0242 
209921_at SLC7A11 solute carrier family 7, (cationic amino acid transporter, y+ 1.47 0.0243 
system) member 11 
200628_s_at WARS tryptophanyl-tRNA synthetase -1.56 0.0245 
230261_at ST8SIA4 ST8 a-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 1.49 0.0246 
217788_s_at GALNT2 UDP-N-acetyl-alpha-D-galactosamine: polypeptide N- 1.45 0.0246 
acetylgalactosaminyltransferase 2 (GaINAc-T2) 
211421_s_at RET Ret proto-oncogene (multiple endocrine neoplasia and -1.62 0.0246 
medullary thyroid carcinoma 1, Hirschsprung disease) 
206632_s_at APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic -1.53 0.0246 
polypeptide-like 3B 
201295_s_at WSB WD repeat and SOCS box-containing 1 1.86 0.0247 
1558014_s_at MLSTD2 male sterility domain containing 2 -1.47 0.0248 
205034_at CCNE2 cyclin E2 -1.60 0.0249 
209344_at TPM4 tropomyosin 4 1.95 0.0251 
202503_s_at KIAA0101 KIAAO101 -1.58 0.0251 
224731_at HMGB1 high-mobility group box 1 -1.58 0.0251 
228692_at --- CDNA FU13569 fis, clone PLACE1008369 -1.52 0.0251 
230748_at SLC16A6 solute carrier family 16, member 6 -1.60 0.0253 
225429_at - "-" -1.41 0.0253 
202436_s_at CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 1.62 0.0256 
235004_at RBM24 RNA binding motif protein 24 -1.42 0.0256 
210735_s_at CA12 carbonic anhydrase XII -1.42 0.0258 
204767_s_at FEN1 flap structure-specific endonuclease 1 -1.49 0.026 
202149_at NEDD9 neural precursor cell expressed, developmentally down- 1.48 0.0261 
regulated 9 
204798_at MYB v-myb myeloblastosis viral oncogene homolog (avian) -1.68 0.0263 
218195_at ' C6orf211 chromosome 6 open reading frame 211 -1.50 0.0267 
238890_at --" --- -1.50 0.0268 
201975_at RSN Reed-Steinberg cell-expressed Intermediate filament- 1.52 0.0269 
associated protein - 224221_s_at VAV3 vav 3 oncogene -1.82 0.0271 209932_s_at DUT dUTP pyrophosphatase "1.55 0.0271 209642_at BUB1 budding uninhibited by benzimidazoles 1 -1.64 0.0271 
203998_s_at SYT1 synaptotagmin I 1.49 0.0274 
201477_s_at RRM1 ribonucleotide reductase M1 polypeptide -1.51 0.0276 
203200_s_at MTRR methyltetrahydrofolate methyltransferase reductase -1.40 0.0283 
259 
231579_s_at TIMP2 TIMP metallopeptidase Inhibitor 2 1.63 0.0284 
212111 at STX12 syntaxin 12 1.46 0.0284 
235976_at SLITRK6 SLIT and NTRK-like family, member 6 1.53 0.0287 
238002_at GOLPH4 golgi phosphoprotein 4 -1.42 0.0287 
217989_at DHRS8 dehydrogenase/reductase (SDR family) member 8 -1.46 0.0287 
202901_x_at CTSS cathepsin S -1.69 0.0287 
201012_at ANXA1 annexin At 2.45 0.0288 
222037_at MCM4 MCM4 minichromosome maintenance deficient 4 -1.65 0.0288 
206500_s_at C14orf106 chromosome 14 open reading frame 106 -1.43 0.0288 
218498_s_at ER01 L ER01-like (S. cerevisiae) 1.55 0.0289 
208886_at H1 FO H1 histone family, member 0 -1.44 0.0289 
235716_at --- Transcribed locus 1.49 0.029 
208827_at PSMB6 proteasome (prosome, macropain) subunit, beta type, 6 -1.40 0.029 
237460_x_at LOC283551 hypothetical protein LOC283551 -1.62 0.029 
205083_at AOX1 aldehyde oxidase 1 -1.40 0.0291 
218493_at C16orf33 chromosome 16 open reading frame 33 -1.63 0.0292 
206658 at UPK3B uroplakin 3B 1.54 0.0298 
214455_at HIST1H2BC histone 1, H2bc 1.70 0.0298 
203231_s_at ATXN1 ataxin 1 1.48 0.0298 
1552609_s_at IL28A interleukin 28A (interferon, lambda 2) -1.53 0.0298 
1566096_x_at ARHGEF12 Rho guanine nucleotide exchange factor (GEF) 12 1.39 0.0302 
213007_at KIAA1794 KIAA1794 -1.63 0.0302 
235698_at ZFP90 zinc finger protein 90 homolog (mouse) 1.52 0.0304 
222646_s_at ER01L ERO1-like (S. cerevisiae) 1.54 0.0306 
219588_s_at LUZP5 leucine zipper protein 5 -1.47 0.031 
243296_at PBEF1 Pre-B-cell colony enhancing factor 1 1.59 0.0311 
208596_s_at UGT1A10 UDP glucuronosyltransferase 1 family, polypeptide Al0 1.46 0.0312 
207928_s_at GLRA3 glycine receptor, alpha 3 1.82 0.0312 
205822_s_at HMGCSI 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 -1.43 0.0312 
207628_s_at WBSCR22 Williams Beuren syndrome chromosome region 22 -1.43 0.0318 
231772_x_at CENPH centromere protein H -1.52 0.0321 
213293_s_at TRIM22 tripartite motif-containing 22 -1.67 0.0322 
201930_at MCM6 MCM6 minichromosome maintenance deficient 6 -1.58 0.0323 
204238_s_at C6orf 108 chromosome 6 open reading frame 108 -1.39 0.0328 
210592_s_at SAT1 spermidine/spermine N1 -acetyltransf erase 1 1.52 0.0331 
1554408_a_at TKI thymidine kinase 1, soluble -1.59 0.0331 
202551_s_at CRIMI cysteine rich transmembrane BMP regulator 1 (chordin-like) 1.39 0.0336 
'202338_at TKI thymidine kinase 1, soluble -1.44 0.034 
1557366_at KIAA0565 KIAA0565 gene product 1.44 0.0343 
224579_at --- CDNA FLJ32108 fis, clone OCBBF2001492 -1.39 0.0345 
214606_at TSPAN2 tetraspanin 2 1.50 0.0346 
230333_at SAT Spermidine/spermine N1 -acetyltransf erase 1.41 0.0347 
238825_at ACRC acidic repeat containing 1.44 0.0351 
208175_s_at DMP1 dentin matrix acidic phosphoprotein -1.39 0.0351 
1560622_at TPARL TPA regulated locus 1.41 0.0358 
211596_s_at LRIG1 leucine-rich repeats and Immunoglobulin-like domains 1 -1.39 0.036 
211429_s_at SERPINA1 serpin peptidase inhibitor, Glade A member 1 1.71 0.0364 
209861 sat METAP2 methionyl aminopeptidase 2 -1.39 0.0367 
223315_at NTN4 netrin 4 1.67 0.0368 
200972_at TSPAN3 tetraspanin 3 1.42 0.0373 
219888_at SPAG4 sperm associated antigen 4 1.49 0.0376 
204222_s_at GLIPR1 GLI pathogenesis-related 1 (glioma) 2.26 0.0376 
205176_s_at ITGB3BP integrin beta 3 binding protein (beta3-endonexin) ' -1.42 0.0377 204083_s_at TPM2 tropomyosin 2 (beta) 1.97 0.0384' 
207996_s_at C18orf1 chromosome 18 open reading frame 1 1.41 0.0388 
218979_at RMI1 RMI1, RecO mediated genome instability 1 -1.39, 0.0395 203650_at PROCR protein C receptor, endothelial (EPCR) -1.38 0.0396 236193_at HIST1H2BC histone 1, H2bc 1.42 0.0403 
210085_s_at ANXA9 annexin A9 . 1.40 0.0408 225239_at --- CDNA FU26120 fis, clone SYNO0419 1.66 0.0409 229553_at PGM2L1 phosphoglucomutase 2-like 1 1.63 0.0411 201667_at GJA1 gap junction protein, alpha 1,43kDa (connexin43) 1.97' 0.0413 226077_at FLJ31951 hypothetical protein FU31951 1.47 0.0413 
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200081_s_at RPS6 ribosomal protein S6 /// ribosomal protein S6 -1.39 0.0413 
206346_at PRLR prolactin receptor -1.53 0.0413 
1553810_a at KIAA1524 KIAA1524 -1.58 0.0413 
202435_s_at CYP1 B1 cytochrome P450, family 1, subfamily B, polypeptide 1 1.66 0.0414 
201294_s_at WSBI WD repeat and SOCS box-containing 1 1.45 0.0416 
214056_at MCL1 Myeloid cell leukemia sequence 1 (BCL2-related) -1.42 0.0416 
220329_s_at C6orf96 chromosome 6 open reading frame 96 -1.48 
0.0416 
211506_s_at IL8 Interleukin 8 1.98 0.0418 
226430_at LOC253981 hypothetical protein LOC253981 -1.42 0.0418 
231202_at ALDHIL2 aldehyde dehydrogenase 1 family, member L2 1.40 0.042 
1561951 at SLC5A1 2 solute carrier family 5, member 12 1.42 0.0423 
228825_at LTB4DH leukotriene B4 12-hydroxydehydrogenase 1.39 0.0423 
203721_s_at UTP18 UTP18, small subunit (SSU) processome component -1.40 0.0423 
211814 sat CCNE2 cyclin E2 -1.64 0.0423 
1554224_at --- CDNA clone IMAGE: 4794631 
1.45 0.0425 
209377_s_at HMGN3 high mobility group nucleosomal binding domain 3 -1.48 0.0425 
200679_x_at HMGB1 high-mobility group box 1 -1.47 0.0426 
217025_s_at DBN1 drebrin 1 1.45 0.0427 
219363_s_at MTERFD1 MTERF domain containing 1 -1.36 0.0427 
218162_at OLFML3 olfactomedin-like 3 1.56 0.0429 
244094_at C9orf93 Chromosome 9 open reading frame 93 -1.38 0.0429 
201656_at ITGA6 Integrin, alpha 6 1.39 0.0432 
1552306_at ALG10 asparagine-linked glycosylation 10 homolog -1.56 0.0436 
225189_s_at RAPH1 Ras association and pleckstrin homology domains 1 -1.56 0.0438 
240383_at UBE2D3 ubiquitin-conjugating enzyme E2D 3 1.43 0.044 
210015_s_at MAP2 microtubule-associated protein 2 1.43 0.044 
244447_at KLF10 Kruppel-like factor 10 1.42 0.044 
201117_s_at CPE carboxypeptidase E 1.60 0.044 
1557915_s_at GSTO1 glutathione S-transferase omega 1 -1.40 0.0447 
206363_at MAF v-maf musculoaponeurotic fibrosarcoma oncogene 1.37 0.0451 
208840_s_at G3BP2 RasGTPase activating protein SH3domain-binding protein 2 1.41 0.0451 
201476_s_at RRM1 ribonucleotide reductase M1 polypeptide -1.47 0.0451 
214113_s_at RBM8A RNA binding motif protein 8A -1.40 0.0451 
1567107_s_at TPM4 tropomyosin 4 1.50 0.0464 
223551_at PKIB protein kinase (cAMP-dependent, catalytic) inhibitor beta -1.47 0.0464 
221521_s_at GINS2 GINS complex subunit 2 (Psf2 homolog) -1.48 0.0464 
208721_s_at ANAPC5 anaphase promoting complex subunit 5 -1.44 0.0464 
223156_at MRPS23 mitochondrial ribosomal protein S23 -1.38 . 
0.0466 
208669_s_at CRl1 CREBBP/EP300 inhibitor 1 -1.61 0.0475 
202619_s_at PLOD2 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 1.45 0.0482 
201614_s_at RUVBLI RuvB-like 1 (E. coli) -1.42 0.0485 
204326_x_at MT1X metallothionein 1X -1.49 0.0485 
225540_at MAP2 microtubule-associated protein 2 1.87- 0.0486 
225957_at LOC153222 adult retina protein 1.52 0.0486 
239845_at --- Transcribed locus 1.37 0.0486 
207181_s_at CASP7 caspase 7, apoptosis-related cysteine peptidase 1.49 0.0487 
203545_at ALG8 asparagine-linked glycosylation 8 homolog -1.43 0.0487 
208828_at POLE3 polymerase (DNA directed), epsilon 3 (p17 subunit) -1.37 0.0493 
210561_s_at WSB1 WD repeat and SOCS box-containing 1 1.38 0.0494 
233085_s_at OBFC2A oligonucleotide/oligosaccharide-binding fold containing 2A 1.51 0.0497 
218907_s_at LRRC61 leucine rich repeat containing 61 1.45 0.0497 
209773_s_at RRM2 ribonucleotide reductase M2 polypeptide -1.89 0.0497 
218802_at CCDC109B coiled-coil domain containing 1098 -1.38 0.0497 
229128_s_at --- Transcribed locus -1.37 0.0497 
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APPENDIX 2 
An AP-2 consensus-binding site analysis conducted using the "HumanGenome9999" human promoter 
sequence data (9999bp up stream sequences of 21787 genes represented in the ENSEMBL database) 
imported into the Genespring package. A subset of 192 genes out of the 254 probe sets that changed their 
expression significantly (FDR corrected, p value <0.01) following AP-2y silencing in MCF-7 cells were 
successfully mapped to the ENSEMBL promoter sequences. The presence of the AP-2 consensus binding 
sequence (SCCNNVRGB) was mapped in a -500 to +50 bp upstream region. The table shows the 
location relative to the start of transcription and the potential AP-2 TFBS sequence. 
Gene Symbol Location Sequence 
ALOX5 91 GCCTGGAGC 
ALOX5 98 GCCGGGAGC 
ALOX5 193 GCCCGAGGC 
ALOX5 216 CCCAGGAGC 
ALOX5 359 GCCTTGGGC 
ALOX5 374 GCCTACAGG 
ALOX5 381 CCCCAGGGC 
ALOX5 394 CCCCGCAGC 
ANLN 137 CCCCGCGGC 
ASK 303 GCCGGCAGT 
ASK 370 GCCTTCAGC 
ASK 417 GCCCCGGGC 
ASPM 97 -000TGAGGG 
ASPM 98 CCCCTGAGG 
ASPM 269 CCCGGAGGT 
ASPM 270 GCCCGGAGG 
ASPM 427 GCCCCGGGT 
ASPM 471 CCCTTCAGC 
ASS 6 GCCCCCGGC 
ASS 63 CCCGGGGGC 
ASS 64 GCCCGGGGG 
ASS 216 CCCGCCGGC 
ASS 255 CCCGCGGGC 
ASS 256 GCCCGCGGG 
ASS 263 GCCTCCAGC 
ASS 306 CCCCTGAGT 
ASS 350 GCCAGGAGG 
ASS 357 CCCCAGGGC 
AURKA 195 GCCACAGGT 
AURKA 211 CCCTGGGGC 
AURKB 326 CCCGGGAGG 
B3GALT3 65 CCCAGAGGG 
B3GALT3 231' GCCTCGAGG 
B3GALT3 243 CCCTCCAGG 
BENE 53 GCCCAGGGG 
BENE 278 CCCAAGAGT 
BENE 343 CCCAGGGGC 
BENE 408 CCCATGAGG 
ELOVL6 282 GCCGCGGGG 
ELOVL6 361 GCCCGGAGT 
ELOVL6 424 CCCAGAGGT 
ELOVL7 27 GCCTTCAGT 
ELOVL7 198 GCCTTCAGT 
ERRFII 46 CCCGGCGGC 
ERRFI1 173 CCCTGCAGC 
ERRFII 298 GCCGCGGGC 
ERRFI1 338 GCCCTCAGT 
ERRFII 383 GCCCGGAGC 
ERRFII 423 GCCAGCGGC 
ERRFII 450 CCCTCCAGG 
ERRFI1 484 GCCGCAAGC 
FANCD2 111 GCCTTCAGC 
FANCD2 306 CCCAGAGGC 
FBN1 47 GCCCCGGGC 
FBN1 94 CCCGGCGGC 
FBN1 125 GCCCGGGGG 
; FBN1 168 GCCTGAAGT 
FBNI 208 GCCTCGGGG 
FBN1 355 GCCGGGGGC 
FBN1 358 GCCGCCGGG 
FBN1 390 CCCGGGAGG 
FBN1 449 GCCCGGGGC 
FBXO5 231 GCCCCCGGC 
FHL1. 292 CCCCGCAGC 
FHL1. 361 GCCCCCGGC 
FHL1, 370 GCCCGAGGC 
FHL1 407 CCCGCAGGC 
FHL1 427 GCCTGCAGT 
FLJ10719 473 GCCTCAAGG 
FLJ11029 210 CCCTCCGGC 
FLJ40869 -2 ' GCCTAAGGC 
FOLR1 -, 42 GCCTTAGGC 
GEM 42 GCCGTCGGG 
GEM 
, 
72 CCCGGCGGG 
GEM 150, CCCTCCGGC 
GEM 237 GCCACGGGT 
GEM 298 CCCGACAGC - 
262 
BICD2 84 GCCGGAGGG GEM 324 CCCCCCAGT 
BICD2 101 CCCAGCGGG GEM 347 CCCGTGGGC 
BICD2 104 GCCCCCAGC GEM 384 GCCTGGAGG 
BICD2 167 GCCGGGGGC GFPT2 68 CCCAGAAGC 
BICD2 206 CCCGAGGGC GFPT2 411 CCCTGGGGG 
BICD2 207 GCCCGAGGG GFPT2 412 GCCCTGGGG 
BICD2 237 CCCCTGGGC GPSM2 35 GCCCGAGGC 
BICD2 246 CCCCACAGC GPSM2 68 GCCTTGGGG 
BICD2 400 GCCGCGGGG GPSM2 114 GCCGGGGGC 
BICD2 467 GCCAGAGGC GPSM2 180 CCCCTAGGT 
BICD2 477 GCCGCCGGC GPSM2 240 GCCTGGAGC 
BIRC5 18 CCCCGCGGC HCAP-G 61 GCCCAAAGC 
BIRC5 63 GCCGCGGGG HCAP-G 194 CCCTCCGGT, 
BIRC5 71 CCCAGAAGG HCAP-G 208 GCCAGCAGC 
C10orf116 60 CCCTGGGGC HCAP-G 315 GCCACAAGG 
C10orf 116 61 GCCCTGGGG HCAP-G 322 CCCTTCGGC 
C10orf 116 120 CCCCGGAGC HCAP-G 431 CCCAGCAGC 
C10orf 116 256 GCCTCCAGC HMGB2 474 CCCAGGAGC 
C10orf 116 343 CCCTGGAGC HRASLS3 -49 CCCATGGGT 
C10orf 116 357 GCCCTGAGC HRASLS3 184 GCCTGCAGG 
ClOorf3 158 CCCAGAAGC ID2 128 CCCGCCGGG 
ClOorf3 233 CCCGTAGGC ID2 290 CCCGCGGGG 
C12orf57 -47 GCCAACAGC ID2 291 CCCCGCGGG 
C13orf18 131 GCCTGCGGC ID2 358 CCCGCCAGC 
C13orfl8 269 GCCGCGGGT IGFBP3 -11 GCCACGAGC 
C16orf75 136 CCCGGCGGT IGFBP3 155 CCCCGCAGC 
C20orf 129 157 GCCAGGAGC IGFBP3 196 CCCCCGAGC 
C20orf 129 404 CCCGAGGGT IGFBP3 309 GCCTGGAGT 
C21orf45 83 CCCTTCAGG IGFBP3 346 GCCAGGAGT 
C4orf34 9 GCCGGCGGC IGFBP3 403 CCCGAGAGC 
C4orf34 89 GCCCGCGGG IGFBP3 421 GCCGCAGGG 
C4orf34 201 GCCGCAGGC INHBA 232 GCCAGAGGT 
C6orf 139 114 CCCTCCAGC KIAA1324 208 CCCCGGGGG 
CA2 133 CCCCCGAGC KIAA1324 217 CCCCTCAGT 
CA2 144 CCCCCGGGC KIAA1324 480 CCCCTCAGT 
CA2 216 GCCCCGAGC KIAA1618 12 CCCAGCAGG 
CA2 268 GCCGAGAGG KIF14 268 GCCTGAAGT 
CA2 282 CCCGCCGGG KIF15 387 CCCGACAGC 
CA2 291 CCCCGGAGC KIF15 442 GCCTGGGGG 
CA2 299 CCCCGGAGC KIF18A 149 GCCGCGAGC 
CA2 307 CCCCGGAGC - KIF18A 282 CCCACCAGC 
CA2 337 GCCGAGGGG KIF18A 325 CCCGCCGGT 
CA2 344 GCCGTGGGC KIF18A 374 GCCCGCAGC 
CA2 390 GCCCAGAGC KIF23 141 CCCTCCAGC 
CA2 416 CCCAGGAGC KIF2C 130 CCCCAAGGC 
CA2 473 GCCGGGAGG KIF2C 131 CCCCCAAGG 
CALML5 0 CCCCCGGGC KIF2C 211 CCCAGAAGG 
CALML5 1 GCCCCCGGG KIF2C 281 CCCCGCAGT 
CALML5 101 CCCTGCGGC KLIPI 313 GCCTTAGGT 
CALML5 213 CCCCAGGGC KRT81 81 GCCCTGAGG 
CALML5 396 CCCTTGGGC KRT81 262 CCCCAGAGC 
CALMLS 489 CCCTCCAGT KRT86 411. CCCCGCAGG 
CBX5 271 GCCAGGAGG KRT86 500 CCCCCAAGT 
CCDC5 23 GCCAACGGC LMNB1 -27 CCCGGAAGT 
263 
CCDC5 83 GCCAGGAGT LMNBI 8 CCCTCCAGC 
CCDC83 66 GCCTGGGGG LMNB1 29 GCCTCCAGG 
CCDC83 225 CCCTGCAGG MCM10 63 GCCTAAAGT 
CCDC83 245 GCCCAGGGC MCM10 83 CCCATGGGG 
CCDC83 277 GCCGGCGGG MCM5 63 GCCGCGAGG 
CCNA2 216 GCCGCGAGC MCM5 159 CCCGGAAGG 
'CCNB1 158 CCCGAGAGC MCM5 201 GCCAGAAGT 
CCNB2 380 CCCGGAGGG MCM5 397 CCCAAGAGG 
CCND1 140 GCCTCAGGG MCM7 29 GCCCTGGGC 
CCND1 159 GCCGCAGGG MCM7 132 CCCGTCAGC 
CCND1 448 CCCGTGGGT MCM7 207 CCCGACGGG 
CDC20 106 CCCGGAAGG MCM7 264 CCCCCAAGT 
CDC20 340 CCCTGAAGC MK167 45 CCCGCGGGC 
CDC20 434 GCCTTGGGC MK167 46 CCCCGCGGG 
CDC20 473 GCCCGCGGC MKI67 116 GCCACCGGG 
CDC42EP5 410 CCCTGAAGG MKI67 371 CCCGCGAGC 
CDC6 114 GCCCAAGGC MSI2 71 GCCGGGGGG 
CDC6 418 CCCATCAGG MSI2 245 GCCGTGGGG 
CDC7 493 GCCAAGGGC MSI2 279 CCCGCGGGG 
CDCA1 1 GCCCACAGC MSI2 280 GCCCGCGGG 
CDCA5 29 CCCGCAGGG MSI2 301 CCCGGAGGC 
CDCA5 134 CCCCTGGGC MSI2 302 GCCCGGAGG 
CDCAS 215 CCCTTCAGC MSI2 364 CCCCGCAGC 
CDCAS 236 CCCCAGGGC NEK2 96 GCCTAGGGT 
CDCA5 432 GCCCCCGGC NEK2 152 CCCACAGGT 
CDCA5 465 GCCTCCGGC NEK2 217 GCCGAGAGG 
CDH26 2 GCCAAAGGT NEK2 278 GCCTGAGGG 
CDH26 328 CCCCAGAGC NEK2 455 CCCGGGAGT 
CDKN3 65 CCCAAAGGC NET1 128 CCCGGGAGC 
CDKN3 144 CCCACAGGG NET1 200 GCCTTAGGG 
CDKN3 245 CCCCCAAGC NOLA2 126 GCCTTAAGG 
CKS1B 86 CCCATAAGG NOLA2 352 CCCGGGAGG 
CKS1B 87 GCCTCGAGC NOLA2 493 GCCTGAGGT 
CKS1B 143 CCCATAAGG NUP50 79 CCCCAAAGC 
CLIC3 61 CCCCTCGGC NUP50 145 CCCCTCAGC 
CLIC3 149 CCCCGGGGC NUP50 232 CCCTGCAGC 
CLIC3 165 CCCTCAGGC NUP50 261 CCCGAGGGT 
CLIC3 178 CCCTGAGGT NUP50 367 CCCTCCGGG 
CLIC3 406 GCCATAGGG NUSAP1 283 GCCCCAAGC 
CXCL2 63 GCCACAGGC, NUSAPI 380 CCCCGGGGC 
CXCL2 206 CCCAGAGGC NUSAPI 381 CCCCCGGGG 
CXCL2 207 CCCCAGAGG NUSAPI 382 CCCCCCGGG 
CXCL2 446 CCCCCCGGT NUSAP1 489 CCCTGCGGG 
CYB5 44 CCCGACGGG NUSAP1 497 GCCCCCAGC 
CYBS 113 GCCCCCAGT OGFR 494 CCCTCCGGG 
CYB5 132 CCCCTGAGC OIP5 90, GCCAAAGGG 
CYB5 393 CCCGCGGGG OIP5 429 CCCTCAGGT 
DEPDCIB 9 GCCAACGGT OIP5 486 CCCCGAGGC 
DEPDCIB 44 CCCGCGGGC OPN3 28, CCCCTCAGT 
DEPDCIB 45 GCCCGCGGG OPN3 93` GCCACGGGG 
DEPDCIB 52 GCCCGCAGC, OPN3 111 GCCGCGGGG 
DEPDCI B 125 GCCGCGGGT OPN3 139 GCCGGGAGC 
DEPDCI B 158 GCCCCGGGC OPN3 168 CCCGCGGGG 
DEPDCIB 228 GCCCCCGGC OPN3 169 GCCCGCGGG 
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DEPDCIB 365 GCCCAAAGC OPN3 182 GCCGCGAGG 
DKFZp762E1312 8 CCCTGCAGT OPN3 257 CCCCCAGGC 
DKFZp762E1312 137 GCCGGAAGG OPN3 258 GCCCCCAGG 
DKFZp762EI312 359 CCCAGCGGC OPN3 271 CCCTGCGGC 
DKK1 21 CCCTGCAGT ORC3L 14 GCCGCGAGG 
DKK1 74 GCCCGCGGT ORC3L 21 CCCTGCAGC 
DKK1 97 CCCAAGGGG ORC3L 76 CCCGGAGGG 
DKK1 244 CCCGAAGGT ORC3L 77 CCCCGGAGG 
DKK1 245 CCCCGAAGG ORC3L 274 GCCCGCAGC 
DKK1 383 CCCCTCGGC ORC3L 296 CCCTCCAGC 
DLG7 157 CCCTCGGGC PDZGEF2 79 CCCTCCAGC 
DLG7 158 CCCCTCGGG PDZGEF2 163 CCCGCCAGT 
DLG7 271 GCCTAAGGG PDZGEF2 499 CCCACGGGT 
DOK7 -42 CCCACCGGT PDZGEF2 500 CCCCACGGG 
DOK7 -23 GCCTGAGGT PDZK1 122 GCCCCCAGC 
DOK7 25 GCCAAGGGT PERP 14 CCCCGCGGC 
DOK7 117 GCCGGGAGT PERP 43 GCCCGGAGC 
DOK7 285 CCCAGGGGG PERP 100 CCCGGCAGG 
DOK7 286 GCCCAGGGG PERP 175 CCCTCGGGC 
DOK7 298 GCCCTCAGT PIR51 91 GCCATCGGC 
DOK7 327 CCCCCAAGC PLEKHF2 60 GCCCGGAGT 
DOK7 352 GCCACCGGG PLEKHF2 161 CCCTAGAGC 
DOK7 498 CCCTGGGGC PLEKHF2 . 175 GCCAAAGGC DOK7 499 CCCCTGGGG PLEKHF2 207 GCCCGCGGC 
DUSP1 37 CCCAGAGGC PLK4 149 CCCCGAAGT 
DUSP1 38 CCCCAGAGG PLK4 270 GCCATAAGT 
DUSP1 210 GCCGCGAGC PMSCL1 60 GCCCAGGGC 
DUSP1 214 GCCAAGGGG PMSCL1 74 CCCCCAAGT 
DUSP1 245 GCCAAGAGC PMSCL1 194 CCCTCAGGC 
DUSP1 282 GCCTGGAGC PMSCLI 472 GCCTCGGGG 
DUSP1 323 GCCTGGAGC POLE2 -47 CCCAGGAGT DUSP1 330 CCCGGAGGT POLE2 201 CCCGGCAGC 
DUSP1 428 GCCGAGGGG POLE2 212 GCCCTCAGT 
DUSP1 475 GCCCTGGGC POLE2 348 CCCAACAGC 
EDG3 24 CCCGGGAGC POLE2 455 CCCTCAAGT 
EDG3 56 GCCGTGGGT PPIL5 91 GCCATCGGG 
EDG3 430 GCCGCCAGC PPIL5 153 CCCAACGGC 
EDG3 496 CCCCTCAGG PPIL5 211 CCCCAAGGC 
EFHD1 74 CCCACCAGG PPILS 212 GCCCCAAGG 
EFHD1 141 GCCGCGGGG PPILS 425 GCCGGGAGC 
EFHD1 148 GCCCGGAGC PPILS 454 CCCCAAGGC 
EFHD1 171 CCCGGGGGG PPILS 455 CCCCCAAGG 
EFHD1 227 CCCCGGAGC PRC1 -9 GCCCAGGGT EFHD1 314 GCCGCGAGC PRC1 105 CCCGAGGGG 
EGR3 271 CCCTTCGGC PRC1 106 GCCCGAGGG 
EGR3 363 GCCGCGAGC PRCI 254 CCCTTGAGG 
ELOVL6 84 GCCAAGGGT PRC1 390 CCCGGCAGC 
ELOVL6 126 CCCCCGGGC PREX 70 CCCGCCGGC 
ELOVL6 127 CCCCCCGGG PREX 100 GCCGGGAGC 
ELOVL6 233 CCCACGAGG PREX 121 GCCCCCAGT 
ELOVL6 282 GCCGCGGGG PREX 141 GCCCCCGGC 
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